<!DOCTYPE html> <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Glucagon‐like peptide analogues for type 2 diabetes mellitus - Shyangdan, DS - 2011 | Cochrane Library</title> <meta property="og:title" content="Glucagon‐like peptide analogues for type 2 diabetes mellitus - Shyangdan, DS - 2011 | Cochrane Library" /> <meta property="og:url" content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006423.pub2/references" /> <meta property="og:type" content="article" /> <meta property=”og:image” content=”https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png” /> <meta content="initial-scale=1.0, width=device-width" name="viewport" /> <meta name="dc.identifier" scheme="DOI" content="10.1002/14651858.CD006423.pub2" /> <meta name="citation_title" content="Glucagon‐like peptide analogues for type 2 diabetes mellitus" /> <meta name="citation_author" content="Deepson S. Shyangdan" /> <meta name="citation_author_institution" content="Health Sciences Research Institute, Warwick Medical School, University of Warwick" /> <meta name="citation_author_email" content="D.S.Shyangdan@warwick.ac.uk" /> <meta name="citation_author" content="Pamela Royle" /> <meta name="citation_author_institution" content="Health Sciences Research Institute, Warwick Medical School, University of Warwick" /> <meta name="citation_author" content="Christine Clar" /> <meta name="citation_author_institution" content="Cochrane Metabolic and Endocrine Disorders Group" /> <meta name="citation_author" content="Pawana Sharma" /> <meta name="citation_author_institution" content="University of Aberdeen" /> <meta name="citation_author" content="Norman Waugh" /> <meta name="citation_author_institution" content="Health Sciences Research Institute, Warwick Medical School, University of Warwick" /> <meta name="citation_author" content="Ailsa Snaith" /> <meta name="citation_author_institution" content="University of Aberdeen, School of Medicine" /> <meta name="citation_journal_title" content="Cochrane Database of Systematic Reviews" /> <meta name="citation_publisher" content="John Wiley &amp; Sons, Ltd" /> <meta name="citation_issue" content="10" /> <meta name="citation_doi" content="10.1002/14651858.CD006423.pub2" /> <meta name="citation_date" content="2011" /> <meta name="citation_online_date" content="2011/10/05" /> <meta name="citation_abstract_html_url" content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006423.pub2/abstract" /> <meta name="citation_fulltext_html_url" content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006423.pub2/full" /> <meta name="citation_pdf_url" content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006423.pub2/pdf/CDSR/CD006423/CD006423.pdf" /> <meta name="citation_issn" content="1465-1858" /> <meta name="citation_language" content="en" /> <meta name="citation_keywords" content="Diabetes Mellitus, Type 2 [blood, *drug therapy]; Glucagon‐Like Peptide 1 [*analogs &amp; derivatives]; Glycated Hemoglobin A [metabolism]; Hypoglycemic Agents [*therapeutic use]; Randomized Controlled Trials as Topic" /> <script type="text/javascript" src="//script.crazyegg.com/pages/scripts/0056/6375.js" async="async"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <script type="text/javascript">var o={auth:{customerIds:["P#DRAAEAC","EAL00000056729","DRAA3TITLES","TSINGH009S","EAL0001468","EAL00000045347"],individualId:null,brandedCustomer:"EAL0001468",roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=UTF-8" http-equiv="content-type" /> <link href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/favicon.ico" rel="Shortcut Icon" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006423&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006423&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" rel="canonical" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;zh&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006423&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006423&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="zh-CN" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;zh_TW&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006423&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006423&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="zh-TW" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;hr&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006423&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006423&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="hr-HR" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006423&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006423&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="x-default" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006423&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006423&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="en-US" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;fr&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006423&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006423&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="fr-FR" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;de&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006423&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006423&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="de-DE" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;ja&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006423&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006423&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="ja-JP" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;ko&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006423&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006423&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="ko-KR" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;ms&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006423&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006423&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="ms-MY" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;fa&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006423&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006423&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="fa-IR" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;pl&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006423&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006423&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="pl-PL" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;pt&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006423&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006423&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="pt-PT" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;ru&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006423&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006423&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="ru-RU" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;es&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006423&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006423&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="es-ES" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;ta&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006423&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006423&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="ta-IN" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;th&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006423&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006423&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="th-TH" rel="alternate" /> <link class="lfr-css-file" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;cochrane-theme&#x2f;css&#x2f;main&#x2e;css&#x3f;browserId&#x3d;other&#x26;themeId&#x3d;cochrane_WAR_cochranetheme&#x26;minifierType&#x3d;css&#x26;languageId&#x3d;en_US&#x26;b&#x3d;6210&#x26;t&#x3d;1581422282000" rel="stylesheet" type="text/css" /> <link class="lfr-css-file" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;cochrane-theme&#x2f;css&#x2f;aui&#x2e;css&#x3f;browserId&#x3d;other&#x26;themeId&#x3d;cochrane_WAR_cochranetheme&#x26;minifierType&#x3d;css&#x26;languageId&#x3d;en_US&#x26;b&#x3d;6210&#x26;t&#x3d;1581422282000" rel="stylesheet" type="text/css" /> <link href="&#x2f;html&#x2f;css&#x2f;main&#x2e;css&#x3f;browserId&#x3d;other&#x26;themeId&#x3d;cochrane_WAR_cochranetheme&#x26;minifierType&#x3d;css&#x26;languageId&#x3d;en_US&#x26;b&#x3d;6210&#x26;t&#x3d;1513680834000" rel="stylesheet" type="text/css" /> <link href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" rel="stylesheet" type="text/css" /> <link href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1581718173000" rel="stylesheet" type="text/css" /> <link href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1581718256000" rel="stylesheet" type="text/css" /> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 13},getRevision:function(){return"605.1"},getVersion:function(){return"13.0"},isAir:function(){return false},isChrome:function(){return false},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return false},isMac:function(){return true},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="EfT7x5RD";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dreferences\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD006423\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD006423\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006423\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006423\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article References"},article:{availableLanguage:["en","es","ko","ms","ja","fr","zh"],languageCode:"en",accessStatus:"licensed",doi:"10.1002/14651858.CD006423.pub2",title:"Glucagon\\u2010like peptide analogues for type 2 diabetes mellitus",firstPublishedDate:"Oct 5, 2011 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Metabolic and Endocrine Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;cochrane-theme&#x2f;css&#x2f;custom&#x2e;css&#x3f;browserId&#x3d;other&#x26;themeId&#x3d;cochrane_WAR_cochranetheme&#x26;minifierType&#x3d;css&#x26;languageId&#x3d;en_US&#x26;b&#x3d;6210&#x26;t&#x3d;1581422282000" rel="stylesheet" type="text/css" /> <style type="text/css"></style> <script src="//assets.adobedtm.com/6e626c9ec247e474f6b98eb15a79a185cf7e26a5/satelliteLib-b0f13d7a13ebe8b0b1b00a9f0730a084926e292f.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1581422282000" type="text/javascript"></script> <![endif]--> </head> <body class=" yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div id="js-cookie-message" class="cookie-message cookie-message--hidden system-message-container"> <div class="container"> <a href="#" class="fa fa-times js-cookie-close pull-right" aria-label="Close cookies message"></a> <div class="system-message-wrapper container"> <i class="fa fa-exclamation-triangle" aria-hidden="true"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/N7XGCZUQPW4C675JNSTYTLUDN7XB/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a href="#" class="btn secondary js-cookie-close js-cookie-accept">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/"> <span class="brand-name">The Cochrane Library</span> <img class="brand-logo" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/en-US_logo.png" alt="Cochrane Library logo" title="Cochrane Library" /> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end " id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img id="owel__null__null" src="/scolaris-search/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_auth=EfT7x5RD&p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=1&p_p_state=normal&p_p_mode=view&_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input type="hidden" name="searchType" value="basic" /> <input type="hidden" name="facetDisplayName" value="" /> <input type="hidden" name="facetQueryTerm" value="" /> <input type="hidden" name="facetQueryField" value="" /> <input type="hidden" name="facetCategory" value="" /> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select title="Search by options" aria-label="Search by options" name="searchBy" class="custom-select-enabled search-type"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" style="display: none;" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=topics-list&p_p_cacheability=cacheLevelPage"> <select class="search-select-topic-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input type="text" size="30" class="field browser-search search-text ui-autocomplete-input" value="" aria-label="Enter search term" id="searchText" name="searchText" placeholder="Search">
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button type="submit" class="searchByBtn" aria-label="Search">
<i class="fa fa-search" aria-hidden="true"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=references&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006423.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006423.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a href="/en/browse-by-topic" class="btn secondary">Browse</a>
<a href="/en/advanced-search" class="btn primary advanced-search-button">Advanced search</a>
</div>
</div>
<a href="#" class="toggle-menu-switch"><i class="fa fa-bars" aria-hidden="true"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<p class="auxiliary-menu-item access">Access provided by: <strong>Tsinghua University</strong></p>
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_  portlet-static portlet-static-end  " id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img id="bvrs__null__null" src="/scolaris-language-portlet/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hr, ja, ko, ms, pl, pt, ru, ta, th, zh, za]"> <a title="Select your preferred language" class="open-language-modal" href="#"> <i class="fa fa-file-text"></i> English </a> <a title="Select your preferred language" class="open-language-modal" href="#"> <i class="fa fa-globe"></i> English </a> </div> <div class="language-selector-modal-content" style="display: none;" data-modal-title="Language selection" data-size="large"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane Review language</h3> <p>Select your preferred language for Cochrane Reviews. You will see translated Review sections in your preferred language. Sections without translation will be in English.</p> <div> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de" class="content-language-selector " data-languagecode="de">Deutsch</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en" class="content-language-selector is-active" data-languagecode="en">English</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es" class="content-language-selector " data-languagecode="es">Español</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa" class="content-language-selector " data-languagecode="fa">فارسی</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr" class="content-language-selector " data-languagecode="fr">Français</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr" class="content-language-selector " data-languagecode="hr">Hrvatski</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja" class="content-language-selector " data-languagecode="ja">日本語</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko" class="content-language-selector " data-languagecode="ko">한국어</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms" class="content-language-selector " data-languagecode="ms">Bahasa Malaysia</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl" class="content-language-selector " data-languagecode="pl">Polski</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt" class="content-language-selector " data-languagecode="pt">Português</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru" class="content-language-selector " data-languagecode="ru">Русский</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta" class="content-language-selector " data-languagecode="ta">தமிழ்</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th" class="content-language-selector " data-languagecode="th">ภาษาไทย</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh" class="content-language-selector " data-languagecode="zh">简体中文</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=za" class="content-language-selector " data-languagecode="za">繁體中文</a> </div> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div> <a href="/en/cdsr/doi/10.1002/14651858.CD006423.pub2/references/en" class="portal-language-selector is-active" data-portallanguage="en">English</a> <a href="/es/cdsr/doi/10.1002/14651858.CD006423.pub2/references/es" class="portal-language-selector " data-portallanguage="es">Español</a> </div> </div> <button class="btn primary btn-cancel" type="button">Cancel</button> <a class="btn secondary ok-btn pull-right" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/c/portal/login?p_l_id=20757&redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006423.pub2%2Freferences" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
</a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
<div class="access-provider-mobile">
<p class="access">Access provided by: <strong>Tsinghua University</strong></p>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class=" nav-root-item parent">
<a href="#">Cochrane Reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
 <li class=" child-nav-item" id="layout_14" role="presentation">
<a aria-labelledby="layout_14" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;reviews" role="menuitem">
Search Reviews (CDSR)
</a>
</li>
<li class=" child-nav-item" id="layout_15" role="presentation">
<a aria-labelledby="layout_15" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;reviews&#x2f;topics" role="menuitem">
Browse Reviews
</a>
</li>
<li class=" child-nav-item" id="layout_18" role="presentation">
<a aria-labelledby="layout_18" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;table-of-contents" role="menuitem">
Issues
</a>
</li>
<li class=" child-nav-item" id="layout_17" role="presentation">
<a aria-labelledby="layout_17" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;editorials" role="menuitem">
Editorials
</a>
</li>
<li class=" child-nav-item" id="layout_19" role="presentation">
<a aria-labelledby="layout_19" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;special-collections" role="menuitem">
Special Collections
</a>
</li>
<li class=" child-nav-item" id="layout_20" role="presentation">
<a aria-labelledby="layout_20" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;supplements" role="menuitem">
Supplements
</a>
</li>
<li class=" child-nav-item" id="layout_13" role="presentation">
<a aria-labelledby="layout_13" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;about-cdsr" role="menuitem">
About the CDSR
</a>
</li>
</ul>
</li>
<li class=" nav-root-item parent">
<a href="#">Trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class=" child-nav-item" id="layout_22" role="presentation">
<a aria-labelledby="layout_22" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;central" role="menuitem">
Search Trials (CENTRAL)
</a>
</li>
<li class=" child-nav-item" id="layout_114" role="presentation">
<a aria-labelledby="layout_114" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;central&#x2f;about-central" role="menuitem">
About CENTRAL
</a>
</li>
</ul>
</li>
<li class=" nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class=" child-nav-item" id="layout_29" role="presentation">
<a aria-labelledby="layout_29" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cca" role="menuitem">
Browse Clinical Answers
</a>
</li>
<li class=" child-nav-item" id="layout_91" role="presentation">
<a aria-labelledby="layout_91" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cca&#x2f;about" role="menuitem">
About Clinical Answers
</a>
</li>
</ul>
</li>
<li class=" nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class=" child-nav-item" id="layout_116" role="presentation">
<a aria-labelledby="layout_116" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;about&#x2f;about-cochrane-library" role="menuitem">
About the Cochrane Library
</a>
</li>
<li class=" child-nav-item" id="layout_34" role="presentation">
<a aria-labelledby="layout_34" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochrane&#x2e;org&#x2f;about-us" role="menuitem">
About Cochrane
</a>
</li>
<li class=" child-nav-item" id="layout_121" role="presentation">
<a aria-labelledby="layout_121" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;about&#x2f;about-cochrane-reviews" role="menuitem">
About Cochrane Reviews
</a>
</li>
<li class=" child-nav-item" id="layout_92" role="presentation">
<a aria-labelledby="layout_92" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;about&#x2f;author-information" role="menuitem">
Information for authors
</a>
</li>
<li class=" child-nav-item" id="layout_188" role="presentation">
<a aria-labelledby="layout_188" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;about&#x2f;releases" role="menuitem">
What&#039;s new
</a>
</li>
</ul>
</li>
<li class=" nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class=" child-nav-item" id="layout_177" role="presentation">
<a aria-labelledby="layout_177" href="https&#x3a;&#x2f;&#x2f;www&#x2e;wiley&#x2e;com&#x2f;network&#x2f;cochranelibrarytraining" role="menuitem">
Cochrane Library Training
</a>
</li>
<li class=" child-nav-item" id="layout_44" role="presentation">
<a aria-labelledby="layout_44" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;help&#x2f;access" role="menuitem">
Access options
</a>
</li>
<li class=" child-nav-item" id="layout_150" role="presentation">
<a aria-labelledby="layout_150" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;help&#x2f;permissions" role="menuitem">
Permissions and reprints
</a>
</li>
<li class=" child-nav-item" id="layout_93" role="presentation">
<a aria-labelledby="layout_93" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;help&#x2f;media" role="menuitem">
Media information
</a>
</li>
<li class=" child-nav-item" id="layout_97" role="presentation">
<a aria-labelledby="layout_97" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;help&#x2f;contact-us" role="menuitem">
Contact us
</a>
</li>
<li class=" child-nav-item" id="layout_125" role="presentation">
<a aria-labelledby="layout_125" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;about&#x2f;terms-and-conditions" role="menuitem">
Terms and conditions
</a>
</li>
<li class=" child-nav-item" id="layout_176" role="presentation">
<a aria-labelledby="layout_176" href="https&#x3a;&#x2f;&#x2f;hub&#x2e;wiley&#x2e;com&#x2f;docs&#x2f;cochrane-library&#x2f;cochrane-library-known-issues-DOC-16221&#x3f;referrer&#x3d;cochrane" role="menuitem">
Known issues
</a>
</li>
</ul>
</li>
<li class="about-link"><a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_  portlet-static portlet-static-end  " id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img id="etlj__null__null" src="/scolaris-language-portlet/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <section class="content-language-banner system-message-container" data-content-language="en" data-portal-language="en" style="display: none"> <div class="container"> <a href="#0" class="fa fa-times content-language-banner-close pull-right" aria-label="Close"></a> <i class="fa fa-globe" aria-hidden="true"></i> <div class="system-message-title">Content Language Selection</div> <div class="system-message-description">Your language preference is set to <strong class="language">English</strong>. Where translations are available, article sections will display in this language. Return to <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=reset-content-language&p_p_cacheability=cacheLevelPage" class="language secondary">English</a>.</div> </div> </section> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
<div id="content" class="">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_  portlet-static portlet-static-end scolaris-content-display-portlet " id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img id="rjus__column1__0" src="/scolaris-content-display/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools"> <li class="cdsr-nav-link pulldown-menu readcube-menu closed"> <a href="#0" class="pulldown-menu-trigger"> <i class="icon fa fa-file-pdf-o"></i>View PDF <i aria-hidden="true" class="fa fa-caret-up"></i> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/pdf/full/en" class="download media pdf-link-full pdf-link" title="Article in PDF format"> <span class="readcube-label "> Full </span> <span class="readcube-description "> All content </span> </a> <a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/epdf/full/en" class="download media pdf-link-full readcube-epdf-link" title="Article in PDF format"> <span class="readcube-label "> Full </span> <span class="readcube-description "> All content </span> </a> </li> <li class=""> <a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/pdf/standard/en" class="download media pdf-link-standard pdf-link" title="Article in PDF format"> <span class="readcube-label "> Standard </span> <span class="readcube-description "> Excludes data and analyses, and appendices </span> </a> <a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/epdf/standard/en" class="download media pdf-link-standard readcube-epdf-link" title="Article in PDF format"> <span class="readcube-label "> Standard </span> <span class="readcube-description "> Excludes data and analyses, and appendices </span> </a> </li> <li class=""> <a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/pdf/abstract/en" class="download media pdf-link-abstract pdf-link" title="Article in PDF format"> <span class="readcube-label "> Summary </span> <span class="readcube-description "> Abstract and plain language summary only </span> </a> <a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/epdf/abstract/en" class="download media pdf-link-abstract readcube-epdf-link" title="Article in PDF format"> <span class="readcube-label "> Summary </span> <span class="readcube-description "> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="cdsr-nav-link cite-article-link" data-article-id="CD006423.PUB2" data-modal-title="Cite this Review"> <a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/#"> <i class="icon fa fa-share"></i>Cite this Review </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-english-only-message="Please note, that requesting permissions is available in English only. Apologies for any inconvenience." href="/cdsr/doi/10.1002/14651858.CD006423.pub2/#" data-copyright="Copyright © 2013 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false"> <span class="request-permissions-icon"></span> Request Permissions </a> </li> <li class="cdsr-nav-link comment-on-review"> <a id="comment-on-review" class="js-old-version-modal-trigger" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/comment" data-new-version="" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience."> <i class="icon fa fa-comment"></i>Comment on Review </a> </li> <li class="cdsr-nav-link comment-on"> <a id="read-comments-on-review" class="js-old-version-modal-trigger" data-new-version="" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/read-comments"> Read comments on this Review(1) </a> </li> </ul> <ul class="share clearfix"> <li class="cdsr-nav-link print-cdsr-link" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD006423.pub2/print" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;アブストラクト&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;za&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;za&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Data and analysis&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;}]}]"> <a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/#"> <i class="icon fa fa-print"></i>Print </a> </li> <li class="cdsr-nav-link share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD006423.pub2/full"> <a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/#"> <i class="icon fa fa-share-alt"></i>Share </a> </li> <li class="cdsr-nav-link"> <a href="/c/portal/login" class="article-not-followed cochrane-link signin"> <span class="article-follow-display"><i class="icon fa fa-plus"></i>Follow</span> </a> </li> </ul> <ul id="linked-articles" data-type="cdsr" class="linked-content tools clearfix linked-content-trigger"> <li> <a href="#0"> <span class="linked-to-this"> Linked to this Review <span class="linked-content-count"></span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> </li> </ul> <ul class="linked-content-dropdown"> <li data-type="cca" class="linked-cca"> <p>Cochrane Clinical Answers</p> </li> <li data-type="editorial" class="linked-editorials"> <p>Editorials</p> </li> <li data-type="podcast" class="linked-podcasts"> <p>Podcasts</p> </li> <li data-type="sc" class="linked-sc"> <p>Special Collections</p> </li> </ul> <ul class="nav-long-form"> <li class="cdsr-nav-link bold-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/full#CD006423-abs-0007"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/full#CD006423-sec1-0006"> Authors' conclusions </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/full#CD006423-sec1-0001"> Background </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/full#CD006423-sec1-0002"> Objectives </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/full#CD006423-sec1-0003"> Methods </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/full#CD006423-sec1-0004"> Results </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/full#CD006423-sec1-0005"> Discussion </a> </li> </ul> <ul class="tools"> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/appendices#CD006423-sec1-0011"> Appendices </a> </li> </ul> <ul> <li class="cdsr-nav-link article-section-link"> <a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/information"> Information </a> </li> <li class="cdsr-nav-link article-section-link"> <a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/information#authors"> Authors </a> </li> <li class="cdsr-nav-link article-section-link"> <a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/information#history"> History </a> </li> <li class="cdsr-nav-link article-section-link"> <a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/information#keywords"> Keywords </a> </li> </ul> <ul> <li class="cdsr-nav-link bold-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/#"> <i class="icon fa fa-globe"></i>Translation notes </a> </li> </ul> <ul> <li class="cdsr-nav-link references-link"> <a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references"> References </a> </li> <li class="cdsr-nav-link references-link"> <a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link references-link"> <a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#dataAndAnalyses"> Data and analyses </a> </li> </ul> <ul class="tools"> <li class="cdsr-nav-link "> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/#"> <i class="icon fa fa-line-chart"></i>Figures and tables </a> </li> <li class="cdsr-nav-link download-stats-data-link " data-download-href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/table_n/CD006423StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/table_n/CD006423StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <i class="icon fa fa-download"></i>Download statistical data </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i>Related content <span class="note podcast-indicator">Podcast available</span> </a> </li> </ul> </nav> </div> <article class="information" data-article-id="CD006423.PUB2"> <header> <h1 class="publication-title"><h1 lang="en" class="publication-title">Glucagon‐like peptide analogues for type 2 diabetes mellitus</h1></h1> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div><h2 class="title section-collapse-title"> References <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <section class="references bibliographies" id="references"> <section> <div class="section-header" id="CD006423-bbs1-0001"> <h3 class="title">References to studies included in this review</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a class="jump-to" href="#CD006423-bbs1-0002">excluded studies</a></li> <li><a class="jump-to" href="#CD006423-bbs1-0003">ongoing studies</a></li> <li><a class="jump-to" href="#CD006423-bbs1-0004">additional references</a></li> </ul> </div> </div> <div class="bibliographies references_includedStudies" id="CD006423-bbs2-0001"> <div class="reference-title-banner"> <h4 class="title">A ‐ Rosenstock 2009 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0001"> <div class="citation-journal">Rosenstock J, Reusch J, Bush M, Yang F, Stewart M. <span class="citation-title">Potential of albiglutide, a long‐acting GLP‐1 receptor agonist, in type 2 diabetes</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2009</span>;<span class="volume">32</span>(10):1880‐6. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19592625" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Potential+of+albiglutide,+a+long%E2%80%90acting+GLP%E2%80%901+receptor+agonist,+in+type+2+diabetes&author=J+Rosenstock&author=J+Reusch&author=M+Bush&author=F+Yang&author=M+Stewart&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD006423-bbs2-0002"> <div class="reference-title-banner"> <h4 class="title">E ‐ Bergenstal 2010 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0002"> <div class="citation-journal">Bergenstal RM, Wysham C, MacConell L, Malloy J, Walsh B, Yan P, et al. <span class="citation-title">Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION‐2): a randomised trial</span>. <span class="citation"> Lancet </span><span class="pubYear">Aug 2010</span>;<span class="volume">376</span>:431‐9. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20580422" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+and+safety+of+exenatide+once+weekly+versus+sitagliptin+or+pioglitazone+as+an+adjunct+to+metformin+for+treatment+of+type+2+diabetes+(DURATION%E2%80%902):+a+randomised+trial+&author=RM+Bergenstal&author=C+Wysham&author=L+MacConell&author=J+Malloy&author=B+Walsh&author=P+Yan&publication_year=Aug2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD006423-bbs2-0003"> <div class="reference-title-banner"> <h4 class="title">E ‐ Blevins 2011 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0003"> <div class="citation-journal">Blevins T, Pullman J, Malloy J, Yan P, Taylor K, Schulteis C, et al. <span class="citation-title">DURATION‐5: Exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes</span>. <span class="citation"> The Journal of Clinical Endocrinology and Metabolism </span><span class="pubYear">2011</span>;<span class="volume">96</span>(5):1301‐10. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21307137" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=DURATION%E2%80%905:+Exenatide+once+weekly+resulted+in+greater+improvements+in+glycemic+control+compared+with+exenatide+twice+daily+in+patients+with+type+2+diabetes+&author=T+Blevins&author=J+Pullman&author=J+Malloy&author=P+Yan&author=K+Taylor&author=C+Schulteis&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD006423-bbs2-0004"> <div class="reference-title-banner"> <h4 class="title">E ‐ Diamant 2010 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0004"> <div class="citation-journal">Diamant M, Van GL, Stranks S, Northrup J, Cao D, Taylor K, et al. <span class="citation-title">Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION‐3): an open‐label randomised trial</span>. <span class="citation"> Lancet </span><span class="pubYear">2010</span>;<span class="volume">375</span>:2234‐43. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20609969" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Once+weekly+exenatide+compared+with+insulin+glargine+titrated+to+target+in+patients+with+type+2+diabetes+(DURATION%E2%80%903):+an+open%E2%80%90label+randomised+trial+&author=M+Diamant&author=GL+Van&author=S+Stranks&author=J+Northrup&author=D+Cao&author=K+Taylor&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD006423-bbs2-0005"> <div class="reference-title-banner"> <h4 class="title">E ‐ Drucker 2008 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0005"> <div class="citation-journal">Best JH, Boye KS, Rubin RR, Cao D, Kim TH, Peyrot M. <span class="citation-title">Improved treatment satisfaction and weight‐related quality of life with exenatide once weekly or twice daily</span>. <span class="citation"> Diabetic Medicine </span><span class="pubYear">2009</span>;<span class="volume">26</span>(7):722‐8. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19573122" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Improved+treatment+satisfaction+and+weight%E2%80%90related+quality+of+life+with+exenatide+once+weekly+or+twice+daily+&author=JH+Best&author=KS+Boye&author=RR+Rubin&author=D+Cao&author=TH+Kim&author=M+Peyrot&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006423-bib-0006"> <div class="citation-journal">Best JH, Rubin RR, Zhuang D, Velez F, Kim T, Peyrot M. <span class="citation-title">Higher diabetes treatment satisfaction associated with improved glucose control for both exenatide once weekly and twice daily</span>. <span class="citation"> Diabetes </span><span class="pubYear">2008</span>;<span class="volume">57</span>:A520. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Higher+diabetes+treatment+satisfaction+associated+with+improved+glucose+control+for+both+exenatide+once+weekly+and+twice+daily+&author=JH+Best&author=RR+Rubin&author=D+Zhuang&author=F+Velez&author=T+Kim&author=M+Peyrot&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006423-bib-0007"> <div class="citation-journal">Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, et al. <span class="citation-title">Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open‐label, non‐inferiority study.[see comment]</span>. <span class="citation"> Lancet </span><span class="pubYear">2008</span>;<span class="volume">372</span>(9645):1240‐50. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18782641" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Exenatide+once+weekly+versus+twice+daily+for+the+treatment+of+type+2+diabetes:+a+randomised,+open%E2%80%90label,+non%E2%80%90inferiority+study.[see+comment]+&author=DJ+Drucker&author=JB+Buse&author=K+Taylor&author=DM+Kendall&author=M+Trautmann&author=D+Zhuang&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD006423-bbs2-0006"> <div class="reference-title-banner"> <h4 class="title">Lixi ‐ Ratner 2010 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0008"> <div class="citation-journal">Ratner RE, Rosenstock J, Boka G, DRI6012 Study Investigators. <span class="citation-title">Dose‐dependent effects of the once‐daily GLP‐1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double‐blind, placebo‐controlled trial</span>. <span class="citation"> Diabetic Medicine </span><span class="pubYear">2010</span>;<span class="volume">27</span>(9):1024‐32. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20722676" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Dose%E2%80%90dependent+effects+of+the+once%E2%80%90daily+GLP%E2%80%901+receptor+agonist+lixisenatide+in+patients+with+Type+2+diabetes+inadequately+controlled+with+metformin:+a+randomized,+double%E2%80%90blind,+placebo%E2%80%90controlled+trial+&author=RE+Ratner&author=J+Rosenstock&author=G+Boka&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD006423-bbs2-0007"> <div class="reference-title-banner"> <h4 class="title">L ‐ Kaku 2010 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0009"> <div class="citation-journal">Kaku K, Rasmussen MF, Clauson P, Seino Y. <span class="citation-title">Improved glycaemic control with minimal hypoglycaemia and no weight change with the once‐daily human glucagon‐like peptide‐1 analogue liraglutide as add‐on to sulphonylurea in Japanese patients with type 2 diabetes</span>. <span class="citation"> Diabetes Obesity and Metabolism </span><span class="pubYear">2010</span>;<span class="volume">12</span>:341‐7. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Improved+glycaemic+control+with+minimal+hypoglycaemia+and+no+weight+change+with+the+once%E2%80%90daily+human+glucagon%E2%80%90like+peptide%E2%80%901+analogue+liraglutide+as+add%E2%80%90on+to+sulphonylurea+in+Japanese+patients+with+type+2+diabetes+&author=K+Kaku&author=MF+Rasmussen&author=P+Clauson&author=Y+Seino&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD006423-bbs2-0008"> <div class="reference-title-banner"> <h4 class="title">L ‐ LEAD 1 Marre 2009 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0010"> <div class="citation-journal">Marre M, Shaw J, Brändle M, Bebakar WMW, Kamaruddin NA, Strand J, et al. <span class="citation-title">Liraglutide, a once‐daily human GLP‐1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD‐1 SU)</span>. <span class="citation"> Diabetic Medicine </span><span class="pubYear">2009</span>;<span class="volume">26</span>:268‐78. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19317822" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Liraglutide,+a+once%E2%80%90daily+human+GLP%E2%80%901+analogue,+added+to+a+sulphonylurea+over+26+weeks+produces+greater+improvements+in+glycaemic+and+weight+control+compared+with+adding+rosiglitazone+or+placebo+in+subjects+with+type+2+diabetes+(LEAD%E2%80%901+SU)+&author=M+Marre&author=J+Shaw&author=M+Br%C3%A4ndle&author=WMW+Bebakar&author=NA+Kamaruddin&author=J+Strand&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD006423-bbs2-0009"> <div class="reference-title-banner"> <h4 class="title">L ‐ LEAD 2 Nauck 2009 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0011"> <div class="citation-journal">Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, et al. <span class="citation-title">Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2009</span>;<span class="volume">32</span>(1):84‐90. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18931095" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+and+safety+comparison+of+liraglutide,+glimepiride,+and+placebo,+all+in+combination+with+metformin,+in+type+2+diabetes:+the+LEAD+(liraglutide+effect+and+action+in+diabetes)%E2%80%902+study+&author=M+Nauck&author=A+Frid&author=K+Hermansen&author=NS+Shah&author=T+Tankova&author=IH+Mitha&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD006423-bbs2-0010"> <div class="reference-title-banner"> <h4 class="title">L ‐ LEAD 4 Zinman 2009 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0012"> <div class="citation-journal">Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, et al. <span class="citation-title">Efficacy and safety of the human glucagon‐like peptide‐1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD‐4 Met+TZD)</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2009</span>;<span class="volume">32</span>(7):1224‐30. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19289857" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+and+safety+of+the+human+glucagon%E2%80%90like+peptide%E2%80%901+analog+liraglutide+in+combination+with+metformin+and+thiazolidinedione+in+patients+with+type+2+diabetes+(LEAD%E2%80%904+Met+TZD)+&author=B+Zinman&author=J+Gerich&author=JB+Buse&author=A+Lewin&author=S+Schwartz&author=P+Raskin&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD006423-bbs2-0011"> <div class="reference-title-banner"> <h4 class="title">L ‐ LEAD 5 Russell‐J 2009 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0013"> <div class="citation-journal">Russell‐Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, et al. <span class="citation-title">Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD‐5 met+SU): a randomised controlled trial</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2009</span>;<span class="volume">52</span>:2046‐55. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19688338" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Liraglutide+vs+insulin+glargine+and+placebo+in+combination+with+metformin+and+sulfonylurea+therapy+in+type+2+diabetes+mellitus+(LEAD%E2%80%905+met+SU):+a+randomised+controlled+trial+&author=D+Russell%E2%80%90Jones&author=A+Vaag&author=O+Schmitz&author=BK+Sethi&author=N+Lalic&author=S+Antic&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD006423-bbs2-0012"> <div class="reference-title-banner"> <h4 class="title">L ‐ LEAD 6 Buse 2009 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0014"> <div class="citation-other">Buse J, Sesti G, Schmidt WE, Montanya E, Chang CT, Xu Y, et al. <span class="citation-title">Switching from twice‐daily exenatide to once‐daily liraglutide improves glycemic control in T2D on oral agents</span>. American Diabetes Association. <span class="pubYear">2009</span>:591‐P. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Switching+from+twice%E2%80%90daily+exenatide+to+once%E2%80%90daily+liraglutide+improves+glycemic+control+in+T2D+on+oral+agents+&author=J+Buse&author=G+Sesti&author=WE+Schmidt&author=E+Montanya&author=CT+Chang&author=Y+Xu&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006423-bib-0015"> <div class="citation-journal">Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, et al. <span class="citation-title">Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26‐week randomised, parallel‐group, multinational, open‐label trial (LEAD‐6).[see comment]</span>. <span class="citation"> Lancet </span><span class="pubYear">2009</span>;<span class="volume">374</span>(9683):39‐47. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19515413" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Liraglutide+once+a+day+versus+exenatide+twice+a+day+for+type+2+diabetes:+a+26%E2%80%90week+randomised,+parallel%E2%80%90group,+multinational,+open%E2%80%90label+trial+(LEAD%E2%80%906).[see+comment]+&author=JB+Buse&author=J+Rosenstock&author=G+Sesti&author=WE+Schmidt&author=E+Montanya&author=JH+Brett&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD006423-bbs2-0013"> <div class="reference-title-banner"> <h4 class="title">L ‐ Pratley 2010 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0016"> <div class="citation-journal">Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, et al. <span class="citation-title">Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26‐week, randomised, parallel‐group, open‐label trial</span>. <span class="citation"> Lancet </span><span class="pubYear">2010</span>;<span class="volume">375</span>:1447‐56. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20417856" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Liraglutide+versus+sitagliptin+for+patients+with+type+2+diabetes+who+did+not+have+adequate+glycaemic+control+with+metformin:+a+26%E2%80%90week,+randomised,+parallel%E2%80%90group,+open%E2%80%90label+trial+&author=RE+Pratley&author=M+Nauck&author=T+Bailey&author=E+Montanya&author=R+Cuddihy&author=S+Filetti&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD006423-bbs2-0014"> <div class="reference-title-banner"> <h4 class="title">LY2189265 ‐Umpierrez 2011 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0017"> <div class="citation-journal">Umpierrez GE, Blevins T, Rosenstock J, Cheng C, Anderson JH, Bastyr EJ, EGO Study Group. <span class="citation-title">The effects of LY2189265, a long‐acting glucagon‐like peptide‐1 analog, in a randomized, placebo‐controlled, double‐blind study of overweight/obese patients with type 2 diabetes: the EGO study</span>. <span class="citation"> Diabetes, Obesity and Metabolism </span><span class="pubYear">Jan 2011</span>;<span class="volume">13</span>:418‐25. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+effects+of+LY2189265,+a+long%E2%80%90acting+glucagon%E2%80%90like+peptide%E2%80%901+analog,+in+a+randomized,+placebo%E2%80%90controlled,+double%E2%80%90blind+study+of+overweight/obese+patients+with+type+2+diabetes:+the+EGO+study+&author=GE+Umpierrez&author=T+Blevins&author=J+Rosenstock&author=C+Cheng&author=JH+Anderson&author=EJ+Bastyr&publication_year=Jan2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD006423-bbs2-0015"> <div class="reference-title-banner"> <h4 class="title">L ‐ Yang 2010 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0018"> <div class="citation-journal">Yang W, Chen L, Ji Q, Liu X, Ma J, Tandon N, et al. <span class="citation-title">Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16‐week, randomized, double‐blind, active control trial</span>. <span class="citation"> Diabetes, Obesity and Metabolism </span><span class="pubYear">Jan 2011</span>;<span class="volume">13</span>(1):81‐88. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Liraglutide+provides+similar+glycaemic+control+as+glimepiride+(both+in+combination+with+metformin)+and+reduces+body+weight+and+systolic+blood+pressure+in+Asian+population+with+type+2+diabetes+from+China,+South+Korea+and+India:+a+16%E2%80%90week,+randomized,+double%E2%80%90blind,+active+control+trial+&author=W+Yang&author=L+Chen&author=Q+Ji&author=X+Liu&author=J+Ma&author=N+Tandon&publication_year=Jan2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD006423-bbs2-0016"> <div class="reference-title-banner"> <h4 class="title">T ‐ Nauck 2009 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0019"> <div class="citation-journal">Nauck MA, Ratner RE, Kapitza C, Berria R, Boldrin M, Balena R. <span class="citation-title">Treatment with the human once‐weekly glucagon‐like peptide‐1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double‐blind placebo‐controlled study</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2009</span>;<span class="volume">32</span>(7):1237‐43. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19366970" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Treatment+with+the+human+once%E2%80%90weekly+glucagon%E2%80%90like+peptide%E2%80%901+analog+taspoglutide+in+combination+with+metformin+improves+glycemic+control+and+lowers+body+weight+in+patients+with+type+2+diabetes+inadequately+controlled+with+metformin+alone:+a+double%E2%80%90blind+placebo%E2%80%90controlled+study+&author=MA+Nauck&author=RE+Ratner&author=C+Kapitza&author=R+Berria&author=M+Boldrin&author=R+Balena&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD006423-bbs2-0017"> <div class="reference-title-banner"> <h4 class="title">T‐ Ratner 2010 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0020"> <div class="citation-journal">Ratner R, Nauck M, Kapitza C, Asnaghi V, Boldrin M, Balena R. <span class="citation-title">Safety and tolerability of high doses of taspoglutide, a once‐weekly human GLP‐1 analogue, in diabetic patients treated with metformin: a randomized double‐blind placebo‐controlled study</span>. <span class="citation"> Diabetic Medicine </span><span class="pubYear">2010</span>;<span class="volume">27</span>:556‐62. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20536952" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Safety+and+tolerability+of+high+doses+of+taspoglutide,+a+once%E2%80%90weekly+human+GLP%E2%80%901+analogue,+in+diabetic+patients+treated+with+metformin:+a+randomized+double%E2%80%90blind+placebo%E2%80%90controlled+study+&author=R+Ratner&author=M+Nauck&author=C+Kapitza&author=V+Asnaghi&author=M+Boldrin&author=R+Balena&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> </section> <section> <div class="section-header" id="CD006423-bbs1-0002"> <h3 class="title">References to studies excluded from this review</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a class="jump-to" href="#CD006423-bbs1-0001">included studies</a></li> <li><a class="jump-to" href="#CD006423-bbs1-0003">ongoing studies</a></li> <li><a class="jump-to" href="#CD006423-bbs1-0004">additional references</a></li> </ul> </div> </div> <div class="bibliographies references_excludedStudies" id="CD006423-bbs2-0018"> <div class="reference-title-banner"> <h4 class="title">Astrup 2009 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0021"> <div class="citation-journal">Astrup A, Rossner S, Gaal L, Rissanen A, Niskanen L, Al Hakim M, et al. NN8022‐1807 Study Group. <span class="citation-title">Effects of liraglutide in the treatment of obesity: a randomised, double‐blind, placebo‐controlled study</span>. <span class="citation"> Lancet </span> 2009 Nov 7;<span class="volume">374</span>:1606‐16. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19853906" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD006423-bbs2-0019"> <div class="reference-title-banner"> <h4 class="title">Barnett 2007 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0022"> <div class="citation-journal">Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A, et al. <span class="citation-title">Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open‐label, two‐period, crossover noninferiority trial</span>. <span class="citation"> Clinical Therapeutics </span><span class="pubYear">2007</span>;<span class="volume">29</span>:2333‐48. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18158075" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Tolerability+and+efficacy+of+exenatide+and+titrated+insulin+glargine+in+adult+patients+with+type+2+diabetes+previously+uncontrolled+with+metformin+or+a+sulfonylurea:+a+multinational,+randomized,+open%E2%80%90label,+two%E2%80%90period,+crossover+noninferiority+trial+&author=AH+Barnett&author=J+Burger&author=D+Johns&author=R+Brodows&author=DM+Kendall&author=A+Roberts&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006423-bib-0023"> <div class="citation-journal">Secnik K, Hayes C, Matza L, Kim S, Oglesby A, Yurgin N, et al. <span class="citation-title">Improved treatment satisfaction in patients with type‐2 diabetes treated with exenatide or insulin glargine</span>. <span class="citation"> Value in Health </span><span class="pubYear">2005</span>;<span class="volume">8</span>:A155‐A156. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Improved+treatment+satisfaction+in+patients+with+type%E2%80%902+diabetes+treated+with+exenatide+or+insulin+glargine+&author=K+Secnik&author=C+Hayes&author=L+Matza&author=S+Kim&author=A+Oglesby&author=N+Yurgin&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006423-bib-0024"> <div class="citation-journal">Trautmann M, Burger J, Johns D, Brodows R, Okerson T, Roberts A, et al. <span class="citation-title">Less hypoglycemia with exenatide versus insulin glargine, despite similar Hba(1c) improvement, in patients with T2dm adjunctively treated with metformin</span>. <span class="citation"> Diabetes </span><span class="pubYear">2007</span>;<span class="volume">56</span>:A45. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Less+hypoglycemia+with+exenatide+versus+insulin+glargine,+despite+similar+Hba(1c)+improvement,+in+patients+with+T2dm+adjunctively+treated+with+metformin+&author=M+Trautmann&author=J+Burger&author=D+Johns&author=R+Brodows&author=T+Okerson&author=A+Roberts&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006423-bib-0025"> <div class="citation-journal">Trautmann M, Burger J, Johns D, Brodows R, Okerson T, Roberts A, et al. <span class="citation-title">Relationship between hypoglycaemia, background oral antidiabetic agent, and glycaemic control in patients treated with exenatide or insulin glargine</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2007</span>;<span class="volume">50</span>:S338. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Relationship+between+hypoglycaemia,+background+oral+antidiabetic+agent,+and+glycaemic+control+in+patients+treated+with+exenatide+or+insulin+glargine+&author=M+Trautmann&author=J+Burger&author=D+Johns&author=R+Brodows&author=T+Okerson&author=A+Roberts&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD006423-bbs2-0020"> <div class="reference-title-banner"> <h4 class="title">Blonde 2006 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0026"> <div class="citation-journal">Blonde L, Klein EJ, Han J, Zhang B, Mac SM, Poon TH, et al. <span class="citation-title">Interim analysis of the effects of exenatide treatment on A1C,weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes</span>. <span class="citation"> Diabetes, Obesity and Metabolism </span><span class="pubYear">2006</span>;<span class="volume">8</span>:436‐47. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Interim+analysis+of+the+effects+of+exenatide+treatment+on+A1C,weight+and+cardiovascular+risk+factors+over+82+weeks+in+314+overweight+patients+with+type+2+diabetes+&author=L+Blonde&author=EJ+Klein&author=J+Han&author=B+Zhang&author=SM+Mac&author=TH+Poon&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD006423-bbs2-0021"> <div class="reference-title-banner"> <h4 class="title">Bode 2010 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0027"> <div class="citation-journal">Bode BW, Testa MA, Magwire M, Hale PM, Hammer M, Blonde L, et al. LEAD‐3 Study Group. <span class="citation-title">Patient‐reported outcomes following treatment with the human GLP‐1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes</span>. <span class="citation"> Diabetes Obesity and Metabolism </span><span class="pubYear">2010 Jul</span>;<span class="volume">12</span>(7):604‐12. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Patient%E2%80%90reported+outcomes+following+treatment+with+the+human+GLP%E2%80%901+analogue+liraglutide+or+glimepiride+in+monotherapy:+results+from+a+randomized+controlled+trial+in+patients+with+type+2+diabetes+&author=BW+Bode&author=MA+Testa&author=M+Magwire&author=PM+Hale&author=M+Hammer&author=L+Blonde&publication_year=2010Jul&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD006423-bbs2-0022"> <div class="reference-title-banner"> <h4 class="title">Brixner 2009 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0028"> <div class="citation-journal">Brixner DI, McAdam‐Marx C, Ye X, Boye KS, Nielsen LL, Wintle M, et al. <span class="citation-title">Six‐month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting</span>. <span class="citation"> Diabetes Obesity and Metabolism </span><span class="pubYear">2009 Dec</span>;<span class="volume">11</span>(12):1122‐30. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Six%E2%80%90month+outcomes+on+A1C+and+cardiovascular+risk+factors+in+patients+with+type+2+diabetes+treated+with+exenatide+in+an+ambulatory+care+setting+&author=DI+Brixner&author=C+McAdam%E2%80%90Marx&author=X+Ye&author=KS+Boye&author=LL+Nielsen&author=M+Wintle&publication_year=2009Dec&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD006423-bbs2-0023"> <div class="reference-title-banner"> <h4 class="title">Buse 2004 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0029"> <div class="citation-journal">Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. <span class="citation-title">Effects of exenatide (exendin‐4) on glycemic control over 30 weeks in sulfonylurea‐treated patients with type 2 diabetes</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2004</span>;<span class="volume">27</span>(11):2628‐35. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15504997" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+exenatide+(exendin%E2%80%904)+on+glycemic+control+over+30+weeks+in+sulfonylurea%E2%80%90treated+patients+with+type+2+diabetes+&author=JB+Buse&author=RR+Henry&author=J+Han&author=DD+Kim&author=MS+Fineman&author=AD+Baron&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD006423-bbs2-0024"> <div class="reference-title-banner"> <h4 class="title">Feingloss 2005 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0030"> <div class="citation-journal">Feinglos MN, Saad MF, Pi‐Sunyer FX, An B, Santiago O, Liraglutide Dose‐Response Study Group. <span class="citation-title">Effects of liraglutide (NN2211), a long‐acting GLP‐1analogue, on glycaemic control and bodyweight in subjects with type 2 diabetes</span>. <span class="citation"> Diabetic Medicine </span><span class="pubYear">2005</span>;<span class="volume">22</span>:1016‐23. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16026367" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+liraglutide+(NN2211),+a+long%E2%80%90acting+GLP%E2%80%901analogue,+on+glycaemic+control+and+bodyweight+in+subjects+with+type+2+diabetes+&author=MN+Feinglos&author=MF+Saad&author=FX+Pi%E2%80%90Sunyer&author=B+An&author=O+Santiago&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD006423-bbs2-0025"> <div class="reference-title-banner"> <h4 class="title">Gallwitz 2010 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0031"> <div class="citation-journal">Gallwitz B, Vaag A, Falahati A, Madsbad S. <span class="citation-title">Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time</span>. <span class="citation"> International Journal of Clinical Practice </span><span class="pubYear">2010 Jan</span>;<span class="volume">64</span>(2):267‐76. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19925617" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Adding+liraglutide+to+oral+antidiabetic+drug+therapy:+onset+of+treatment+effects+over+time+&author=B+Gallwitz&author=A+Vaag&author=A+Falahati&author=S+Madsbad&publication_year=2010Jan&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD006423-bbs2-0026"> <div class="reference-title-banner"> <h4 class="title">Garber 2009 (LEAD 3) {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0032"> <div class="citation-journal">Garber A, Henry R, Ratner R, Garcia‐Hernandez PA, Rodriguez‐Pattzi H, Olvera‐Alvarez I, et al. <span class="citation-title">Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD‐3 Mono): a randomised, 52‐week, phase III, double‐blind, parallel‐treatment trial.[see comment]</span>. <span class="citation"> Lancet </span><span class="pubYear">2009</span>;<span class="volume">373</span>(9662):473‐81. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18819705" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Liraglutide+versus+glimepiride+monotherapy+for+type+2+diabetes+(LEAD%E2%80%903+Mono):+a+randomised,+52%E2%80%90week,+phase+III,+double%E2%80%90blind,+parallel%E2%80%90treatment+trial.[see+comment]+&author=A+Garber&author=R+Henry&author=R+Ratner&author=PA+Garcia%E2%80%90Hernandez&author=H+Rodriguez%E2%80%90Pattzi&author=I+Olvera%E2%80%90Alvarez&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD006423-bbs2-0027"> <div class="reference-title-banner"> <h4 class="title">Kapitza 2009 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0033"> <div class="citation-journal">Kapitza C, Heise T, Birman P, Jallet K, Ramis J, Balena R. <span class="citation-title">Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once‐weekly, human GLP‐1 analogue, after single‐dose administration in patients with Type 2 diabetes</span>. <span class="citation"> Diabetic Medicine </span><span class="pubYear">2009 Nov</span>;<span class="volume">26</span>(11):1156‐64. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19929995" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Pharmacokinetic+and+pharmacodynamic+properties+of+taspoglutide,+a+once%E2%80%90weekly,+human+GLP%E2%80%901+analogue,+after+single%E2%80%90dose+administration+in+patients+with+Type+2+diabetes+&author=C+Kapitza&author=T+Heise&author=P+Birman&author=K+Jallet&author=J+Ramis&author=R+Balena&publication_year=2009Nov&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD006423-bbs2-0028"> <div class="reference-title-banner"> <h4 class="title">Kim 2007 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0034"> <div class="citation-journal">Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, Fineman M, et al. <span class="citation-title">Effects of once‐weekly dosing of a long‐acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2007</span>;<span class="volume">30</span>:1487‐93. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17353504" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+once%E2%80%90weekly+dosing+of+a+long%E2%80%90acting+release+formulation+of+exenatide+on+glucose+control+and+body+weight+in+subjects+with+type+2+diabetes+&author=D+Kim&author=L+MacConell&author=D+Zhuang&author=PA+Kothare&author=M+Trautmann&author=M+Fineman&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD006423-bbs2-0029"> <div class="reference-title-banner"> <h4 class="title">Madsbad 2004 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0035"> <div class="citation-journal">Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR, NN2211‐1310 International study group. <span class="citation-title">Improved glycemic control with no weight increase in patients with type 2 diabetes after once‐daily treatment with the long‐acting glucagon‐like peptide 1 analog liraglutide (NN2211)</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2004</span>;<span class="volume">27</span>:1335‐42. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15161785" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Improved+glycemic+control+with+no+weight+increase+in+patients+with+type+2+diabetes+after+once%E2%80%90daily+treatment+with+the+long%E2%80%90acting+glucagon%E2%80%90like+peptide+1+analog+liraglutide+(NN2211)+&author=S+Madsbad&author=O+Schmitz&author=J+Ranstam&author=G+Jakobsen&author=DR+Matthews&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD006423-bbs2-0030"> <div class="reference-title-banner"> <h4 class="title">Malloy 2009 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0036"> <div class="citation-journal">Malloy J, Capparelli E, Gottschalk M, Guan X, Kothare P, Fineman M. <span class="citation-title">Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo‐controlled, single‐blind, dose‐escalation, crossover study</span>. <span class="citation"> Clinical Therapeutics </span><span class="pubYear">2009 Apr</span>;<span class="volume">31</span>(4):806‐15. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19446153" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Pharmacology+and+tolerability+of+a+single+dose+of+exenatide+in+adolescent+patients+with+type+2+diabetes+mellitus+being+treated+with+metformin:+a+randomized,+placebo%E2%80%90controlled,+single%E2%80%90blind,+dose%E2%80%90escalation,+crossover+study+&author=J+Malloy&author=E+Capparelli&author=M+Gottschalk&author=X+Guan&author=P+Kothare&author=M+Fineman&publication_year=2009Apr&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD006423-bbs2-0031"> <div class="reference-title-banner"> <h4 class="title">Moretto 2008 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0037"> <div class="citation-journal">Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, et al. <span class="citation-title">Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug‐naive patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled, parallel‐group study</span>. <span class="citation"> Clinical Therapeutics </span><span class="pubYear">2008</span>;<span class="volume">30</span>:1448‐60. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18803987" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+and+tolerability+of+exenatide+monotherapy+over+24+weeks+in+antidiabetic+drug%E2%80%90naive+patients+with+type+2+diabetes:+a+randomized,+double%E2%80%90blind,+placebo%E2%80%90controlled,+parallel%E2%80%90group+study+&author=TJ+Moretto&author=DR+Milton&author=TD+Ridge&author=LA+Macconell&author=T+Okerson&author=AM+Wolka&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD006423-bbs2-0032"> <div class="reference-title-banner"> <h4 class="title">Nauck 2009 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0038"> <div class="citation-journal">Harder H, Nielsen L, Thi TDT, Astrup A. <span class="citation-title">The effect of liraglutide, a long‐acting glucagon‐like peptide 1 derivative, on glycemic control, body composition, and 24‐h energy expenditure in patients with type 2 diabetes</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2004</span>;<span class="volume">27</span>:1915‐21. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15277417" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+effect+of+liraglutide,+a+long%E2%80%90acting+glucagon%E2%80%90like+peptide+1+derivative,+on+glycemic+control,+body+composition,+and+24%E2%80%90h+energy+expenditure+in+patients+with+type+2+diabetes+&author=H+Harder&author=L+Nielsen&author=TDT+Thi&author=A+Astrup&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006423-bib-0039"> <div class="citation-journal">Nauck M, Marre M. <span class="citation-title">Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits</span>. <span class="citation"> Postgraduate Medicine </span><span class="pubYear">2009</span>;<span class="volume">121</span>(3):5‐15. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19491535" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Adding+liraglutide+to+oral+antidiabetic+drug+monotherapy:+efficacy+and+weight+benefits&author=M+Nauck&author=M+Marre&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD006423-bbs2-0033"> <div class="reference-title-banner"> <h4 class="title">Okerson 2010 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0040"> <div class="citation-journal">Okerson T, Yan P, Stonehouse A, Brodows R. <span class="citation-title">Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes</span>. <span class="citation"> American Journal of Hypertension </span><span class="pubYear">2010 Mar</span>;<span class="volume">23</span>(3):334‐39. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20019672" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+exenatide+on+systolic+blood+pressure+in+subjects+with+type+2+diabetes&author=T+Okerson&author=P+Yan&author=A+Stonehouse&author=R+Brodows&publication_year=2010Mar&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD006423-bbs2-0034"> <div class="reference-title-banner"> <h4 class="title">Riddle 2006 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0041"> <div class="citation-journal">Riddle MC, Henry RR, Poon TH, Zhang B, Mac MS, John HH, et al. <span class="citation-title">Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin</span>. <span class="citation"> Diabetes/Metabolism Research and Reviews </span><span class="pubYear">2006</span>;<span class="volume">22</span>:483‐91. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Exenatide+elicits+sustained+glycaemic+control+and+progressive+reduction+of+body+weight+in+patients+with+type+2+diabetes+inadequately+controlled+by+sulphonylureas+with+or+without+metformin+&author=MC+Riddle&author=RR+Henry&author=TH+Poon&author=B+Zhang&author=MS+Mac&author=HH+John&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD006423-bbs2-0035"> <div class="reference-title-banner"> <h4 class="title">Seino 2008 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0042"> <div class="citation-journal">Seino Y, Rasmussen MF, Zdravkovic M, Kaku K. <span class="citation-title">Dose‐dependent improvement in glycemia with once‐daily liraglutide without hypoglycemia or weight gain: A double‐blind, randomized, controlled trial in Japanese patients with type 2 diabetes</span>. <span class="citation"> Diabetes Research and Clinical Practice </span><span class="pubYear">2008</span>;<span class="volume">81</span>(2):161‐8. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18495285" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Dose%E2%80%90dependent+improvement+in+glycemia+with+once%E2%80%90daily+liraglutide+without+hypoglycemia+or+weight+gain:+A+double%E2%80%90blind,+randomized,+controlled+trial+in+Japanese+patients+with+type+2+diabetes+&author=Y+Seino&author=MF+Rasmussen&author=M+Zdravkovic&author=K+Kaku&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD006423-bbs2-0036"> <div class="reference-title-banner"> <h4 class="title">Trescoli‐Serrano 2005 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0043"> <div class="citation-journal">Trescoli‐Serrano C, Rivas M, Fajardo‐Montanana C, Pino I, Garcia‐Zarco M, Martorrell‐Barraquet A, et al. <span class="citation-title">Clinical site experience comparing insulin glargine with exenatide treatment in type 2 diabetic patients</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2005</span>;<span class="volume">48</span>:A3. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16163567" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Clinical+site+experience+comparing+insulin+glargine+with+exenatide+treatment+in+type+2+diabetic+patients+&author=C+Trescoli%E2%80%90Serrano&author=M+Rivas&author=C+Fajardo%E2%80%90Montanana&author=I+Pino&author=M+Garcia%E2%80%90Zarco&author=A+Martorrell%E2%80%90Barraquet&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD006423-bbs2-0037"> <div class="reference-title-banner"> <h4 class="title">Vilsboll 2007 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0044"> <div class="citation-journal">Courreges JP, Vilsboll T, Zdravkovic M, Le‐Thi T, Krarup T, Schmitz O, et al. <span class="citation-title">Beneficial effects of once‐daily liraglutide, a human glucagon‐like peptide‐1 analogue, on cardiovascular risk biomarkers in patients with type 2 diabetes</span>. <span class="citation"> Diabetic Medicine </span><span class="pubYear">2008</span>;<span class="volume">25</span>(9):1129‐31. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19183322" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Beneficial+effects+of+once%E2%80%90daily+liraglutide,+a+human+glucagon%E2%80%90like+peptide%E2%80%901+analogue,+on+cardiovascular+risk+biomarkers+in+patients+with+type+2+diabetes+&author=JP+Courreges&author=T+Vilsboll&author=M+Zdravkovic&author=T+Le%E2%80%90Thi&author=T+Krarup&author=O+Schmitz&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006423-bib-0045"> <div class="citation-journal">Horowitz M. <span class="citation-title">Patient‐reported rating of gastrointestinal adverse effects during treatment of type 2 diabetes with the once‐daily human GLP‐1 analogue, liraglutide</span>. <span class="citation"> Diabetes, Obesity and Metabolism </span><span class="pubYear">2008</span>;<span class="volume">10</span>:593‐02. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Patient%E2%80%90reported+rating+of+gastrointestinal+adverse+effects+during+treatment+of+type+2+diabetes+with+the+once%E2%80%90daily+human+GLP%E2%80%901+analogue,+liraglutide+&author=M+Horowitz&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006423-bib-0046"> <div class="citation-journal">Valentine WJ, Hammer M, Palmer AJ, Ray JA. <span class="citation-title">Projecting the long‐term clinical benefits of treatment with the GLP‐1 analogue liraglutide in subjects with type 2 diabetes</span>. <span class="citation"> Diabetes </span><span class="pubYear">2007</span>;<span class="volume">56</span>:A568. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Projecting+the+long%E2%80%90term+clinical+benefits+of+treatment+with+the+GLP%E2%80%901+analogue+liraglutide+in+subjects+with+type+2+diabetes+&author=WJ+Valentine&author=M+Hammer&author=AJ+Palmer&author=JA+Ray&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006423-bib-0047"> <div class="citation-journal">Vilsboll T, Brock B, Perrild H, Levin K, Lervang HH, Kolendorf K, et al. <span class="citation-title">Liraglutide, a once‐daily human GLP‐1 analogue, improves pancreatic B‐cell function and arginine‐stimulated insulin secretion during hyperglycaemia in patients with type 2 diabetes mellitus</span>. <span class="citation"> Diabetic Medicine </span><span class="pubYear">2008</span>;<span class="volume">25</span>(2):152‐56. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18201212" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Liraglutide,+a+once%E2%80%90daily+human+GLP%E2%80%901+analogue,+improves+pancreatic+B%E2%80%90cell+function+and+arginine%E2%80%90stimulated+insulin+secretion+during+hyperglycaemia+in+patients+with+type+2+diabetes+mellitus+&author=T+Vilsboll&author=B+Brock&author=H+Perrild&author=K+Levin&author=HH+Lervang&author=K+Kolendorf&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006423-bib-0048"> <div class="citation-journal">Vilsboll T, Zdravkovic M, Le‐Thi T, Krarup T, Schmitz O, Courreges JP, et al. <span class="citation-title">Liraglutide, a long‐acting human glucagon‐like peptide‐1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2007</span>;<span class="volume">30</span>:1608‐10. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17372153" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Liraglutide,+a+long%E2%80%90acting+human+glucagon%E2%80%90like+peptide%E2%80%901+analog,+given+as+monotherapy+significantly+improves+glycemic+control+and+lowers+body+weight+without+risk+of+hypoglycemia+in+patients+with+type+2+diabetes+&author=T+Vilsboll&author=M+Zdravkovic&author=T+Le%E2%80%90Thi&author=T+Krarup&author=O+Schmitz&author=JP+Courreges&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> </section> <section> <div class="section-header" id="CD006423-bbs1-0003"> <h3 class="title">References to ongoing studies</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a class="jump-to" href="#CD006423-bbs1-0001">included studies</a></li> <li><a class="jump-to" href="#CD006423-bbs1-0002">excluded studies</a></li> <li><a class="jump-to" href="#CD006423-bbs1-0004">additional references</a></li> </ul> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD006423-bbs2-0038"> <div class="reference-title-banner"> <h4 class="title">Albiglutide NCT00838903 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0049"> <div class="citation-other">NCT00838903. <span class="citation-title">Efficacy and safety of albiglutide in treatment of type 2 diabetes</span>. http://clinicaltrials.gov/ct2/show/NCT00838903. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD006423-bbs2-0039"> <div class="reference-title-banner"> <h4 class="title">Albiglutide NCT00838916 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0050"> <div class="citation-other">NCT00838916. <span class="citation-title">A study to determine the safety and efficacy of albiglutide in patients with type 2 diabetes</span>. http://clinicaltrials.gov/ct2/show/NCT00838916. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD006423-bbs2-0040"> <div class="reference-title-banner"> <h4 class="title">Albiglutide NCT00849017 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0051"> <div class="citation-other">NCT00849017. <span class="citation-title">Safety and efficacy study of albiglutide in type 2 diabetes</span>. http://clinicaltrials.gov/ct2/show/NCT00849017. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD006423-bbs2-0041"> <div class="reference-title-banner"> <h4 class="title">Albiglutide NCT00849056 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0052"> <div class="citation-other">NCT00849056. <span class="citation-title">Safety and efficacy of albiglutide in type 2 diabetes</span>. http://clinicaltrials.gov/ct2/show/NCT00849056. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD006423-bbs2-0042"> <div class="reference-title-banner"> <h4 class="title">Albiglutide NCT01098461 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0053"> <div class="citation-other">NCT01098461. <span class="citation-title">Dose ranging study of albiglutide in Japanese subjects</span>. http://clinicaltrials.gov/ct2/show/NCT01098461. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD006423-bbs2-0043"> <div class="reference-title-banner"> <h4 class="title">Albiglutide NCT01128894 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0054"> <div class="citation-other">NCT01128894. <span class="citation-title">A study to determine the efficacy and safety of albiglutide as compared with liraglutide.</span>. http://clinicaltrials.gov/ct2/show/NCT01128894 accessed 17 June 2011. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD006423-bbs2-0044"> <div class="reference-title-banner"> <h4 class="title">Exenatide QW NCT00641056 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0055"> <div class="citation-other">NCT00641056. <span class="citation-title">Efficacy of exenatide once weekly and once‐daily insulin glargine in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylurea (DURATION ‐ 3)</span>. http://clinicaltrials.gov/ct2/show/NCT00641056. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD006423-bbs2-0045"> <div class="reference-title-banner"> <h4 class="title">Exenatide QW NCT00917267 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0056"> <div class="citation-other">NCT00917267. <span class="citation-title">A study to examine the effects of exenatide once‐weekly injection on glucose control and safety in Asian subjects</span>. http://clinicaltrials.gov/ct2/show/NCT00917267. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD006423-bbs2-0046"> <div class="reference-title-banner"> <h4 class="title">Exenatide QW NCT00935532 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0057"> <div class="citation-other">NCT00935532. <span class="citation-title">Study to evaluate the efficacy and safety of exenatide once‐weekly injection compared to once‐daily insulin in type 2 diabetes mellitus</span>. http://clinicaltrials.gov/ct2/show/NCT00935532. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD006423-bbs2-0047"> <div class="reference-title-banner"> <h4 class="title">Exenatide QW NCT01003184 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0058"> <div class="citation-other">NCT01003184. <span class="citation-title">Efficacy of once‐weekly exenatide versus once or twice daily insulin detemir in patients with type 2 diabetes</span>. http://clinicaltrials.gov/ct2/show/NCT01003184. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD006423-bbs2-0048"> <div class="reference-title-banner"> <h4 class="title">Exenatide QW NCT01029886 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0059"> <div class="citation-other">NCT01029886. <span class="citation-title">Safety and efficacy of exenatide once weekly versus liraglutide in subjects with type 2 diabetes</span>. http://clinicaltrials.gov/ct2/show/NCT01029886 accessed 17 June 2011. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD006423-bbs2-0049"> <div class="reference-title-banner"> <h4 class="title">Exenatide QW NCT01144338 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0060"> <div class="citation-other">NCT01144338. <span class="citation-title">Exenatide study of cardiovascular event lowering trial (EXSCEL): a trial to evaluate cardiovascular outcomes after treatment with exenatide once weekly in patients with type 2 diabetes mellitus</span>. http://clinicaltrials.gov/ct2/show/NCT01144338. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD006423-bbs2-0050"> <div class="reference-title-banner"> <h4 class="title">Liraglutide NCT00856986 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0061"> <div class="citation-other">NCT00856986. <span class="citation-title">The effect of insulin detemir in combination with liraglutide and metformin compared to liraglutide and metformin in subjects with type 2 diabetes</span>. http://clinicaltrials.gov/ct2/show/NCT00856986 accessed 17 June 2011. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD006423-bbs2-0051"> <div class="reference-title-banner"> <h4 class="title">Liraglutide NCT01117350 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0062"> <div class="citation-other">NCT01117350. <span class="citation-title">Efficacy assessment of insulin glargine versus liraglutide after oral agent failure (EAGLE)</span>. http://clinicaltrials.gov/ct2/show/NCT01117350 accessed 17 June 2011. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD006423-bbs2-0052"> <div class="reference-title-banner"> <h4 class="title">Liraglutide NCT01296412 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0063"> <div class="citation-other">NCT01296412. <span class="citation-title">Comparison of two treatment regimens (sitagliptin versus liraglutide) on participants who failed to achieve good glucose control on metformin alone (MK‐0431‐403)</span>. http://clinicaltrials.gov/ct2/show/NCT01296412 accessed 17 June 2011. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD006423-bbs2-0053"> <div class="reference-title-banner"> <h4 class="title">Liraglutide NCT01336023 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0064"> <div class="citation-other">NCT01336023. <span class="citation-title">Dual action of liraglutide and insulin degludec in type 2 diabetes: a trial comparing the efficacy and safety of insulin degludec/liraglutide, insulin degludec and liraglutide in subjects with type 2 diabetes (DUAL™ I)</span>. http://clinicaltrials.gov/ct2/show/NCT01336023 accessed 17 June 2011. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD006423-bbs2-0054"> <div class="reference-title-banner"> <h4 class="title">Lixisenatide NCT00707031 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0065"> <div class="citation-other">NCT00707031. <span class="citation-title">GLP‐1 agonist AVE0010 versus exenatide in patients with type 2 diabetes for glycemic control and safety evaluation, on top of metformin (GETGOAL‐X)</span>. http://clinicaltrials.gov/ct2/show/NCT00707031 accessed 17 June 2011. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD006423-bbs2-0055"> <div class="reference-title-banner"> <h4 class="title">Lixisenatide NCT00713830 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0066"> <div class="citation-other">NCT00713830. <span class="citation-title">GLP‐1 agonist AVE0010 in patients with type 2 diabetes for glycemic control and safety evaluation, on top of sulfonylurea (GETGOAL‐S)</span>. http://clinicaltrials.gov/ct2/show/NCT00713830 accessed 17 June 2011. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD006423-bbs2-0056"> <div class="reference-title-banner"> <h4 class="title">Lixisenatide NCT00763815 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0067"> <div class="citation-other">NCT00763815. <span class="citation-title">GLP‐1 agonist AVE0010 in patients with type 2 diabetes for glycemic control and safety evaluation, on top of pioglitazone (GETGOAL‐P)</span>. http://clinicaltrials.gov/ct2/show/NCT00763815 accessed 17 June 2011. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD006423-bbs2-0057"> <div class="reference-title-banner"> <h4 class="title">Lixisenatide NCT00975286 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0068"> <div class="citation-other">NCT00975286. <span class="citation-title">24‐week treatment with lixisenatide in type 2 diabetes insufficiently controlled with metformin and insulin glargine</span>. http://clinicaltrials.gov/ct2/show/NCT00975286 accessed 17 June 2011. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD006423-bbs2-0058"> <div class="reference-title-banner"> <h4 class="title">Lixisenatide NCT00976937 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0069"> <div class="citation-other">NCT00976937. <span class="citation-title">24‐week study comparing lixisenatide to sitagliptin as add‐on to metformin in obese type 2 diabetic patients younger than 50</span>. http://clinicaltrials.gov/ct2/show/NCT00976937 accessed 17 June 2011. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD006423-bbs2-0059"> <div class="reference-title-banner"> <h4 class="title">Semaglutide NCT00696657 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0070"> <div class="citation-other">NCT00696657. <span class="citation-title">A randomised controlled clinical trial in type 2 diabetes comparing semaglutide to placebo and liraglutide</span>. http://clinicaltrials.gov/ct2/show/NCT00696657 accessed 17 June 2011. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD006423-bbs2-0060"> <div class="reference-title-banner"> <h4 class="title">Taspoglutide NCT00717457 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0071"> <div class="citation-other">NCT00717457. <span class="citation-title">A study of taspoglutide versus exenatide for the treatment of patients with type 2 diabetes mellitus inadequately controlled with metformin, thiazolidinedione or a combination of both</span>. http://clinicaltrials.gov/ct2/show/NCT00717457 accessed 17 June 2011. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD006423-bbs2-0061"> <div class="reference-title-banner"> <h4 class="title">Taspoglutide NCT00744367 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0072"> <div class="citation-other">NCT00744367. <span class="citation-title">A study of taspoglutide versus placebo for the treatment of patients with type 2 diabetes mellitus inadequately controlled with metformin plus pioglitazone</span>. http://clinicaltrials.gov/ct2/show/NCT00744367 accessed 17 June 2011. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD006423-bbs2-0062"> <div class="reference-title-banner"> <h4 class="title">Taspoglutide NCT00754988 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0073"> <div class="citation-other">NCT00754988. <span class="citation-title">A study of taspoglutide versus sitagliptin for the treatment of patients with type 2 diabetes mellitus inadequately controlled with metformin</span>. http://clinicaltrials.gov/ct2/show/NCT00754988 accessed 17 June 2011. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD006423-bbs2-0063"> <div class="reference-title-banner"> <h4 class="title">Taspoglutide NCT00755287 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0074"> <div class="citation-other">NCT00755287. <span class="citation-title">A study of the safety, tolerability and effect on glycemic control of taspoglutide versus insulin glargine in insulin naive type 2 diabetic patients inadequately controlled with metformin plus sulphonylurea</span>. http://clinicaltrials.gov/ct2/show/NCT00755287 accessed 17 June 2011. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD006423-bbs2-0064"> <div class="reference-title-banner"> <h4 class="title">Taspoglutide NCT00823992 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0075"> <div class="citation-other">NCT00823992. <span class="citation-title">A study of taspoglutide versus placebo for the treatment of obese patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy</span>. http://clinicaltrials.gov/ct2/show/NCT00823992 accessed 17 June 2011. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD006423-bbs2-0065"> <div class="reference-title-banner"> <h4 class="title">Taspoglutide NCT00909597 {published data only} </h4> </div> <div class="bibliography-section" id="CD006423-bib-0076"> <div class="citation-other">NCT00909597. <span class="citation-title">A study of taspoglutide versus pioglitazone in patients with type 2 diabetes</span>. http://clinicaltrials.gov/ct2/show/NCT00909597 accessed 17 June 2011. <ul class="citation-link-group"> </ul> </div> </div> </div> </section> <section> <div class="section-header" id="CD006423-bbs1-0004"> <h3 class="title">Additional references</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a class="jump-to" href="#CD006423-bbs1-0001">included studies</a></li> <li><a class="jump-to" href="#CD006423-bbs1-0002">excluded studies</a></li> <li><a class="jump-to" href="#CD006423-bbs1-0003">ongoing studies</a></li> </ul> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006423-bbs2-0066"> <div class="reference-title-banner"> <h4 class="title">Abraham 2002</h4> </div> <div class="bibliography-section" id="CD006423-bib-0077"> <div class="citation-journal">Abraham EJ, Leech CA, Lin JC, Zulewski H, Habener JF. <span class="citation-title">Insulinotropic hormone glucagon‐like peptide‐1 differentiation of human pancreatic islet‐derived progenitor cells into insulin‐producing cells</span>. <span class="citation"> Endocrinology </span><span class="pubYear">2002</span>;<span class="volume">143</span>(8):3152‐61. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12130581" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Insulinotropic+hormone+glucagon%E2%80%90like+peptide%E2%80%901+differentiation+of+human+pancreatic+islet%E2%80%90derived+progenitor+cells+into+insulin%E2%80%90producing+cells+&author=EJ+Abraham&author=CA+Leech&author=JC+Lin&author=H+Zulewski&author=JF+Habener&publication_year=2002&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006423-bbs2-0067"> <div class="reference-title-banner"> <h4 class="title">ADA 1997</h4> </div> <div class="bibliography-section" id="CD006423-bib-0078"> <div class="citation-journal">American Diabetes Association. <span class="citation-title">Report on the Expert Committee on the Diagnosis and Classication of Diabetes Mellitus</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">1997</span>;<span class="volume">20</span>(Suppl 1):S5‐20. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006423-bbs2-0068"> <div class="reference-title-banner"> <h4 class="title">ADA 1999</h4> </div> <div class="bibliography-section" id="CD006423-bib-0079"> <div class="citation-journal">The Expert Committee on the Diagnosis and Classication of Diabetes Mellitus. <span class="citation-title">Report of the Expert Committee on the diagnosis and classification of diabetes mellitus</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">1999</span>;<span class="volume">22</span>(Suppl 1):S5‐19. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006423-bbs2-0069"> <div class="reference-title-banner"> <h4 class="title">Amori 2007</h4> </div> <div class="bibliography-section" id="CD006423-bib-0080"> <div class="citation-journal">Amori RE, Lau J, Pittas, AG. <span class="citation-title">Efficacy and safety of incretin therapy in type 2 diabetes</span>. <span class="citation"> Journal of the American Medical Association </span><span class="pubYear">2007</span>;<span class="volume">298</span>(2):194‐206. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17622601" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+and+safety+of+incretin+therapy+in+type+2+diabetes&author=RE+Amori&author=J+Lau&author=+Pittas&author=+AG&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006423-bbs2-0070"> <div class="reference-title-banner"> <h4 class="title">Baggio 2004</h4> </div> <div class="bibliography-section" id="CD006423-bib-0081"> <div class="citation-journal">Baggio LL, Huang Q, Brown TJ, Drucker DJ. <span class="citation-title">A recombinant human glucagon‐like peptide (GLP)‐1‐albumin protein (albugon) mimics peptidergic activation of GLP‐1 receptor‐dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis</span>. <span class="citation"> Diabetes </span><span class="pubYear">2004</span>;<span class="volume">53</span>(9):2492‐500. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15331566" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+recombinant+human+glucagon%E2%80%90like+peptide+(GLP)%E2%80%901%E2%80%90albumin+protein+(albugon)+mimics+peptidergic+activation+of+GLP%E2%80%901+receptor%E2%80%90dependent+pathways+coupled+with+satiety,+gastrointestinal+motility,+and+glucose+homeostasis+&author=LL+Baggio&author=Q+Huang&author=TJ+Brown&author=DJ+Drucker&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006423-bbs2-0071"> <div class="reference-title-banner"> <h4 class="title">Barnett 2009</h4> </div> <div class="bibliography-section" id="CD006423-bib-0082"> <div class="citation-journal">Barnett AH. <span class="citation-title">New treatments in type 2 diabetes: a focus on the incretin‐based therapies</span>. <span class="citation"> Clinical Endocrinology </span><span class="pubYear">2009</span>;<span class="volume">70</span>:343‐53. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18771570" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=New+treatments+in+type+2+diabetes:+a+focus+on+the+incretin%E2%80%90based+therapies&author=AH+Barnett&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006423-bbs2-0072"> <div class="reference-title-banner"> <h4 class="title">Butler 2010</h4> </div> <div class="bibliography-section" id="CD006423-bib-0083"> <div class="citation-journal">Butler PC, Matveyenko AV, Dry S, Bhushan A, Elashoff R. <span class="citation-title">Glucagon‐like peptide‐1 therapy and the exocrine pancreas: innocent bystander or friendly fire?</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2010</span>;<span class="volume">53</span>:1‐5. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19894028" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Glucagon%E2%80%90like+peptide%E2%80%901+therapy+and+the+exocrine+pancreas:+innocent+bystander+or+friendly+fire?+&author=PC+Butler&author=AV+Matveyenko&author=S+Dry&author=A+Bhushan&author=R+Elashoff&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006423-bbs2-0073"> <div class="reference-title-banner"> <h4 class="title">Dore 2011</h4> </div> <div class="bibliography-section" id="CD006423-bib-0084"> <div class="citation-journal">Dore DD, Bloomgren GL, Wenten M, Hoffman C, Clifford CR, Quinn SG, et al. <span class="citation-title">A cohort study of acute pancreatitis in relation to exenatide use</span>. <span class="citation"> Diabetes, Obesity and Metabolism </span><span class="pubYear">Jun 2011</span>;<span class="volume">13</span>(6):559‐66. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+cohort+study+of+acute+pancreatitis+in+relation+to+exenatide+use&author=DD+Dore&author=GL+Bloomgren&author=M+Wenten&author=C+Hoffman&author=CR+Clifford&author=SG+Quinn&publication_year=Jun2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006423-bbs2-0074"> <div class="reference-title-banner"> <h4 class="title">EMEA 2009</h4> </div> <div class="bibliography-section" id="CD006423-bib-0085"> <div class="citation-other">EMEA. <span class="citation-title">Assessment report for Victoza (liraglutide)</span>. http://www.emea.europa.eu/humandocs/PDFs/EPAR/victoza/H‐1026‐en6.pdf accessed 10 March 2010. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006423-bbs2-0075"> <div class="reference-title-banner"> <h4 class="title">Farilla 2003</h4> </div> <div class="bibliography-section" id="CD006423-bib-0086"> <div class="citation-journal">Farilla L, Bulotta A, Hirshberg B, Li CS, Khoury N, Noushmehr H, et al. <span class="citation-title">Glucagon‐like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets.[see comment]</span>. <span class="citation"> Endocrinology </span><span class="pubYear">2003</span>;<span class="volume">144</span>(12):5149‐58. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12960095" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Glucagon%E2%80%90like+peptide+1+inhibits+cell+apoptosis+and+improves+glucose+responsiveness+of+freshly+isolated+human+islets.[see+comment]+&author=L+Farilla&author=A+Bulotta&author=B+Hirshberg&author=CS+Li&author=N+Khoury&author=H+Noushmehr&publication_year=2003&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006423-bbs2-0076"> <div class="reference-title-banner"> <h4 class="title">FDA 2008</h4> </div> <div class="bibliography-section" id="CD006423-bib-0087"> <div class="citation-other">FDA. <span class="citation-title">Information for Healthcare Professionals: Exenatide (marketed as Byetta)</span>. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124713.htm accessed 10 March 2010. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006423-bbs2-0077"> <div class="reference-title-banner"> <h4 class="title">FDA 2009</h4> </div> <div class="bibliography-section" id="CD006423-bib-0088"> <div class="citation-other">FDA. <span class="citation-title">Byetta (exenatide) prescribing information</span>. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021773s9s11s18s22s25lbl.pdf accessed 10 March 2010. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006423-bbs2-0078"> <div class="reference-title-banner"> <h4 class="title">FDA 2009 (kidney function)</h4> </div> <div class="bibliography-section" id="CD006423-bib-0089"> <div class="citation-other">FDA. <span class="citation-title">Information for Healthcare Professionals: Reports of Altered Kidney Function in patients using Exenatide (Marketed as Byetta)</span>. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm188656.htm accessed 10 March 2010. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006423-bbs2-0079"> <div class="reference-title-banner"> <h4 class="title">FDA 2009 (safety update)</h4> </div> <div class="bibliography-section" id="CD006423-bib-0090"> <div class="citation-other">FDA. <span class="citation-title">Byetta Safety Update for Healthcare Professionals</span>. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm190406.htm accessed 10 March 2010. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006423-bbs2-0080"> <div class="reference-title-banner"> <h4 class="title">Girman 2010</h4> </div> <div class="bibliography-section" id="CD006423-bib-0091"> <div class="citation-journal">Girman CJ, Kou TD, Cai B, Alexander CM, O'Neill EA, Williams‐Herman DE, et al. <span class="citation-title">Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes</span>. <span class="citation"> Diabetes Obesity and Metabolism </span><span class="pubYear">Sep 2010</span>;<span class="volume">12</span>(9):766‐71. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Patients+with+type+2+diabetes+mellitus+have+higher+risk+for+acute+pancreatitis+compared+with+those+without+diabetes+&author=CJ+Girman&author=TD+Kou&author=B+Cai&author=CM+Alexander&author=EA+O'Neill&author=DE+Williams‐Herman&publication_year=Sep2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006423-bbs2-0081"> <div class="reference-title-banner"> <h4 class="title">Higgins 2002</h4> </div> <div class="bibliography-section" id="CD006423-bib-0092"> <div class="citation-journal">Higgins JPT, Thompson SG. <span class="citation-title">Quantifying heterogeneity in a meta‐analysis</span>. <span class="citation"> Statistics in Medicine </span><span class="pubYear">2002</span>;<span class="volume">21</span>:1539‐58. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12111919" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Quantifying+heterogeneity+in+a+meta%E2%80%90analysis&author=JPT+Higgins&author=SG+Thompson&publication_year=2002&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006423-bbs2-0082"> <div class="reference-title-banner"> <h4 class="title">Higgins 2003</h4> </div> <div class="bibliography-section" id="CD006423-bib-0093"> <div class="citation-journal">Higgins JPT, Thompson SG, Deeks JJ, Altman DG. <span class="citation-title">Measuring inconsistency in meta‐analysis</span>. <span class="citation"> BMJ </span><span class="pubYear">2003</span>;<span class="volume">327</span>:557‐60. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12958120" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Measuring+inconsistency+in+meta%E2%80%90analysis&author=JPT+Higgins&author=SG+Thompson&author=JJ+Deeks&author=DG+Altman&publication_year=2003&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006423-bbs2-0083"> <div class="reference-title-banner"> <h4 class="title">Higgins 2011</h4> </div> <div class="bibliography-section" id="CD006423-bib-0094"> <div class="citation-other">Higgins JPT, Green S (editors). <span class="citation-title">Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]</span>. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006423-bbs2-0084"> <div class="reference-title-banner"> <h4 class="title">Journal Watch 2011</h4> </div> <div class="bibliography-section" id="CD006423-bib-0095"> <div class="citation-other">Journal Watch. <span class="citation-title">FDA Reminds Clinicians of Liraglutide's Risks for Pancreatitis and Cancer</span>. http://firstwatch.jwatch.org/cgi/content/full/2011/614/2?q=topic_diabetes accessed 17 June 2011. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006423-bbs2-0085"> <div class="reference-title-banner"> <h4 class="title">Kaku 2010</h4> </div> <div class="bibliography-section" id="CD006423-bib-0096"> <div class="citation-journal">Kaku K, Rasmussen MF, Clauson P, Seino Y. <span class="citation-title">Improved glycaemic control with minimal hypoglycaemiaand no weight change with the once‐daily humanglucagon‐like peptide‐1 analogue liraglutide as add‐onto sulphonylurea in Japanese patients with type 2 diabetes</span>. <span class="citation"> Diabetes, Obesity and Metabolism </span><span class="pubYear">2010</span>;<span class="volume">12</span>:341–7. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Improved+glycaemic+control+with+minimal+hypoglycaemiaand+no+weight+change+with+the+once%E2%80%90daily+humanglucagon%E2%80%90like+peptide%E2%80%901+analogue+liraglutide+as+add%E2%80%90onto+sulphonylurea+in+Japanese+patients+with+type+2+diabetes+&author=K+Kaku&author=MF+Rasmussen&author=P+Clauson&author=Y+Seino&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006423-bbs2-0086"> <div class="reference-title-banner"> <h4 class="title">Li 2003</h4> </div> <div class="bibliography-section" id="CD006423-bib-0097"> <div class="citation-journal">Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ. <span class="citation-title">Glucagon‐like peptide‐1 receptor signaling modulates beta cell apoptosis</span>. <span class="citation"> The Journal of Biological Chemistry </span><span class="pubYear">2003</span>;<span class="volume">278</span>(1):471‐8. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12409292" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Glucagon%E2%80%90like+peptide%E2%80%901+receptor+signaling+modulates+beta+cell+apoptosis&author=Y+Li&author=T+Hansotia&author=B+Yusta&author=F+Ris&author=PA+Halban&author=DJ+Drucker&publication_year=2003&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006423-bbs2-0087"> <div class="reference-title-banner"> <h4 class="title">Loh and Clement 2007</h4> </div> <div class="bibliography-section" id="CD006423-bib-0098"> <div class="citation-journal">Loh JA, Clement SC. <span class="citation-title">Efficacy of exenatide therapy over 12 months in a &quot;real world&quot; setting</span>. <span class="citation"> Diabetes </span><span class="pubYear">2007</span>;<span class="volume">56</span>:A152. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+of+exenatide+therapy+over+12+months+in+a+" real+world"+setting&author=JA+Loh&author=SC+Clement&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006423-bbs2-0088"> <div class="reference-title-banner"> <h4 class="title">Moher 2009</h4> </div> <div class="bibliography-section" id="CD006423-bib-0099"> <div class="citation-journal">Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA group. <span class="citation-title">Preferred reporting items for systematic reviews and meta‐analysis: the PRISMA statement</span>. <span class="citation"> British Medical Journal </span><span class="pubYear">2009</span>;<span class="volume">339</span>:b2535. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19622551" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Preferred+reporting+items+for+systematic+reviews+and+meta%E2%80%90analysis:+the+PRISMA+statement&author=D+Moher&author=A+Liberati&author=J+Tetzlaff&author=DG+Altman&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006423-bbs2-0089"> <div class="reference-title-banner"> <h4 class="title">Monami 2009</h4> </div> <div class="bibliography-section" id="CD006423-bib-0100"> <div class="citation-journal">Monami M, Marchionni N, Mannucci E. <span class="citation-title">Glucagon like peptide‐1 receptor agonists in type 2 diabetes: a meta‐analysis of randomized clinical trials</span>. <span class="citation"> European Journal of Endocrinology </span><span class="pubYear">2009</span>;<span class="volume">160</span>:909‐17. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19318378" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Glucagon+like+peptide%E2%80%901+receptor+agonists+in+type+2+diabetes:+a+meta%E2%80%90analysis+of+randomized+clinical+trials+&author=M+Monami&author=N+Marchionni&author=E+Mannucci&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006423-bbs2-0090"> <div class="reference-title-banner"> <h4 class="title">Nathan 2009</h4> </div> <div class="bibliography-section" id="CD006423-bib-0101"> <div class="citation-journal">Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. American Diabetes Association, European Association for Study of Diabetes. <span class="citation-title">Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2009</span>;<span class="volume">32</span>(1):193‐03. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18945920" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Medical+management+of+hyperglycemia+in+type+2+diabetes:+a+consensus+algorithm+for+the+initiation+and+adjustment+of+therapy:+a+consensus+statement+of+the+American+Diabetes+Association+and+the+European+Association+for+the+Study+of+Diabetes+&author=DM+Nathan&author=JB+Buse&author=MB+Davidson&author=E+Ferrannini&author=RR+Holman&author=R+Sherwin&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006423-bbs2-0091"> <div class="reference-title-banner"> <h4 class="title">Nauck 1993</h4> </div> <div class="bibliography-section" id="CD006423-bib-0102"> <div class="citation-journal">Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. <span class="citation-title">Normalization of fasting hyperglycaemia by exogenous glucagon‐like peptide 1 (7‐36 amide) in type 2 (non‐insulin‐dependent) diabetic patients</span>. <span class="citation"> Diabetologia </span><span class="pubYear">1993</span>;<span class="volume">36</span>(8):741‐4. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/8405741" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Normalization+of+fasting+hyperglycaemia+by+exogenous+glucagon%E2%80%90like+peptide+1+(7%E2%80%9036+amide)+in+type+2+(non%E2%80%90insulin%E2%80%90dependent)+diabetic+patients+&author=MA+Nauck&author=N+Kleine&author=C+Orskov&author=JJ+Holst&author=B+Willms&author=W+Creutzfeldt&publication_year=1993&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006423-bbs2-0092"> <div class="reference-title-banner"> <h4 class="title">Nauck 2002</h4> </div> <div class="bibliography-section" id="CD006423-bib-0103"> <div class="citation-journal">Nauck MA, Heimesaat MM, Behle K, Holst JJ, Nauck MS, Ritzel R, et a. <span class="citation-title">Effects of glucagon‐like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycaemic clamp experiments in healthy volunteers</span>. <span class="citation"> The Journal of Clinical Endocrinology and Metabolism </span><span class="pubYear">2002</span>;<span class="volume">87</span>(3):1239‐46. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/11889194" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+glucagon%E2%80%90like+peptide+1+on+counterregulatory+hormone+responses,+cognitive+functions,+and+insulin+secretion+during+hyperinsulinemic,+stepped+hypoglycaemic+clamp+experiments+in+healthy+volunteers+&author=MA+Nauck&author=MM+Heimesaat&author=K+Behle&author=JJ+Holst&author=MS+Nauck&author=R+Ritzel&author=a+et&publication_year=2002&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006423-bbs2-0093"> <div class="reference-title-banner"> <h4 class="title">NICE CG66 2008</h4> </div> <div class="bibliography-section" id="CD006423-bib-0104"> <div class="citation-other">National Collaborating Centre for Chronic Conditions. <span class="citation-title">Type 2 diabetes: national clinical guideline for management in primary and secondary care</span>. London: Royal College of Physicians<span class="pubYear">2008</span>; Vol. http://www.nice.org.uk/nicemedia/pdf/CG66FullGuideline0509.pdf. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006423-bbs2-0094"> <div class="reference-title-banner"> <h4 class="title">NICE CG87 2009</h4> </div> <div class="bibliography-section" id="CD006423-bib-0105"> <div class="citation-other">National Institute for Health and Clinical Excellence. <span class="citation-title">Type 2 diabetes: the management of type 2 diabetes</span>. NICE clinical guideline 87<span class="pubYear">2009</span>; Vol. http://www.nice.org.uk/cg87. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006423-bbs2-0095"> <div class="reference-title-banner"> <h4 class="title">NICE TA203 2010</h4> </div> <div class="bibliography-section" id="CD006423-bib-0106"> <div class="citation-other">National Institute for Health and Clinical Excellence. <span class="citation-title">Liraglutide for the treatment of type 2 diabetes mellitus. NICE technology appraisal guidance 203</span>. http://guidance.nice.org.uk/TA203<span class="pubYear">2010</span>. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006423-bbs2-0096"> <div class="reference-title-banner"> <h4 class="title">Norris 2009</h4> </div> <div class="bibliography-section" id="CD006423-bib-0107"> <div class="citation-journal">Norris SL, Lee N, Thakurta S, Chan BKS. <span class="citation-title">Exenatide efficacy and safety: a systematic review</span>. <span class="citation"> Diabetic Medicine </span><span class="pubYear">2009</span>;<span class="volume">26</span>:837‐46. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19719703" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Exenatide+efficacy+and+safety:+a+systematic+review&author=SL+Norris&author=N+Lee&author=S+Thakurta&author=BKS+Chan&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006423-bbs2-0097"> <div class="reference-title-banner"> <h4 class="title">Pratley 2008</h4> </div> <div class="bibliography-section" id="CD006423-bib-0108"> <div class="citation-journal">Pratley RE. <span class="citation-title">Overview of glucagon‐like peptide‐1 analogs and dipeptidyl peptidase‐4 inhibitors for type 2 diabetes</span>. <span class="citation"> Medscape Journal of Medicine </span><span class="pubYear">2008</span>;<span class="volume">10</span>(7):171. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18769687" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Overview+of+glucagon%E2%80%90like+peptide%E2%80%901+analogs+and+dipeptidyl+peptidase%E2%80%904+inhibitors+for+type+2+diabetes+&author=RE+Pratley&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006423-bbs2-0098"> <div class="reference-title-banner"> <h4 class="title">Shyangdan 2010</h4> </div> <div class="bibliography-section" id="CD006423-bib-0109"> <div class="citation-journal">Shyangdan DS, Royle PL, Clar C, Sharma P, Waugh NR. <span class="citation-title">Glucagon‐like peptide analogues for type 2 diabetes mellitus: systematic review and meta‐analysis</span>. <span class="citation"> BMC Endocrine Disorders </span><span class="pubYear">2010</span>;<span class="volume">10</span>:20. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21143938" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Glucagon%E2%80%90like+peptide+analogues+for+type+2+diabetes+mellitus:+systematic+review+and+meta%E2%80%90analysis+&author=DS+Shyangdan&author=PL+Royle&author=C+Clar&author=P+Sharma&author=NR+Waugh&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006423-bbs2-0099"> <div class="reference-title-banner"> <h4 class="title">Shyangdan 2011</h4> </div> <div class="bibliography-section" id="CD006423-bib-0110"> <div class="citation-journal">Shyangdan D, Cummins E, Royle P, Waugh N. <span class="citation-title">Liraglutide for the treatment of type 2 diabetes</span>. <span class="citation"> Health Technology Assessment </span><span class="pubYear">2011</span>;<span class="volume">15</span>(Suppl. 1):75‐84. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Liraglutide+for+the+treatment+of+type+2+diabetes&author=D+Shyangdan&author=E+Cummins&author=P+Royle&author=N+Waugh&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006423-bbs2-0100"> <div class="reference-title-banner"> <h4 class="title">Turner 1996</h4> </div> <div class="bibliography-section" id="CD006423-bib-0111"> <div class="citation-journal">Turner RC, Holman RR. <span class="citation-title">The UK Prospective Diabetes Study. UK Prospective Diabetes Study Group</span>. <span class="citation"> Annals of Medicine </span><span class="pubYear">1996</span>;<span class="volume">28</span>(5):439‐44. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/8949976" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+UK+Prospective+Diabetes+Study.+UK+Prospective+Diabetes+Study+Group&author=RC+Turner&author=RR+Holman&publication_year=1996&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006423-bbs2-0101"> <div class="reference-title-banner"> <h4 class="title">UKPDS 16</h4> </div> <div class="bibliography-section" id="CD006423-bib-0112"> <div class="citation-journal">UKPDS Study Group. <span class="citation-title">UKPDS 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. UK Prospective Diabetes Study Group</span>. <span class="citation"> Diabetes </span><span class="pubYear">1995</span>;<span class="volume">44</span>:1249‐58. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/7589820" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006423-bbs2-0102"> <div class="reference-title-banner"> <h4 class="title">Waugh 2010</h4> </div> <div class="bibliography-section" id="CD006423-bib-0113"> <div class="citation-journal">Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, et al. <span class="citation-title">Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation</span>. <span class="citation"> Health Technology Assessment </span><span class="pubYear">July 2010</span>;<span class="volume">14</span>(36):1‐248. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Newer+agents+for+blood+glucose+control+in+type+2+diabetes:+systematic+review+and+economic+evaluation+&author=N+Waugh&author=E+Cummins&author=P+Royle&author=C+Clar&author=M+Marien&author=B+Richter&publication_year=July2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006423-bbs2-0103"> <div class="reference-title-banner"> <h4 class="title">WHO 1998</h4> </div> <div class="bibliography-section" id="CD006423-bib-0114"> <div class="citation-journal">Alberti KM, Zimmet PZ. <span class="citation-title">Definition, diagnosis and classification of diabetes mellitus and its compliactions. Part I: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation</span>. <span class="citation"> Diabetic Medicine </span><span class="pubYear">1998</span>;<span class="volume">15</span>:539‐53. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9686693" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Definition,+diagnosis+and+classification+of+diabetes+mellitus+and+its+compliactions.+Part+I:+diagnosis+and+classification+of+diabetes+mellitus.+Provisional+report+of+a+WHO+consultation+&author=KM+Alberti&author=PZ+Zimmet&publication_year=1998&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006423-bbs2-0104"> <div class="reference-title-banner"> <h4 class="title">Xu 1999</h4> </div> <div class="bibliography-section" id="CD006423-bib-0115"> <div class="citation-journal">Xu G, Stoffers DA, Habener JF, Bonner‐Weir S. <span class="citation-title">Exendin‐4 stimulates both beta‐cell replication and neogenesis, resulting in increased beta‐ cell mass and improved glucose tolerance in diabetic rats</span>. <span class="citation"> Diabetes </span><span class="pubYear">1999</span>;<span class="volume">48</span>(12):2270‐6. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/10580413" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Exendin%E2%80%904+stimulates+both+beta%E2%80%90cell+replication+and+neogenesis,+resulting+in+increased+beta%E2%80%90+cell+mass+and+improved+glucose+tolerance+in+diabetic+rats+&author=G+Xu&author=DA+Stoffers&author=JF+Habener&author=S+Bonner%E2%80%90Weir&publication_year=1999&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> </section> </section> <section class="characteristicStudies" id="characteristicStudies"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title"> Characteristics of studies <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="characteristicIncludedStudiesContent" lang=""> <div class="section-header" id="CD006423-sec2-0021"> <h3 class="title">Characteristics of included studies [ordered by study ID]</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a href="#CD006423-sec2-0022" class="jump-to">excluded studies</a></li> <li><a href="#CD006423-sec2-0023" class="jump-to">ongoing studies</a></li> </ul> </div> </div> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">A ‐ Rosenstock 2009 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>TRIAL DESIGN</b>: Randomised double‐blind, placebo‐controlled parallel group phase II trial, multi‐centre (118 sites) </p> <p><b>DURATION OF INTERVENTION</b>: 16 weeks </p> <p><b>DURATION OF FOLLOW‐UP</b>: 11 week washout phase to assess safety and immunogeneity </p> <p><b>RUN‐IN PERIOD:</b> None </p> <p><b>SETTING</b>: Not reported (NR) </p> <p><b>COUNTRY</b>: US (106 sites), Mexico (9 sites), Chile (2 sites), Dominican Republic (1 site) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>INCLUSION CRITERIA</b>: Patients with type 2 diabetes diagnosed ≥ 3 months before screening, men and women aged 18 to 75 years, drug‐naive (diet and exercise) or treated with metformin monotherapy and stable for &gt; 3 months before prescreening; BMI ≥ 20 and ≤ 40 kg/m<sup>2</sup>, HbA1c at screening ≥ 7 and ≤ 10%; only participants treated with metformin monotherapy were eligible for the exenatide arm (consistent with labelling). </p> <p><b>EXCLUSION CRITERIA</b>: Any oral antidiabetic monotherapy (except metformin) ≤ 3 months prior to screening or insulin &lt; 1 month prior to screening and not used for &gt; 7 days; history of pancreatitis, cardiovascular, cerebrovascular, renal or hepatobiliary diseases; fasting serum triglycerides ≥ 9 mmol/L at screening; or haematological profiles considered to be clinically significant; use of lipid lowering medications must have been maintained at same dose for 3 months prior to treatment, no prescription or over the counter weight loss drugs 3 months prior to enrolment. </p> <p><b>AGE</b>: mean 54.0 to 55.5 years (SD 9.7 to 10.6) </p> <p><b>SEX</b>: 45.1% to 74.2% female (74.2% in ALBI 30 mg weekly group, 50% in ALBI 30 mg every 2 weeks group, 45.1% in placebo group) </p> <p><b>DIABETES DURATION</b>: mean 4.9 years [range 3.9 to 5.5 years (SD 3.0 to 5.4)] </p> <p><b>ETHNICITY</b>: Caucasian (43.8% to 71%) (87.1% and 12.9% of participants were from U.S. and Latin American clinics respectively) </p> <p><b>HbA1c (%)</b>: ALBI Weekly 30 mg: 8.0 (SD 0.9), Placebo: 7.9 (SD 0.9), ALBI every 2 weeks 30 mg: 8.0 (SD 1.0) </p> <p><b>BMI (kg/m<sup>2</sup>)</b>: ALBI weekly 30 mg: 33.0 (SD 3.9), ALBI every 2 weeks 30 mg: 31.2 (SD 4.1), Placebo: 31.8 (SD 5.4) </p> <p><b>PREVIOUS THERAPY</b>: Diet and exercise only: 29.0% to 34.4%, MET: 65.6% to 71.0% </p> <p><b>NUMBERS</b>: Randomised: 361, received treatment (and included in the safety analysis): 356, efficacy analysis: 345; ITT: placebo: 51, exenatide: 35; ALBI weekly 4 mg: 35, 15 mg: 35, 30 mg: 31; ALBI every 2 weeks 15 mg: 33, 30 mg: 32, 50 mg: 35; ALBI monthly 50 mg: 35, 100 mg: 34 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>COMPARISON:</b> Albiglutide (ALBI, 8 doses/schedules) +/‐ Metformin (MET) VERSUS Exenatide (EX) + MET VERSUS Placebo +/‐ MET </p> <p><b>NO. OF COMPARISON GROUPS</b>: 10 </p> <p>For the current review, the following groups were excluded: EX (as this included co‐medication with metformin in all patients, whereas only 65.6% to 74.3% of the patients in the other groups received metformin, so this was not really a comparison of exenatide versus albiglutide); ALBI 4 or 15 mg weekly or 15 mg every two weeks (smaller effect on HbA1c), and ALBI 50 mg every two weeks or 50 or 100 mg monthly (no improvement in HbA1c compared to groups with largest effect, significantly more adverse events) </p> <p><b>DOSE ALBI:</b> 30 mg weekly or 30 mg every 2 weeks injected subcutaneously to the abdomen </p> <p><b>DOSE PLACEBO:</b> Placebo injections </p> <p><b>DOSE MET:</b> Not reported, presumably pre study levels </p> <p><b>OTHER TREATMENT:</b> Not reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>PRIMARY OUTCOMES</b>: Change from baseline in HbA1c at week 16 </p> <p><b>SECONDARY OUTCOMES</b>: Fasting plasma glucose (FPG), fasting fructosamine, C‐peptide, glucagon, insulin, lipid profiles, beta‐cell function (homeostasis model) </p> <p><b>OTHER OUTCOMES:</b> Adverse event assessments and safety analyses (nausea and vomiting, immunogenicity), 11 week washout post‐intervention (HbA1c, FPG, ALBI concentrations, fasting fructosamine, C‐peptide, glucagon, insulin, lipid profiles, immunogenicity) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>AIM</b>: To evaluate the efficacy, safety and tolerability of incremental doses of albiglutide, administered using three dosing schedules in patients with type 2 diabetes inadequately controlled with diet and exercise or metformin monotherapy. </p> <p><b>SOURCE OF FUNDING</b>: GlaxoSmithKline, Middlesex, UK </p> <p><b>OTHER</b>: Conflict of interest: One author has received research grants and consulting honoraria for serving on scientific advisory boards from GlaxoSmithKline. Another author has received research grants from and acted as a consultant for GlaxoSmithKline, MB FY, and MS are employees/stockholders of GlaxoSmithKline. </p> <p><b>SAMPLE SIZE:</b> With 30 participants planned in each arm, a two‐sided 95% CI for each group mean response had a half‐width of 0.36% on HbA1c scale, assuming a standard deviation of 1%. </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No details given</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding (performance bias and detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Double blind (study personnel and patients)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comparisons made on the intent to treat population, using last observation carried forward, adequate description of withdrawals or losses to follow‐up (28% withdrawals or losses to follow‐up) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>All pre‐specified (primary and secondary) outcomes were reported</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">E ‐ Bergenstal 2010 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>TRIAL DESIGN</b>:Randomised, double‐blind, double‐dummy, superiority trial </p> <p><b>DURATION OF INTERVENTION</b>: 26 weeks </p> <p><b>DURATION OF FOLLOW‐UP</b>: NR </p> <p><b>RUN‐IN PERIOD:</b> NR </p> <p><b>SETTING</b>: 72 hospitals and clinics </p> <p><b>COUNTRY</b>: USA, India and Mexico. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>INCLUSION CRITERIA</b>: participants aged between 18 years and older; type 2 diabetes but otherwise healthy; treated with a stable metformin regimen for at least 2 months before screening; HbA1c of 7.1% to 11.0%; BMI 25 to 45 kg/m<sup>2</sup>; FPG &lt; 15.5 mmol/L; not taking or has been stable on other medications of a minimum of 2 months‐hormone replacement therapy, OCPs, antihypertensives, lipid‐lowering agents, thyroid replacement therapy, antidepressant agents and drugs known to affect body weight including prescription medications, sibutramine, topiramate and over‐the‐counter antiobesity agents. </p> <p><b>EXCLUSION CRITERIA</b>: pregnant or lactating women; clinically significant medical conditions like hepatic disease, renal disease, cardiovascular disease, gastroparesis, malignancy, macular edema or chronic infections; drugs or alcohol abuse; fasting triglycerides ≥ 600 mg/dL; previously exposed to exenatide LAR (long acting release); blood donated within 60 days of screening or is planning to do during study; major surgery or a blood transfusion within 2 months of screening; currently taking drugs that are excluded or is expected to be treated with one; received any investigational drug within 1 month of screening; known allergies or hypersensitivity to any component of study treatment; previous experience of clinically significant adverse events with TZD or DPP‐4 inhibitors; immediate family or affiliation with the personnel; employed by Amylin, Eli Lilly or Alkermes </p> <p><b>AGE</b>: 52 to 53 years (SD 10 to 11) </p> <p><b>SEX</b>: 44% to 52% female [44% in EX 2 mg group; 48% in sitagliptin (SITA) 100 mg group; 52% in pioglitazone (PIO) 45 mg group] </p> <p><b>DIABETES DURATION</b>: 5 to 6 years (SD 4 to 5) </p> <p><b>ETHNICITY</b>: 30% to 39% White; 8% to 12% Black; 27% to 31% Hispanic; 23% to 25% Asian; 0% to 2% Native American; 1% to 2% other </p> <p><b>HbA1c (%)</b>: EX 2 mg: 8.6 SD 1.2; SITA 100 mg: 8.5 SD 1.2; PIO 45 mg: 8.5 SD 1.1 </p> <p><b>BMI (kg/m<sup>2</sup>)</b>: EX 2 mg: 32 SD 5; SITA 100 mg: 32 SD 5; PIO 45 mg: 32 SD 6 </p> <p><b>PREVIOUS THERAPY</b>: NR </p> <p><b>NUMBERS</b>: Screened: 958; randomised: 514 (EX 2 mg: 170, SITA 100 mg: 172, PIO 45 mg: 172); evaluable patient: 387 (EX 2 mg: 122, SITA 100 mg: 137, PIO 45 mg: 128); ITT: 491 (EX 2 mg: 160, SITA 100 mg: 166, PIO 45 mg: 165) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>COMPARISON:</b> EX 2 mg once weekly + MET + placebo, versus SITA 100 mg once daily + MET + placebo, versus PIO 45 mg once daily + MET + placebo </p> <p><b>NO. OF COMPARISON GROUPS</b>: 3 </p> <p><b>DOSE EX:</b> EX 2 mg once weekly injection plus oral placebo once daily </p> <p><b>DOSE SITA:</b> SITA 100 mg orally once daily plus placebo once weekly injection </p> <p><b>DOSE PIO:</b> PIO 45 mg orally once daily plus placebo once weekly injection </p> <p><b>DOSE MET:</b> Mean oral dose between 1480 to 1583 mg </p> <p><b>OTHER TREATMENT:</b> NR </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>PRIMARY OUTCOMES</b>: Change in HbA1c </p> <p><b>SECONDARY OUTCOMES</b>: Proportion of participants achieving the HbA1c target of 6.5% or lower, or 7.0% or lower; FPG ≤ 7 mmol/L; six‐point self‐monitored blood glucose profile; body weight; fasting lipid profile; fasting insulin profile; SBP and DBP; cardiovascular risk markers (urinary albumin‐to‐creatinine ratio, serum adiponectin, B‐type natriuretic peptide, high‐sensitivity C‐reactive protein, and plasminogen activator inhibitor‐1); patient‐reported outcomes from the Impact of Weight on Quality of Life Questionnaire‐Lite (IWQOL), Psychological General Well‐being (PGWB) index, the Diabetes Treatment Satisfaction Questionnaire (DTSQ), and EuroQol‐5 dimensions (EQ‐5D). </p> <p><b>OTHER OUTCOMES:</b> Safety and tolerability; exenatide antibodies; hypoglycaemia </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>AIM</b>: To compare the efficacy, safety, and tolerability of three recommended therapies for patients not sufficiently controlled on metformin. </p> <p><b>SOURCE OF FUNDING</b>: Amylin Pharmaceuticals and Eli Lilly </p> <p><b>OTHER</b>: Conflict of interest: First author's institution has received consultancy fees or research grant support, or both, with receipt of travel and accomodation expenses in some cases, from different pharmaceutical companies. This author also owns stock in Merck. Another author is a member of the scientific advisory board for Amylin Pharmaceuticals, is a consultant for Amylin Pharmaceuticals, Eli Lilly and AstraZeneca, is on the speaker's bureau of Amylin Pharmaceuticals, Eli Lilly, Merck, Novo Nordisk, and Sanofi‐Aventis and has received travel and accomodation expenses from Amylin Pharmaceuticals. Some authors are employees and stockholders of Amylin Pharmaceuticals. One author is an employee and stockholder of Eli Lilly. All research activity and advisory or consultancy services were done under contract with the non‐profit International Diabetes Center at Park Nicollet. </p> <p><b>SAMPLE SIZE:</b> Estimated that 500 participants would provide at least 90% power to detect a statistically significant difference between exenatide and sitagliptin or pioglitazone, and assumptions of a difference of 0.5% between groups, a common SD of 1.2% and an early withdrawal of 10%. </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Computer‐generated randomisation; done centrally by UBC Clinical Technologies via an interactive voice response system and was independent of the sponsor, investigators, study‐site staff and participants; allocated in a 1:1:1 ratio&nbsp; </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interactive voice response system to conceal allocation</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding (performance bias and detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Double‐blind</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Intention‐to‐treat analysis; missing data were imputed by last‐observation‐carried forward method; adequate description of withdrawals and losses to follow up </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>All the predefined and prespecified outcomes were reported</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">E ‐ Blevins 2011 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>TRIAL DESIGN</b>: Randomised, open‐label, comparator‐controlled study </p> <p><b>DURATION OF INTERVENTION</b>: 24 weeks </p> <p><b>DURATION OF FOLLOW‐UP</b>: NR </p> <p><b>RUN‐IN PERIOD:</b> NR </p> <p><b>SETTING</b>: 43 sites </p> <p><b>COUNTRY</b>: United States </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>INCLUSION CRITERIA</b>: At least 18 years of age and diagnosed with type 2 diabetes, otherwise healthy, and treated for at least 2 months with diet and exercise alone or with a stable, maximally effective regimen of metformin, sulphonylurea (SU), thiazolidinedione, or a combination of these medications; HbA1c of 7.1% to 11.0%, FPG less than 280 mg/dL (15.5 mmol/L), BMI from 25 to 45 kg/m<sup>2</sup>. </p> <p><b>EXCLUSION CRITERIA</b>: Patients using concomitant weight loss agents. </p> <p><b>AGE</b>: 55 to 56 years (SD 10 to 11) </p> <p><b>SEX</b>: 40% to 45% female (40% in EX 2 mg once weekly group; 45% in EX 10 µg twice daily group) </p> <p><b>DIABETES DURATION</b>: 7 SD5 years </p> <p><b>ETHNICITY</b>: 55% to 63% Caucasian; 5% to 7% Black; 4% Asian; 29% to 33% Hispanic </p> <p><b>HbA1c (%)</b>: EX 10 µg BID: 8.4 SD 1.2; EX 2 mg QW: 8.5 SD 1.1 </p> <p><b>BMI (kg/m<sup>2</sup>)</b>: EX 10 µg BID: 33.0 SD 5.3; EX 2 mg QW: 33.6 SD 5.5 </p> <p><b>PREVIOUS THERAPY</b>: Diet and exercise only: 16% to 21%; single oral antidiabetic therapy: 43% to 50%; combination oral antidiabetic therapy: 28% to 40% (alone or in combination of: 71% to 80% MET; 28% to 31% SU; 10% to 17% TZD) </p> <p><b>NUMBERS</b>: EX 10 µg BID: 123; EX 2 mg QW: 129 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>COMPARISON:</b> EX 2 mg QW +/‐ MET +/‐ SU +/‐ TZD or EX 10 µg BID +/‐ MET +/‐ SU +/‐ TZD </p> <p><b>NO. OF COMPARISON GROUPS</b>: 2 </p> <p><b>DOSE EX QW:</b> Subcutaneous injection of exenatide 2 mg once weekly or exenatide 10 µg twice daily. </p> <p>lead‐in for 2 mg EX QW: 2 mg once weekly for 24 weeks<br> lead‐in for 10 µg EX BID: 5 µg EX twice daily for 4 weeks, then 10 µg EX twice daily for the remainder of the 20 weeks </p> <p><b>OTHER TREATMENT:</b> Patients not allowed to change their oral antidiabetic, lipid‐lowering, and antihypertensive medications during the study, unless instructed otherwise by the investigator. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>PRIMARY OUTCOMES</b>: Change in HbA1c from baseline to week 24. </p> <p><b>SECONDARY OUTCOMES</b>: Body weight, FPG, proportion of subjects achieving HbA1c targets of less than 7% and 6.5% or less at week 24, proportion of patients achieving FPG target of 126 mg/dL (7.0 mmol/L) or less at week 24, SBP, DBP, fasting lipid concentrations, </p> <p><b>OTHER OUTCOMES:</b> Safety and tolerability; antibody titres. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>AIM</b>: To compare the effects of exenatide once weekly and exenatide twice daily on glycaemic control, body weight, and safety. </p> <p><b>SOURCE OF FUNDING</b>: Amylin Pharmaceuticals </p> <p><b>OTHER</b>: Two authors have received research grants from Amylin Pharmaceuticals, Inc. and serve as advisers and speaker's bureau members for Amylin Pharmaceuticals, Inc. First author has also served as an adviser and speaker's bureau member for Eli Lilly &amp; Co. Some authors are employees and stockholders of Amylin Pharmaceuticals, Inc. One author is an employee and stockholder of Eli Lilly &amp; Co. </p> <p><b>SAMPLE SIZE:</b> A sample size of approximately 250 patients (ratio of 1:1) was estimated to provide 90% power to demonstrate that EX QW was non‐inferior to EX BID by a 0.4% difference in the HbA1c change from baseline to week 24, using a one‐sided, two‐sample t test with a significance level of 0.025 and assuming a greater (0.1%) reduction in HbA1c by EX QW compared with EX BID, a 15% withdrawal rate, and a common SD of 1.1%. </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants were randomised 1:1 to treatment with EX BID or EX QW, with randomisation performed centrally via an interactive voice or web response system. Randomization was stratified according to concomitant SU use at screening and baseline HbA1c stratum (&lt; 9.0% or ≥ 9.0%). </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Randomization performed centrally via an interactive voice or web response system.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding (performance bias and detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Open label; Sponsor personnel remained blinded to HbA1c and FPG data throughout treatment.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>intent‐to‐treat (ITT) population consisted of all randomised patients receiving at least one dose of randomised study medication; Missing post baseline efficacy data were imputed using the last observation carried forward (LOCF) approach; adequate description of withdrawals and loss to follow‐up. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>All the prespecified and predefined outcomes were reported.</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">E ‐ Diamant 2010 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>TRIAL DESIGN</b>: Phase 3, parallel, open‐label, randomised controlled trial </p> <p><b>DURATION OF INTERVENTION</b>: 26 weeks </p> <p><b>DURATION OF FOLLOW‐UP</b>: NR </p> <p><b>RUN‐IN PERIOD:</b> NR </p> <p><b>SETTING</b>: 72 sites </p> <p><b>COUNTRY</b>: USA (and Puerto Rico), the European Union, Russia, Australia, Korea, Taiwan, and Mexico. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>INCLUSION CRITERIA</b>: Participants with type 2 diabetes aged 18 years or older (no upper limit specified) with sub optimum glycaemic control despite maximum tolerated doses of metformin or combined metformin and sulphonylurea treatment for 3 months or longer; HbA1c between 7.1% and 11.0%, inclusive, BMI between 25 kg/m<sup>2</sup> and 45&nbsp; kg/m<sup>2</sup>, stable bodyweight for 3 months or more; participants have had to be treated with a stable dose of metformin of 1500 mg or more per day for 8 or more weeks before screening. </p> <p><b>EXCLUSION CRITERIA</b>: more than three episodes of major hypoglycaemia within 6 months of screening; treatment within 4 weeks of screening with systemic glucocorticoids; and treatment for longer than 2 weeks with insulin, thiazolidinediones, α‐glucosidase inhibitors, meglitinides, exenatide twice‐a‐day formulation, dipeptidyl peptidase‐4 inhibitors or pramlintide acetate within 3 months of screening. Prescription and non‐prescription weight‐loss drugs were excluded within 3 months of screening and during the entire 26‐week study. </p> <p><b>AGE</b>: 58 SD 9 to 10 years </p> <p><b>SEX</b>: 45% to 48% female (EX 2 mg: 48%, GLAR: 45%) </p> <p><b>DIABETES DURATION</b>: 7.8 to 8.0 years (SD 6.0) </p> <p><b>ETHNICITY</b>: &lt; 1% to 1% African American; 82% to 85% White; 6% Asian; 9% to 12% Hispanic </p> <p><b>HbA1c (%)</b>: EX: 8.3 SD 1.1; GLAR: 8.3 SD 1.0 </p> <p><b>BMI (kg/m<sup>2</sup>)</b>: 32 SD 5.0 for both groups </p> <p><b>PREVIOUS THERAPY</b>: 70% MET; 30% MET + SU </p> <p><b>NUMBERS</b>: Screened: 659; randomised: 456 (EX: 233, GLAR: 223) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>COMPARISON:</b> EX 2 mg once weekly + 70% MET/30% MET + SU VERSUS GLAR + MET/MET + SU </p> <p><b>NO. OF COMPARISON GROUPS</b>: 2 </p> <p><b>DOSE EX:</b> EX 2 mg injected into abdominal subcutaneous tissue at randomisation and once a week (within 2 days of date of first injection) thereafter. </p> <p><b>DOSE GLAR:</b> GLAR implemented by INITIATE (Initiate Insulin by Aggressive Titration and Education) dosing algorithm; GLAR treatment started with 10 IU per day, measured FBG concentrations every morning and the dose of insulin adjusted to achieve a target glucose of 4.0 to 5.5 mmol/L. Participants and investigators were asked to adhere to titration targets however there was no central supervision to enforce titration. Insulin was injected at the same time every day, preferably at bedtime. Mean doses of GLAR increased from a baseline of 10 IU per day to 31 IU per day at endpoint (last measurement brought forward). </p> <p><b>DOSE MET:</b> MET was continued in their stable dose until week 26. Mean doses of MET ˜ 2000 mg throughout study, </p> <p><b>DOSE SU:</b> If a participant taking metformin and sulphonylureas had confirmed hypoglycaemia, the dose of sulphonylurea was reduced. 46 (21%) of 223 patients had a reduction in SU dose. </p> <p><b>BOTH GROUPS:</b> Specific instructions for eight‐point self‐monitored blood‐glucose profiles (measured before and 2 hour after morning, midday, and evening meals, at bedtime, and at 0300 hours) were given to both treatment groups. </p> <p><b>OTHER TREATMENT:</b> NR </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>PRIMARY OUTCOMES</b>: Change in HbA1c at week 26 compared with baseline. </p> <p><b>SECONDARY OUTCOMES</b>: Proportion of participants achieving HbA1c targets (&lt; 7.0% and &lt; 6.5%), fasting serum glucose concentrations, self‐monitored blood glucose concentrations, bodyweight, fasting serum lipid concentrations, urinary albumin‐to‐creatinine ratio, high‐sensitivity C‐reactive protein, homeostasis model assessment of β‐cell function and insulin sensitivity, alanine aminotransferase, and 1,5‐anhydroglucitol (a short term marker for glycaemic control). Administered five health outcomes questionnaires: Impact of weight on quality of life‐lite (IWQOL‐Lite), EuroQol instrument (EQ‐5D), binge eating scale (BES) and diabetes treatment satisfaction questionnaire (status version; DTSQs). </p> <p><b>OTHER OUTCOMES:</b> Adverse events, clinical laboratory assessments, vital signs, and hypoglycaemia. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>AIM</b>: To test the hypothesis that improvement in HbA1c concentration achieved with once‐weekly exenatide is better than that achieved with the existing standard second‐line treatment for patients not responding to oral blood‐glucose lowering agents, insulin glargine titrated to glucose targets. </p> <p><b>SOURCE OF FUNDING</b>: Amylin and Eli Lilly </p> <p><b>OTHER</b>: Conflict of interest: First author is a consultant and speaker for Eli Lilly, Novo Nordisk, and Merck, Sharp and Dohme; and a consultant of Sanofi‐Aventis. Through this author, the VU University Medical Centre in Amsterdam has received research grants from Amylin Pharmaceuticals, Eli Lilly, Novo Nordisk, Merck, Sharp and Dohme, Novartis and Takeda. Another author has served on advisory panels for Abbott Laboratories, AstraZeneca, Bristol‐Myers Squibb, Eli Lilly, Novo Nordisk and Sanofi‐Aventis, and has received honoraria as member of the speakers's bureau for Abbott Laboratories, AstraZeneca, Bristol‐Myers Squibb and Eli Lilly. Another author has served on an advisory panel for Eli Lilly, has received travel grants from Novo Nordisk, Eli Lilly, Merck, Sharp and Dohme and Servier and has received research funding support from Sanofi‐Aventis. Some authors are employees of Eli Lilly. One author is an employees of Amylin Pharmaceuticals. </p> <p><b>SAMPLE SIZE:</b> A sample size of 205 patients per treatment was needed to achieve 92% power to detect a difference of 0.4% in change in HbA1c from baseline. </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>One to one allocation and block (size four) randomisation, stratified according to country and oral blood glucose lowering treatment (70% metformin only; 30% metformin plus sulphonylurea). Computer‐generated randomisation sequence administered by the sponsor via an automated voice‐response system. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Computer‐generated randomisation sequence administered by the sponsor via an automated voice‐response system. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding (performance bias and detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Open label (study participants and clinical investigators were not blinded); investigators analysing data were blinded to treatment assignment.&nbsp; </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Modified intention‐to‐treat analysis, details of withdrawals and losses to follow up </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>All the predefined and prespecified outcomes were reported</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">E ‐ Drucker 2008 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>TRIAL DESIGN:</b> Randomised comparator‐controlled, open label trial, non‐inferiority study </p> <p><b>DURATION OF INTERVENTION:</b> 30 weeks </p> <p><b>DURATION OF FOLLOW‐UP:</b> No post‐intervention follow‐up </p> <p><b>SETTING:</b> Not reported </p> <p><b>COUNTRY:</b> Canada/USA </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>INCLUSION CRITERIA:</b> People with type 2 diabetes, aged at least 16 years old, HbA1c between 7% and 11%, FPG &lt; 16 mmol/L, BMI between 25 and 45 kg/m<sup>2</sup>, therapy with diet modification and exercise, or pharmacological treatment with MET, a SU, a TZD, or any combination of two of these agents; weight stable (weight did not vary &gt; 10%) for 6 months prior screening, no abnormal results of clinical significance on blood testing. </p> <p><b>EXCLUSION CRITERIA:</b> Patients who had used meglitinides, alpha‐glucosidase inhibitors, insulin therapy, weight‐loss drugs, corticosteroids, drugs known to affect gastrointestinal motility, or any investigational drug; any exposure to exenatide or a GLP‐1 analogue; or evidence of clinically significant medical conditions that might preclude safe participation in the study. </p> <p><b>AGE:</b> 55 SD 10 years </p> <p><b>SEX:</b> 45% to 49% female </p> <p><b>DIABETES DURATION:</b> 6 to 7 years (SD 5 to 6) </p> <p><b>ETHNICITY:</b> 73% to 83% White, 6% to 13% Black, 11% to 14% Hispanic, 0% to 1% Asian </p> <p><b>HbA1c (%) :</b> EX 2 mg QW: 8.3 SD 1.0; EX 10 µg BID: 8.3 SD 1.0 </p> <p><b>BMI (kg/m<sup>2</sup>):</b> EX 2 mg QW: 35 SD 5; EX 10 µg BID: 35 SD 5 </p> <p><b>PREVIOUS THERAPY:</b> Monotherapy: 43% to 46%, combination therapy: 36% to 39%; all MET: 69% to 77%, all SU: 37%, all TZD: 15% to 17%; diet/exercise only: 14% to 16% </p> <p><b>NUMBERS:</b> Randomised: 303, Analysed as ITT: 295 (8 withdrew before lead‐in); EX 2 mg QW: 148, EX 10 µg BID: 147 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>COMPARISON:</b> EX twice daily + previous therapy VERSUS EX once weekly + previous therapy </p> <p><b>NO. OF COMPARISON GROUPS:</b> 2 </p> <p><b>RUN‐IN:</b> None </p> <p><b>DOSE EX:</b> subcutaneous injection of exenatide 2 mg once a week or 10 µg twice a day<br> lead‐in for 2 mg QW: 3 days 5 µg EX BID, then 2 mg QW<br> lead‐in for 10 µg EX BID: 5 µg EX BID for 28 days, then 10 µg EX BID for the remainder of the 30 weeks </p> <p><b>PREVIOUS THERAPY:</b> Diet/exercise or metformin (MET), sulphonylurea (SU), or thiazolidinedione (TZD) as monotherapy or combination of any two; see above for combinations used, doses of MET, SU and TZD were not reported; to avoid hypoglycaemia, SU dose was reduced to minimum labelled dose until week 10, then up‐titrated to reach target FPG of ≤ 6 mmol/L </p> <p><b>OTHER TREATMENT:</b> Not reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>PRIMARY OUTCOMES:</b> Change in HbA1c at the end of the study i.e. 30 weeks (non‐inferiority within 0.4%) </p> <p><b>SECONDARY OUTCOMES:</b> Safety and tolerability, body weight, fasting plasma glucose (FPG), postprandial glucose (PPG), fasting glucagon, fasting lipids, blood pressure, proportion of patients achieving HbA1c concentrations of ≤ 7.0%, ≤ 6.5%, ≤ 6.0%, overall and by baseline HbA1c strata; HbA1c by antibody titre; bodyweight in the presence and absence of nausea </p> <p><b>OTHER OUTCOMES:</b> Treatment‐emergent adverse events (defined as those occurring on or after receiving the first injection of study medication): patients who lost glucose control (1.5% increase in HbA1c or HbA1c of ≥11.5% at or after week 14; patients with loss of glucose control withdrawn from the study); hypoglycaemic episodes: minor (symptoms of hypoglycaemia and a plasma glucose &lt; 3 mmol/L) and major (loss of consciousness, seizure, or coma; third party assistance to resolve or administration of glucose or glucagon; and a plasma glucose &lt; 3 mmol/L); vital signs, ECG reports, or haematological, chemistry, or urinalysis values </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>AIM:</b> To compare the efficacy and safety of exenatide once a week to that of exenatide given twice daily, over 30 weeks, in patients with type 2 diabetes. </p> <p><b>SOURCE OF FUNDING:</b> Amylin Pharmaceuticals and Eli Lilly and Company. </p> <p><b>OTHER:</b> Conflict of interest: One author has been a consultant for and received lecture honoraria from Amylin, Eli Lilly and Novo Nordisk. </p> <p><b>SAMPLE SIZE:</b> A sample size of 300 patients was estimated to provide 90% power to test the hypothesis that the treatments were non‐inferior with respect to HbA1c control. </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Randomisation method not stated; randomisation was stratified according to concomitant sulphonylurea use at screening and HbA1c strata (&lt; 9.0% vs ≥ 9.0%) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding (performance bias and detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Open label; the investigators, sponsor, patients, and all personnel involved with the study were not blinded to the identity of the study medication; blinding of HbA1c and FPG results </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Missing data were imputed as the last observation carried forward, ITT analysis, adequate description of withdrawals and losses to follow‐up (12% withdrawals, no significant difference between groups) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Included all expected and prespecified outcomes</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">L ‐ Kaku 2010 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>TRIAL DESIGN</b>: Double‐blind, multicenter, randomised, parallel‐group, three arm trial </p> <p><b>DURATION OF INTERVENTION</b>: 24 weeks </p> <p><b>DURATION OF FOLLOW‐UP</b>: This trial was part of a 52 week, multicenter, double‐blind, randomised, parallel‐group trial in which the initial 24 week double‐blind period was followed by a 28 week open label period </p> <p><b>RUN‐IN PERIOD:</b> 4 week preceeded randomisation, after which subjects were stratified according to their pretrial SU therapy. </p> <p><b>SETTING</b>: 49 centres </p> <p><b>COUNTRY</b>: Japan </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>INCLUSION CRITERIA</b>: Japanese men and women ≥ 20 years of age with type 2 diabetes mellitus currently treated with an SU [glibenclamide (1.25 to 10 mg), gliclazide (40 to 160 mg) or glimepiride (1 to 6 mg) for ≥ 8 weeks, HbA1c between 7.0% to &lt; 10%, BMI &lt; 35.0 kg/m<sup>2</sup>. </p> <p><b>EXCLUSION CRITERIA</b>: Treated with insulin within 12 weeks, were receiving or expecting to receive systemic corticosteroids, or had known hypoglycaemia unawareness or recurrent major hypoglycaemia, impaired renal or hepatic function, significant cardiovascular disease (heart failure, coronary artery disease or uncontrolled hypertension) or non stabilized proliferative retinopathy or maculopathy. </p> <p><b>AGE</b>: 58.6 SD 9.7 to 61.3 SD 11.0 years </p> <p><b>SEX</b>: 33% to 40% female (LIR 0.6 mg: 40%; LIR 0.9 mg: 33%; Placebo: 35%) </p> <p><b>DIABETES DURATION</b>: 9.3 SD 5.8 to 11.6 SD 7.7 years </p> <p><b>ETHNICITY</b>: All Japanese patients. </p> <p><b>HbA1c (%)</b>: LIR 0.6 mg: 8.6 SD 0.91; LIR 0.9 mg: 8.21 SD 0.78; Placebo: 8.45 SD 0.99 </p> <p><b>BMI (kg/m<sup>2</sup>)</b>: LIR 0.6 mg: 25.3 SD 3.6; LIR 0.9 mg: 24.4 SD 3.4; Placebo: 24.9 SD 4.0 </p> <p><b>PREVIOUS THERAPY</b>: Treated with SU [glibenclamide (1.25 to 10 mg), gliclazide (40 to 160 mg) or glimepiride (1 to 6 mg) </p> <p><b>NUMBERS</b>: Screened: 308; Randomised: 264 (LIR 0.6 mg: 88; LIR 0.9 mg: 88; Placebo: 88); Fully analysis set: 264 (LIR 0.6 mg: 88; LIR 0.9 mg: 88; Placebo: 88); per‐protocol set: 235 (LIR 0.6 mg: 79; LIR 0.9 mg: 83; Placebo: 73) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>COMPARISON:</b> Liraglutide (LIR) 0.6 mg/0.9 mg + SU VERSUS Placebo + SU </p> <p><b>NO. OF COMPARISON GROUPS</b>: 3 </p> <p><b>DOSE LIR:</b> LIR 0.6 mg or 0.9 mg once daily: LIR doses were up titrated from 0.3 mg/day (50 µl) to 0.6 mg/day (100 µl) after the first week, with an additional increase to 0.9 mg/day (150 µl) for the 0.9 mg cohort after the second week. LIR was injected once daily in the morning or evening s.c. into the upper arm, thigh or abdomen. </p> <p><b>DOSE SU:</b> SU continued in prestudy dose. </p> <p><b>OTHER TREATMENT:</b> NR </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>PRIMARY OUTCOMES</b>: HbA1c level at 24 weeks </p> <p><b>SECONDARY OUTCOMES</b>: 7‐point self‐measured PPG profiles, body weight, FPG, mean PPG, lipid profile and biomarkers for cardiovascular effects, proportions of subjects reaching HbA1c ≤ 7% or ≤ 6.5% </p> <p><b>OTHER OUTCOMES:</b> Incidence of hypoglycaemic episodes (self‐treated hypoglycaemic episodes were classified as minor, while those requiring third party assistance were considered as major and the remainder as symptoms‐only), incidence of adverse events, vital signs and clinical laboratory assessments. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>AIM</b>: the efficacy and safety of two doses of liraglutide (0.6 and 0.9 mg/day) over 24 weeks compared with placebo, in each case as add‐on to SU monotherapy </p> <p><b>SOURCE OF FUNDING</b>: Novo Nordisk </p> <p><b>OTHER</b>: Conflict of interest: NR </p> <p><b>SAMPLE SIZE:</b> No information. </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subjects were stratified according to pretrial SU therapy. Insufficient information</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No information</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding (performance bias and detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Double‐blind</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Efficacy endpoints: Full analysis set; Per protocol set; LOCF; adequate description of adverse events, withdrawals and losses to follow‐up </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>All predefined and prespecified outcomes were reported</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">L ‐ LEAD 1 Marre 2009 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>TRIAL DESIGN</b>: Randomised double‐blind, double dummy, active control, five armed parallel trial, multi‐centre (116 sites) </p> <p><b>DURATION OF INTERVENTION</b>: 26 weeks </p> <p><b>DURATION OF FOLLOW‐UP</b>: No post‐intervention follow‐up </p> <p><b>RUN‐IN PERIOD:</b> 2 weeks </p> <p><b>SETTING</b>: NR </p> <p><b>COUNTRY</b>: 21 countries (mainly in Europe and Asia) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>INCLUSION CRITERIA</b>: Patients with type 2 diabetes, OADs for ≥ 3 months, aged 18 to 80 years old, HbA1c 7% to 11% (previous OAD monotherapy) or 7% to 10% (previous OAD combination therapy), BMI ≤ 45 kg/m<sup>2</sup> </p> <p><b>EXCLUSION CRITERIA</b>: Using insulin within 3 months, impaired liver or renal function, uncontrolled hypertension (≥ 180/100 mm Hg), cancer, use of any drug apart from OAD likely to affect glucose concentrations </p> <p><b>AGE</b>: 54.7 SD 10.0 to 57.7 SD 9.0 years </p> <p><b>SEX</b>: 47% to 55% female </p> <p><b>DIABETES DURATION</b>: (median, 25<sup>th</sup> and 75<sup>th</sup> percentile) 6.5 (3.7, 10.5) to 6.7 (4.0, 10.7) years </p> <p><b>ETHNICITY</b>: NR </p> <p><b>HbA1c (%)</b>: LIR 1.2 mg: 8.5 SD 1.1; LIR 1.8 mg: 8.5 SD 0.9; Placebo: 8.4 SD 1.0; ROS (rosiglitazone): 8.4 SD 1.0 </p> <p><b>BMI (kg/m<sup>2</sup>)</b>: LIR 1.2 mg: 29.8 SD 5.1; LIR 1.8 mg: 30 SD 5.1; Placebo: 30.3 SD 5.4; ROS: 29.4 SD 4.8 </p> <p><b>PREVIOUS THERAPY</b>: Previously on mono‐therapy: 27% to 32%, on combination therapy: 68% to 73% </p> <p><b>NUMBERS</b>: 1712 screened; Randomised: 1041 (1 to 37 participants per centre); LIR 0.6 mg: 233; LIR 1.2 mg: 228; LIR 1.8 mg: 234; Placebo: 114; ROS: 232 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>COMPARISON:</b> LIR (3 doses) + Glimepiride (SU) VERSUS Placebo + SU VERSUS ROS (TZD) + SU </p> <p><b>NO. OF COMPARISON GROUPS</b>: 5 (LIR 0.6 mg not considered in the present review) </p> <p><b>DOSE LIR:</b> 1.2 mg and 1.8 mg: LIR up‐titrated weekly in 0.6 mg increments until the allocated dose reached; injected subcutaneously once daily </p> <p><b>DOSE SU:</b> Forced glimepiride titration for 2 weeks and then 2 weeks maintenance period; glimepiride 2 to 4 mg/day </p> <p><b>DOSE TZD:</b> 4 mg/day rosiglitazone </p> <p><b>OTHER TREATMENT:</b> NR </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>PRIMARY OUTCOMES:</b> &nbsp;HbA1c (change from baseline to end of treatment) </p> <p><b>SECONDARY OUTCOMES</b>: Proportion of participants reaching targeted goals of HbA1c (≤ 7%, ≤ 6.5%), FPG (5 to ≤ 7.2 mmol/L), PPG (10 mmol/L); body weight, FPG (fasting plasma glucose), PPG (post prandial glucose), beta‐cell function, blood pressure; superiority of liraglutide to placebo and non‐inferiority to rosiglitazone was tested </p> <p><b>OTHER OUTCOMES</b>: Hypoglycaemic episodes based on PG levels (&lt; 3.1 mmol/L) (minor: self‐treated; major: requiring third party assistance), liraglutide antibodies including cross‐reacting and neutralizing antibodies, tolerability (gastrointestinal complaints), pulse, adverse events, vital signs, ECG, biochemical and haematological parameters, calcitonin </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>AIM</b>: To compare efficacy and safety of liraglutide and glimepiride combination therapy with either placebo or rosiglitazone added to glimepiride. </p> <p><b>SOURCE OF FUNDING</b>: Novo Nordisk </p> <p><b>OTHER</b>: Conflict of interest: One author had received lecture fees from Novo Nordisk, Servier, MSD. The second author had received honoraria, grants and lecture fees from Novo Nordisk. The remaining authors had no conflict of interest </p> <p><b>SAMPLE SIZE:</b> A combined power (calculated as the product of the marginal powers for HbA1c and body weight) of at least 85% was required. </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information; participants were stratified according to previous treatment (monotherapy or combination therapy) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding (performance bias and detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Double‐blind</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comparisons made on the intent to treat population, missing data imputed using last observation carried forward, adequate description of withdrawals and losses to follow‐up (overall 14% withdrawals, 9 to 27% in the individual groups) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>All pre‐specified (primary and secondary) outcomes were reported</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">L ‐ LEAD 2 Nauck 2009 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>TRIAL DESIGN:</b> RCT, double dummy, active control, parallel group trial (part of a phase 3 clinical development program for liraglutide), multicenter (170 sites) </p> <p><b>DURATION OF INTERVENTION:</b> 26 weeks </p> <p><b>DURATION OF FOLLOW‐UP:</b> No post‐intervention follow‐up </p> <p><b>RUN‐IN PERIOD:</b> 6 weeks </p> <p><b>SETTING:</b> Not reported </p> <p><b>COUNTRY:</b> Multinational (21 countries) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>INCLUSION CRITERIA:</b> People with type 2 diabetes, age 18 to 80 years old, HbA1c between 7% and 11% (prestudy OAD monotherapy for ≥ 3 months) or between 7% and 10% (prestudy combination OAD therapy for ≥ 3 months), BMI ≤ 40 kg/m<sup>2</sup> </p> <p><b>EXCLUSION CRITERIA:</b> Patients who had used insulin during the previous 3 months (except short term treatment) </p> <p><b>AGE:</b> mean 56 to 57 years (SD 9) </p> <p><b>SEX:</b> 40% to 46% female </p> <p><b>DIABETES DURATION:</b> mean 7 to 8 years (SD 5) </p> <p><b>ETHNICITY:</b> 88% to 89% White, 2% to 4% Black, 7% to 9% Asian, 1% to 3% other </p> <p><b>HbA1c (%):</b> LIR 1.2 mg: 8.3 SD 1, LIR 1.8 mg: 8.4 SD 1, SU: 8.4 SD 1, Placebo: 8.4 SD 1.1 </p> <p><b>BMI (kg/m<sup>2</sup>):</b> LIR 1.2 mg: 31.1 SD 4.8, LIR 1.8 mg: 30.9 SD 4.6, SU: 31.2 SD 4.6, Placebo: 31.6 SD 4.4 </p> <p><b>PREVIOUS THERAPY:</b> 65% combination therapy, 35% monotherapy (88% metformin) </p> <p><b>NUMBERS:</b> Randomised: 1091 (4 withdrew consent before treatment), Analysed as ITT: 1087; LIR 0.6 mg: 242, LIR 1.2 mg: 240, LIR 1.8 mg: 242, SU: 242, Placebo: 121 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>COMPARISON:</b> Liraglutide (LIR) (3 doses) + Metformin (MET) VERSUS Glimepiride (SU) + MET VERSUS Placebo + MET </p> <p><b>NO. OF COMPARISON GROUPS:</b> 5 </p> <p><b>RUN‐IN:</b> Forced titration period of metformin for three weeks (dose increased up to 2000 mg/day: 1000 mg in the morning and 1000 mg in the evening) followed by a 3 week metformin maintenance period before randomisation. </p> <p><b>DOSE LIR:</b> 0.6, 1.2 or 1.8 mg/day injected subcutaneously once daily (0.6 mg not included in this review). LIR titrated after randomisation for 2 to 3 weeks (increase by 0.6 mg/day per week) </p> <p><b>DOSE MET:</b> 1500 to 2000 mg/day </p> <p><b>DOSE SU:</b> 4 mg glimepiride OD with&nbsp; the first meal of the day. Glimepiride (SU) titrated after randomisation for 2 to 3 weeks (1 mg in week 1, 2 mg week 2, 4 mg week 3) </p> <p><b>OTHER TREATMENT:</b> not reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>PRIMARY OUTCOMES:</b> Change in HbA1c at the end of the study </p> <p><b>SECONDARY OUTCOMES:</b> Body weight, fasting plasma glucose (FPG), postprandial glucose (PPG) (7 point plasma glucose profiles: before each meal, 90 min after breakfast), beta cell function (based on fasting insulin, fasting C‐peptide, fasting proinsulin‐to‐insulin ratio and the homeostasis model assessment index of beta cell function (HOMA‐B)) </p> <p><b>OTHER OUTCOMES:</b> Adverse events, vital signs, electrocardiogram, biochemical and hematology measures, and subject‐reported hypoglycaemic episodes (based on symptoms and plasma glucose &lt;3.1 mmol/L) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>AIM:</b> To study the efficacy and safety of Liraglutide as a combination therapy with metformin as compared with placebo and glimepiride in addition to metformin </p> <p><b>SOURCE OF FUNDING:</b> Novo Nordisk (presumably) </p> <p><b>OTHER:</b> Conflict of interest: Some authors are members of advisory board and have received honoraria from Novo Nordisk, and work for Novo Nordisk. </p> <p><b>SAMPLE SIZE:</b> The combined power (calculated as the product of the marginal powers for A1C and weight) was at least 85%. </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Randomly assigned as 2:2:2:1:2. Telephone or web based randomisation. Patients randomly assigned to the lowest available randomisation number and stratified with respect to their previous use of OAD monotherapy or combination therapy </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Telephone or web based randomisation</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding (performance bias and detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Double blinding</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Missing data were imputed as the last observation carried forward, ITT analysis, adequate description of withdrawals and losses to follow‐up (19% withdrawals and losses to follow‐up) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Included all expected outcomes, including those prespecified</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">L ‐ LEAD 4 Zinman 2009 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>TRIAL DESIGN:</b> RCT (1:1:1), placebo control, parallel group, multicenter (96 sites) </p> <p><b>DURATION OF INTERVENTION:</b> 26 weeks </p> <p><b>DURATION OF FOLLOW‐UP:</b> No post‐intervention follow‐up </p> <p><b>RUN‐IN PERIOD:</b> 6 to 9 weeks </p> <p><b>SETTING:</b> Not reported </p> <p><b>COUNTRY:</b> USA and Canada </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>INCLUSION CRITERIA:</b> people with type 2 diabetes, 18 to 80 years of age HbA1c between 7% to 11% (prestudy OAD monotherapy for ≥ 3 months or 7% to 10% (prestudy OAD combination therapy for ≥ 3 months, BMI ≤ 45kg/m<sup>2</sup>; eligibility for randomisation: participants tolerating maximum doses of OAD (metformin and rosiglitazone) and with FPG values of 135 to 230 mg/dL (7.5 to 12.8 mmol/L) after 6 weeks treatment with titrated dose </p> <p><b>EXCLUSION CRITERIA:</b> Participants using insulin during the previous 3 months (except short term treatment) </p> <p><b>AGE:</b> mean 55 years (SD 10) </p> <p><b>SEX:</b> 38% to 49% female </p> <p><b>DIABETES DURATION:</b> mean 9 years (SD 6) </p> <p><b>ETHNICITY:</b> 81% to 84% White, 10% to 15% Black, 1% to 3% Asian, 1% American Indian, 2% to 3% other </p> <p><b>HbA1c (%):</b> LIR 1.2 mg: 8.5 SD 1.2, LIR 1.8 mg: 8.6 SD 1.2, Placebo: 8.4 SD 1.2 </p> <p><b>BMI (kg/m<sup>2</sup>):</b> LIR 1.2 mg: 33.2 SD 5.4, LIR 1.8 mg: 33.5 SD 5.1, Placebo: 33.9 SD 5.2 </p> <p><b>PREVIOUS THERAPY:</b> 17% monotherapy, 83% combination therapy </p> <p><b>NUMBERS:</b> 533 randomised; LIR 1.2 mg:178; LIR 1.8 mg:178; Placebo:177 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>COMPARISON:</b> Liraglutide (LIR) (2 doses) + Metformin (MET) + Rosiglitazone (TZD) VERSUS Placebo + MET + TZD </p> <p><b>NO. OF COMPARISON GROUPS:</b> 3 </p> <p><b>RUN‐IN:</b> Treatment with other OADs except MET and TZD were discontinued prior to randomisation. MET dose started at 500 mg and was titrated up to 2000 mg/day. Rosiglitazone (TZD) dose started at 4 mg and was titrated up to 8 mg/day. </p> <p><b>DOSE LIR:</b> LIR 1.2 mg/day or 1.8 mg/day injected subcutaneously once daily. LIR started with 0.6 mg/day for a week and increased up to 1.2 mg/day and then to 1.8 mg/day after an additional week for those randomised to highest dose </p> <p><b>DOSE MET:</b> 2000 mg/day (1000 mg in the morning and 1000 mg in the evening) </p> <p><b>DOSE TZD:</b> Rosiglitazone 8 mg/day (4 mg in the morning and 4 mg in the evening) </p> <p><b>OTHER TREATMENT:</b> None </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>PRIMARY OUTCOMES:</b> HbA1c (change from randomisation to end of study) </p> <p><b>SECONDARY OUTCOMES:</b> Change in following parameters: body weight, FPG (Fasting plasma glucose), PPG (Postprandial glucose) (from 7‐point plasma glucose profiles), beta‐cell function (based on fasting insulin, fasting C‐peptide, fasting pro‐insulin to insulin ratio, and the homeostasis model assessment (HOMA) for beta cells (HOMA‐B) and insulin resistance (HOMA‐IR)), blood pressure, lipids </p> <p><b>OTHER OUTCOMES:</b> Safety variables including adverse events, vital signs, ECG, biochemical and haematology measures, and subject reported hypoglycaemic episodes (plasma glucose &lt; 3.1 mmol/L) </p> <p>Superiority of liraglutide tested</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>AIM:</b>To study the efficacy and safety of Liraglutide as a combination therapy with metformin and rosiglitazone in type 2 diabetes </p> <p><b>SOURCE OF FUNDING:</b> Novo Nordisk (presumably) </p> <p><b>OTHER:</b> Conflict of interest Novo Nordisk, Denmark </p> <p><b>SAMPLE SIZE:</b> The combined power (calculated as the product of the marginal powers for HbA1c and weight) was &gt; 95%. </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Randomised as 1:1:1. Telephone or web based randomisation; protocol states: "Randomisation will be carried out centrally using a randomisation system, IVRS/IWRS" [Interactive voice (or web) response system] </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Telephone or web based randomisation</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding (performance bias and detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Double blinding</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Missing data were imputed as the last observation carried forward (LOCF), ITT analysis, adequate description of withdrawals and losses to follow‐up (24% withdrawals and losses to follow‐up) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Included all prespecified outcomes</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">L ‐ LEAD 5 Russell‐J 2009 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>TRIAL DESIGN:</b> RCT (2:1:2), parallel group, placebo‐controlled, multicenter (107 sites) </p> <p><b>DURATION OF INTERVENTION:</b> 26 weeks </p> <p><b>DURATION OF FOLLOW‐UP:</b> 1 week post‐intervention follow‐up (but no data given) </p> <p><b>RUN‐IN PERIOD:</b> 6 weeks </p> <p><b>SETTING:</b> Not reported </p> <p><b>COUNTRY:</b> Multinational (17 countries) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>INCLUSION CRITERIA:</b> People with type 2 diabetes, 18 to 80 years, treated with OAD for at least 3 months before screening, HbA1c level between 7.5% to 10% (monotherapy) or 7% to 10% (combination therapy), BMI ≤ 45kg/m<sup>2</sup> </p> <p><b>EXCLUSION CRITERIA:</b> Patients who had used insulin within 3 months prior to the trial; patients with impaired renal or hepatic function, cardiovascular disease, cancer, hypertension, retinopathy, maculopathy; pregnant patients; those with recurrent hypoglycaemia or hypoglycaemia awareness; those who were seropositive for hepatitis B antigen or hepatitis C antibody; or who have used any other drugs except OAD that could affect blood glucose levels </p> <p><b>AGE:</b> mean 57.5 years (SD10) </p> <p><b>SEX:</b> 40% to 51% female </p> <p><b>DIABETES DURATION:</b> mean 9.2 to 9.7 years (SD 6) </p> <p><b>ETHNICITY:</b> Not reported </p> <p><b>HbA1c (%):</b> LIR: 8.3 SD 0.9, Placebo: 8.3 SD 0.9, GLAR (insulin glargine): 8.2 SD 0.9 </p> <p><b>BMI (kg/m<sup>2</sup>):</b> LIR: 30.4 SD5 .3, Placebo: 31.3 SD 5.0, GLAR: 30.3 SD 5.3 </p> <p><b>EXISTING THERAPY:</b> 5 to 6% monotherapy, 94% to 95% combination treatment </p> <p><b>NUMBERS:</b> 581 randomised, ITT population 576; LIR: 230, Placebo: 114, GLAR: 232 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>COMPARISON:</b> Liraglutide (LIR) + Metformin (MET) + Glimepiride (SU) VERSUS Placebo + MET + SU VERSUS GLAR + MET + SU </p> <p><b>NO. Of COMPARISON GROUPS:</b> 3 </p> <p><b>RUN‐IN:</b> Forced MET and SU dose escalation over 3 weeks followed by 3 weeks maintenance </p> <p><b>DOSE LIR:</b> 1.8 mg OD. Dose escalation starting at 0.6 mg and increasing weekly by 0.6 mg over 2 weeks. </p> <p><b>DOSE MET:</b> 2 gm (1 gm BID) </p> <p><b>DOSE SU:</b> Glimepiride 4 mg OD, reduction to 2 mg allowed in case of adverse events or hypoglycaemia </p> <p><b>DOSE GLAR:</b> Insulin glargine (open label). Insulin was titrated according to patient‐driven algorithm (average dose at the end of study was 24 IU/day) </p> <p><b>OTHER TREATMENT:</b> None </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>PRIMARY OUTCOMES:</b> HbA1c (change from baseline to end) </p> <p><b>SECONDARY OUTCOMES:</b> Change in weight, FPG, eight point plasma glucose (PG) profiles, beta‐cell function, and blood pressure </p> <p><b>OTHER OUTCOMES:</b> Safety variables like hypoglycaemic episodes, adverse events </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>AIM:</b> To compare the efficacy and safety of liraglutide to insulin glargine all as add on to combination therapy of metformin and glimepiride </p> <p><b>SOURCE OF FUNDING:</b> Novo Nordisk (presumably) </p> <p><b>OTHER:</b> Conflict of interest: Novo Nordisk, Amylin Pharmaceuticals </p> <p><b>SAMPLE SIZE:</b> Study was powered to determine a 3% difference in weight with a combined power &gt; 85%. </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Randomised as 2:1:1 using a telephone or web‐based randomisation system</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Central randomisation using a telephone or web‐based randomisation system</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding (performance bias and detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Investigators, participants, and study monitors were blinded to liraglutide, open label glargine </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Missing data were imputed as the last observation carried forward (LOCF), ITT analysis, adequate description of withdrawals and losses to follow‐up (9.4% withdrawals and losses to follow‐up) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Included all prespecified outcomes</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">L ‐ LEAD 6 Buse 2009 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>TRIAL DESIGN:</b> RCT, open label, active comparator, parallel group, multi‐centre (132 sites) </p> <p><b>DURATION OF INTERVENTION:</b> 26 weeks </p> <p><b>DURATION OF FOLLOW‐UP:</b> No post‐intervention follow‐up </p> <p><b>RUN‐IN PERIOD:</b> None </p> <p><b>COUNTRY:</b> 15 countries </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>INCLUSION CRITERIA:</b> People with type 2 diabetes, 18 to 80 years old, HbA1c between 7% and 11%, BMI ≤ 45 kg/m<sup>2</sup>, stable on treatment with maximally tolerated dose of metformin, sulphonylurea, or both, for 3 months or more </p> <p><b>EXCLUSION CRITERIA:</b> Previous insulin treatment (except short term treatment), previous treatment with exenatide or liraglutide, impaired renal or liver function, diseases like retinopathy or maculopathy or related to cardiovascular requiring acute treatment, uncontrolled hypertension, cancer </p> <p><b>AGE:</b> mean 56 to 57 years (SD 10) </p> <p><b>SEX:</b> 45% to 51% female </p> <p><b>DIABETES DURATION:</b> mean 7.9 to 8.5 years (SD 6) </p> <p><b>ETHNICITY:</b> 91% to 93% White, 1% to 5% Asian, 12% to 13% Black, 3% to 4% other </p> <p><b>HbA1c (%):</b> LIR: 8.2 SD 1.0, EX: 8.1 SD 1.0 </p> <p><b>BMI (kg/m<sup>2</sup>):</b> LIR: 32.9 SD 5.5, EX: 32.9 SD 5.7 </p> <p><b>PREVIOUS THERAPY:</b> 62% to 64% MET plus SU, 27% MET monotherapy, 9% to 10% SU monotherapy </p> <p><b>NUMBERS:</b> 464 randomised; LIR: 233; EX: 231; (exposed LIR: 235; EX: 232) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>COMPARISON:</b> LIR + existing therapy MET and/or SU VERSUS EX + existing MET and/or SU therapy </p> <p><b>NO. OF COMPARSION GROUPS:</b> 2 </p> <p><b>RUN‐IN:</b> None </p> <p><b>DOSE LIR:</b> Liraglutide 1.8 mg OD; 2 week dose escalation starting at 0.6 mg/day increasing weekly by 0.6 mg up to 1.8 mg </p> <p><b>DOSE EX:</b> Exenatide 10 μg BID; 4 week dose escalation starting at 5 μg BID increasing to 10 μg BID at 4 weeks </p> <p><b>DOSE MET:</b> Prestudy dose </p> <p><b>DOSE SU:</b> Prestudy dose, in case of unacceptable hypoglycaemia SU dose could be reduced to no less than 50% of starting dose </p> <p><b>OTHER TREATMENT:</b> None </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>PRIMARY OUTCOMES:</b> Change in HbA1c % from baseline to end point </p> <p><b>SECONDARY OUTCOMES:</b> Reduction in FPG levels (mmol/L), % of patients who achieved a target HbA1c level ≤ 7%, % of patients who achieved a target HbA1c level ≤ 6.5%, mean change in body weight %, mean changes in self measured 7‐point plasma glucose profiles, % change in HOMA‐B from baseline, mean changes in glucagon, blood pressure and lipid profiles, overall treatment satisfaction (Diabetes Treatment Satisfaction questionnaire) assessed in a subgroup of patients </p> <p><b>OTHER OUTCOMES:</b> Safety variables including adverse events, vital signs, electrocardiogram, biochemical and haematological measures, and patient reported hypoglycaemic episodes were assessed. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>AIM:</b> To compare the effectiveness of liraglutide to exenatide as an add on therapy to metformin and/or sulphonylurea. </p> <p><b>SOURCE OF FUNDING:</b> Novo Nordisk </p> <p><b>OTHER:</b> Conflict of interest: main author is a member of advisory board and have received honoraria from Novo Nordisk and various other pharmaceutical companies, and work as consultant for various other pharmaceutical companies. </p> <p><b>SAMPLE SIZE:</b> 85% power to detect an HbA1c difference of 0.4% between groups. </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Randomly assigned (1:1) to the lowest available number of the numbers allocated to the site </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Randomisation was done with telephone based or web based system</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding (performance bias and detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Open label</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Last observation carried forward data with repeated measures analysis and multiple imputation methods, ITT analysis, adequate description of withdrawals and losses to follow‐up (17% withdrawals and losses to follow‐up) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>All prespecified outcomes reported</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">L ‐ Pratley 2010 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>TRIAL DESIGN</b>: Active comparator, parallel‐group, open label trial; non‐inferiority and superiority comparison </p> <p><b>DURATION OF INTERVENTION</b>: 26 weeks </p> <p><b>DURATION OF FOLLOW‐UP</b>: After the 26 week study, participants could continue into a 12 month follow‐up trial </p> <p><b>RUN‐IN PERIOD:</b> </p> <p><b>SETTING</b>: 158 office‐based sites </p> <p><b>COUNTRY</b>: Multinational (11 European countries: Croatia, Germany, Ireland, Italy, Netherlands, Romania, Serbia, Slovakia, Slovenia, Spain and UK; the USA and Canada) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>INCLUSION CRITERIA</b>: Participants aged between 18 to 80 years; type 2 diabetes mellitus, HbA1c of 7.5% to10.0%; BMI ≤ 45 kg/m<sup>2</sup>; treated with metformin ≥ 1500 mg daily for 3 months or longer. </p> <p><b>EXCLUSION CRITERIA</b>: Previous treatment with any antihyperglycaemic drug apart from metformin within 3 months of the trial; recurrent major hypoglycaemia or hypoglycaemia unawareness; present use of any drug except metformin that could affect glucose; contraindications to trial drugs; impaired renal or hepatic function; clinically significant cardiovascular disease; or cancer. </p> <p><b>AGE</b>: 55.0 SD 9.0 to 55.9 SD9.6 years </p> <p><b>SEX</b>: 45% to 48% female (LIR 1.2 mg: 48%; LIR 1.8 mg: 48%; SITA: 45%) </p> <p><b>DIABETES DURATION</b>: 6.0 SD 4.5 to 6.4 SD 5.4 years </p> <p><b>ETHNICITY</b>: 82% to 91% White (15% to 17% Hispanic or Latino); 5% to 10% Black; 1% to 2% Asian or Pacific Islander; 4% to 5% Other </p> <p><b>HbA1c (%)</b>: LIR 1.2 mg: 8.4 SD 8.0; LIR 1.8 mg: 8.4 SD 0.7; SITA: 8.5 SD 0.7 </p> <p><b>BMI (kg/m<sup>2</sup>)</b>: LIR 1.2 mg: 32.6 SD 5.2; LIR 1.8 mg: 33.1 SD 5.1; SITA: 32.6 SD 5.4 </p> <p><b>PREVIOUS THERAPY</b>: MET </p> <p><b>NUMBERS</b>: Assessed: 1302; randomised: 665 (LIR 1.2 mg: 225; LIR 1.8 mg: 221; SITA: 219); full analysis set: 658 (LIR 1.2 mg: 221; LIR 1.8 mg: 218; SITA: 219); fully analysis/safety analysis set: 658 (LIR 1.2 mg: 221; LIR 1.8 mg: 218; SITA: 219) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>COMPARISON:</b> LIR 1.2 mg or 1.8 mg once daily&nbsp; + MET VERSUS SITA 100 mg daily + MET </p> <p><b>NO. OF COMPARISON GROUPS</b>: 3 </p> <p><b>DOSE LIR:</b> LIR started at 0.6 mg/day and escalated by 0.6 mg/week to the allocated dose; s.c. with a pen device. </p> <p><b>DOSE SITA:</b> SITA was started and maintained at 100 mg/day. </p> <p><b>DOSE MET:</b> Background treatment with MET remained stable. </p> <p><b>OTHER TREATMENT:</b> NR </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>PRIMARY OUTCOMES</b>: Change in HbA1c from baseline to week 26 </p> <p><b>SECONDARY OUTCOMES</b>: Superiority and non‐inferiority comparisons; proportions of participants reaching HbA1c targets of less than 7.0% (ADA) or of 6.5% or lower (AACE, IDF, NICE); FPG; PPG; bodyweight; β‐cell function; fasting lipid profile; cardiovascular risk markers (high sensitivity C‐reactive protein, plasminogen activator inhibitor type 1, N‐terminal pro‐B‐type natriuretic peptide, adiponectin, interleukin‐6, tumour necrosis factor α, and von Willebrand factor); BP; HR; physical measures (waist circumference, waist‐to‐hip ratio); treatment satisfaction; and a composite endpoint of proportions of participants with HbA1c &lt; 7% with no hypoglycaemia, and weight change of 0kg or less. </p> <p><b>OTHER OUTCOMES:</b> Adverse events, self‐reported hypoglycaemia, and selected haematological and biochemical measures including calcitonin.<br> Minor hypoglycaemic episodes (PG &lt; 3.1 mmol/L); Major hypoglycaemic episodes (third‐party assistance irrespective of glucose concentrations). </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>AIM</b>: To compare the efficacy and safety of treatment with liraglutide or sitagliptin for 26 weeks in individuals with type 2 diabetes who did not achieve adequate glycaemic control with metformin. </p> <p><b>SOURCE OF FUNDING</b>: Novo Nordisk </p> <p><b>OTHER</b>: Conflict of interest: Authors have received grants and consultancy fees from different pharmaceutical companies. </p> <p><b>SAMPLE SIZE:</b> To show that 1.8 mg liraglutide plus metformin was non‐inferior to 100 mg sitagliptin with metformin with a margin of 0.4%, 163 participants per group were needed for 85% power and with a predicted withdrawal of 25%, 217 participants per group were needed.&nbsp; </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Computer‐generated by Novo Nordisk; participants randomly assigned in a 1:1:1 ratio, stratified by country, to receive 1.2 mg or 1.8 mg s.c. liraglutide once daily or 100 mg oral sitagliptin once daily. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Computer‐generated; consecutive allocation of the randomisation code to individual participants was concealed by use of a telephone‐based (interactive voice response system) or web‐based (interactive web response system) randomisation system. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding (performance bias and detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Open label; data were masked from the statistician until database release</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Primary efficacy analyses: full analysis set with missing values imputed by last observation carried forward; Secondary efficacy analyses: full analysis set, apart from treatment satisfaction analyses, in which missing data were no imputed; Superiority: full analysis set; Non‐inferiority: full analysis and per‐protocol sets.<br> Adequate description of withdrawals and loss to follow up. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>All prespecified outcomes reported</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">L ‐ Yang 2010 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>TRIAL DESIGN</b>: Double‐blind, double dummy, randomised, four‐arm, active control trial </p> <p><b>DURATION OF INTERVENTION</b>: 16 weeks </p> <p><b>DURATION OF FOLLOW‐UP</b>: </p> <p><b>RUN‐IN PERIOD:</b> Eligible participants discontinued their pretrial OADs except metformin and entered a 3‐week run‐in with forced escalation of metformin to 2000 mg/day, followed by another 3‐week metformin maintenance period. </p> <p><b>SETTING</b>: China (17 sites), South Korea (10 sites) and India (24 sites) </p> <p><b>COUNTRY</b>: China, South Korea and India </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>INCLUSION CRITERIA</b>: Participants diagnosed with type 2 diabetes and treated with one or more oral antidiabetic drugs (OADs) for at least 3 months, aged 18 to 80 years (18 to 75 years for Chinese subjects), with HbA1c ≥ 7.0% and ≤ 11.0% for subjects on OAD monotherapy or ≥ 7.0% and ≤ 10.0% for subjects on OAD combination therapy and BMI ≤ 45.0 kg/m<sup>2</sup>. </p> <p><b>EXCLUSION CRITERIA</b>: Participants treated with insulin within the last 3 months.&nbsp; </p> <p><b>AGE</b>: 52.7 SD 9.1 to 53.6 SD9.7 years </p> <p><b>SEX</b>: 41.6% to 46.2% female (LIR 1.2 mg: 45.1%; LIR 1.8 mg: 46.2%; GLIM (Glimepiride): 41.6%) </p> <p><b>DIABETES DURATION</b>: 7.2 SD 5.2 to 7.8 SD 6.1 years </p> <p><b>ETHNICITY</b>: NR </p> <p><b>HbA1c (%)</b>: LIR 1.2 mg: 8.6 SD 1.1; LIR 1.8 mg: 8.6 SD 1.1; GLIM: 8.5 SD 1.1 </p> <p><b>BMI (kg/m<sup>2</sup>)</b>: LIR 1.2 mg: 25.4 SD 3.7; LIR 1.8 mg: 25.8 SD 3.8; GLIM: 25.3 SD 3.7 </p> <p><b>PREVIOUS THERAPY</b>: OAD monotherapy: 29.4% to 32.1%; OAD combination: 67.9% to 70.6% </p> <p><b>NUMBERS</b>: Randomised: 926; Exposed: 928 (LIR 1.2 mg: 233; LIR 1.8 mg: 233; GLIM: 231); per‐protocol set: 562 (LIR 1.2 mg: 179; LIR 1.8 mg: 172; GLIM: 211) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>COMPARISON:</b> LIR 0.6 mg/1.2 mg/1.8 mg + MET + GLIM Placebo VERSUS GLIM + MET + LIR placebo </p> <p><b>NO. OF COMPARISON GROUPS</b>: 3 (LIR 0.6 mg arm excluded) </p> <p><b>DOSE LIR 1.2 mg/ LIR 1.8 mg:</b> dose of LIR was increased from 0.6 mg/day to the respective target dose level (in steps of 0.6 mg/day per week) LIR was injected once daily at any time of the day. </p> <p><b>DOSE GLIM:</b> Subjects were instructed to start dose escalation of GLIM by daily administration of a 1 mg capsule. Further dose escalation took place over a 2‐week period, incrementing to a maximum dose of 4 mg/day. </p> <p><b>DOSE LIR PLACEBO:</b> dose of LIR placebo was increased from 0.6 mg/day to the respective target dose level (in steps of 0.6 mg/day per week) LIR was injected once daily at any time of the day. </p> <p><b>DOSE GLIM PLACEBO:</b> start dose escalation of GLIM placebo by daily administration of a 1 mg capsule. Further dose escalation took place over a 2‐week period, incrementing to a maximum dose of 4 mg/day. </p> <p><b>OTHER TREATMENT:</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>PRIMARY OUTCOMES</b>: Change in HbA1c from baseline to the end of the trial </p> <p><b>SECONDARY OUTCOMES</b>: Changes in body weight, FPG, 7‐point self‐measured plasma glucose profile [before each main meal (breakfast, lunch and dinner), 90 min after start of each main meal, and at bedtime], blood pressure (BP) and β‐cell function measured by the homeostasis model assessment index of β‐cell function and the pro‐insulin to insulin ratio. </p> <p><b>OTHER OUTCOMES:</b> Safety variables included AEs, physical examination, pulse rate, electrocardiogram, haematology, biochemistry and urine measures, formation of liraglutide antibodies and subject reported hypoglycaemic events (based on symptoms and plasma glucose &lt; 3.1 mmol/L). Minor hypoglycaemic events were self‐treated; major events required third‐party assistance. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>AIM</b>: To assess and compare the efficacy and safety of liraglutide with those of glimepiride, both in combination with metformin for the treatment of type 2 diabetes in Asian population from China, South Korea and India. </p> <p><b>SOURCE OF FUNDING</b>: Novo Nordisk </p> <p><b>OTHER</b>: Conflict of interest: Two authors are employees of Novo Nordisk. Other authors have no competing interests. </p> <p><b>SAMPLE SIZE:</b> In order to be able to show that liraglutide was non‐inferior to glimepiride when using a 1 : 1 : 1 : 1 randomisation and a non‐inferiority margin of 0.4% (difference in HbA1c reduction) with a power of at least 85%, the sample size needed was 168 subjects per group. Assuming a drop out rate of 25%, the total number of subjects to be randomised was 896 (224 subjects for each dose of the liraglutide + metformin group and 224 in glimepiride + metformin group). </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Inadequate information; participants were stratified with respect to their pretrial OAD therapy (monotherapy or combination) and randomised into 1:1:1:1 ratio </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No information</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding (performance bias and detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Double blind</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Full analysis set (FAS) with LOCF; adequate description of adverse events, withdrawals and loss to follow‐up. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>All the pre‐defined and pre‐specified outcomes were reported.</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Lixi ‐ Ratner 2010 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>TRIAL DESIGN</b>: Multinational, randomised, double‐blind, parallel‐group, placebo controlled trial </p> <p><b>DURATION OF INTERVENTION</b>: 13 weeks </p> <p><b>DURATION OF FOLLOW‐UP</b>: </p> <p><b>RUN‐IN PERIOD:</b> Initial 2 week screening phase, then, a 2 week, single‐blind, placebo run‐in period. </p> <p><b>SETTING</b>: 133 centres </p> <p><b>COUNTRY</b>: Multinational </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>INCLUSION CRITERIA</b>: Participants with type 2 diabetes at least 1 year's duration aged 30 to 75 years and inadequately controlled (HbA1c ≥ 7.0 and &lt; 9.0%) on stable metformin monotherapy (≥ 1000 mg day) for at least 3 months prior to screening. </p> <p><b>EXCLUSION CRITERIA</b>: History of gastrointestinal disease with prolonged nausea and vomiting during the previous 6 months; history of chronic pancreatitis or stomach/gastric surgery; severe cardiovascular events during the previous 6 months; or hepatic or renal disease at screening [serum creatinine ≥ 114.4 µmol/L for males and ≥ 106.8 µmol/L for females. </p> <p><b>AGE</b>: 55.4 SD 9.2 to 56.8 SD 7.8 years </p> <p><b>SEX</b>: 40.4% to 63% female </p> <p><b>DIABETES DURATION</b>: 6.0 SD 4.8 to 7.2 SD 4.9 years </p> <p><b>ETHNICITY</b>: 64.8% to 86.8% Caucasian, 1.8% to 16.7% Black, 9.3% to 21.8% Other </p> <p><b>HbA1c (%)</b>: LIXI 5 μg QD: 7.58 SD 0.7; LIXI 10 μg QD: 7.52 SD 0.6; LIXI 20 μg QD: 7.58 SD 0.7; LIXI 30 μg QD: 7.52 SD 0.7; LIXI 5 μg BID: 7.60 SD 0.6; LIXI 10 μg BID: 7.54 SD 0.6; LIXI 20 μg BID: 7.61 SD 0.7; LIXI 30 μg BID: 7.46 SD 0.5; Placebo: 7.53 SD 0.6 </p> <p><b>BMI (kg/m<sup>2</sup>)</b>: LIXI 5 μg QD: 30.7 SD 4.6; LIXI 10 μg QD: 31.9 SD 4.0; LIXI 20 μg QD: 32.0 SD 4.3; LIXI 30 μg QD: 31.6 SD 3.6; LIXI 5 μg BID: 31.6 SD 4.2; LIXI 10 μg BID: 32.8 SD 4.4; LIXI 20 μg BID: 32.7 SD 4.4; LIXI 30 μg BID: 32.3 SD 4.5; Placebo: 31.7 SD 4.2 </p> <p><b>PREVIOUS THERAPY</b>: MET </p> <p><b>NUMBERS</b>: Screened: 1466; randomised: 542 (LIXI 5 μg QD: 55; LIXI 10 μg QD: 52; LIXI 20 μg QD: 55; LIXI 30 μg QD: 54; LIXI 5 μg BID: 53; LIXI 10 μg BID: 56; LIXI 20 μg BID: 54; LIXI 30 μg BID: 54; Placebo: 55) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>COMPARISON:</b> Lixisenatide (LIXI) 5 μg, 10 μg, 20 μg and 30 μg QD or BID VERSUS Placebo </p> <p><b>NO. OF COMPARISON GROUPS</b>: 9 </p> <p><b>DOSE LIXI:</b> Subcutaneous injections of LIXI doses of 5, 10, 20 or 30 μg administered once daily or, twice daily within 1 hour before breakfast </p> <p><b>DOSE PLACEBO:</b> One of four volume‐matched placebo treatments administered twice daily. </p> <p><b>DOSE MET:</b> Stable doses of MET </p> <p><b>OTHER TREATMENT:</b> All patients received diet and lifestyle counselling according to the American Diabetes Association guidelines. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>PRIMARY OUTCOMES</b>: Change in HbA1c from baseline to end of study. </p> <p><b>SECONDARY OUTCOMES</b>: Percentage of patients achieving an HbA1c ≤ 7.0 or ≤ 6.5%, changes in body weight, FPG, and 2 h post‐prandial plasma glucose after a standardized breakfast. Measurement of anti‐lixisenatide antibody levels; safety and tolerability. </p> <p><b>OTHER OUTCOMES:</b> Assessed by physical examination, adverse event reporting, blood pressure, heart rate, 12‐lead ECG and standard laboratory measurements. Symptomatic hypoglycaemia was defined as symptoms consistent with hypoglycaemia, with an accompanying blood glucose &lt; 3.3 mmol/L or prompt recovery with carbohydrate. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>AIM</b>: To evaluate thoroughly the dose–response effect of lixisenatide using once‐ or twice‐daily regimens (5 to 30 µg once or twice daily) on HbA1c changes over 13 weeks in metformin‐treated patients with Type 2 diabetes. </p> <p><b>SOURCE OF FUNDING</b>: sanofi‐aventis, the manufacturer of lixisenatide. </p> <p><b>OTHER</b>: Conflict of interest: First author has received research support from different pharmaceutical companies and has acted as a consultant for some of the companies. Another author has served on advisory boards and received honorarium or consulting fees from different pharmaceutical companies. He has also received research grants from Merck, Pfizer, sanofi‐aventis, Novo Nordisk, Bristol‐Myers Squibb, Eli Lilly, GlaxoSmithKline, Forest, Takeda, Novartis, AstraZeneca, Amylin, Johnson &amp; Johnson, Daiichi Sankyo, Boehringer Ingelheim and MannKind. One author is an employee of sanofi‐aventis. </p> <p><b>SAMPLE SIZE:</b> Sample sizes of 50 patients in each active treatment group and 100 patients in the placebo group were calculated to provide a statistical power of 81% to detect a 0.6% (6.6 mmol/mol) difference in HbA1c between an active treatment and placebo assuming a standard deviation of 1.2% (13.1 mmol/L). Statistical significance was assumed at the 5% level. </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Randomised to one of 12 treatment arms (2:2:2:2:2:2:2:2:1:1:1:1) using interactive voice response system. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>&nbsp;Interactive voice response system.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding (performance bias and detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The study drug, added‐on to stable metformin, was double‐blind regarding active treatment or placebo and open‐label regarding the treatment volume. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ITT analysis; adequate description of withdrawals and losses to follow up.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>All the prespecified and predefined outcomes were reported.</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">LY2189265 ‐Umpierrez 2011 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>TRIAL DESIGN</b>: Randomised, placebo‐controlled, double‐blind study </p> <p><b>DURATION OF INTERVENTION</b>: 16 weeks </p> <p><b>DURATION OF FOLLOW‐UP</b>: </p> <p><b>SETTING</b>: multiple (36 sites in United States and 3 sites in Puerto Rico) </p> <p><b>COUNTRY</b>: United States; Puerto Rico </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>INCLUSION CRITERIA</b>: Participants at least 18 years of age with type 2 diabetes; BMI between 27 and 40 kg/m<sup>2</sup>; HbA1c &gt; 7.0% but ≤ 10.5%; stable weight for at least 3 months at entry; receiving stable therapy for at least 3 months with an oral antihyperglycaemic medications from each of the two different classes (sulphonylurea, biguanide, thiazolidinedione or DPP‐IV inhibitors). </p> <p><b>EXCLUSION CRITERIA</b>: previous use of GLP‐1 or a GLP‐1 analogue, or current use of insulin or weight‐loss medication; history of clinically significant gastric emptying abnormality, cardiovascular disorders or uncontrolled diabetes requiring hospitalisation more than once in the previous 6 months. </p> <p><b>AGE</b>: 54 SD 11 to 59 SD 12 years </p> <p><b>SEX</b>: 46% to 56% of female </p> <p><b>DIABETES DURATION</b>: 7.5 SD 5.4 to 9.0 SD 7.6 years </p> <p><b>ETHNICITY</b>: 55% to 61% Caucasians; 29% to 39% Hispanic; </p> <p><b>HbA1c (%)</b>: LY 0.5/1.0 QW: 8.25 SD 0.9; LY 1.0/1.0 QW: 8.25 SD 1.0; LY 1.0/2.0 QW: 8.43 SD 1.0; Placebo: 8.05 SD 0.8 </p> <p><b>BMI (kg/m<sup>2</sup>)</b>: LY 0.5/1.0 QW: 33.7 SD 4.1; LY 1.0/1.0 QW: 33.9 SD 4.0; LY 1.0/2.0 QW: 34.2 SD 4.1; Placebo: 33.9 SD 4.3 </p> <p><b>PREVIOUS THERAPY</b>: 72.7% to 73.8% MET + SU; 12.3% to 13.6% MET + TZD; 7.6% to 9.1% MET + DPP‐IV: 4.5% to 6.2% other; 9.1% to 13.8% discontinued </p> <p><b>NUMBERS</b>: LY 0.5/1.0 QW: 66; LY 1.0/1.0 QW: 65; LY 1.0/2.0 QW: 65; Placebo: 66 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>COMPARISON</b>: LY 0.5/1.0 QW or LY 1.0/1.0 QW or LY 1.0/2.0 QW VERSUS Placebo </p> <p><b>NO. OF COMPARISON GROUPS</b>: 4 </p> <p><b>LEAD‐ IN PERIOD</b>: All participants under went two weeks lead‐in period of placebo injection </p> <p><b>DOSE LY 0.5/1.0</b>: Once weekly subcutaneous injection of LY 0.5 mg for 4 weeks followed by 1.0 mg for 12 weeks. </p> <p><b>DOSE LY 1.0/1.0</b>: Once weekly subcutaneous injection of LY 1.0 for 16 weeks </p> <p><b>DOSE LY 1.0/2.0</b>: Once weekly subcutaneous injection of LY 1.0 for 4 weeks then 2.0 mg for 12 weeks. </p> <p><b>DOSE Placebo</b>: Once weekly subcutaneous injection of placebo for 16 weeks </p> <p><b>OTHER TREATMENT</b>: Participants continued their baseline oral antihyperglycaemic medications regimen. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>PRIMARY OUTCOMES</b>: Change in HbA1c </p> <p><b>SECONDARY OUTCOMES</b>: Changes in FPG, blood glucose responses following a solid mixed‐meal test, body weight, HOMA‐2 algorithm to assess β ‐cell function (%‐B), insulin sensitivity (%‐S) and resistance (%‐IR) </p> <p><b>OTHER OUTCOMES</b>: Safety and tolerability that includes treatment emergent adverse events, hypoglycaemia, vital signs and laboratory tests. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>AIM</b>: To evaluate the efficacy and tolerability of once‐weekly LY2189265 (LY), a GLP‐1 IgG4‐Fc fusion protein, in participants with type 2 diabetes failing oral antihyperglycaemic medications. </p> <p><b>SOURCE OF FUNDING</b>: Eli Lilly and Company </p> <p><b>OTHER</b>: First author has received research support from different pharmaceutical companies and has acted as a consultant for some of the companies. Another author has served on advisory boards and received honorarium or consulting fees from different pharmaceutical companies. He has also received research grants from some of these companies. Two authors are employees and shareholders of Eli Lilly and Company. One author was a shareholder, and during the conduct of the study and preparation of the paper, an employee, of Eli Lilly and Company. </p> <p><b>SAMPLE SIZE:</b> Sixty patients per arm were estimated to provide 90% power at a 2‐sided α of 0.05 to detect a 0.9% change from baseline in HbA1c relative to placebo, assuming a standard deviation of 1.3 and 20% dropout rate. </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Randomisation was carried out using a computer‐generated random sequence and was stratified according to oral antihyperglycaemic medication. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Inadequate information</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding (performance bias and detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Double‐blind</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>All efficacy and safety analyses were performed using the intent‐to‐treat population</p> <p>Adequate description of withdrawals and losses to follow up</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>All the prespecified and predefined outcomes were reported.</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">T ‐ Nauck 2009 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>TRIAL DESIGN:</b> RCT, parallel group, placebo controlled, multi‐centre, phase 2b trial </p> <p><b>DURATION OF INTERVENTION:</b> 8 weeks </p> <p><b>DURATION OF FOLLOW‐UP:</b> 4 weeks post‐intervention </p> <p><b>RUN‐IN PERIOD:</b> Up to 3 week screening period </p> <p><b>COUNTRY:</b> Germany and Switzerland </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>INCLUSION CRITERIA:</b> Participants with type 2 diabetes, on metformin monotherapy (≥ 1500 mg/day) for at least 3 months before screening, age 18 to 75 years, HbA1c between 7.0% and 9.5%, BMI &gt; 25 and ≤ 45 kg/m<sup>2</sup> and stable weight (± 10%) for at least 3 months before screening </p> <p><b>EXCLUSION CRITERIA:</b> Type 1 diabetes; patient on any OAD other than metformin during the prior three months (except insulin); previous exposure to any GLP‐1 analogues; impaired liver or kidney function, GI disease, uncontrolled hypertension or stroke or myocardial infarction </p> <p><b>AGE:</b> mean 53 to 57 years (SD 6 to 11) </p> <p><b>SEX:</b> 39% to 64% female </p> <p><b>DIABETES DURATION:</b> mean 5 to 6 years (SD 4 to 5) </p> <p><b>ETHNICITY:</b> Not reported </p> <p><b>HbA1c (%):</b> Placebo: 8.0 SE 0.1, TAS 10 mg QW: 7.9 SE 0.1, TAS 20 mg QW: 7.8 SE 0.1, TAS 20 mg Q2W: 7.9 SE 0.1 </p> <p><b>BMI (kg/m<sup>2</sup>):</b> Placebo: 31.8 SE 4.9, TAS 10 mg QW: 32.6 SE 4.7, TAS 20 mg QW: 32.4 SE 5.2, TAS 20 mg Q2W: 33.2 SE 5.1 </p> <p><b>PREVIOUS THERAPY:</b> Metformin monotherapy (mean 1888 mg to 2019 mg) </p> <p><b>NUMBERS:</b> 306 randomised (safety database 297); Placebo: 49, TAS 5 mg QW: 50, TAS 10 mg QW: 49, TAS 20 mg QW: 50, TAS 10 mg Q2W: 50, TAS 20 mg Q2W: 49 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>COMPARISON:</b> Taspoglutide (TAS) (5 dose schedules) + Metformin (MET) VERSUS Placebo + MET </p> <p><b>NO. OF COMPARISON GROUPS:</b> 6 </p> <p>For the current review, the following groups were excluded: 5 mg weekly and 10 mg every 2 weeks as the effect of those groups were less favourable than those of the other groups. </p> <p><b>RUN‐IN:</b> Screening only </p> <p><b>DOSE TAS:</b> Taspoglutide 10 mg or 20 mg once weekly, or 20 mg once every 2 weeks </p> <p><b>DOSE MET:</b> Pre‐study MET regimen </p> <p><b>OTHER TREATMENT:</b> Patients continued their prestudy diet and exercise plan throughout the study; patients were on a variety of other medication, such as ACE inhibitors, thiazide diuretics, angiotensin receptor blockers, statins, beta‐blockers </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>PRIMARY OUTCOMES:</b> Change in HbA1c from baseline to end of the study (assessed 1 week after 8 consecutive weeks of treatment) </p> <p><b>SECONDARY OUTCOMES:</b> % of patients achieving HbA1c ≤ 7% and ≤ 6.5%; changes in following parameters from baseline: FPG, body weight, fructosamine, C‐peptide, fasting insulin, pro‐insulin, pro‐insulin‐to‐insulin molar ratio, fasting glucagon, lipids </p> <p><b>OTHER OUTCOMES:</b> Safety variables including adverse events, vital signs, physical examination, clinical laboratory tests, electrocardiogram, local tolerance at the injection site, anti‐taspoglutide antibodies </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>AIM:</b> To assess the efficacy and safety of taspoglutide in patient with type 2 diabetes inadequately controlled with metformin therapy. </p> <p><b>SOURCE OF FUNDING:</b> Hoffmann‐La Roche, Switzerland. </p> <p><b>OTHER:</b> Association of some of the authors with Roche </p> <p><b>SAMPLE SIZE:</b> Sample size provided 90% power to detect a 1% difference in HbA1c. </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Patients were randomly assigned by central randomisation system</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Patients were randomly assigned by interactive voice response system</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding (performance bias and detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Double‐blinded</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Missing data were imputed as the last observation carried forward, ITT analysis (ITT population comprised of all patients who were randomly assigned, received at least one dose of study medication, and had a baseline and at least post‐baseline HbA1C assessment), adequate description of withdrawals and losses to follow‐up (6.5% withdrawals / losses to follow‐up) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Included all expected outcomes, including those prespecified</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">T‐ Ratner 2010 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>TRIAL DESIGN</b>: Randomized, double‐blind, placebo‐controlled phase II trial </p> <p><b>DURATION OF INTERVENTION</b>: 8 weeks </p> <p><b>DURATION OF FOLLOW‐UP</b>: 4 weeks follow up </p> <p><b>RUN‐IN PERIOD:</b> NR </p> <p><b>SETTING</b>: 27 sites </p> <p><b>COUNTRY</b>: Australia, France, Germany, Mexico, Peru and USA </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>INCLUSION CRITERIA</b>: Men and post‐menopausal or surgically sterilised women aged 18 to 75 years with type 2 diabetes mellitus, treated with a stable daily dose of metformin monotherapy for at least 3 months before screening; dose of metformin not adjusted during the study; HbA1c between 7.0% and 9.5%; FPG &gt; 7 mmol/L and ≤ 13.3 mmol/L; BMI &gt; 25 kg/m<sup>2</sup> and ≤ 45.0 kg/m<sup>2</sup>; weight ≤ ± 10% for at least 3 months before screening. </p> <p><b>EXCLUSION CRITERIA</b>: Subjects with serious co‐morbidities or abnormalities in laboratory tests; those who had previously been treated with GLP‐1 receptor agonists (including GLP‐1 itself) at any time, or with other glucose‐lowering medications (apart from metformin) or weight‐loss medications within 12 to 6 weeks respectively. </p> <p><b>AGE</b>: 55 SE 2.0 to 60 SE 2.0 years </p> <p><b>SEX</b>: 53% to 59% female (TAS 20/20 mg QW: 53%; TAS 20/30 mg QW; 55%; TAS 20/40 mg QW: 59%; Placebo: 59%) </p> <p><b>DIABETES DURATION</b>: 6 SE 1.0 to 8 SE 1.0 years </p> <p><b>ETHNICITY</b>: NR </p> <p><b>HbA1c (%)</b>: TAS 20/20 mg QW: 8.0 SE0.1; TAS 20/30 mg QW: 8.0 SE0.1; TAS 20/40 mg QW: 7.8 SE0.1; Placebo: 7.8 SE0.1 </p> <p><b>BMI (kg/m<sup>2</sup>)</b>: TAS 20/20 mg QW: 33.3 SE0.9; TAS 20/30 mg QW: 31.6 SE1.0; TAS 20/40 mg QW: 31.5 SE0.9; Plaebo: 33.2 SE1.0 </p> <p><b>PREVIOUS THERAPY</b>: MET </p> <p><b>NUMBERS</b>: Randomised: 133 (TAS 20 mg QW: 32, TAS 20/30 mg QW: 33; TAS 20/40 QW: 32; Placebo: 32); safety population: 129; ITT population: 125 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>COMPARISON:</b> TAS + MET VERSUS Placebo + MET </p> <p><b>NO. OF COMPARISON GROUPS</b>: 4 </p> <p><b>DOSE TAS:</b> 20 mg taspoglutide once weekly s.c. for 4 weeks followed by 4 weeks of 20 mg once weekly (20/20) or titration up to 30 mg once weekly (20/30) or 40 mg once weekly (20/40) taspoglutide; </p> <p><b>DOSE PLACEBO:</b> placebo s.c. once weekly </p> <p><b>DOSE MET:</b> pre‐study metformin regimen throughout the study </p> <p><b>DIET and EXERCISE:</b> pre‐study diet and exercise plan throughout the study </p> <p><b>OTHER TREATMENT:</b> Some patients received medications for cardiovascular risk factors: statins (22%); ACE‐inhibitors (21%), fibrates (5%). ACE, thiazide diuretics, thyroid hormones and/or lipid‐lowering medications were permitted but only with doses stable for at least 6 weeks prior to screening. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>PRIMARY OUTCOMES</b>: GI tolerability, assessed by comparing the number of subjects who withdrew from study because of GI adverse events. </p> <p><b>SECONDARY OUTCOMES</b>: FPG, HbA1c, body weight and pharmacokinetic parameters. </p> <p><b>OTHER OUTCOMES:</b> NR </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>AIM</b>: To investigate the safety and tolerability of up titration to high doses of taspoglutide in patients with type 2 diabetes mellitus. </p> <p><b>SOURCE OF FUNDING</b>: Hoffmann‐La Roche </p> <p><b>OTHER</b>: Conflict of interest: Two authors have received consulting and advisory board honoraria from F. Hoffmann‐La Roche as well as from other pharmaceutical companies developing incretin‐based therapies whose products may be perceived as competitive to taspoglutide. One author has received consulting and research fees from F. Hoffman‐La Roche and Ispen. Some authors are employees of F. Hoffman‐La Roche. </p> <p><b>SAMPLE SIZE:</b> The paper says 'it was planned to enrol approximately 120 subjects into the study assigned randomly and equally to each of the treatment groups. This sample size was determined by practical considerations rather than formal calculations'. </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Central system using a stratified randomisation procedure based on disease severity (HbA1c &lt; 8.0% or ≥ 8.0%) to avoid imbalances between treatment groups. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Central system; insufficient information</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding (performance bias and detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Double‐blind</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Descriptive statistics were used to report the safety results; data on secondary endpoints were analysed for the ITT population using the last observation carried forward; description of withdrawals and loss to follow up given. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>All prespecified and predefined outcomes reported.</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>BMI: Body mass index, HbA1c: Glycosylated haemoglobin, ALBI: Albiglutide, MET: Metformin, EX: Exenatide, TZD: Thiazolidinedione, SU: Sulphonylurea, DPP‐4: Dipeptidyl peptidase‐4 inhibitor, SITA: Sitagliptin, PIO: Pioglitazone, GLAR: Insulin glargine, GLP: Glucagon like peptide, LIR: Liraglutide, ROS: Rosiglitazone, GLIM: Glimepiride, LIXI: Lixisenatide, LY: LY2189265, TAS: Taspoglutide, OCP: Oral contraceptive pill, LAR: Long acting release, ACE: Angiotensin‐converting enzyme, FPG: Fasting plasma glucose, PPG: Post‐prandial glucose, PG: Plasma glucose, HOMA‐B: Homeostasis model assessment‐beta cell function, ITT: Intention‐to‐treat, LOCF: Last observation carried forward, AE: Adverse event, ECG: Electrocardiography, GI: Gastrointestinal, SE: Standard error, SD: standard deviation, QD: Once daily, BID: Twice daily, QW: Once weekly, NR: Not reported, IWQOL: Impact of weight on quality of life questionnaire‐lite, PGWB: Psychological general well‐being index, DTSQ: Diabetes treatment satisfaction questionnaire, and EQ‐5D: EuroQol‐5 dimensions.</sup> </p> </div> </div> </p> </section> <section class="characteristicsOfExcludedStudies" lang=""> <div class="section-header" id="CD006423-sec2-0022"> <h3 class="title">Characteristics of excluded studies [ordered by study ID]</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a href="#CD006423-sec2-0021" class="jump-to">included studies</a></li> <li><a href="#CD006423-sec2-0023" class="jump-to">ongoing studies</a></li> </ul> </div> </div> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Reason for exclusion</p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD006423-bbs2-0018">Astrup 2009</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants without type 2 diabetes mellitus</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD006423-bbs2-0019">Barnett 2007</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Patients failing on either metformin therapy or sulphonylurea treatment were included, but less than 70% of patients were on metformin therapy (only 55%). </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD006423-bbs2-0020">Blonde 2006</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Combined analysis of three different trials, so patients included for analysis not actually randomised. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD006423-bbs2-0021">Bode 2010</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Monotherpay compared to glimepiride only.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD006423-bbs2-0022">Brixner 2009</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>All patient received exenatide.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD006423-bbs2-0023">Buse 2004</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Include patients failing on sulphonylurea only.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD006423-bbs2-0024">Feingloss 2005</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Liraglutide doses used in the study are clinically not relevant.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD006423-bbs2-0025">Gallwitz 2010</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Combined analysis of 3 LEAD trials (LEAD 1, 2 and 4).</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD006423-bbs2-0026">Garber 2009 (LEAD 3)</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Previous treatment with OADs discontinued at randomisation and compared to monotherapy only. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD006423-bbs2-0027">Kapitza 2009</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Single‐dose administration of taspoglutide with follow up duration of less than 8 weeks. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD006423-bbs2-0028">Kim 2007</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Patients on diet/exercise or metformin were included, but less than 70% were on metformin therapy (60%). </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD006423-bbs2-0029">Madsbad 2004</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Liraglutide doses used in the study are clinically not relevant.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD006423-bbs2-0030">Malloy 2009</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants aged less than 18 years of age.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD006423-bbs2-0031">Moretto 2008</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Monotherapy compared to placebo only.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD006423-bbs2-0032">Nauck 2009</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Combined analysis of subset of participants from two different trials, so patients included for analysis not actually randomised. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD006423-bbs2-0033">Okerson 2010</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Combined analysis of six different trials.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD006423-bbs2-0034">Riddle 2006</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Combined analysis of two different trials, so patients included for analysis not actually randomised. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD006423-bbs2-0035">Seino 2008</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Liraglutide doses used in the study are clinically not relevant.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD006423-bbs2-0036">Trescoli‐Serrano 2005</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Published as abstract only.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD006423-bbs2-0037">Vilsboll 2007</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Monotherapy and compared to placebo only.</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>LEAD: Liraglutide Effect and Action in Diabetes, OAD: Oral antidiabetic drug</sup> </p> </div> </div> </p> </section> <section class="characteristicsOfOngoingStudies" lang=""> <div class="section-header" id="CD006423-sec2-0023"> <h3 class="title">Characteristics of ongoing studies [ordered by study ID]</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a href="#CD006423-sec2-0021" class="jump-to">included studies</a></li> <li><a href="#CD006423-sec2-0022" class="jump-to">excluded studies</a></li> </ul> </div> </div> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Albiglutide NCT00838903 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Efficacy and safety of albiglutide in treatment of type 2 diabetes</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>TRIAL DESIGN</b>: Phase III, randomised, double‐blind, placebo‐ and active‐controlled, parallel‐group study </p> <p><b>DURATION OF INTERVENTION</b>: two years </p> <p><b>COUNTRY</b>: USA, Germany, HongKong, Mexico, Peru, Phillipines, Russian Federation, South Africa, Spain, UK </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>INCLUSION CRITERIA</b>: </p> <p> <ul id="CD006423-lst1-0016"> <li> <p>participants aged 18 years or more</p> </li> <li> <p>type 2 diabetes</p> </li> <li> <p>BMI 20 to 45 kg/m<sup>2</sup> inclusive </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Albiglutide:</b> Alibiglutide + metformin + placebo sitagliptin + placebo glimepiride </p> <p><b>Sitagliptin:</b> sitagliptin + metformin + placebo albiglutide + placebo glimepiride </p> <p><b>Glimepiride:</b> glimepiride + metformin + placebo albiglutide + placebo sitagliptin </p> <p><b>Metformin:</b> metformin + placebo albiglutide + placebo sitagliptin + placebo glimepiride </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>PRIMARY OUTCOME</b>: change in HbA1c </p> <p><b>SECONDARY OUTCOMES</b>: change in FPG and body weight </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>February 2009, estimated completion date December 2012 (last updated on June 2, 2011)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>GlaxoSmithKline</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ClinicalTrials.gov Identifier: NCT00838903; other study ID number: 112753</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Albiglutide NCT00838916 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A study to determine the safety and efficacy of albiglutide in patients with type 2 diabetes </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>TRIAL DESIGN</b>: Phase III, randomised, open‐label, parallel‐group study </p> <p><b>DURATION OF INTERVENTION</b>: one year </p> <p><b>COUNTRY</b>: USA, Russian Federation, South Africa, UK </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>INCLUSION CRITERIA</b>: </p> <p> <ul id="CD006423-lst1-0017"> <li> <p>participants aged 18 years or more</p> </li> <li> <p>type 2 diabetes</p> </li> <li> <p>BMI 20 to 45 kg/m<sup>2</sup> </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Albiglutide:</b> albiglutide weekly injection </p> <p><b>Insulin glargine:</b> insulin glargine </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>PRIMARY OUTCOME</b>: change in HbA1c </p> <p><b>SECONDARY OUTCOMES</b>: change in FPG and body weight </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>February 2009, estimated completion date December 2012 (last updated on June 9, 2011)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>GlaxoSmithKline</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ClinicalTrials.gov identifier: NCT00838916; other study ID number: 112754</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Albiglutide NCT00849017 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Safety and efficacy study of albiglutide in type 2 diabetes</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>TRIAL DESIGN</b>: Phase III, randomised, double‐blind, placebo‐controlled, parallel‐group study </p> <p><b>DURATION OF INTERVENTION</b>: one year </p> <p><b>COUNTRY</b>: USA, Mexico </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>INCLUSION CRITERIA</b>: </p> <p> <ul id="CD006423-lst1-0018"> <li> <p>participants aged 18 years or more</p> </li> <li> <p>type 2 diabetes</p> </li> <li> <p>BMI 20 to 45 kg/m<sup>2</sup> </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Albiglutide:</b> albiglutide weekly injection </p> <p><b>Placebo:</b> matching albiglutide placebo weekly injection </p> <p><b>Albiglutide uptitration:</b> albiglutide uptitration at week 12 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>PRIMARY OUTCOME</b>: change in HbA1c </p> <p><b>SECONDARY OUTCOMES</b>: change in FPG and body weight </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>January 2009, estimated completion date October 2012 (last updated on June 9, 2011)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>GlaxoSmithKline</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ClinicalTrials.gov identifier: NCT00849017; other study ID number: 112756</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Albiglutide NCT00849056 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Safety and efficacy of albiglutide in type 2 diabetes</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>TRIAL DESIGN</b>: Phase III, randomised, double‐blind, placebo‐controlled, parallel‐group trial </p> <p><b>DURATION OF INTERVENTION</b>: one year </p> <p><b>COUNTRY</b>: USA, India, Peru, South Africa, UK </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>INCLUSION CRITERIA</b>: </p> <p> <ul id="CD006423-lst1-0019"> <li> <p>participants aged 18 years or more</p> </li> <li> <p>type 2 diabetes</p> </li> <li> <p>BMI 20 to 45 kg/m<sup>2</sup> </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Albiglutide:</b> albiglutide weekly injection + pioglitazone (with or without metformin) </p> <p><b>Placebo:</b> placebo albiglutide weekly injection + pioglitazone (with or without metformin) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>PRIMARY OUTCOME</b>: change in HbA1c </p> <p><b>SECONDARY OUTCOMES</b>: change in FPG and body weight </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>January 2009, estimated completion date October 2012 (last updated on June 9, 2011)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>GlaxoSmithKline</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ClinicalTrials.gov identifier: NCT00849056; other study ID number: 112755</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Albiglutide NCT01098461 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Dose ranging study of albiglutide in Japanese subjects</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>TRIAL DESIGN</b>: Phase II, double‐blind, randomised, placebo‐controlled, multicenter, 4‐parallel‐group, dose ranging study </p> <p><b>DURATION OF INTERVENTION</b>: 16 weeks </p> <p><b>COUNTRY</b>: Japan </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>INCLUSION CRITERIA</b>: </p> <p> <ul id="CD006423-lst1-0020"> <li> <p>Participants aged between 20 and 75 years with a historical diagnosis of type 2 diabetes mellitus who is currently treated with diet and exercise only or one OAD </p> </li> <li> <p>BMI ≥ 18 kg/m<sup>2</sup> and &lt; 35 kg/m<sup>2</sup> at Screening </p> </li> <li> <p>HbA1c between 7.0% and 10.0%</p> </li> <li> <p>Fasting C‐peptide ≥ 0.8 ng/mL (≥ 0.26 nmol/L)</p> </li> <li> <p>Female subjects of childbearing potential must be practicing adequate contraception . </p> </li> <li> <p>Able and willing to monitor his/her own blood glucose concentrations with a home glucose monitor. </p> </li> <li> <p>Able and willing to provide written informed consent</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Albiglutide:</b> subcutaneous injection albiglutide 15 mg or 30 mg weekly or 30 mg every two weeks </p> <p><b>Placebo:</b> subcutaneous injection of placebo to match albiglutide </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>PRIMARY OUTCOME</b>: change in HbA1c </p> <p><b>SECONDARY OUTCOMES</b>: change in HbA1c over time, change in FPG and body weight; Proportion of subjects who achieve HbA1c treatment goal; pharmacokinetic levels of albiglutide </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>April 2010, estimated completion date March 2011 (last updated on November 18, 2010)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>GlaxoSmithKline</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ClinicalTrials.gov Identifier: NCT01098461; other study ID number: 110932</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Albiglutide NCT01128894 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A study to determine the efficacy and safety of albiglutide as compared with liraglutide.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>TRIAL DESIGN</b>: Phase III, randomised, open‐label, parallel‐group, multicenter study </p> <p><b>DURATION OF INTERVENTION</b>: 32 weeks </p> <p><b>COUNTRY</b>: USA, Australia, Israel, Korea, Peru, Phillipines, Spain, UK </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>INCLUSION CRITERIA</b>: </p> <p> <ul id="CD006423-lst1-0021"> <li> <p>Diagnosis of type 2 diabetes mellitus and experiencing inadequate glycaemic control on their current regimen of metformin, TZD, SU, or any combination of these oral antidiabetic medications </p> </li> <li> <p>BMI ≥ 20 kg/m<sup>2</sup> and ≤ 45 kg/m<sup>2</sup> </p> </li> <li> <p>Fasting C‐peptide ≥ 0.8 ng/mL (≥ 0.26 nmol/L)</p> </li> <li> <p>HbA1c between 7.0% and 10.0%, inclusive</p> </li> <li> <p>Female subjects of childbearing potential must be practicing adequate contraception.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Albiglutide:</b> once weekly injection </p> <p><b>Liraglutide:</b> liraglutide daily subcutaneous injection, starting at 0.6 mg, then up‐titrating to 1.2 mg then 1.8 mg in accordance with prescribing information. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>PRIMARY OUTCOME</b>: Evaluation of change from baseline of HbA1c levels of albiglutide as compared with liraglutide. </p> <p><b>SECONDARY OUTCOMES</b>: HbA1c change from baseline over time; proportion of subjects at an HbA1c treatment goal of &lt; 7.0% and/or &lt; 6.5%; FPG, body weight, time for hyperglycaemia rescue </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>May 2010, estimated completion date September 2011 (last updated on June 9, 2011)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>GlaxoSmithKline</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ClinicalTrials.gov identifier: NCT01128894</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Exenatide QW NCT00641056 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Efficacy of exenatide once weekly and once‐daily insulin glargine in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylurea (DURATION ‐ 3) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>TRIAL DESIGN</b>: Phase III, open label, randomised, parallel assignment study (extension study) </p> <p><b>DURATION OF INTERVENTION</b>: 26 weeks </p> <p><b>COUNTRY</b>: USA, Australia, Belgium, Czech Republic, Denmark, France, Germany, Greece, Hungary, Korea, Mexico, Netherlands, Puerto Rico, Russian Federation, Spain, Taiwan, </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>INCLUSION CRITERIA</b>: </p> <p> <ul id="CD006423-lst1-0022"> <li> <p>Has type 2 diabetes and at least 18 years of age at screening.</p> </li> <li> <p>HbA1c of 7.1% to 11.0%, inclusive, at screening.</p> </li> <li> <p>BMI of 25 kg/m<sup>2</sup> to 45 kg/m<sup>2</sup>, inclusive, at screening. </p> </li> <li> <p>Have a history of stable body weight (not varying by &gt; 5% for at least 3 months prior to screening). </p> </li> <li> <p>Have been treated with metformin for at least 3 months and have been taking a stable dose for at least 8 weeks prior to screening or, </p> </li> <li> <p>Have been treated with metformin for at least 3 months and have been taking a stable dose for at least 8 weeks prior to screening and have been treated with SU for at least 3 months and have been taking a stable dose of at least an optimally effective dose of brand of SU for 8 weeks prior to screening. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Exenatide:</b> exenatide 2 mg once weekly subcutaneous injection </p> <p><b>Insulin glargine:</b> variable dose once daily subcutaneous injection, </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>PRIMARY OUTCOME</b>: Estimate the difference in change in HbA1c from baseline to treatment endpoint between 2.0 mg exenatide once weekly and insulin glargine QD in patients with type 2 diabetes and inadequate glycaemic control using Met alone or in combination with SU. </p> <p><b>SECONDARY OUTCOMES</b>: </p> <p> <ul id="CD006423-lst1-0023"> <li> <p>Compare exenatide once weekly and insulin glargine with respect to the proportion of patients achieving HbA1c ≤ 7% and ≤ 6.5%; fasting serum glucose; change in body weight; 1,5‐anhydroglucitol; 8‐point self‐monitored blood glucose profile; serum lipids </p> </li> <li> <p>Compare exenatide once weekly and insulin glargine with respect to frequency and rate of hypoglycaemic events; patient‐reported health outcomes; long‐term maintenance of glycaemic control, safety, and tolerability. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>April 2008, estimated completion date January 2012 (last updated on December 3, 2010)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Eli Lilly and Company</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ClinicalTrials.gov identifier: NCT00641056; other study ID number: H8O‐MC‐GWBR (DURATION ‐ 3) </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Exenatide QW NCT00917267 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A study to examine the effects of exenatide once‐weekly injection on glucose control and safety in Asian subjects </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>TRIAL DESIGN</b>: Phase III, randomised, open‐label trial </p> <p><b>DURATION OF INTERVENTION</b>: 26 weeks </p> <p><b>COUNTRY</b>: China, India, Japan, Korea, Taiwan </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>INCLUSION CRITERIA</b>: </p> <p> <ul id="CD006423-lst1-0024"> <li> <p>Have been diagnosed with type 2 diabetes.</p> </li> <li> <p>Have suboptimal glycaemic control as evidenced by an HbA1c between 7.1% and 11.0% inclusive. </p> </li> <li> <p>Have a BMI of &gt; 21 kg/m<sup>2</sup> and &lt; 35 kg/m2, inclusive. </p> </li> <li> <p>Have a history of stable body weight (not varying by &gt; 5% for at least 90 days prior to study start). </p> </li> <li> <p>Have been treated with a stable dose regimen of Met, SU, TZD, Met plus SU, Met plus TZD, or SU plus TZD for at least 90 days prior to study start. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Exenatide QW:</b> 2 mg once weekly subcutaneous injection </p> <p><b>Exenatide BID:</b> 5 μg subcutaneous injection twice a day in the first four weeks then, 10 μg subcutaneous injection twice a day (22 weeks) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>PRIMARY OUTCOME</b>: change in HbA1c </p> <p><b>SECONDARY OUTCOMES</b>: proportion of patients achieving HbA1c ≤ 7% and ≤ 6.5%; fasting serum glucose; body weight; parameters related to glycaemic control, including fasting &amp; postprandial plasma glucose &amp; 6‐point SMBG profiles; serum lipids; incidence and rate of hypoglycaemic events; safety, tolerability, and treatment‐emergent events; beta‐cell function (HOMA‐B) and insulin sensitivity (HOMA‐S) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>July 2009, estimated completion date June 2011 (last updated on December 16, 2010)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Eli Lilly and Company</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ClinicalTrials.gov Identifier: NCT00917267; other study ID number: H8O‐MC‐GWCK</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Exenatide QW NCT00935532 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study to evaluate the efficacy and safety of exenatide once‐weekly injection compared to once‐daily insulin in type 2 diabetes mellitus </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>TRIAL DESIGN</b>: Phase III, randomised, open‐label study </p> <p><b>DURATION OF INTERVENTION</b>: 26 weeks </p> <p><b>COUNTRY</b>: Japan </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>INCLUSION CRITERIA</b>: </p> <p> <ul id="CD006423-lst1-0025"> <li> <p>present with type 2 diabetes mellitus</p> </li> <li> <p>HbA1c between 7.1% and 11.0% inclusive</p> </li> <li> <p>BMI of &gt; 18 kg/m<sup>2</sup> and &lt; 35kg/m<sup>2</sup>, inclusive </p> </li> <li> <p>treated with a stable dose regimen of either of biguanide (BG) alone, BG + thiazolidinedione (TZD), BG + sulphonylurea (SU), or BG + TZD + SU for 90 days prior to study start </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Exenatide:</b> 2 mg once weekly subcutaneous injection </p> <p><b>Insulin glargine:</b> subcutaneous injection, titrated to achieve fasting serum glucose target, once a day </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>PRIMARY OUTCOME</b>: change in HbA1c </p> <p><b>SECONDARY OUTCOMES</b>: proportion of subjects achieving HBA1c ≤ 7% or ≤ 6.5%; fasting serum glucose; body weight; 1,5‐anhydroglucitol; self‐monitored blood glucose profile at 7 time points; serum lipids; hypoglycaemia; vital signs; waist &amp; hip circumference; waist‐hip ratio; safety &amp; tolerability; patient‐reported health outcomes </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>July 2009, estimated completion date June 2011 (last updated on February 28, 2011)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Eli Lilly and Company</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ClinicalTrials.gov Identifier: NCT00935532; other study ID number: H8O‐JE‐GWBX</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Exenatide QW NCT01003184 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Efficacy of once‐weekly exenatide versus once or twice daily insulin detemir in patients with type 2 diabetes </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>TRIAL DESIGN</b>: Phase III, randomised, open‐label trial </p> <p><b>DURATION OF INTERVENTION</b>: 26 weeks </p> <p><b>COUNTRY</b>: Ireland, UK, </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>INCLUSION CRITERIA</b>: </p> <p> <ul id="CD006423-lst1-0026"> <li> <p>Have suboptimal glycaemic control as evidenced by an HbA1c 7.1% to 10.0%, inclusive</p> </li> <li> <p>Have a BMI of 25 kg/m<sup>2</sup> to 45 kg/m<sup>2</sup>, inclusive </p> </li> <li> <p>Are receiving metformin at a stable dose (consistent with country specific requirements) of a minimum of 1000mg for at least 3 months prior to start or are receiving metformin at a minimum dose (consistent with country specific requirements) of 1000 mg and sulphonylurea (as separate medications not as a fixed dose combination) at stable doses for 3 months prior to study start </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Exenatide:</b> 2 mg once weekly subcutaneous injection </p> <p><b>Insulin detemir:</b> subcutaneous injection, with dosage titrated according to the detemir label and published titration schedule, once or twice a day </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>PRIMARY OUTCOME</b>: To test the hypothesis that exenatide given once weekly is superior to a titration of insulin detemir given once or twice daily assessed by the proportion of patients who have achieved HbA1c concentration ≤ 7.0% with weight loss (≥ 1.0 kg) at endpoint. </p> <p><b>SECONDARY OUTCOMES</b>: Proportion of patients who have achieved HbA1c ≤ 7.0% with weight loss (≥ 1.0 kg) at 12 weeks; proportion of patients who have achieved HbA1c ≤ 7.4% with weight loss (≥ 1.0 kg) at endpoint; proportion of patients who have achieved HbA1c ≤ 7.0% and ≤ 7.4%, with minimal weight gain (≤ 1 kg) at endpoint; change in HbA1c and body weight; proportion of patients achieving HbA1c ≤ 7.4%, ≤ 7.0% and ≤ 6.5% at endpoint; change in fasting serum glucose; 7‐point self‐monitored blood glucose (SMBG) profile; changes in CV risk parameters; incidence and rate of hypoglycaemic events; safety and tolerability </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>October 2009, estimated completion date September 2011 (last updated on January 13, 2011) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Eli Lilly and Company</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ClinicalTrials.gov Identifier: NCT01003184; other study ID number: H8O‐EW‐GWDL</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Exenatide QW NCT01029886 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Safety and efficacy of exenatide once weekly versus liraglutide in subjects with type 2 diabetes </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>TRIAL DESIGN</b>: Phase III, randomised, parallel&nbsp;assignment, open‐label trial </p> <p><b>DURATION OF INTERVENTION</b>: 26 weeks </p> <p><b>COUNTRY</b>: Argentina, Austria, Australia, Belgium, Canada, Czech Republic, France, Germany, Greece, Hungary, India, Israel, Italy, Korea, Mexico, Poland, Romania, Slovakia, South Africa, Spain, Taiwan </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>INCLUSION CRITERIA</b>: </p> <p> <ul id="CD006423-lst1-0027"> <li> <p>Diagnosed with type 2 diabetes</p> </li> <li> <p>Have suboptimal glycaemic control as evidenced by an HbA1c measurement at study start between 7.1% and 11.0%, inclusive </p> </li> <li> <p>Have a BMI of ≤ 45 kg/m<sup>2</sup> </p> </li> <li> <p>Have been treated with lifestyle modification (diet and exercise) and with one of the following single OADs or combinations of OADs administered at maximum tolerated dose:metformin, SU, metformin plus an SU' metformin plus pioglitazone </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Exenatide:</b> 2 mg once weekly subcutaneous injection </p> <p><b>Liraglutide:</b> subcutaneous injection, forced titration to 1.8 mg, once daily </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>PRIMARY OUTCOME</b>: change in HbA1c from baseline to treatment endpoint </p> <p><b>SECONDARY OUTCOMES</b>: proportion of subjects achieving HbA1c &lt; 7%; FPG, body weight, lipid profile, safety and tolerability, hypoglycaemia and blood pressure </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>January 2010, estimation completion date January 2011 (last updated on January 18, 2011) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Amylin Pharmaceuticals, Inc. and Eli Lilly and Company</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ClinicalTrials.gov Identifier: NCT01029886 ; other study ID number: H8O‐MC‐GWDE</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Exenatide QW NCT01144338 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Exenatide study of cardiovascular event lowering trial (EXSCEL): a trial to evaluate cardiovascular outcomes after treatment with exenatide once weekly in patients with type 2 diabetes mellitus </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>TRIAL DESIGN</b>:Phase III, randomised, double‐blind, placebo‐controlled trial </p> <p><b>DURATION OF INTERVENTION</b>: 5.5 years </p> <p><b>COUNTRY</b>: USA, Argentina, Australia, Austria, Brazil, Bulgaria, Chile, Colombia, Czech Republic, France, Germany, HongKong, Hungary, India, Israel, Italy, Korea, Latvia, Lithuania, Malaysia, Mexico, New Zealand, Peru, Phillipines, Poland, Romania, Russian Federation, Slovakia, Taiwan, Ukraine, UK </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>INCLUSION CRITERIA</b>: </p> <p> <ul id="CD006423-lst1-0028"> <li> <p>Patient has type 2 diabetes mellitus</p> </li> <li> <p>Patient has an HbA1c of ≥ 7.0 % and ≤ 10.0% on stable doses of up to three oral antihyperglycaemic agents for at least 3 months (i.e. no oral antihyperglycaemic agent adjustments in the past 3 months) </p> </li> <li> <p>Female patients must not be breast feeding and agree to use an effective method of contraception or must not otherwise be at risk of becoming pregnant. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Exenatide:</b> 2 mg once weekly subcutaneous injection </p> <p><b>Placebo:</b> matching volume of placebo, once weekly subcutaneous injection </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>PRIMARY OUTCOME</b>: Time to first confirmed cardiovascular event in the primary composite cardiovascular endpoint </p> <p><b>SECONDARY OUTCOMES</b>: Time to all‐cause mortality; time to first confirmed cardiovascular event for each component of the primary composite endpoint; time to hospitalisation for acute coronary syndrome; time to hospitalisation for heart failure </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>June 2010; estimation completion date March 2017 (last updated on June 3, 2011)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Amylin Pharmaceuticals, Inc.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ClinicalTrials.gov Identifier: NCT01144338; other study ID number: BCB109</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Liraglutide NCT00856986 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The effect of insulin detemir in combination with liraglutide and metformin compared to liraglutide and metformin in participants with type 2 diabetes. A 26 week, randomised, open‐label, parallel‐group, multicenter, multinational trial with a 26 week extension </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>TRIAL DESIGN</b>: Randomised, open label, active control, parallel group, phase III trial, multicenter and multinational </p> <p><b>DURATION OF INTERVENTION</b>: 26 weeks with a 26 week extension </p> <p><b>COUNTRY</b>: Europe and North America </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>INCLUSION CRITERIA</b>: </p> <p> <ul id="CD006423-lst1-0029"> <li> <p>Patients (18 years to 80 years of both sexes) with type 2 diabetes, insulin naive and treated with metformin as monotherapy for at least 3 months prior to screening. </p> </li> <li> <p>For at least 3 months: treatment with a stable dose of metformin ≥ 1.5 g/day or a combination of metformin (≥ 1.5 g/day) and a sulphonylureas (≤ half of the maximum approved dose) </p> </li> <li> <p>previous history of short term use of insulin during intercurrent illness is allowed</p> </li> <li> <p>Level of HbA1c 7.0 to 10.0% on metformin monotherapy and HbA1c of 7.0% to 8.5% in participants on combination therapy of metformin and sulphonylureas </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Insulin detemir</b>: Liraglutide 1.8 mg/day and insulin detemir (dose titrated based on fasting plasma glucose) both as injection subcutaneously and metformin at least 1.5 g every day. </p> <p><b>Liraglutide</b>: Liraglutide 1.8 mg/day subcutaneous injection and metformin at least 1.5 g every day (randomised treatment arm without intensification with insulin detemir despite HbA1c equal to or greater than 7.0%) </p> <p><b>Liraglutide</b>: Liraglutide 1.8 mg/day subcutaneous injection and metformin at least 1.5 g every day (non‐randomised trial arm with participants continuing liraglutide and metformin treatment without intensification with insulin detemir. Participants with HbA1c less than 7.0% after 12 weeks of run‐in will continue in the trial in this arm) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>PRIMARY OUTCOME</b>:Change in HbA1c from baseline at 26 weeks. </p> <p><b>SECONDARY OUTCOMES</b>:All these outcomes measured at weeks 26 and 52. Change in fasting plasma glucose concentrations, 7 point plasma glucose profile, fasting insulin, fasting proinsulin, fasting C‐peptide, lipids, body weight, waist and hip circumference, adverse events and hypoglycaemic events. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>March 2010, completed (last updated April 2011)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Novo Nordisk</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study ID number: NN2211‐1842, EudraCT No: 2007‐005317‐19, ClinicalTrials.gov Identifier: NCT00856986 </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Liraglutide NCT01117350 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Efficacy assessment of insulin glargine versus liraglutide after oral agent failure (EAGLE) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>TRIAL DESIGN</b>: Multicenter, international, randomised (1:1), parallel‐group, open‐label, comparative, phase IV study </p> <p><b>DURATION OF INTERVENTION</b>: 24 weeks comparative period; 24 weeks extension period </p> <p><b>COUNTRY</b>:USA, Austria, Brazil, Canada, Czech Republic, Finland, France, Ireland, Mexico, Netherlands, Slovakia, Spain, Sweden </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>INCLUSION CRITERIA (comparative period):</b> </p> <p> <ul id="CD006423-lst1-0030"> <li> <p>Patients with type 2 diabetes diagnosed for at least 1 year,</p> </li> <li> <p>Treated with lifestyle interventions and metformin at the maximum tolerated dosage (with a minimum daily dosage of 1g), either alone or in combination with an oral insulin secretagogue (sulphonylurea, glinide or DPP‐IV inhibitor), for more than 3 months, </p> </li> <li> <p>HbA1c &lt; 7.5% to ≤ 12%,</p> </li> <li> <p>BMI between 25 and 40 kg/m<sup>2</sup> inclusively, </p> </li> <li> <p>Ability and willingness to perform PG self monitoring using the sponsor‐provided glucose meter and to complete the patient diary, </p> </li> <li> <p>Willingness and ability to comply with the study protocol,</p> </li> <li> <p>Signed informed consent obtained prior to any study procedure.</p> </li> </ul> </p> <p><b>INCLUSION CRITERIA (extension period)</b>:Patients treated with liraglutide (at the maximal tolerated dosage), having a mean FPG ≥ 250 mg/dL at visit 10 (Week 12) or visit 11 (Week 18), or a HbA1c ≥ 7% at visit 12 (Week 24). Dosage of metformin compliant with the inclusion criteria of visit 1 (i.e. maximum tolerated dosage, with a minimum daily dosage of 1g), and maintained stable during the comparative period. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liralutide:</b> 1.8 mg once a day </p> <p><b>Insulin glargine:</b> 100 U/mL once a day </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>PRIMARY OUTCOME:</b> percentage of patients reaching HbA1c &lt; 7 % </p> <p><b>SECONDARY OUTCOMES:</b> Percentage of patients whose HbA1c has decreased but remains ≥ 7%; percentage of patients whose HbA1c has increased; HbA1c change; PPG; FPG, vital signs; hypoglycaemia; dose of insulin glargine or liraglutide </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>July 2010, estimated completion date June 2012 (Last Updated on June 14, 2011)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact‐<a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="93e6e0d3e0f2fdfcf5fa">[email&#160;protected]</a>‐aventis.com</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ClinicalTrials.gov Identifier: NCT01117350; other study ID numbers: LANTU_C_03680, 2010‐018437‐21, U1111‐1116‐9684 </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Liraglutide NCT01296412 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comparison of two treatment regimens (sitagliptin versus liraglutide) on participants who failed to achieve good glucose control on metformin alone (MK‐0431‐403) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>TRIAL DESIGN</b>: Phase III, multicenter, randomised, open‐label clinical trial </p> <p><b>DURATION OF INTERVENTION</b>: 26 weeks </p> <p><b>COUNTRY</b>: USA, Canada, France, Hungary, Italy, Lithuania, Puerto Rico, Slovenia, Sweden, UK </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>INCLUSION CRITERIA:</b> </p> <p> <ul id="CD006423-lst1-0031"> <li> <p>Type 2 diabetes mellitus.</p> </li> <li> <p>On stable dose of metformin monotherapy at a dose of at least 1500 mg per day for at least 12 weeks and a HbA1c ≥ 7.0% and ≤ 11.0%. </p> </li> <li> <p>Capable of using a liraglutide pen device.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide:</b> 0.6 mg by subcutaneous (pen) injection, once daily, on days 1 to 7; in subsequent weeks, the dose may be up‐titrated to 1.8 mg once daily. </p> <p><b>Sitagliptin:</b> 100 mg tablet, orally, once daily. </p> <p><b>Glimepiride:</b> starting dose of 1 mg tablet (up‐titrated as needed), once daily, as needed, after week 12 therapy. </p> <p><b>Metformin:</b> metformin tablets at a dose of ≥ 1500 mg per day </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>PRIMARY OUTCOME:</b> Glycaemic control </p> <p><b>SECONDARY OUTCOMES:</b> Percentage of patients reaching haemoglobin A1C goals (&lt; 7.0% and &lt; 6.5%); FPG </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>March 2011, estimated completion date May 2012 (last updated on May 3, 2011)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Toll Free Number 1‐888‐577‐8839 (Merck)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ClinicalTrials.gov identifier: NCT01296412</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Liraglutide NCT01336023 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Dual action of liraglutide and insulin degludec in type 2 diabetes: a trial comparing the efficacy and safety of insulin degludec/liraglutide, insulin degludec and liraglutide in subjects with type 2 diabetes (DUAL™ I) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>TRIAL DESIGN</b>: Phase III, randomised, parallel three‐arm, open‐label, multi‐centre, multinational treat‐to‐target trial </p> <p><b>DURATION OF INTERVENTION</b>: 26 weeks </p> <p><b>COUNTRY</b>: USA, Australia, Canada, Finland, Germany, Hungary, India, Ireland, Italy, Malaysia, Mexico, Puerto Rico, Russian Federation, Singapore, Slovakia, South Africa, Spain, Taiwan, Thailand, UK </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>INCLUSION CRITERIA:</b> </p> <p> <ul id="CD006423-lst1-0032"> <li> <p>For certain countries the minimum age is 20 or 21, according to local legislation</p> </li> <li> <p>Subjects with type 2 diabetes</p> </li> <li> <p>HbA1c (glycosylated haemoglobin) 7.0 to 10.0% (both inclusive)</p> </li> <li> <p>Subjects on stable dose of 1 to 2 OADs (metformin or metformin + pioglitazone for at least 90 days prior to trial start) </p> </li> <li> <p>BMI below or equal to 40 kg/m<sup>2</sup> </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Insulin degludec/liraglutide:</b> insulin degludec/liraglutide treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean SMPG (fasting). Insulin degludec/liraglutide is injected subcutaneously (under the skin) once daily. </p> <p><b>Insulin degludec:</b> insulin degludec treatment will be initiated with 10 U and titrated (individually adjusted) twice weekly according to the mean SMPG (fasting). Insulin degludec is injected subcutaneously (under the skin) once daily. </p> <p><b>Liraglutide:</b> liraglutide will be started with 0.6 mg and subsequent 0.6 mg weekly dose escalation to 1.8 mg. Liraglutide dose of 1.8 mg/day will be continued for the remaining part of the trial. Liraglutide is injected subcutaneously (under the skin) once daily. </p> <p>Subjects should continue their pre‐trial treatment with metformin or metformin + pioglitazone throughout the entire trial </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>PRIMARY OUTCOME:</b> Change from baseline in HbA1c </p> <p><b>SECONDARY OUTCOMES:</b> body weight, hypoglycaemia, meal test, daily insulin dose </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>May 2011, estimated completion date October 2012 (last updated on May 23, 2011)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Klaus Kjær Laigaard (Novo Nordisk)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ClinicalTrials.gov Identifier: NCT01336023; other study ID numbers: NN9068‐3697, U1111‐1119‐1174, 2010‐021560‐15 </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Lixisenatide NCT00707031 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>GLP‐1 agonist AVE0010 versus exenatide in patients with type 2 diabetes for glycaemic control and safety evaluation, on top of metformin (GETGOAL‐X) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>TRIAL DESIGN</b>: Phase III, randomised, open‐label, active‐controlled, 2‐arm parallel‐group, multicenter study </p> <p><b>DURATION OF INTERVENTION</b>: 24 weeks </p> <p><b>COUNTRY</b>: </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>INCLUSION CRITERIA:</b> </p> <p> <ul id="CD006423-lst1-0033"> <li> <p>Type 2 diabetes mellitus, diagnosed for at least 1 year before screening visit, insufficiently controlled with metformin </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Lixisenatide (AVE0010)</b> at least 24 weeks of treatment, extension period of variable duration </p> <p><b>Exenatide: a</b>t least 24 weeks of treatment extension period of variable duration </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>PRIMARY OUTCOME:</b> Absolute change from baseline in HbA1c </p> <p><b>SECONDARY OUTCOMES:</b> body weight, FPG, treatment satisfaction </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>June 2008, completed (last updated on November 25, 2010)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Sanofi‐Aventis</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ClinicalTrials.gov identifier: NCT00707031 other study ID numbers: EFC6019, EudraCT 2007‐005883‐28 </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Lixisenatide NCT00713830 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>GLP‐1 agonist AVE0010 in patients with type 2 diabetes for glycaemic control and safety evaluation, on top of sulphonylurea (GETGOAL‐S) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>TRIAL DESIGN</b>: Phase III, randomised, double‐blind, placebo‐controlled, 2‐arm parallel‐group, multicenter study </p> <p><b>DURATION OF INTERVENTION</b>: 24 weeks </p> <p><b>COUNTRY</b>: USA, Bulgaria, Czech Republic, Egypt, Germany, India, Israel, Japan, Korea, Netherlands, Romania, Russian Federation, Taiwan, Thailand, Tunisia, Turkey </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>INCLUSION CRITERIA:</b> </p> <p> <ul id="CD006423-lst1-0034"> <li> <p>Type 2 diabetes mellitus, diagnosed for at least 1 year before screening visit, insufficiently controlled with a sulphonylurea alone or a sulphonylurea in association with metformin </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Lixisenatide (AVE0010)</b> at least 24 weeks of treatment, extension period of variable duration </p> <p><b>Placebo:</b> at least 24 weeks of treatment, extension period of variable duration </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>PRIMARY OUTCOME:</b> Absolute change from baseline in HbA1c </p> <p><b>SECONDARY OUTCOMES:</b> body weight, FPG, 2‐hours post‐prandial plasma glucose, glucagon, insulin, pro‐insulin, C‐peptide </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>July 2008, completed (last updated on January 25, 2011)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Sanofi‐Aventis</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ClinicalTrials.gov Identifier: NCT00713830, other study ID numbers: EFC6015, EudraCT 2007‐005881‐11 </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Lixisenatide NCT00763815 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>GLP‐1 agonist AVE0010 in patients with type 2 diabetes for glycaemic control and safety evaluation, on top of pioglitazone (GETGOAL‐P) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>TRIAL DESIGN</b>: Phase III, randomised, double‐blind, placebo‐controlled, 2‐arm parallel‐group, multicenter study </p> <p><b>DURATION OF INTERVENTION</b>:24 weeks </p> <p><b>COUNTRY</b>:USA, Austria, Canada, France, Germany, Greece, Guatemala, India, Mexico, Peru, Puerto Rico, Romania, Turkey </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>INCLUSION CRITERIA:</b> </p> <p> <ul id="CD006423-lst1-0035"> <li> <p>Type 2 diabetes mellitus, diagnosed for at least 1 year before screening visit, insufficiently controlled with pioglitazone with or without metformin </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Lixisenatide:</b> AVE0010 </p> <p><b>Placebo:</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>PRIMARY OUTCOME:</b> Glycaemic control </p> <p><b>SECONDARY OUTCOMES:</b> body weight, FPG, fasting insulin levels </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>September 2008, estimated completion date June 2011 (last updated on June 22, 2010)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Sanofi‐Aventis</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ClinicalTrials.gov Identifier: NCT00763815</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Lixisenatide NCT00975286 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A randomised, placebo‐controlled, 2‐arm parallel‐group, multicenter study with a 24‐week double‐blind treatment period assessing the efficacy and safety of lixisenatide in patients with type 2 diabetes insufficiently controlled with insulin glargine and metformin </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>TRIAL DESIGN</b>: Randomised, placebo‐controlled parallel group phase III trial, multi‐centre </p> <p><b>DURATION OF INTERVENTION</b>: 24 weeks </p> <p><b>COUNTRY</b>: USA, Canada, Sweden, Estonia </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>INCLUSION CRITERIA:</b> </p> <p>At screening:</p> <p> <ul id="CD006423-lst1-0036"> <li> <p>Patients (18 years or older) with type 2 diabetes mellitus, as defined by WHO (fasting plasma glucose ≥ 7 mmol/L (126 mg/dL) or 2 hours postprandial plasma glucose ≥ 11.1 mmol/L (200 mg/dL), diagnosed at least 1 year before the screening visit </p> </li> <li> <p>For at least 3 months: treatment with a stable dose of metformin ≥ 1.5 g/day or combination of stable doses of metformin ≥ 1.5 g/day with SUs (to be stopped at visit 1) and/or TZDs </p> </li> <li> <p>HbA1c of ≥ 7.0 and ≤ 10%</p> </li> </ul> </p> <p>At the end of the run in phase and before randomisation:</p> <p> <ul id="CD006423-lst1-0037"> <li> <p>HbA1c ≥ 7.0 and ≤ 9%</p> </li> <li> <p>Mean fasting SMPG calculated from the self measurements for the 7 days prior to visit 12 (week ‐1) is less than or equal to 126 mg/dL (7.0 mmol/L) </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Lixisenatide:</b> Lixisenatide once daily on top of insulin glargine (both injected in the morning within 1 hour prior to breakfast) and metformin (at least 1.5 g/day) </p> <p><b>Placebo:</b> Placebo once daily on top of insulin glargine (both injected in the morning within 1 hour prior to breakfast) and metformin (at least 1.5 g/day) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>PRIMARY OUTCOME:</b> Glycaemic control </p> <p><b>SECONDARY OUTCOMES:</b> percentage of patients reaching HbA1c &lt; 7% and ≤ 6.5 %, on plasma glucose (fasting, post‐prandial during a standardised meal challenge test, 7‐point self monitored profiles), body weight, insulin glargine doses; safety and tolerability, treatment satisfaction (diabetes treatment satisfaction questionnaire) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>October 2009, estimated completion August 2011</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>GV‐Contact‐<a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="d4a1a794a7b5babbb2bd">[email&#160;protected]</a>‐aventis.com</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study ID Numbers: EFC10781, EudraCT: 2008‐007335‐40; ClinicalTrials.gov identifier: NCT00975286 </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Lixisenatide NCT00976937 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A randomised, double‐blind, double‐dummy, 2‐arm parallel‐group, multicenter 24‐week study comparing the efficacy and safety of ave0010 to sitagliptin as add‐on to metformin in obese type 2 diabetic patients younger than 50 and not adequately controlled with metformin </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>TRIAL DESIGN</b>: Randomised double‐blind, placebo‐controlled parallel group phase III trial, multi‐centre </p> <p><b>DURATION OF INTERVENTION</b>: 24 weeks </p> <p><b>COUNTRY</b>: USA, Australia, Canada, Chile, Mexico, Russian Federation </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>INCLUSION CRITERIA:</b> </p> <p> <ul id="CD006423-lst1-0038"> <li> <p>Patients with type 2 diabetes mellitus, age 18 to 49 years, as defined by WHO, diagnosed for at least 1 year at the time of screening visit, insufficiently controlled with metformin at a stable dose of at least 1.5 g/day (1.0 g/day for patients from South Korea) for at least 3 months prior to the screening visit. </p> </li> <li> <p>Patients with obesity (BMI ≥ 30 kg/m<sup>2</sup>) </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Lixisenatide:</b> Injection of lixisenatide once a day in the morning within 1 hour prior to breakfast (first 2 weeks of double‐blind period: titration 10 to 15 µg, then 15 to 20 µg) and one capsule of sitagliptin placebo intake in the morning with or without food. On top of metformin background therapy </p> <p><b>Sitagliptin:</b> One capsule of sitagliptin intake in the morning with or without food and lixisenatide matched placebo injection once a day in the morning within 1 hour prior to breakfast. On top of metformin background therapy. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>PRIMARY OUTCOME:</b> Percentage of patients with HbA1c values &lt; 7% and a weight loss of at least 5% of baseline body weight </p> <p><b>SECONDARY OUTCOMES:</b> Absolute change in HbA1c values, percentage of patients with HbA1c values ≤ 6.5%, absolute change in body weight, change in fasting plasma glucose, change in plasma glucose and in beta‐cell function during a test meal, change in insulin resistance assessed by HOMA‐IR, change in beta‐cell function assessed by HOMA‐beta, percentage of patients requiring rescue therapy during the double‐blind treatment period; safety and tolerability </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>August 2009, completed (last updated on May 6, 20 2011)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>GV‐Contact‐<a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="a2d7d1e2d1c3cccdc4cb">[email&#160;protected]</a>‐aventis.com</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study ID Numbers: EFC10780, EudraCT: 2008‐007 334‐22</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Semaglutide NCT00696657 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A randomised controlled clinical trial in type 2 diabetes comparing semaglutide to placebo and liraglutide </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>TRIAL DESIGN</b>: Phase II, multi‐centre, multi national, double‐blind, placebo‐controlled, randomised, nine armed parallel group, dose finding trial </p> <p><b>DURATION OF INTERVENTION</b>: 12 weeks </p> <p><b>COUNTRY</b>: Austria, Bulgaria, Finland, Former Serbia and Montenegro, France, Germany, Hungary, India, Italy, South Africa, Spain, Switzerland, Turkey, UK </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>INCLUSION CRITERIA:</b> </p> <p> <ul id="CD006423-lst1-0039"> <li> <p>Men and women‐not‐of‐childbearing potential diagnosed with type 2 diabetes for at least three months </p> </li> <li> <p>Stable treatment regimen with either metformin (at least 1500 mg) or diet and exercise alone for at least three months </p> </li> <li> <p>HbA1c: 7.0 to 10.0% (both inclusive)</p> </li> <li> <p>Body weight between 60 kg and 110 kg</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Semaglutide:</b> 0.1 or 0.2 or 0.4 or 0.8 mg once weekly s.c. injection; 0.8 mg or 1.6 mg with titration, once weekly s.c. injection </p> <p><b>Placebo:</b> 0.1 or 0.2 or 0.4 mg once weekly s.c. injection; 0.8 mg or 1.6 mg with titration, once weekly s.c. injection </p> <p><b>Liraglutide:</b> 1.2 or 1.8 mg with titration, once daily, s.c. injection </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>PRIMARY OUTCOME:</b> Change in HbA1c </p> <p><b>SECONDARY OUTCOMES</b>: Percentage of subjects with an adverse events; percentage of subjects with hypoglycaemic episode; ECG, vital signs; safety laboratory parameters; percentage of subjects developing anti‐semaglutide antibodies and calcitonin </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>June 2008, Final data collection date for primary outcome measure February 2009 (last updated on March 16, 2011) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Novo Nordisk</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ClinicalTrials.gov Identifier: NCT00696657; other study ID numbers: NN9535‐1821, 2007‐003956‐12</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Taspoglutide NCT00717457 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Randomised, active controlled, open label study to compare taspoglutide with exenatide as add‐on treatment to metformin and/or thiazolidinediones in patients with type 2 diabetes mellitus </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>TRIAL DESIGN</b>: Randomised, open label, active controlled, parallel assigned, phase III trial, multi centre, multinational, safety and efficacy study </p> <p><b>DURATION OF INTERVENTION</b>: 3+ years </p> <p><b>COUNTRY</b>: USA, Europe, America, South Africa, Asia </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>INCLUSION CRITERIA:</b> </p> <p> <ul id="CD006423-lst1-0040"> <li> <p>Patients (18 years to 75 years of age and both sexes) with type 2 diabetes treated with metformin and/or pioglitazone or rosiglitazone for at least 12 weeks </p> </li> <li> <p>HbA1c ≥ 7.0% and ≤ 10% at screening</p> </li> <li> <p>BMI ≥ 25 kg/m<sup>2</sup> (&gt; 23 kg/m<sup>2</sup> for Asians) and ≤ 45 kg/m<sup>2</sup> at screening </p> </li> <li> <p>stable weight ± 5% for at least 12 weeks prior to screening</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Taspoglutide</b>: 10 mg subcutaneous injection once weekly </p> <p><b>Taspoglutide</b>: 10 mg subcutaneous injection once weekly for 4 weeks followed by 20 mg subcutaneous once weekly </p> <p><b>Exenatide</b>: Exenatide 5 mg twice daily for 4 weeks followed by 10 mg twice daily [should presumably read "µg"?] </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>PRIMARY OUTCOME:</b> Change in HbA1c at 24 weeks </p> <p><b>SECONDARY OUTCOMES</b>: All the outcomes measured at 24 weeks. Fasting body weight, proportion of participants reaching target HbA1c ≤ 7.0%, ≤ 6.5%, relative change in glucose, insulin, C‐peptide and glucagon values during a meal tolerance test in a subset of patients, beta cell function (proinsulin/insulin ratio) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>July 2008, estimated completion April 2012 (last updated on March 15, 2011)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Hoffmann‐La Roche</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study ID numbers:BC21625, 2008‐001856‐36, ClinicalTrials.gov Identifier: NCT00717457</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Taspoglutide NCT00744367 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A multicenter, randomised, double‐blind, placebo‐controlled study to assess the safety, tolerability and effect of taspoglutide on glycaemic control compared to placebo in patients with type 2 diabetes mellitus inadequately controlled with metformin plus pioglitazone </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>TRIAL DESIGN</b>: Randomised, double‐blind, placebo‐controlled, phase III trial, multicenter, multinational, safety and efficacy study </p> <p><b>DURATION OF INTERVENTION</b>: 1 to 2 years </p> <p><b>COUNTRY</b>: USA, Europe and America </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>INCLUSION CRITERIA:</b> </p> <p> <ul id="CD006423-lst1-0041"> <li> <p>Patients (18 years to 75 years of age and both sexes) with type 2 diabetes receiving pioglitazone (≥ 30 mg/day) and metformin (≥ 1500 mg/day) for at least 12 weeks prior to screening </p> </li> <li> <p>HbA1c ≥ 7.0% and ≤ 10.0% at screening</p> </li> <li> <p>BMI ≥ 25 (&gt; 23 for Asians) and ≤ 45 kg/m<sup>2</sup> at screening </p> </li> <li> <p>stable weight ± 5% for at least 12 weeks prior to screening</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Taspoglutide</b>: 10 mg subcutaneous injection once weekly, metformin &gt; 1.5 g/day, pioglitazone ≥ 30 mg/day </p> <p><b>Taspoglutide</b>: 10 mg subcutaneous injection once weekly for 4 weeks followed by 20 mg subcutaneous once weekly, metformin as prescribed and placebo orally once daily, metformin &gt; 1.5 g/day, pioglitazone ≥ 30 mg/day </p> <p><b>Placebo</b>: Placebo subcutaneous once weekly, metformin &gt; 1.5 g/day, pioglitazone ≥ 30 mg/day </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>PRIMARY OUTCOME</b>: Absolute change from baseline in HbA1c at 24 weeks </p> <p><b>SECONDARY OUTCOMES</b>: Change from baseline in fasting plasma glucose, change from baseline in body weight, responder rates for HbA1c (target ≤ 7.0%, ≤ 6.5%), responder rates for body weight and beta cell function at 24 weeks; safety: adverse events, vital signs, physical examination, clinical laboratory tests, ECG and anti‐taspoglutide antibodies throughout the study </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>October 2008, estimated completion September 2010 (last updated on March 15, 2011)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Hoffmann‐La Roche</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study ID numbers: BC20963, 2008‐001744‐39, ClinicalTrials.gov Identifier: NCT00744367</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Taspoglutide NCT00754988 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A multicenter, randomised, double‐dummy, placebo and active‐controlled study to assess the safety, tolerability and effect of taspoglutide on glycaemic control compared to sitagliptin and placebo in patients with type 2 diabetes mellitus inadequately controlled with metformin </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>TRIAL DESIGN</b>: Randomised, double blind, placebo and active controlled, phase III trial, multicenter, multinational, safety and efficacy study </p> <p><b>DURATION OF INTERVENTION</b>: 2+ years </p> <p><b>COUNTRY</b>: USA, Europe, Asia, America, Australia </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>INCLUSION CRITERIA:</b> </p> <p> <ul id="CD006423-lst1-0042"> <li> <p>Patients (18 years to 75 years of age and both sexes) with type 2 diabetes receiving metformin ≥ 1.5 g/day for at least 12 weeks </p> </li> <li> <p>HbA1c ≥ 7.0% and ≤ 10.0% at screening</p> </li> <li> <p>BMI ≥ 25 (&gt; 23 for Asians) and ≤ 45 kg/m<sup>2</sup> at screening </p> </li> <li> <p>stable weight ± 5% for at least 12 weeks prior to screening</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Taspoglutide</b>: 10 mg subcutaneous injection once weekly, metformin as prescribed and placebo per orally once daily </p> <p><b>Taspoglutide</b>: 10 mg subcutaneous injection once weekly for 4 weeks followed by 20 mg subcutaneous once weekly, metformin as prescribed and placebo per orally once daily </p> <p><b>Sitagliptin</b>: Sitagliptin 100 mg per orally once daily, placebo subcutaneous once weekly and metformin as prescribed </p> <p><b>Placebo</b>: Placebo subcutaneous once daily, metformin as prescribed and placebo per orally once daily </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>PRIMARY OUTCOME</b>:Mean changes in HbA1c at 24 weeks </p> <p><b>SECONDARY OUTCOMES</b>:Change from baseline in fasting plasma glucose, change from baseline in body weight, responder rates for HbA1c (target ≤ 7.0%, ≤ 6.5%), responder rates for body weight, change from baseline in lipid profile and beta cell function at 24 weeks; safety: adverse events, vital signs, physical examination, clinical laboratory tests, ECG and anti‐taspoglutide antibodies throughout study </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>October 2008, estimated completion May 2012 (last updated on March 15, 2011)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Hoffmann‐La Roche</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study ID numbers: BC21713, 2008‐001854‐42, ClinicalTrials.gov Identifier: NCT00754988</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Taspoglutide NCT00755287 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A multicenter, randomised, open‐label, active‐controlled study to compare the safety, tolerability and effect on glycaemic control of taspoglutide versus insulin glargine in insulin‐naïve type 2 diabetic patients inadequately controlled with metformin and sulphonylurea combination therapy </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>TRIAL DESIGN</b>: Randomised, open‐label, active controlled, parallel assignment, multicenter, multinational, phase III trial </p> <p><b>DURATION OF INTERVENTION</b>: 2+ years </p> <p><b>COUNTRY</b>: USA, Australia, Asia, Europe </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>INCLUSION CRITERIA:</b> </p> <p> <ul id="CD006423-lst1-0043"> <li> <p>Patients (18 years to 75 years of age and both sexes) with type 2 diabetes treated with a stable dose of metformin and sulphonylurea for at least 12 weeks </p> </li> <li> <p>C‐peptide (fasting) ≥1.0 ng/mL</p> </li> <li> <p>HbA1c ≥ 7.0% and ≤ 10.0% at screening</p> </li> <li> <p>BMI ≥ 25 (&gt; 23 for Asians) and ≤ 45 kg/m<sup>2</sup> at screening </p> </li> <li> <p>stable weight ± 5% for at least 12 weeks prior to screening</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Taspoglutide</b>: 10 mg subcutaneous injection once weekly and metformin as prescribed </p> <p><b>Taspoglutide</b>: 10 mg subcutaneous injection once weekly for 4 weeks followed by 20 mg subcutaneous once weekly and metformin as prescribed </p> <p><b>Insulin glargine</b>: Starting dose at 10 IU daily and metformin as prescribed </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>PRIMARY OUTCOME</b>: Absolute change from baseline in HbA1c at 24 weeks </p> <p><b>SECONDARY OUTCOMES</b>: Change from baseline in fasting plasma glucose, change from baseline in body weight, responder rates for HbA1c (target ≤ 7.0%, ≤ 6.5%), incidence of hypoglycaemia and change from baseline in lipid profile at 24 weeks; relative change in glucose, insulin, C‐peptide and glucagon during a meal tolerance test at 24 weeks; safety: adverse events, vital signs, physical examination, clinical laboratory tests, ECG and anti‐taspoglutide antibodies measured throughout study </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>October 2008, estimated completion June 2012 (last updated on March 15, 2011)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Hoffmann‐La Roche</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study ID numbers: BC20965, 2008‐001855‐23, ClinicalTrials.gov Identifier: NCT00755287</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Taspoglutide NCT00823992 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A randomised, double‐blind, placebo‐controlled study to assess the effect of taspoglutide on glycaemic control, and its safety and tolerability, in obese patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>TRIAL DESIGN</b>: Randomised, double‐blind, placebo‐controlled, parallel assigned, phase III trial, multicenter, multinational, safety and efficacy study </p> <p><b>DURATION OF INTERVENTION</b>: 52 weeks (12 months) </p> <p><b>COUNTRY</b>: USA, Europe </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>INCLUSION CRITERIA:</b> </p> <p> <ul id="CD006423-lst1-0044"> <li> <p>Patients (18 years to 75 years of age and both sexes) with type 2 diabetes treated with stable dose of metformin of ≥ 1.5 g/day for at least 12 weeks </p> </li> <li> <p>HbA1c ≥ 6.5% and ≤ 9.5% at screening</p> </li> <li> <p>BMI ≥ 30 and ≤ 50 kg/m<sup>2</sup> at screening </p> </li> <li> <p>Stable weight ± 5% for at least 12 weeks prior to screening</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Taspoglutide</b>: 10 mg subcutaneous injection once weekly for 4 weeks followed by 20 mg subcutaneous once weekly </p> <p><b>Placebo</b>: Subcutaneous once weekly </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>PRIMARY OUTCOME</b>: Absolute change from baseline in HbA1c at 24 weeks </p> <p><b>SECONDARY OUTCOMES</b>: Change from baseline in body weight, % of patients achieving ≥ 5% weight loss at weeks 24; % of patients achieving target HbA1c ≤ 6.5%, ≤ 7.0%, change from baseline in fasting plasma glucose, change from baseline in lipid profile, relative change in glucose, insulin, C‐peptide and glucagon during a meal tolerance test and beta cell function at 24 weeks; safety: adverse events,clinical laboratory tests, vital signs, physical examination, ECG, anti‐taspoglutide antibodies at planned clinical visits for 12 months </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>January 2009, completed (last updated on April 18, 2011)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Hoffmann‐La Roche</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study ID numbers: BC22092, 2008‐005809‐20, ClinicalTrials.gov Identifier: NCT00823992</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Taspoglutide NCT00909597 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A multicenter, randomised, double blind (double dummy), active controlled study to compare the safety, tolerability and effect on glycaemic control of taspoglutide versus pioglitazone in type 2 diabetes patients inadequately controlled on therapy with sulphonylurea or metformin plus sulphonylurea </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>TRIAL DESIGN</b>: Randomised, double blind (participant, investigator), three arm, phase III trial, parallel assignment, multi centre, multinational, safety and efficacy study </p> <p><b>DURATION OF INTERVENTION</b>: 104 weeks (24 months) </p> <p><b>COUNTRY</b>: USA, Europe, North and South America </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>INCLUSION CRITERIA:</b> </p> <p> <ul id="CD006423-lst1-0045"> <li> <p>Patients (18 years to 75 years of age and both sexes) with type 2 diabetes treated with stable dose of sulphonylurea monotherapy or metformin plus sulphonylurea for ≥ 12 weeks prior to screening. </p> </li> <li> <p>HbA1c ≥ 7.0% and ≤ 10.0% at screening</p> </li> <li> <p>stable weight ± 5% for ≥ 12 weeks prior to screening</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Taspoglutide</b>: 10 mg subcutaneous injection once weekly </p> <p><b>Taspoglutide</b>: 10 mg subcutaneous injection once weekly for 4 weeks followed by 20 mg subcutaneous once weekly </p> <p><b>Pioglitazone</b>: 30 mg orally once daily for 4 weeks followed by 45 mg once daily </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>PRIMARY OUTCOME:</b> Absolute change in HbA1c from baseline at 24 weeks </p> <p><b>SECONDARY OUTCOMES</b>: Proportion of participants achieving target HbA1c ≤ 6.5%, ≤ 7.0% at weeks 24, 52 and 104; absolute/percentage change from baseline in body weight, responder rates for body weight, absolute/percentage change from baseline in waist and hip circumference, absolute/percentage change from baseline in fasting plasma glucose at weeks 24, 52 and 104; adverse events, laboratory parameters, cardiovascular events at each clinic visit up to 106 weeks </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>May 2009, completed (last updated on June 15, 2011)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Hoffmann‐La Roche</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study ID numbers: BC21893, 2009‐009157‐24, ClinicalTrials.gov Identifier: NCT00909597</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>BG: biguanide; BMI: body mass index; , CV: cardiovascular; DPP‐4: dipeptidyl peptidase‐4 inhibitor; ECG: electrocardiography; FPG: fasting plasma glucose; HbA1c: glycosylated haemoglobin A1c; HOMA‐B: homeostatic model assessment‐beta cell function; HOMA‐IS: homeostatic model assessment‐insulin sensitivity; HOMA‐IR: homeostatic model assessment‐insulin resistance; Met: metformin; OAD: oral antidiabetic drug; PG: plasma glucose; PPG: post‐prandial glucose; QD: once daily; SMPG: self‐measured plasma glucose; SU: sulphonylurea; TZD: thiazolidinedione; WHO: World Health Organization.</sup> </p> </div> </div> </p> </section> </section> <section class="dataAndAnalyses" id="dataAndAnalyses"> <section class="dataAndAnalyses" lang="en"> <div class="section-header section-collapse-header" id="CD006423-sec1-0010"> <h2 class="title section-collapse-title">Data and analyses<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <div class="table" id="CD006423-tbl-0001"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 1.</span>&nbsp;<span class="table-title">Albiglutide versus placebo</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00101"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=1.1&amp;caption=Comparison%201%20Albiglutide%20versus%20placebo%2C%20Outcome%201%20HbA1c%20%28%25%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.1</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Albiglutide versus placebo, Outcome 1 HbA1c (%).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 HbA1c ‐ with plot <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00102"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-001-02.png?filename=nCD006423-CMP-001-02.ppt&amp;title=1.2&amp;caption=Comparison%201%20Albiglutide%20versus%20placebo%2C%20Outcome%202%20HbA1c%20%E2%80%90%20with%20plot.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.2</div> </div> <hr class="top"><img data-id="CD006423-fig-00102" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-001-02.png" alt="Comparison 1 Albiglutide versus placebo, Outcome 2 HbA1c ‐ with plot."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Albiglutide versus placebo, Outcome 2 HbA1c ‐ with plot.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.1 ALBI 30 mg weekly</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>79</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.7 [‐1.07, ‐0.33]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.2 ALBI 30 mg every 2 weeks</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>82</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.62 [‐1.06, ‐0.18]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 HbA1c &lt; 7% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00103"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=1.3&amp;caption=Comparison%201%20Albiglutide%20versus%20placebo%2C%20Outcome%203%20HbA1c%20%3C%207%25.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.3</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Albiglutide versus placebo, Outcome 3 HbA1c &lt; 7%.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00104"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=1.4&amp;caption=Comparison%201%20Albiglutide%20versus%20placebo%2C%20Outcome%204%20Hypoglycaemia.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.4</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Albiglutide versus placebo, Outcome 4 Hypoglycaemia.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Weight change ‐ with plot <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00105"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-001-05.png?filename=nCD006423-CMP-001-05.ppt&amp;title=1.5&amp;caption=Comparison%201%20Albiglutide%20versus%20placebo%2C%20Outcome%205%20Weight%20change%20%E2%80%90%20with%20plot.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.5</div> </div> <hr class="top"><img data-id="CD006423-fig-00105" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-001-05.png" alt="Comparison 1 Albiglutide versus placebo, Outcome 5 Weight change ‐ with plot."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Albiglutide versus placebo, Outcome 5 Weight change ‐ with plot.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.1 ALBI 30 mg weekly</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>79</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.7 [‐1.89, 0.49]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.2 ALBI 30 mg every 2 weeks</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>82</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.9 [‐2.08, 0.28]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Weight change (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00106"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=1.6&amp;caption=Comparison%201%20Albiglutide%20versus%20placebo%2C%20Outcome%206%20Weight%20change%20%28kg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.6</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Albiglutide versus placebo, Outcome 6 Weight change (kg).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00107"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=1.7&amp;caption=Comparison%201%20Albiglutide%20versus%20placebo%2C%20Outcome%207%20Adverse%20events.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.7</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Albiglutide versus placebo, Outcome 7 Adverse events.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Blood pressure (mm Hg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00108"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=1.8&amp;caption=Comparison%201%20Albiglutide%20versus%20placebo%2C%20Outcome%208%20Blood%20pressure%20%28mm%20Hg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.8</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Albiglutide versus placebo, Outcome 8 Blood pressure (mm Hg).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">9 Fasting plasma glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00109"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=1.9&amp;caption=Comparison%201%20Albiglutide%20versus%20placebo%2C%20Outcome%209%20Fasting%20plasma%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.9</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Albiglutide versus placebo, Outcome 9 Fasting plasma glucose (mmol/L).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">10 Lipid profiles <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00110"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=1.10&amp;caption=Comparison%201%20Albiglutide%20versus%20placebo%2C%20Outcome%2010%20Lipid%20profiles.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.10</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Albiglutide versus placebo, Outcome 10 Lipid profiles.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">11 Beta‐cell function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00111"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=1.11&amp;caption=Comparison%201%20Albiglutide%20versus%20placebo%2C%20Outcome%2011%20Beta%E2%80%90cell%20function.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.11</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Albiglutide versus placebo, Outcome 11 Beta‐cell function.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">12 Subgroups <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00112"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=1.12&amp;caption=Comparison%201%20Albiglutide%20versus%20placebo%2C%20Outcome%2012%20Subgroups.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.12</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Albiglutide versus placebo, Outcome 12 Subgroups.</p> </div> </div> </div> </td> </tr> </tbody> </table> </div> <div class="table" id="CD006423-tbl-0002"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 2.</span>&nbsp;<span class="table-title">Exenatide 2 mg once weekly versus thiazolidinedione</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00201"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-002-01.png?filename=nCD006423-CMP-002-01.ppt&amp;title=2.1&amp;caption=Comparison%202%20Exenatide%202%20mg%20once%20weekly%20versus%20thiazolidinedione%2C%20Outcome%201%20HbA1c%20%28%25%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.1</div> </div> <hr class="top"><img data-id="CD006423-fig-00201" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-002-01.png" alt="Comparison 2 Exenatide 2 mg once weekly versus thiazolidinedione, Outcome 1 HbA1c (%)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 Exenatide 2 mg once weekly versus thiazolidinedione, Outcome 1 HbA1c (%). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 HbA1c &lt; 7% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00202"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-002-02.png?filename=nCD006423-CMP-002-02.ppt&amp;title=2.2&amp;caption=Comparison%202%20Exenatide%202%20mg%20once%20weekly%20versus%20thiazolidinedione%2C%20Outcome%202%20HbA1c%20%3C%207%25.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.2</div> </div> <hr class="top"><img data-id="CD006423-fig-00202" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-002-02.png" alt="Comparison 2 Exenatide 2 mg once weekly versus thiazolidinedione, Outcome 2 HbA1c < 7%."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 Exenatide 2 mg once weekly versus thiazolidinedione, Outcome 2 HbA1c &lt; 7%. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Hypoglycaemia (minor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00203"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-002-03.png?filename=nCD006423-CMP-002-03.ppt&amp;title=2.3&amp;caption=Comparison%202%20Exenatide%202%20mg%20once%20weekly%20versus%20thiazolidinedione%2C%20Outcome%203%20Hypoglycaemia%20%28minor%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.3</div> </div> <hr class="top"><img data-id="CD006423-fig-00203" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-002-03.png" alt="Comparison 2 Exenatide 2 mg once weekly versus thiazolidinedione, Outcome 3 Hypoglycaemia (minor)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 Exenatide 2 mg once weekly versus thiazolidinedione, Outcome 3 Hypoglycaemia (minor). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Weight change (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00204"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-002-04.png?filename=nCD006423-CMP-002-04.ppt&amp;title=2.4&amp;caption=Comparison%202%20Exenatide%202%20mg%20once%20weekly%20versus%20thiazolidinedione%2C%20Outcome%204%20Weight%20change%20%28kg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.4</div> </div> <hr class="top"><img data-id="CD006423-fig-00204" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-002-04.png" alt="Comparison 2 Exenatide 2 mg once weekly versus thiazolidinedione, Outcome 4 Weight change (kg)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 Exenatide 2 mg once weekly versus thiazolidinedione, Outcome 4 Weight change (kg). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00205"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=2.5&amp;caption=Comparison%202%20Exenatide%202%20mg%20once%20weekly%20versus%20thiazolidinedione%2C%20Outcome%205%20Quality%20of%20life.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.5</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 Exenatide 2 mg once weekly versus thiazolidinedione, Outcome 5 Quality of life. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00206"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=2.6&amp;caption=Comparison%202%20Exenatide%202%20mg%20once%20weekly%20versus%20thiazolidinedione%2C%20Outcome%206%20Adverse%20events.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.6</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 Exenatide 2 mg once weekly versus thiazolidinedione, Outcome 6 Adverse events. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Blood pressure (mm Hg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00207"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=2.7&amp;caption=Comparison%202%20Exenatide%202%20mg%20once%20weekly%20versus%20thiazolidinedione%2C%20Outcome%207%20Blood%20pressure%20%28mm%20Hg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.7</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 Exenatide 2 mg once weekly versus thiazolidinedione, Outcome 7 Blood pressure (mm Hg). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Fasting plasma glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00208"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-002-08.png?filename=nCD006423-CMP-002-08.ppt&amp;title=2.8&amp;caption=Comparison%202%20Exenatide%202%20mg%20once%20weekly%20versus%20thiazolidinedione%2C%20Outcome%208%20Fasting%20plasma%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.8</div> </div> <hr class="top"><img data-id="CD006423-fig-00208" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-002-08.png" alt="Comparison 2 Exenatide 2 mg once weekly versus thiazolidinedione, Outcome 8 Fasting plasma glucose (mmol/L)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 Exenatide 2 mg once weekly versus thiazolidinedione, Outcome 8 Fasting plasma glucose (mmol/L). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">9 Post‐prandial glucose / glucose profiles <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00209"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=2.9&amp;caption=Comparison%202%20Exenatide%202%20mg%20once%20weekly%20versus%20thiazolidinedione%2C%20Outcome%209%20Post%E2%80%90prandial%20glucose%20%2F%20glucose%20profiles.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.9</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 Exenatide 2 mg once weekly versus thiazolidinedione, Outcome 9 Post‐prandial glucose / glucose profiles. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">10 Lipid profiles <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00210"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=2.10&amp;caption=Comparison%202%20Exenatide%202%20mg%20once%20weekly%20versus%20thiazolidinedione%2C%20Outcome%2010%20Lipid%20profiles.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.10</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 Exenatide 2 mg once weekly versus thiazolidinedione, Outcome 10 Lipid profiles. </p> </div> </div> </div> </td> </tr> </tbody> </table> </div> <div class="table" id="CD006423-tbl-0003"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 3.</span>&nbsp;<span class="table-title">Exenatide 2 mg once weekly versus DPP‐4 inhibitors</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00301"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-003-01.png?filename=nCD006423-CMP-003-01.ppt&amp;title=3.1&amp;caption=Comparison%203%20Exenatide%202%20mg%20once%20weekly%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%201%20HbA1c%20%28%25%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 3.1</div> </div> <hr class="top"><img data-id="CD006423-fig-00301" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-003-01.png" alt="Comparison 3 Exenatide 2 mg once weekly versus DPP‐4 inhibitors, Outcome 1 HbA1c (%)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 3 Exenatide 2 mg once weekly versus DPP‐4 inhibitors, Outcome 1 HbA1c (%).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 HbA1c &lt; 7% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00302"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-003-02.png?filename=nCD006423-CMP-003-02.ppt&amp;title=3.2&amp;caption=Comparison%203%20Exenatide%202%20mg%20once%20weekly%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%202%20HbA1c%20%3C%207%25.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 3.2</div> </div> <hr class="top"><img data-id="CD006423-fig-00302" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-003-02.png" alt="Comparison 3 Exenatide 2 mg once weekly versus DPP‐4 inhibitors, Outcome 2 HbA1c < 7%."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 3 Exenatide 2 mg once weekly versus DPP‐4 inhibitors, Outcome 2 HbA1c &lt; 7%. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Hypoglycaemia (minor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00303"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-003-03.png?filename=nCD006423-CMP-003-03.ppt&amp;title=3.3&amp;caption=Comparison%203%20Exenatide%202%20mg%20once%20weekly%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%203%20Hypoglycaemia%20%28minor%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 3.3</div> </div> <hr class="top"><img data-id="CD006423-fig-00303" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-003-03.png" alt="Comparison 3 Exenatide 2 mg once weekly versus DPP‐4 inhibitors, Outcome 3 Hypoglycaemia (minor)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 3 Exenatide 2 mg once weekly versus DPP‐4 inhibitors, Outcome 3 Hypoglycaemia (minor). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Weight change (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00304"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-003-04.png?filename=nCD006423-CMP-003-04.ppt&amp;title=3.4&amp;caption=Comparison%203%20Exenatide%202%20mg%20once%20weekly%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%204%20Weight%20change%20%28kg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 3.4</div> </div> <hr class="top"><img data-id="CD006423-fig-00304" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-003-04.png" alt="Comparison 3 Exenatide 2 mg once weekly versus DPP‐4 inhibitors, Outcome 4 Weight change (kg)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 3 Exenatide 2 mg once weekly versus DPP‐4 inhibitors, Outcome 4 Weight change (kg). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00305"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=3.5&amp;caption=Comparison%203%20Exenatide%202%20mg%20once%20weekly%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%205%20Quality%20of%20life.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 3.5</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 3 Exenatide 2 mg once weekly versus DPP‐4 inhibitors, Outcome 5 Quality of life. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00306"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=3.6&amp;caption=Comparison%203%20Exenatide%202%20mg%20once%20weekly%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%206%20Adverse%20events.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 3.6</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 3 Exenatide 2 mg once weekly versus DPP‐4 inhibitors, Outcome 6 Adverse events. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Blood pressure (mm Hg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00307"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=3.7&amp;caption=Comparison%203%20Exenatide%202%20mg%20once%20weekly%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%207%20Blood%20pressure%20%28mm%20Hg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 3.7</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 3 Exenatide 2 mg once weekly versus DPP‐4 inhibitors, Outcome 7 Blood pressure (mm Hg). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Fasting plasma glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00308"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-003-08.png?filename=nCD006423-CMP-003-08.ppt&amp;title=3.8&amp;caption=Comparison%203%20Exenatide%202%20mg%20once%20weekly%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%208%20Fasting%20plasma%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 3.8</div> </div> <hr class="top"><img data-id="CD006423-fig-00308" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-003-08.png" alt="Comparison 3 Exenatide 2 mg once weekly versus DPP‐4 inhibitors, Outcome 8 Fasting plasma glucose (mmol/L)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 3 Exenatide 2 mg once weekly versus DPP‐4 inhibitors, Outcome 8 Fasting plasma glucose (mmol/L). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">9 Post‐prandial glucose / glucose profiles <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00309"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=3.9&amp;caption=Comparison%203%20Exenatide%202%20mg%20once%20weekly%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%209%20Post%E2%80%90prandial%20glucose%20%2F%20glucose%20profiles.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 3.9</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 3 Exenatide 2 mg once weekly versus DPP‐4 inhibitors, Outcome 9 Post‐prandial glucose / glucose profiles. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">10 Lipid profiles <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00310"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=3.10&amp;caption=Comparison%203%20Exenatide%202%20mg%20once%20weekly%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%2010%20Lipid%20profiles.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 3.10</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 3 Exenatide 2 mg once weekly versus DPP‐4 inhibitors, Outcome 10 Lipid profiles. </p> </div> </div> </div> </td> </tr> </tbody> </table> </div> <div class="table" id="CD006423-tbl-0004"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 4.</span>&nbsp;<span class="table-title">Exenatide 2 mg once weekly versus insulin glargine</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00401"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-004-01.png?filename=nCD006423-CMP-004-01.ppt&amp;title=4.1&amp;caption=Comparison%204%20Exenatide%202%20mg%20once%20weekly%20versus%20insulin%20glargine%2C%20Outcome%201%20HbA1c%20%28%25%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 4.1</div> </div> <hr class="top"><img data-id="CD006423-fig-00401" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-004-01.png" alt="Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 1 HbA1c (%)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 1 HbA1c (%).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 HbA1c &lt; 7% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00402"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-004-02.png?filename=nCD006423-CMP-004-02.ppt&amp;title=4.2&amp;caption=Comparison%204%20Exenatide%202%20mg%20once%20weekly%20versus%20insulin%20glargine%2C%20Outcome%202%20HbA1c%20%3C%207%25.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 4.2</div> </div> <hr class="top"><img data-id="CD006423-fig-00402" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-004-02.png" alt="Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 2 HbA1c < 7%."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 2 HbA1c &lt; 7%. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Hypoglycaemia (symptoms only) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00403"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-004-03.png?filename=nCD006423-CMP-004-03.ppt&amp;title=4.3&amp;caption=Comparison%204%20Exenatide%202%20mg%20once%20weekly%20versus%20insulin%20glargine%2C%20Outcome%203%20Hypoglycaemia%20%28symptoms%20only%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 4.3</div> </div> <hr class="top"><img data-id="CD006423-fig-00403" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-004-03.png" alt="Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 3 Hypoglycaemia (symptoms only)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 3 Hypoglycaemia (symptoms only). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Hypoglycaemia (minor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00404"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-004-04.png?filename=nCD006423-CMP-004-04.ppt&amp;title=4.4&amp;caption=Comparison%204%20Exenatide%202%20mg%20once%20weekly%20versus%20insulin%20glargine%2C%20Outcome%204%20Hypoglycaemia%20%28minor%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 4.4</div> </div> <hr class="top"><img data-id="CD006423-fig-00404" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-004-04.png" alt="Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 4 Hypoglycaemia (minor)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 4 Hypoglycaemia (minor). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Severe hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00405"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=4.5&amp;caption=Comparison%204%20Exenatide%202%20mg%20once%20weekly%20versus%20insulin%20glargine%2C%20Outcome%205%20Severe%20hypoglycaemia.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 4.5</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 5 Severe hypoglycaemia. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Weight change (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00406"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-004-06.png?filename=nCD006423-CMP-004-06.ppt&amp;title=4.6&amp;caption=Comparison%204%20Exenatide%202%20mg%20once%20weekly%20versus%20insulin%20glargine%2C%20Outcome%206%20Weight%20change%20%28kg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 4.6</div> </div> <hr class="top"><img data-id="CD006423-fig-00406" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-004-06.png" alt="Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 6 Weight change (kg)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 6 Weight change (kg). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00407"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=4.7&amp;caption=Comparison%204%20Exenatide%202%20mg%20once%20weekly%20versus%20insulin%20glargine%2C%20Outcome%207%20Adverse%20events.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 4.7</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 7 Adverse events. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00408"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=4.8&amp;caption=Comparison%204%20Exenatide%202%20mg%20once%20weekly%20versus%20insulin%20glargine%2C%20Outcome%208%20Quality%20of%20life.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 4.8</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 8 Quality of life. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">9 Fasting plasma glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00409"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-004-09.png?filename=nCD006423-CMP-004-09.ppt&amp;title=4.9&amp;caption=Comparison%204%20Exenatide%202%20mg%20once%20weekly%20versus%20insulin%20glargine%2C%20Outcome%209%20Fasting%20plasma%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 4.9</div> </div> <hr class="top"><img data-id="CD006423-fig-00409" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-004-09.png" alt="Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 9 Fasting plasma glucose (mmol/L)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 9 Fasting plasma glucose (mmol/L). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">10 Postprandial glucose / glucose profiles <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00410"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=4.10&amp;caption=Comparison%204%20Exenatide%202%20mg%20once%20weekly%20versus%20insulin%20glargine%2C%20Outcome%2010%20Postprandial%20glucose%20%2F%20glucose%20profiles.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 4.10</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 10 Postprandial glucose / glucose profiles. </p> </div> </div> </div> </td> </tr> </tbody> </table> </div> <div class="table" id="CD006423-tbl-0005"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 5.</span>&nbsp;<span class="table-title">Liraglutide 0.6 mg daily versus placebo</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00501"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-005-01.png?filename=nCD006423-CMP-005-01.ppt&amp;title=5.1&amp;caption=Comparison%205%20Liraglutide%200.6%20mg%20daily%20versus%20placebo%2C%20Outcome%201%20HbA1c%20%28%25%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 5.1</div> </div> <hr class="top"><img data-id="CD006423-fig-00501" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-005-01.png" alt="Comparison 5 Liraglutide 0.6 mg daily versus placebo, Outcome 1 HbA1c (%)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 5 Liraglutide 0.6 mg daily versus placebo, Outcome 1 HbA1c (%).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 HbA1c &lt; 7% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00502"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-005-02.png?filename=nCD006423-CMP-005-02.ppt&amp;title=5.2&amp;caption=Comparison%205%20Liraglutide%200.6%20mg%20daily%20versus%20placebo%2C%20Outcome%202%20HbA1c%20%3C%207%25.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 5.2</div> </div> <hr class="top"><img data-id="CD006423-fig-00502" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-005-02.png" alt="Comparison 5 Liraglutide 0.6 mg daily versus placebo, Outcome 2 HbA1c < 7%."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 5 Liraglutide 0.6 mg daily versus placebo, Outcome 2 HbA1c &lt; 7%.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Hypoglycaemia rate (events/patient‐year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00503"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=5.3&amp;caption=Comparison%205%20Liraglutide%200.6%20mg%20daily%20versus%20placebo%2C%20Outcome%203%20Hypoglycaemia%20rate%20%28events%2Fpatient%E2%80%90year%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 5.3</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 5 Liraglutide 0.6 mg daily versus placebo, Outcome 3 Hypoglycaemia rate (events/patient‐year). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Severe hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00504"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=5.4&amp;caption=Comparison%205%20Liraglutide%200.6%20mg%20daily%20versus%20placebo%2C%20Outcome%204%20Severe%20hypoglycaemia.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 5.4</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 5 Liraglutide 0.6 mg daily versus placebo, Outcome 4 Severe hypoglycaemia.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Weight change (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00505"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=5.5&amp;caption=Comparison%205%20Liraglutide%200.6%20mg%20daily%20versus%20placebo%2C%20Outcome%205%20Weight%20change%20%28kg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 5.5</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 5 Liraglutide 0.6 mg daily versus placebo, Outcome 5 Weight change (kg).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00506"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=5.6&amp;caption=Comparison%205%20Liraglutide%200.6%20mg%20daily%20versus%20placebo%2C%20Outcome%206%20Adverse%20events.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 5.6</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 5 Liraglutide 0.6 mg daily versus placebo, Outcome 6 Adverse events.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Blood pressure (mm Hg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00507"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=5.7&amp;caption=Comparison%205%20Liraglutide%200.6%20mg%20daily%20versus%20placebo%2C%20Outcome%207%20Blood%20pressure%20%28mm%20Hg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 5.7</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 5 Liraglutide 0.6 mg daily versus placebo, Outcome 7 Blood pressure (mm Hg). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Fasting plasma glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00508"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=5.8&amp;caption=Comparison%205%20Liraglutide%200.6%20mg%20daily%20versus%20placebo%2C%20Outcome%208%20Fasting%20plasma%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 5.8</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 5 Liraglutide 0.6 mg daily versus placebo, Outcome 8 Fasting plasma glucose (mmol/L). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">9 Post‐prandial glucose / glucose profiles <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00509"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=5.9&amp;caption=Comparison%205%20Liraglutide%200.6%20mg%20daily%20versus%20placebo%2C%20Outcome%209%20Post%E2%80%90prandial%20glucose%20%2F%20glucose%20profiles.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 5.9</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 5 Liraglutide 0.6 mg daily versus placebo, Outcome 9 Post‐prandial glucose / glucose profiles. </p> </div> </div> </div> </td> </tr> </tbody> </table> </div> <div class="table" id="CD006423-tbl-0006"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 6.</span>&nbsp;<span class="table-title">Liraglutide 0.9 mg daily versus placebo</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00601"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-006-01.png?filename=nCD006423-CMP-006-01.ppt&amp;title=6.1&amp;caption=Comparison%206%20Liraglutide%200.9%20mg%20daily%20versus%20placebo%2C%20Outcome%201%20HbA1c%20%28%25%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 6.1</div> </div> <hr class="top"><img data-id="CD006423-fig-00601" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-006-01.png" alt="Comparison 6 Liraglutide 0.9 mg daily versus placebo, Outcome 1 HbA1c (%)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 6 Liraglutide 0.9 mg daily versus placebo, Outcome 1 HbA1c (%).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 HbA1c &lt; 7% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00602"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-006-02.png?filename=nCD006423-CMP-006-02.ppt&amp;title=6.2&amp;caption=Comparison%206%20Liraglutide%200.9%20mg%20daily%20versus%20placebo%2C%20Outcome%202%20HbA1c%20%3C%207%25.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 6.2</div> </div> <hr class="top"><img data-id="CD006423-fig-00602" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-006-02.png" alt="Comparison 6 Liraglutide 0.9 mg daily versus placebo, Outcome 2 HbA1c < 7%."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 6 Liraglutide 0.9 mg daily versus placebo, Outcome 2 HbA1c &lt; 7%.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Hypoglycaemia rate (events/patient‐year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00603"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=6.3&amp;caption=Comparison%206%20Liraglutide%200.9%20mg%20daily%20versus%20placebo%2C%20Outcome%203%20Hypoglycaemia%20rate%20%28events%2Fpatient%E2%80%90year%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 6.3</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 6 Liraglutide 0.9 mg daily versus placebo, Outcome 3 Hypoglycaemia rate (events/patient‐year). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Severe hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00604"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=6.4&amp;caption=Comparison%206%20Liraglutide%200.9%20mg%20daily%20versus%20placebo%2C%20Outcome%204%20Severe%20hypoglycaemia.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 6.4</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 6 Liraglutide 0.9 mg daily versus placebo, Outcome 4 Severe hypoglycaemia.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Weight change (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00605"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=6.5&amp;caption=Comparison%206%20Liraglutide%200.9%20mg%20daily%20versus%20placebo%2C%20Outcome%205%20Weight%20change%20%28kg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 6.5</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 6 Liraglutide 0.9 mg daily versus placebo, Outcome 5 Weight change (kg).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00606"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=6.6&amp;caption=Comparison%206%20Liraglutide%200.9%20mg%20daily%20versus%20placebo%2C%20Outcome%206%20Adverse%20events.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 6.6</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 6 Liraglutide 0.9 mg daily versus placebo, Outcome 6 Adverse events.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Blood pressure (mm Hg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00607"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=6.7&amp;caption=Comparison%206%20Liraglutide%200.9%20mg%20daily%20versus%20placebo%2C%20Outcome%207%20Blood%20pressure%20%28mm%20Hg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 6.7</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 6 Liraglutide 0.9 mg daily versus placebo, Outcome 7 Blood pressure (mm Hg). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Fasting plasma glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00608"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=6.8&amp;caption=Comparison%206%20Liraglutide%200.9%20mg%20daily%20versus%20placebo%2C%20Outcome%208%20Fasting%20plasma%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 6.8</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 6 Liraglutide 0.9 mg daily versus placebo, Outcome 8 Fasting plasma glucose (mmol/L). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">9 Postprandial glucose / glucose profiles <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00609"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=6.9&amp;caption=Comparison%206%20Liraglutide%200.9%20mg%20daily%20versus%20placebo%2C%20Outcome%209%20Postprandial%20glucose%20%2F%20glucose%20profiles.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 6.9</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 6 Liraglutide 0.9 mg daily versus placebo, Outcome 9 Postprandial glucose / glucose profiles. </p> </div> </div> </div> </td> </tr> </tbody> </table> </div> <div class="table" id="CD006423-tbl-0007"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 7.</span>&nbsp;<span class="table-title">Liraglutide 1.2 mg versus placebo</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1058</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.15 [‐1.33, ‐0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00701"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-007-01.png?filename=nCD006423-CMP-007-01.ppt&amp;title=7.1&amp;caption=Comparison%207%20Liraglutide%201.2%20mg%20versus%20placebo%2C%20Outcome%201%20HbA1c.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 7.1</div> </div> <hr class="top"><img data-id="CD006423-fig-00701" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-007-01.png" alt="Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 1 HbA1c."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 1 HbA1c.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 HbA1c &lt; 7% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1058</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.91 [1.74, 4.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00702"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-007-02.png?filename=nCD006423-CMP-007-02.ppt&amp;title=7.2&amp;caption=Comparison%207%20Liraglutide%201.2%20mg%20versus%20placebo%2C%20Outcome%202%20HbA1c%20%3C%207%25.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 7.2</div> </div> <hr class="top"><img data-id="CD006423-fig-00702" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-007-02.png" alt="Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 2 HbA1c < 7%."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 2 HbA1c &lt; 7%.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1058</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.54 [0.54, 4.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00703"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-007-03.png?filename=nCD006423-CMP-007-03.ppt&amp;title=7.3&amp;caption=Comparison%207%20Liraglutide%201.2%20mg%20versus%20placebo%2C%20Outcome%203%20Hypoglycaemia.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 7.3</div> </div> <hr class="top"><img data-id="CD006423-fig-00703" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-007-03.png" alt="Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 3 Hypoglycaemia."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 3 Hypoglycaemia.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Weight change <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1058</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.75 [‐1.95, 0.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00704"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-007-04.png?filename=nCD006423-CMP-007-04.ppt&amp;title=7.4&amp;caption=Comparison%207%20Liraglutide%201.2%20mg%20versus%20placebo%2C%20Outcome%204%20Weight%20change.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 7.4</div> </div> <hr class="top"><img data-id="CD006423-fig-00704" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-007-04.png" alt="Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 4 Weight change."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 4 Weight change.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00705"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=7.5&amp;caption=Comparison%207%20Liraglutide%201.2%20mg%20versus%20placebo%2C%20Outcome%205%20Adverse%20events.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 7.5</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 5 Adverse events.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Systolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>716</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐3.26 [‐7.71, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00706"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-007-06.png?filename=nCD006423-CMP-007-06.ppt&amp;title=7.6&amp;caption=Comparison%207%20Liraglutide%201.2%20mg%20versus%20placebo%2C%20Outcome%206%20Systolic%20blood%20pressure.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 7.6</div> </div> <hr class="top"><img data-id="CD006423-fig-00706" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-007-06.png" alt="Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 6 Systolic blood pressure."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 6 Systolic blood pressure.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Fasting plasma glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1058</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐2.13 [‐2.59, ‐1.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00707"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-007-07.png?filename=nCD006423-CMP-007-07.ppt&amp;title=7.7&amp;caption=Comparison%207%20Liraglutide%201.2%20mg%20versus%20placebo%2C%20Outcome%207%20Fasting%20plasma%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 7.7</div> </div> <hr class="top"><img data-id="CD006423-fig-00707" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-007-07.png" alt="Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 7 Fasting plasma glucose (mmol/L)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 7 Fasting plasma glucose (mmol/L).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Post‐prandial glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00708"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=7.8&amp;caption=Comparison%207%20Liraglutide%201.2%20mg%20versus%20placebo%2C%20Outcome%208%20Post%E2%80%90prandial%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 7.8</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 8 Post‐prandial glucose (mmol/L).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">9 Triglycerides (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00709"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-007-09.png?filename=nCD006423-CMP-007-09.ppt&amp;title=7.9&amp;caption=Comparison%207%20Liraglutide%201.2%20mg%20versus%20placebo%2C%20Outcome%209%20Triglycerides%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 7.9</div> </div> <hr class="top"><img data-id="CD006423-fig-00709" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-007-09.png" alt="Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 9 Triglycerides (mmol/L)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 9 Triglycerides (mmol/L).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">10 Total cholesterol (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00710"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-007-10.png?filename=nCD006423-CMP-007-10.ppt&amp;title=7.10&amp;caption=Comparison%207%20Liraglutide%201.2%20mg%20versus%20placebo%2C%20Outcome%2010%20Total%20cholesterol%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 7.10</div> </div> <hr class="top"><img data-id="CD006423-fig-00710" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-007-10.png" alt="Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 10 Total cholesterol (mmol/L)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 10 Total cholesterol (mmol/L).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">11 HDL‐cholesterol (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00711"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-007-11.png?filename=nCD006423-CMP-007-11.ppt&amp;title=7.11&amp;caption=Comparison%207%20Liraglutide%201.2%20mg%20versus%20placebo%2C%20Outcome%2011%20HDL%E2%80%90cholesterol%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 7.11</div> </div> <hr class="top"><img data-id="CD006423-fig-00711" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-007-11.png" alt="Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 11 HDL‐cholesterol (mmol/L)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 11 HDL‐cholesterol (mmol/L).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">12 LDL‐cholesterol (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00712"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-007-12.png?filename=nCD006423-CMP-007-12.ppt&amp;title=7.12&amp;caption=Comparison%207%20Liraglutide%201.2%20mg%20versus%20placebo%2C%20Outcome%2012%20LDL%E2%80%90cholesterol%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 7.12</div> </div> <hr class="top"><img data-id="CD006423-fig-00712" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-007-12.png" alt="Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 12 LDL‐cholesterol (mmol/L)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 12 LDL‐cholesterol (mmol/L).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">13 Beta‐cell function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00713"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=7.13&amp;caption=Comparison%207%20Liraglutide%201.2%20mg%20versus%20placebo%2C%20Outcome%2013%20Beta%E2%80%90cell%20function.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 7.13</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 13 Beta‐cell function.</p> </div> </div> </div> </td> </tr> </tbody> </table> </div> <div class="table" id="CD006423-tbl-0008"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 8.</span>&nbsp;<span class="table-title">Liraglutide 1.8 mg versus placebo</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1410</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.15 [‐1.31, ‐0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00801"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-008-01.png?filename=nCD006423-CMP-008-01.ppt&amp;title=8.1&amp;caption=Comparison%208%20Liraglutide%201.8%20mg%20versus%20placebo%2C%20Outcome%201%20HbA1c.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 8.1</div> </div> <hr class="top"><img data-id="CD006423-fig-00801" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-008-01.png" alt="Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 1 HbA1c."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 1 HbA1c.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 HbA1c &lt; 7% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1410</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.25 [1.97, 5.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00802"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-008-02.png?filename=nCD006423-CMP-008-02.ppt&amp;title=8.2&amp;caption=Comparison%208%20Liraglutide%201.8%20mg%20versus%20placebo%2C%20Outcome%202%20HbA1c%20%3C%207%25.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 8.2</div> </div> <hr class="top"><img data-id="CD006423-fig-00802" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-008-02.png" alt="Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 2 HbA1c < 7%."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 2 HbA1c &lt; 7%.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1410</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.66 [1.15, 2.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00803"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-008-03.png?filename=nCD006423-CMP-008-03.ppt&amp;title=8.3&amp;caption=Comparison%208%20Liraglutide%201.8%20mg%20versus%20placebo%2C%20Outcome%203%20Hypoglycaemia.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 8.3</div> </div> <hr class="top"><img data-id="CD006423-fig-00803" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-008-03.png" alt="Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 3 Hypoglycaemia."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 3 Hypoglycaemia.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Weight change <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1410</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.33 [‐2.38, ‐0.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00804"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-008-04.png?filename=nCD006423-CMP-008-04.ppt&amp;title=8.4&amp;caption=Comparison%208%20Liraglutide%201.8%20mg%20versus%20placebo%2C%20Outcome%204%20Weight%20change.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 8.4</div> </div> <hr class="top"><img data-id="CD006423-fig-00804" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-008-04.png" alt="Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 4 Weight change."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 4 Weight change.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00805"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=8.5&amp;caption=Comparison%208%20Liraglutide%201.8%20mg%20versus%20placebo%2C%20Outcome%205%20Adverse%20events.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 8.5</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 5 Adverse events.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Systolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1062</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐2.42 [‐4.90, 0.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00806"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-008-06.png?filename=nCD006423-CMP-008-06.ppt&amp;title=8.6&amp;caption=Comparison%208%20Liraglutide%201.8%20mg%20versus%20placebo%2C%20Outcome%206%20Systolic%20blood%20pressure.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 8.6</div> </div> <hr class="top"><img data-id="CD006423-fig-00806" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-008-06.png" alt="Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 6 Systolic blood pressure."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 6 Systolic blood pressure.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Fasting plasma glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1410</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐2.21 [‐2.49, ‐1.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00807"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-008-07.png?filename=nCD006423-CMP-008-07.ppt&amp;title=8.7&amp;caption=Comparison%208%20Liraglutide%201.8%20mg%20versus%20placebo%2C%20Outcome%207%20Fasting%20plasma%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 8.7</div> </div> <hr class="top"><img data-id="CD006423-fig-00807" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-008-07.png" alt="Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 7 Fasting plasma glucose (mmol/L)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 7 Fasting plasma glucose (mmol/L).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Post‐prandial glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00808"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=8.8&amp;caption=Comparison%208%20Liraglutide%201.8%20mg%20versus%20placebo%2C%20Outcome%208%20Post%E2%80%90prandial%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 8.8</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 8 Post‐prandial glucose (mmol/L).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">9 Triglycerides (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00809"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-008-09.png?filename=nCD006423-CMP-008-09.ppt&amp;title=8.9&amp;caption=Comparison%208%20Liraglutide%201.8%20mg%20versus%20placebo%2C%20Outcome%209%20Triglycerides%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 8.9</div> </div> <hr class="top"><img data-id="CD006423-fig-00809" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-008-09.png" alt="Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 9 Triglycerides (mmol/L)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 9 Triglycerides (mmol/L).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">10 Total cholesterol (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00810"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-008-10.png?filename=nCD006423-CMP-008-10.ppt&amp;title=8.10&amp;caption=Comparison%208%20Liraglutide%201.8%20mg%20versus%20placebo%2C%20Outcome%2010%20Total%20cholesterol%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 8.10</div> </div> <hr class="top"><img data-id="CD006423-fig-00810" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-008-10.png" alt="Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 10 Total cholesterol (mmol/L)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 10 Total cholesterol (mmol/L).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">11 HDL‐cholesterol (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00811"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-008-11.png?filename=nCD006423-CMP-008-11.ppt&amp;title=8.11&amp;caption=Comparison%208%20Liraglutide%201.8%20mg%20versus%20placebo%2C%20Outcome%2011%20HDL%E2%80%90cholesterol%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 8.11</div> </div> <hr class="top"><img data-id="CD006423-fig-00811" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-008-11.png" alt="Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 11 HDL‐cholesterol (mmol/L)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 11 HDL‐cholesterol (mmol/L).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">12 LDL‐cholesterol (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00812"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-008-12.png?filename=nCD006423-CMP-008-12.ppt&amp;title=8.12&amp;caption=Comparison%208%20Liraglutide%201.8%20mg%20versus%20placebo%2C%20Outcome%2012%20LDL%E2%80%90cholesterol%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 8.12</div> </div> <hr class="top"><img data-id="CD006423-fig-00812" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-008-12.png" alt="Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 12 LDL‐cholesterol (mmol/L)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 12 LDL‐cholesterol (mmol/L).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">13 Beta‐cell function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00813"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=8.13&amp;caption=Comparison%208%20Liraglutide%201.8%20mg%20versus%20placebo%2C%20Outcome%2013%20Beta%E2%80%90cell%20function.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 8.13</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 13 Beta‐cell function.</p> </div> </div> </div> </td> </tr> </tbody> </table> </div> <div class="table" id="CD006423-tbl-0009"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 9.</span>&nbsp;<span class="table-title">Liraglutide 1.2 mg versus 1.8 mg</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1739</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.10 [‐0.03, 0.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00901"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-009-01.png?filename=nCD006423-CMP-009-01.ppt&amp;title=9.1&amp;caption=Comparison%209%20Liraglutide%201.2%20mg%20versus%201.8%20mg%2C%20Outcome%201%20HbA1c.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 9.1</div> </div> <hr class="top"><img data-id="CD006423-fig-00901" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-009-01.png" alt="Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 1 HbA1c."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 1 HbA1c.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Patients reaching HbA1c &lt; 7% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2206</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.99 [0.84, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00902"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-009-02.png?filename=nCD006423-CMP-009-02.ppt&amp;title=9.2&amp;caption=Comparison%209%20Liraglutide%201.2%20mg%20versus%201.8%20mg%2C%20Outcome%202%20Patients%20reaching%20HbA1c%20%3C%207%25.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 9.2</div> </div> <hr class="top"><img data-id="CD006423-fig-00902" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-009-02.png" alt="Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 2 Patients reaching HbA1c < 7%."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 2 Patients reaching HbA1c &lt; 7%. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Weight <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1739</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.48 [0.16, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00903"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-009-03.png?filename=nCD006423-CMP-009-03.ppt&amp;title=9.3&amp;caption=Comparison%209%20Liraglutide%201.2%20mg%20versus%201.8%20mg%2C%20Outcome%203%20Weight.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 9.3</div> </div> <hr class="top"><img data-id="CD006423-fig-00903" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-009-03.png" alt="Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 3 Weight."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 3 Weight.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Systolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1739</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.22 [‐1.48, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-00904"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-009-04.png?filename=nCD006423-CMP-009-04.ppt&amp;title=9.4&amp;caption=Comparison%209%20Liraglutide%201.2%20mg%20versus%201.8%20mg%2C%20Outcome%204%20Systolic%20blood%20pressure.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 9.4</div> </div> <hr class="top"><img data-id="CD006423-fig-00904" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-009-04.png" alt="Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 4 Systolic blood pressure."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 4 Systolic blood pressure.</p> </div> </div> </div> </td> </tr> </tbody> </table> </div> <div class="table" id="CD006423-tbl-0010"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 10.</span>&nbsp;<span class="table-title">Liraglutide versus insulin glargine</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-010-01.png?filename=nCD006423-CMP-010-01.ppt&amp;title=10.1&amp;caption=Comparison%2010%20Liraglutide%20versus%20insulin%20glargine%2C%20Outcome%201%20HbA1c.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 10.1</div> </div> <hr class="top"><img data-id="CD006423-fig-01001" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-010-01.png" alt="Comparison 10 Liraglutide versus insulin glargine, Outcome 1 HbA1c."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 10 Liraglutide versus insulin glargine, Outcome 1 HbA1c.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 HbA1c &lt; 7% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-010-02.png?filename=nCD006423-CMP-010-02.ppt&amp;title=10.2&amp;caption=Comparison%2010%20Liraglutide%20versus%20insulin%20glargine%2C%20Outcome%202%20HbA1c%20%3C%207%25.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 10.2</div> </div> <hr class="top"><img data-id="CD006423-fig-01002" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-010-02.png" alt="Comparison 10 Liraglutide versus insulin glargine, Outcome 2 HbA1c < 7%."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 10 Liraglutide versus insulin glargine, Outcome 2 HbA1c &lt; 7%.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-010-03.png?filename=nCD006423-CMP-010-03.ppt&amp;title=10.3&amp;caption=Comparison%2010%20Liraglutide%20versus%20insulin%20glargine%2C%20Outcome%203%20Hypoglycaemia.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 10.3</div> </div> <hr class="top"><img data-id="CD006423-fig-01003" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-010-03.png" alt="Comparison 10 Liraglutide versus insulin glargine, Outcome 3 Hypoglycaemia."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 10 Liraglutide versus insulin glargine, Outcome 3 Hypoglycaemia.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Weight change <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-010-04.png?filename=nCD006423-CMP-010-04.ppt&amp;title=10.4&amp;caption=Comparison%2010%20Liraglutide%20versus%20insulin%20glargine%2C%20Outcome%204%20Weight%20change.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 10.4</div> </div> <hr class="top"><img data-id="CD006423-fig-01004" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-010-04.png" alt="Comparison 10 Liraglutide versus insulin glargine, Outcome 4 Weight change."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 10 Liraglutide versus insulin glargine, Outcome 4 Weight change.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=10.5&amp;caption=Comparison%2010%20Liraglutide%20versus%20insulin%20glargine%2C%20Outcome%205%20Adverse%20events.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 10.5</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 10 Liraglutide versus insulin glargine, Outcome 5 Adverse events.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Systolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-010-06.png?filename=nCD006423-CMP-010-06.ppt&amp;title=10.6&amp;caption=Comparison%2010%20Liraglutide%20versus%20insulin%20glargine%2C%20Outcome%206%20Systolic%20blood%20pressure.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 10.6</div> </div> <hr class="top"><img data-id="CD006423-fig-01006" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-010-06.png" alt="Comparison 10 Liraglutide versus insulin glargine, Outcome 6 Systolic blood pressure."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 10 Liraglutide versus insulin glargine, Outcome 6 Systolic blood pressure.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Fasting plasma glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-010-07.png?filename=nCD006423-CMP-010-07.ppt&amp;title=10.7&amp;caption=Comparison%2010%20Liraglutide%20versus%20insulin%20glargine%2C%20Outcome%207%20Fasting%20plasma%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 10.7</div> </div> <hr class="top"><img data-id="CD006423-fig-01007" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-010-07.png" alt="Comparison 10 Liraglutide versus insulin glargine, Outcome 7 Fasting plasma glucose (mmol/L)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 10 Liraglutide versus insulin glargine, Outcome 7 Fasting plasma glucose (mmol/L). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Post‐prandial glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=10.8&amp;caption=Comparison%2010%20Liraglutide%20versus%20insulin%20glargine%2C%20Outcome%208%20Post%E2%80%90prandial%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 10.8</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 10 Liraglutide versus insulin glargine, Outcome 8 Post‐prandial glucose (mmol/L). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">9 Beta‐cell function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=10.9&amp;caption=Comparison%2010%20Liraglutide%20versus%20insulin%20glargine%2C%20Outcome%209%20Beta%E2%80%90cell%20function.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 10.9</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 10 Liraglutide versus insulin glargine, Outcome 9 Beta‐cell function.</p> </div> </div> </div> </td> </tr> </tbody> </table> </div> <div class="table" id="CD006423-tbl-0011"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 11.</span>&nbsp;<span class="table-title">Liraglutide 1.2 mg daily versus thiazolidinedione</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01101"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-011-01.png?filename=nCD006423-CMP-011-01.ppt&amp;title=11.1&amp;caption=Comparison%2011%20Liraglutide%201.2%20mg%20daily%20versus%20thiazolidinedione%2C%20Outcome%201%20HbA1c%20%28%25%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 11.1</div> </div> <hr class="top"><img data-id="CD006423-fig-01101" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-011-01.png" alt="Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 1 HbA1c (%)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 1 HbA1c (%).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 HbA1c &lt; 7% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01102"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-011-02.png?filename=nCD006423-CMP-011-02.ppt&amp;title=11.2&amp;caption=Comparison%2011%20Liraglutide%201.2%20mg%20daily%20versus%20thiazolidinedione%2C%20Outcome%202%20HbA1c%20%3C%207%25.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 11.2</div> </div> <hr class="top"><img data-id="CD006423-fig-01102" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-011-02.png" alt="Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 2 HbA1c < 7%."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 2 HbA1c &lt; 7%. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Hypoglycaemia (mild/moderate/overall) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01103"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-011-03.png?filename=nCD006423-CMP-011-03.ppt&amp;title=11.3&amp;caption=Comparison%2011%20Liraglutide%201.2%20mg%20daily%20versus%20thiazolidinedione%2C%20Outcome%203%20Hypoglycaemia%20%28mild%2Fmoderate%2Foverall%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 11.3</div> </div> <hr class="top"><img data-id="CD006423-fig-01103" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-011-03.png" alt="Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 3 Hypoglycaemia (mild/moderate/overall)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 3 Hypoglycaemia (mild/moderate/overall). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Severe hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01104"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=11.4&amp;caption=Comparison%2011%20Liraglutide%201.2%20mg%20daily%20versus%20thiazolidinedione%2C%20Outcome%204%20Severe%20hypoglycaemia.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 11.4</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 4 Severe hypoglycaemia. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Weight change <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01105"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-011-05.png?filename=nCD006423-CMP-011-05.ppt&amp;title=11.5&amp;caption=Comparison%2011%20Liraglutide%201.2%20mg%20daily%20versus%20thiazolidinedione%2C%20Outcome%205%20Weight%20change.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 11.5</div> </div> <hr class="top"><img data-id="CD006423-fig-01105" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-011-05.png" alt="Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 5 Weight change."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 5 Weight change. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01106"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=11.6&amp;caption=Comparison%2011%20Liraglutide%201.2%20mg%20daily%20versus%20thiazolidinedione%2C%20Outcome%206%20Adverse%20events.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 11.6</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 6 Adverse events. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Systolic blood pressure (mm Hg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01107"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=11.7&amp;caption=Comparison%2011%20Liraglutide%201.2%20mg%20daily%20versus%20thiazolidinedione%2C%20Outcome%207%20Systolic%20blood%20pressure%20%28mm%20Hg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 11.7</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 7 Systolic blood pressure (mm Hg). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Diastolic blood pressure (mm Hg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01108"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=11.8&amp;caption=Comparison%2011%20Liraglutide%201.2%20mg%20daily%20versus%20thiazolidinedione%2C%20Outcome%208%20Diastolic%20blood%20pressure%20%28mm%20Hg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 11.8</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 8 Diastolic blood pressure (mm Hg). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">9 Fasting plasma glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01109"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-011-09.png?filename=nCD006423-CMP-011-09.ppt&amp;title=11.9&amp;caption=Comparison%2011%20Liraglutide%201.2%20mg%20daily%20versus%20thiazolidinedione%2C%20Outcome%209%20Fasting%20plasma%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 11.9</div> </div> <hr class="top"><img data-id="CD006423-fig-01109" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-011-09.png" alt="Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 9 Fasting plasma glucose (mmol/L)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 9 Fasting plasma glucose (mmol/L). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">10 Post‐prandial glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01110"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=11.10&amp;caption=Comparison%2011%20Liraglutide%201.2%20mg%20daily%20versus%20thiazolidinedione%2C%20Outcome%2010%20Post%E2%80%90prandial%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 11.10</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 10 Post‐prandial glucose (mmol/L). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">11 Beta‐cell function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01111"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=11.11&amp;caption=Comparison%2011%20Liraglutide%201.2%20mg%20daily%20versus%20thiazolidinedione%2C%20Outcome%2011%20Beta%E2%80%90cell%20function.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 11.11</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 11 Beta‐cell function. </p> </div> </div> </div> </td> </tr> </tbody> </table> </div> <div class="table" id="CD006423-tbl-0012"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 12.</span>&nbsp;<span class="table-title">Liraglutide 1.8 mg daily versus thiazolidinedione</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01201"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-012-01.png?filename=nCD006423-CMP-012-01.ppt&amp;title=12.1&amp;caption=Comparison%2012%20Liraglutide%201.8%20mg%20daily%20versus%20thiazolidinedione%2C%20Outcome%201%20HbA1c%20%28%25%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 12.1</div> </div> <hr class="top"><img data-id="CD006423-fig-01201" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-012-01.png" alt="Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 1 HbA1c (%)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 1 HbA1c (%).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 HbA1c &lt; 7% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01202"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-012-02.png?filename=nCD006423-CMP-012-02.ppt&amp;title=12.2&amp;caption=Comparison%2012%20Liraglutide%201.8%20mg%20daily%20versus%20thiazolidinedione%2C%20Outcome%202%20HbA1c%20%3C%207%25.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 12.2</div> </div> <hr class="top"><img data-id="CD006423-fig-01202" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-012-02.png" alt="Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 2 HbA1c < 7%."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 2 HbA1c &lt; 7%. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01203"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-012-03.png?filename=nCD006423-CMP-012-03.ppt&amp;title=12.3&amp;caption=Comparison%2012%20Liraglutide%201.8%20mg%20daily%20versus%20thiazolidinedione%2C%20Outcome%203%20Hypoglycaemia.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 12.3</div> </div> <hr class="top"><img data-id="CD006423-fig-01203" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-012-03.png" alt="Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 3 Hypoglycaemia."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 3 Hypoglycaemia.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Severe hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01204"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=12.4&amp;caption=Comparison%2012%20Liraglutide%201.8%20mg%20daily%20versus%20thiazolidinedione%2C%20Outcome%204%20Severe%20hypoglycaemia.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 12.4</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 4 Severe hypoglycaemia. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Weight change (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01205"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-012-05.png?filename=nCD006423-CMP-012-05.ppt&amp;title=12.5&amp;caption=Comparison%2012%20Liraglutide%201.8%20mg%20daily%20versus%20thiazolidinedione%2C%20Outcome%205%20Weight%20change%20%28kg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 12.5</div> </div> <hr class="top"><img data-id="CD006423-fig-01205" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-012-05.png" alt="Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 5 Weight change (kg)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 5 Weight change (kg). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01206"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=12.6&amp;caption=Comparison%2012%20Liraglutide%201.8%20mg%20daily%20versus%20thiazolidinedione%2C%20Outcome%206%20Adverse%20events.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 12.6</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 6 Adverse events. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Systolic blood pressure (mm Hg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01207"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=12.7&amp;caption=Comparison%2012%20Liraglutide%201.8%20mg%20daily%20versus%20thiazolidinedione%2C%20Outcome%207%20Systolic%20blood%20pressure%20%28mm%20Hg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 12.7</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 7 Systolic blood pressure (mm Hg). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Diastolic blood pressure (mm Hg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01208"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=12.8&amp;caption=Comparison%2012%20Liraglutide%201.8%20mg%20daily%20versus%20thiazolidinedione%2C%20Outcome%208%20Diastolic%20blood%20pressure%20%28mm%20Hg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 12.8</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 8 Diastolic blood pressure (mm Hg). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">9 Fasting plasma glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01209"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-012-09.png?filename=nCD006423-CMP-012-09.ppt&amp;title=12.9&amp;caption=Comparison%2012%20Liraglutide%201.8%20mg%20daily%20versus%20thiazolidinedione%2C%20Outcome%209%20Fasting%20plasma%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 12.9</div> </div> <hr class="top"><img data-id="CD006423-fig-01209" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-012-09.png" alt="Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 9 Fasting plasma glucose (mmol/L)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 9 Fasting plasma glucose (mmol/L). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">10 Post‐prandial glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01210"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=12.10&amp;caption=Comparison%2012%20Liraglutide%201.8%20mg%20daily%20versus%20thiazolidinedione%2C%20Outcome%2010%20Post%E2%80%90prandial%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 12.10</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 10 Post‐prandial glucose (mmol/L). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">11 Beta‐cell function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01211"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=12.11&amp;caption=Comparison%2012%20Liraglutide%201.8%20mg%20daily%20versus%20thiazolidinedione%2C%20Outcome%2011%20Beta%E2%80%90cell%20function.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 12.11</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 11 Beta‐cell function. </p> </div> </div> </div> </td> </tr> </tbody> </table> </div> <div class="table" id="CD006423-tbl-0013"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 13.</span>&nbsp;<span class="table-title">Liraglutide 1.2 mg daily versus DPP‐4 inhibitors</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01301"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-013-01.png?filename=nCD006423-CMP-013-01.ppt&amp;title=13.1&amp;caption=Comparison%2013%20Liraglutide%201.2%20mg%20daily%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%201%20HbA1c%20%28%25%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 13.1</div> </div> <hr class="top"><img data-id="CD006423-fig-01301" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-013-01.png" alt="Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 1 HbA1c (%)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 1 HbA1c (%).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 HbA1c &lt; 7% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01302"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-013-02.png?filename=nCD006423-CMP-013-02.ppt&amp;title=13.2&amp;caption=Comparison%2013%20Liraglutide%201.2%20mg%20daily%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%202%20HbA1c%20%3C%207%25.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 13.2</div> </div> <hr class="top"><img data-id="CD006423-fig-01302" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-013-02.png" alt="Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 2 HbA1c < 7%."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 2 HbA1c &lt; 7%. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Hypoglycaemia (mild/moderate/overall) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01303"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-013-03.png?filename=nCD006423-CMP-013-03.ppt&amp;title=13.3&amp;caption=Comparison%2013%20Liraglutide%201.2%20mg%20daily%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%203%20Hypoglycaemia%20%28mild%2Fmoderate%2Foverall%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 13.3</div> </div> <hr class="top"><img data-id="CD006423-fig-01303" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-013-03.png" alt="Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 3 Hypoglycaemia (mild/moderate/overall)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 3 Hypoglycaemia (mild/moderate/overall). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Severe hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01304"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=13.4&amp;caption=Comparison%2013%20Liraglutide%201.2%20mg%20daily%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%204%20Severe%20hypoglycaemia.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 13.4</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 4 Severe hypoglycaemia.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Weight change (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01305"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-013-05.png?filename=nCD006423-CMP-013-05.ppt&amp;title=13.5&amp;caption=Comparison%2013%20Liraglutide%201.2%20mg%20daily%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%205%20Weight%20change%20%28kg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 13.5</div> </div> <hr class="top"><img data-id="CD006423-fig-01305" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-013-05.png" alt="Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 5 Weight change (kg)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 5 Weight change (kg). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01306"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=13.6&amp;caption=Comparison%2013%20Liraglutide%201.2%20mg%20daily%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%206%20Adverse%20events.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 13.6</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 6 Adverse events. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Systolic blood pressure (mm Hg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01307"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-013-07.png?filename=nCD006423-CMP-013-07.ppt&amp;title=13.7&amp;caption=Comparison%2013%20Liraglutide%201.2%20mg%20daily%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%207%20Systolic%20blood%20pressure%20%28mm%20Hg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 13.7</div> </div> <hr class="top"><img data-id="CD006423-fig-01307" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-013-07.png" alt="Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 7 Systolic blood pressure (mm Hg)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 7 Systolic blood pressure (mm Hg). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Diastolic blood pressure (mm Hg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01308"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=13.8&amp;caption=Comparison%2013%20Liraglutide%201.2%20mg%20daily%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%208%20Diastolic%20blood%20pressure%20%28mm%20Hg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 13.8</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 8 Diastolic blood pressure (mm Hg). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">9 Fasting plasma glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01309"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-013-09.png?filename=nCD006423-CMP-013-09.ppt&amp;title=13.9&amp;caption=Comparison%2013%20Liraglutide%201.2%20mg%20daily%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%209%20Fasting%20plasma%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 13.9</div> </div> <hr class="top"><img data-id="CD006423-fig-01309" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-013-09.png" alt="Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 9 Fasting plasma glucose (mmol/L)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 9 Fasting plasma glucose (mmol/L). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">10 Post‐prandial glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01310"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=13.10&amp;caption=Comparison%2013%20Liraglutide%201.2%20mg%20daily%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%2010%20Post%E2%80%90prandial%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 13.10</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 10 Post‐prandial glucose (mmol/L). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">11 Beta‐cell function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01311"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=13.11&amp;caption=Comparison%2013%20Liraglutide%201.2%20mg%20daily%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%2011%20Beta%E2%80%90cell%20function.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 13.11</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 11 Beta‐cell function. </p> </div> </div> </div> </td> </tr> </tbody> </table> </div> <div class="table" id="CD006423-tbl-0014"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 14.</span>&nbsp;<span class="table-title">Liraglutide 1.8 mg daily versus DPP‐4 inhibitors</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01401"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-014-01.png?filename=nCD006423-CMP-014-01.ppt&amp;title=14.1&amp;caption=Comparison%2014%20Liraglutide%201.8%20mg%20daily%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%201%20HbA1c%20%28%25%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 14.1</div> </div> <hr class="top"><img data-id="CD006423-fig-01401" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-014-01.png" alt="Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 1 HbA1c (%)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 1 HbA1c (%).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 HbA1c &lt; 7% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01402"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-014-02.png?filename=nCD006423-CMP-014-02.ppt&amp;title=14.2&amp;caption=Comparison%2014%20Liraglutide%201.8%20mg%20daily%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%202%20HbA1c%20%3C%207%25.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 14.2</div> </div> <hr class="top"><img data-id="CD006423-fig-01402" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-014-02.png" alt="Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 2 HbA1c < 7%."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 2 HbA1c &lt; 7%. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01403"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-014-03.png?filename=nCD006423-CMP-014-03.ppt&amp;title=14.3&amp;caption=Comparison%2014%20Liraglutide%201.8%20mg%20daily%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%203%20Hypoglycaemia.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 14.3</div> </div> <hr class="top"><img data-id="CD006423-fig-01403" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-014-03.png" alt="Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 3 Hypoglycaemia."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 3 Hypoglycaemia.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Severe hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01404"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=14.4&amp;caption=Comparison%2014%20Liraglutide%201.8%20mg%20daily%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%204%20Severe%20hypoglycaemia.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 14.4</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 4 Severe hypoglycaemia.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Weight change (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01405"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-014-05.png?filename=nCD006423-CMP-014-05.ppt&amp;title=14.5&amp;caption=Comparison%2014%20Liraglutide%201.8%20mg%20daily%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%205%20Weight%20change%20%28kg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 14.5</div> </div> <hr class="top"><img data-id="CD006423-fig-01405" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-014-05.png" alt="Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 5 Weight change (kg)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 5 Weight change (kg). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01406"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=14.6&amp;caption=Comparison%2014%20Liraglutide%201.8%20mg%20daily%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%206%20Adverse%20events.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 14.6</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 6 Adverse events. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Systolic blood pressure (mm Hg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01407"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-014-07.png?filename=nCD006423-CMP-014-07.ppt&amp;title=14.7&amp;caption=Comparison%2014%20Liraglutide%201.8%20mg%20daily%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%207%20Systolic%20blood%20pressure%20%28mm%20Hg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 14.7</div> </div> <hr class="top"><img data-id="CD006423-fig-01407" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-014-07.png" alt="Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 7 Systolic blood pressure (mm Hg)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 7 Systolic blood pressure (mm Hg). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Diastolic blood pressure (mm Hg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01408"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=14.8&amp;caption=Comparison%2014%20Liraglutide%201.8%20mg%20daily%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%208%20Diastolic%20blood%20pressure%20%28mm%20Hg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 14.8</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 8 Diastolic blood pressure (mm Hg). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">9 Fasting plasma glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01409"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-014-09.png?filename=nCD006423-CMP-014-09.ppt&amp;title=14.9&amp;caption=Comparison%2014%20Liraglutide%201.8%20mg%20daily%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%209%20Fasting%20plasma%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 14.9</div> </div> <hr class="top"><img data-id="CD006423-fig-01409" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-014-09.png" alt="Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 9 Fasting plasma glucose (mmol/L)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 9 Fasting plasma glucose (mmol/L). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">10 Post‐prandial glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01410"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=14.10&amp;caption=Comparison%2014%20Liraglutide%201.8%20mg%20daily%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%2010%20Post%E2%80%90prandial%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 14.10</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 10 Post‐prandial glucose (mmol/L). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">11 Beta‐cell function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01411"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=14.11&amp;caption=Comparison%2014%20Liraglutide%201.8%20mg%20daily%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%2011%20Beta%E2%80%90cell%20function.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 14.11</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 11 Beta‐cell function. </p> </div> </div> </div> </td> </tr> </tbody> </table> </div> <div class="table" id="CD006423-tbl-0015"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 15.</span>&nbsp;<span class="table-title">Lixisenatide versus placebo</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01501"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=15.1&amp;caption=Comparison%2015%20Lixisenatide%20versus%20placebo%2C%20Outcome%201%20HbA1c%20%28%25%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 15.1</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 15 Lixisenatide versus placebo, Outcome 1 HbA1c (%).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 HbA1c &lt; 7% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01502"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-015-02.png?filename=nCD006423-CMP-015-02.ppt&amp;title=15.2&amp;caption=Comparison%2015%20Lixisenatide%20versus%20placebo%2C%20Outcome%202%20HbA1c%20%3C%207%25.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 15.2</div> </div> <hr class="top"><img data-id="CD006423-fig-01502" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-015-02.png" alt="Comparison 15 Lixisenatide versus placebo, Outcome 2 HbA1c < 7%."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 15 Lixisenatide versus placebo, Outcome 2 HbA1c &lt; 7%.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.1 LIXI 5 µg QD</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.2 LIXI 10 µg QD</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.3 LIXI 20 µg QD</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.4 LIXI 30 µg QD</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.5 LIXI 5 µg BID</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.6 LIXI 10 µg BID</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.7 LIXI 20 µg BID</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.8 LIXI 30 µg BID</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Symptomatic hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01503"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-015-03.png?filename=nCD006423-CMP-015-03.ppt&amp;title=15.3&amp;caption=Comparison%2015%20Lixisenatide%20versus%20placebo%2C%20Outcome%203%20Symptomatic%20hypoglycaemia.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 15.3</div> </div> <hr class="top"><img data-id="CD006423-fig-01503" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-015-03.png" alt="Comparison 15 Lixisenatide versus placebo, Outcome 3 Symptomatic hypoglycaemia."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 15 Lixisenatide versus placebo, Outcome 3 Symptomatic hypoglycaemia.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.1 LIXI 5 µg QD</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.2 LIXI 10 µg QD</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.3 LIXI 20 µg QD</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.4 LIXI 30 µg QD</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.5 LIXI 5 µg BID</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.6 LIXI 10 µg BID</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.7 LIXI 20 µg BID</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.8 LIXI 30 µg BID</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Weight change (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01504"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-015-04.png?filename=nCD006423-CMP-015-04.ppt&amp;title=15.4&amp;caption=Comparison%2015%20Lixisenatide%20versus%20placebo%2C%20Outcome%204%20Weight%20change%20%28kg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 15.4</div> </div> <hr class="top"><img data-id="CD006423-fig-01504" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-015-04.png" alt="Comparison 15 Lixisenatide versus placebo, Outcome 4 Weight change (kg)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 15 Lixisenatide versus placebo, Outcome 4 Weight change (kg).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.1 LIXI 5 μg QD</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.2 LIXi 10 μg QD</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.3 LIXI 20 μg QD</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.4 LIXI 30 μg QD</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.5 LIXI 5 μg BID</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.6 LIXI 10 μg BID</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.7 LIXI 20 μg BID</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.8 LIXI 30 μg BID</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01505"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=15.5&amp;caption=Comparison%2015%20Lixisenatide%20versus%20placebo%2C%20Outcome%205%20Adverse%20events.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 15.5</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 15 Lixisenatide versus placebo, Outcome 5 Adverse events.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Fasting plasma glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01506"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-015-06.png?filename=nCD006423-CMP-015-06.ppt&amp;title=15.6&amp;caption=Comparison%2015%20Lixisenatide%20versus%20placebo%2C%20Outcome%206%20Fasting%20plasma%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 15.6</div> </div> <hr class="top"><img data-id="CD006423-fig-01506" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-015-06.png" alt="Comparison 15 Lixisenatide versus placebo, Outcome 6 Fasting plasma glucose (mmol/L)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 15 Lixisenatide versus placebo, Outcome 6 Fasting plasma glucose (mmol/L).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6.1 LIXI 5 μg QD</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6.2 LIXI 10 μg QD</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6.3 LIXI 20 μg QD</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6.4 LIXI 30 μg QD</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6.5 LIXI 5 μg BID</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6.6 LIXI 10 μg BID</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6.7 LIXI 20 μg BID</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6.8 LIXI 30 μg BID</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Post‐prandial glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01507"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-015-07.png?filename=nCD006423-CMP-015-07.ppt&amp;title=15.7&amp;caption=Comparison%2015%20Lixisenatide%20versus%20placebo%2C%20Outcome%207%20Post%E2%80%90prandial%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 15.7</div> </div> <hr class="top"><img data-id="CD006423-fig-01507" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-015-07.png" alt="Comparison 15 Lixisenatide versus placebo, Outcome 7 Post‐prandial glucose (mmol/L)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 15 Lixisenatide versus placebo, Outcome 7 Post‐prandial glucose (mmol/L).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.1 LIXI 5μg QD</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.2 LIXI 10μg QD</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.3 LIXI 20μg QD</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.4 LIXI 30μg QD</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.5 LIXI 5μg BID</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.6 LIXI 10μg BID</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.7 LIXI 20μg BID</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.8 LIXI 30μg BID</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Average self‐monitored 7‐point blood glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01508"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-015-08.png?filename=nCD006423-CMP-015-08.ppt&amp;title=15.8&amp;caption=Comparison%2015%20Lixisenatide%20versus%20placebo%2C%20Outcome%208%20Average%20self%E2%80%90monitored%207%E2%80%90point%20blood%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 15.8</div> </div> <hr class="top"><img data-id="CD006423-fig-01508" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-015-08.png" alt="Comparison 15 Lixisenatide versus placebo, Outcome 8 Average self‐monitored 7‐point blood glucose (mmol/L)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 15 Lixisenatide versus placebo, Outcome 8 Average self‐monitored 7‐point blood glucose (mmol/L). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8.1 LIXI 5 μg QD</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8.2 LIXI 10 μg QD</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8.3 LIXI 20 μg QD</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8.4 LIXI 30 μg QD</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8.5 LIXI 5 μg BID</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8.6 LIXI 10 μg BID</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8.7 LIXI 20 μg BID</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8.8 LIXI 30 μg BID</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD006423-tbl-0016"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 16.</span>&nbsp;<span class="table-title">Liraglutide 1.2 mg versus SU</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01601"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-016-01.png?filename=nCD006423-CMP-016-01.ppt&amp;title=16.1&amp;caption=Comparison%2016%20Liraglutide%201.2%20mg%20versus%20SU%2C%20Outcome%201%20HbA1c.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 16.1</div> </div> <hr class="top"><img data-id="CD006423-fig-01601" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-016-01.png" alt="Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 1 HbA1c."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 1 HbA1c.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 HbA1c (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01602"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=16.2&amp;caption=Comparison%2016%20Liraglutide%201.2%20mg%20versus%20SU%2C%20Outcome%202%20HbA1c%20%28%25%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 16.2</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 2 HbA1c (%).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 HbA1c &lt; 7% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>946</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.98 [0.84, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01603"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-016-03.png?filename=nCD006423-CMP-016-03.ppt&amp;title=16.3&amp;caption=Comparison%2016%20Liraglutide%201.2%20mg%20versus%20SU%2C%20Outcome%203%20HbA1c%20%3C%207%25.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 16.3</div> </div> <hr class="top"><img data-id="CD006423-fig-01603" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-016-03.png" alt="Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 3 HbA1c < 7%."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 3 HbA1c &lt; 7%.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>946</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.06 [0.00, 1.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01604"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-016-04.png?filename=nCD006423-CMP-016-04.ppt&amp;title=16.4&amp;caption=Comparison%2016%20Liraglutide%201.2%20mg%20versus%20SU%2C%20Outcome%204%20Hypoglycaemia.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 16.4</div> </div> <hr class="top"><img data-id="CD006423-fig-01604" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-016-04.png" alt="Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 4 Hypoglycaemia."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 4 Hypoglycaemia.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Weight change <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01605"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-016-05.png?filename=nCD006423-CMP-016-05.ppt&amp;title=16.5&amp;caption=Comparison%2016%20Liraglutide%201.2%20mg%20versus%20SU%2C%20Outcome%205%20Weight%20change.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 16.5</div> </div> <hr class="top"><img data-id="CD006423-fig-01605" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-016-05.png" alt="Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 5 Weight change."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 5 Weight change.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Weight change (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01606"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=16.6&amp;caption=Comparison%2016%20Liraglutide%201.2%20mg%20versus%20SU%2C%20Outcome%206%20Weight%20change%20%28kg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 16.6</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 6 Weight change (kg).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01607"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=16.7&amp;caption=Comparison%2016%20Liraglutide%201.2%20mg%20versus%20SU%2C%20Outcome%207%20Adverse%20events.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 16.7</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 7 Adverse events.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Systolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01608"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-016-08.png?filename=nCD006423-CMP-016-08.ppt&amp;title=16.8&amp;caption=Comparison%2016%20Liraglutide%201.2%20mg%20versus%20SU%2C%20Outcome%208%20Systolic%20blood%20pressure.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 16.8</div> </div> <hr class="top"><img data-id="CD006423-fig-01608" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-016-08.png" alt="Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 8 Systolic blood pressure."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 8 Systolic blood pressure.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">9 Blood pressure (mm Hg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01609"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=16.9&amp;caption=Comparison%2016%20Liraglutide%201.2%20mg%20versus%20SU%2C%20Outcome%209%20Blood%20pressure%20%28mm%20Hg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 16.9</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 9 Blood pressure (mm Hg).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">10 Fasting plasma glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01610"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-016-10.png?filename=nCD006423-CMP-016-10.ppt&amp;title=16.10&amp;caption=Comparison%2016%20Liraglutide%201.2%20mg%20versus%20SU%2C%20Outcome%2010%20Fasting%20plasma%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 16.10</div> </div> <hr class="top"><img data-id="CD006423-fig-01610" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-016-10.png" alt="Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 10 Fasting plasma glucose (mmol/L)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 10 Fasting plasma glucose (mmol/L).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">11 Fasting plasma glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01611"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=16.11&amp;caption=Comparison%2016%20Liraglutide%201.2%20mg%20versus%20SU%2C%20Outcome%2011%20Fasting%20plasma%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 16.11</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 11 Fasting plasma glucose (mmol/L).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">12 Post‐prandial glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01612"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=16.12&amp;caption=Comparison%2016%20Liraglutide%201.2%20mg%20versus%20SU%2C%20Outcome%2012%20Post%E2%80%90prandial%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 16.12</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 12 Post‐prandial glucose (mmol/L).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">13 Beta‐cell function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01613"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=16.13&amp;caption=Comparison%2016%20Liraglutide%201.2%20mg%20versus%20SU%2C%20Outcome%2013%20Beta%E2%80%90cell%20function.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 16.13</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 13 Beta‐cell function.</p> </div> </div> </div> </td> </tr> </tbody> </table> </div> <div class="table" id="CD006423-tbl-0017"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 17.</span>&nbsp;<span class="table-title">Liraglutide 1.8 mg daily versus SU</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01701"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-017-01.png?filename=nCD006423-CMP-017-01.ppt&amp;title=17.1&amp;caption=Comparison%2017%20Liraglutide%201.8%20mg%20daily%20versus%20SU%2C%20Outcome%201%20HbA1c%20%28%25%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 17.1</div> </div> <hr class="top"><img data-id="CD006423-fig-01701" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-017-01.png" alt="Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 1 HbA1c (%)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 1 HbA1c (%).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 HbA1c (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01702"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=17.2&amp;caption=Comparison%2017%20Liraglutide%201.8%20mg%20daily%20versus%20SU%2C%20Outcome%202%20HbA1c%20%28%25%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 17.2</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 2 HbA1c (%).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 HbA1c &lt; 7% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>949</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.09 [0.94, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01703"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-017-03.png?filename=nCD006423-CMP-017-03.ppt&amp;title=17.3&amp;caption=Comparison%2017%20Liraglutide%201.8%20mg%20daily%20versus%20SU%2C%20Outcome%203%20HbA1c%20%3C%207%25.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 17.3</div> </div> <hr class="top"><img data-id="CD006423-fig-01703" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-017-03.png" alt="Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 3 HbA1c < 7%."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 3 HbA1c &lt; 7%.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>949</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.13 [0.07, 0.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01704"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-017-04.png?filename=nCD006423-CMP-017-04.ppt&amp;title=17.4&amp;caption=Comparison%2017%20Liraglutide%201.8%20mg%20daily%20versus%20SU%2C%20Outcome%204%20Hypoglycaemia.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 17.4</div> </div> <hr class="top"><img data-id="CD006423-fig-01704" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-017-04.png" alt="Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 4 Hypoglycaemia."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 4 Hypoglycaemia.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Weight change (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01705"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-017-05.png?filename=nCD006423-CMP-017-05.ppt&amp;title=17.5&amp;caption=Comparison%2017%20Liraglutide%201.8%20mg%20daily%20versus%20SU%2C%20Outcome%205%20Weight%20change%20%28kg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 17.5</div> </div> <hr class="top"><img data-id="CD006423-fig-01705" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-017-05.png" alt="Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 5 Weight change (kg)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 5 Weight change (kg).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Weight change (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01706"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=17.6&amp;caption=Comparison%2017%20Liraglutide%201.8%20mg%20daily%20versus%20SU%2C%20Outcome%206%20Weight%20change%20%28kg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 17.6</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 6 Weight change (kg).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01707"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=17.7&amp;caption=Comparison%2017%20Liraglutide%201.8%20mg%20daily%20versus%20SU%2C%20Outcome%207%20Adverse%20events.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 17.7</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 7 Adverse events.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Systolic blood pressure (mm Hg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01708"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-017-08.png?filename=nCD006423-CMP-017-08.ppt&amp;title=17.8&amp;caption=Comparison%2017%20Liraglutide%201.8%20mg%20daily%20versus%20SU%2C%20Outcome%208%20Systolic%20blood%20pressure%20%28mm%20Hg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 17.8</div> </div> <hr class="top"><img data-id="CD006423-fig-01708" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-017-08.png" alt="Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 8 Systolic blood pressure (mm Hg)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 8 Systolic blood pressure (mm Hg). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">9 Blood pressure (mm Hg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01709"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=17.9&amp;caption=Comparison%2017%20Liraglutide%201.8%20mg%20daily%20versus%20SU%2C%20Outcome%209%20Blood%20pressure%20%28mm%20Hg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 17.9</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 9 Blood pressure (mm Hg).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">10 Fasting plasma glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01710"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-017-10.png?filename=nCD006423-CMP-017-10.ppt&amp;title=17.10&amp;caption=Comparison%2017%20Liraglutide%201.8%20mg%20daily%20versus%20SU%2C%20Outcome%2010%20Fasting%20plasma%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 17.10</div> </div> <hr class="top"><img data-id="CD006423-fig-01710" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-017-10.png" alt="Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 10 Fasting plasma glucose (mmol/L)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 10 Fasting plasma glucose (mmol/L). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">11 Fasting plasma glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01711"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=17.11&amp;caption=Comparison%2017%20Liraglutide%201.8%20mg%20daily%20versus%20SU%2C%20Outcome%2011%20Fasting%20plasma%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 17.11</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 11 Fasting plasma glucose (mmol/L). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">12 Post‐prandial glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01712"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=17.12&amp;caption=Comparison%2017%20Liraglutide%201.8%20mg%20daily%20versus%20SU%2C%20Outcome%2012%20Post%E2%80%90prandial%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 17.12</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 12 Post‐prandial glucose (mmol/L). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">13 Beta‐cell function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01713"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=17.13&amp;caption=Comparison%2017%20Liraglutide%201.8%20mg%20daily%20versus%20SU%2C%20Outcome%2013%20Beta%E2%80%90cell%20function.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 17.13</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 13 Beta‐cell function.</p> </div> </div> </div> </td> </tr> </tbody> </table> </div> <div class="table" id="CD006423-tbl-0018"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 18.</span>&nbsp;<span class="table-title">Taspoglutide versus placebo</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01801"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-018-01.png?filename=nCD006423-CMP-018-01.ppt&amp;title=18.1&amp;caption=Comparison%2018%20Taspoglutide%20versus%20placebo%2C%20Outcome%201%20HbA1c%20%28%25%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 18.1</div> </div> <hr class="top"><img data-id="CD006423-fig-01801" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-018-01.png" alt="Comparison 18 Taspoglutide versus placebo, Outcome 1 HbA1c (%)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 18 Taspoglutide versus placebo, Outcome 1 HbA1c (%).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.1 Taspoglutide 10 mg once weekly verus placebo</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>98</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.0 [‐1.19, ‐0.81]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.2 Taspoglutide 20 mg once weekly versus placebo</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>163</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.87 [‐1.16, ‐0.58]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.3 Taspoglutide 20 mg once every 2 weeks versus placebo</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>98</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.8 [‐0.99, ‐0.61]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 HbA1c (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01802"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=18.2&amp;caption=Comparison%2018%20Taspoglutide%20versus%20placebo%2C%20Outcome%202%20HbA1c%20%28%25%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 18.2</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 18 Taspoglutide versus placebo, Outcome 2 HbA1c (%).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 HbA1c &lt; 7% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01803"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-018-03.png?filename=nCD006423-CMP-018-03.ppt&amp;title=18.3&amp;caption=Comparison%2018%20Taspoglutide%20versus%20placebo%2C%20Outcome%203%20HbA1c%20%3C%207%25.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 18.3</div> </div> <hr class="top"><img data-id="CD006423-fig-01803" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-018-03.png" alt="Comparison 18 Taspoglutide versus placebo, Outcome 3 HbA1c < 7%."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 18 Taspoglutide versus placebo, Outcome 3 HbA1c &lt; 7%.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.1 Taspoglutide 10 mg once weekly versus placebo</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>98</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.88 [2.55, 9.33]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.2 Taspoglutide 20 mg once weekly versus placebo</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>163</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.41 [2.70, 7.22]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.3 Taspoglutide 20 mg once every two weeks versus placebo</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>98</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.88 [1.99, 7.56]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 HbA1c &lt; 7% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01804"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=18.4&amp;caption=Comparison%2018%20Taspoglutide%20versus%20placebo%2C%20Outcome%204%20HbA1c%20%3C%207%25.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 18.4</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 18 Taspoglutide versus placebo, Outcome 4 HbA1c &lt; 7%.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01805"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-018-05.png?filename=nCD006423-CMP-018-05.ppt&amp;title=18.5&amp;caption=Comparison%2018%20Taspoglutide%20versus%20placebo%2C%20Outcome%205%20Hypoglycaemia.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 18.5</div> </div> <hr class="top"><img data-id="CD006423-fig-01805" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-018-05.png" alt="Comparison 18 Taspoglutide versus placebo, Outcome 5 Hypoglycaemia."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 18 Taspoglutide versus placebo, Outcome 5 Hypoglycaemia.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.1 Taspoglutide 20/20 mg once weekly versus placebo</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>64</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.0 [0.07, 15.30]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.2 Taspoglutide 20/30 mg once weekly versus placebo</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>65</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.91 [0.32, 26.53]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.3 Taspoglutide 20/40 mg once weekly versus placebo</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>64</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.0 [0.19, 20.97]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01806"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=18.6&amp;caption=Comparison%2018%20Taspoglutide%20versus%20placebo%2C%20Outcome%206%20Hypoglycaemia.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 18.6</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 18 Taspoglutide versus placebo, Outcome 6 Hypoglycaemia.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Weight change (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01807"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-018-07.png?filename=nCD006423-CMP-018-07.ppt&amp;title=18.7&amp;caption=Comparison%2018%20Taspoglutide%20versus%20placebo%2C%20Outcome%207%20Weight%20change%20%28kg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 18.7</div> </div> <hr class="top"><img data-id="CD006423-fig-01807" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-018-07.png" alt="Comparison 18 Taspoglutide versus placebo, Outcome 7 Weight change (kg)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 18 Taspoglutide versus placebo, Outcome 7 Weight change (kg).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.1 Taspoglutide 10 mg once weekly versus placebo</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>88</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.3 [‐2.13, ‐0.47]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.2 Taspoglutide 20 mg once weekly versus placebo</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>153</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.07 [‐2.93, 0.79]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.3 Taspoglutide 20 mg once every two weeks versus placebo</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>80</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.10 [‐1.93, ‐0.27]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Weight change <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01808"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=18.8&amp;caption=Comparison%2018%20Taspoglutide%20versus%20placebo%2C%20Outcome%208%20Weight%20change.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 18.8</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 18 Taspoglutide versus placebo, Outcome 8 Weight change.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">9 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01809"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=18.9&amp;caption=Comparison%2018%20Taspoglutide%20versus%20placebo%2C%20Outcome%209%20Adverse%20events.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 18.9</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 18 Taspoglutide versus placebo, Outcome 9 Adverse events.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">10 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01810"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=18.10&amp;caption=Comparison%2018%20Taspoglutide%20versus%20placebo%2C%20Outcome%2010%20Adverse%20events.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 18.10</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 18 Taspoglutide versus placebo, Outcome 10 Adverse events.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">11 Fasting plasma glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01811"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-018-11.png?filename=nCD006423-CMP-018-11.ppt&amp;title=18.11&amp;caption=Comparison%2018%20Taspoglutide%20versus%20placebo%2C%20Outcome%2011%20Fasting%20plasma%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 18.11</div> </div> <hr class="top"><img data-id="CD006423-fig-01811" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-018-11.png" alt="Comparison 18 Taspoglutide versus placebo, Outcome 11 Fasting plasma glucose (mmol/L)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 18 Taspoglutide versus placebo, Outcome 11 Fasting plasma glucose (mmol/L).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>11.1 Taspoglutide 20/20 mg once weekly versus placebo</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>64</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.70 [‐2.53, ‐0.87]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>11.2 Taspoglutide 20/30 mg once weekly versus placebo</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>65</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.0 [‐1.83, ‐0.17]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>11.3 Taspoglutide 20/40 mg once weekly versus placebo</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>64</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.6 [‐2.43, ‐0.77]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">12 Fasting plasma glucose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01812"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=18.12&amp;caption=Comparison%2018%20Taspoglutide%20versus%20placebo%2C%20Outcome%2012%20Fasting%20plasma%20glucose.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 18.12</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 18 Taspoglutide versus placebo, Outcome 12 Fasting plasma glucose.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">13 Postprandial glucose and insulin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01813"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=18.13&amp;caption=Comparison%2018%20Taspoglutide%20versus%20placebo%2C%20Outcome%2013%20Postprandial%20glucose%20and%20insulin.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 18.13</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 18 Taspoglutide versus placebo, Outcome 13 Postprandial glucose and insulin.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">14 Lipid profiles <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01814"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=18.14&amp;caption=Comparison%2018%20Taspoglutide%20versus%20placebo%2C%20Outcome%2014%20Lipid%20profiles.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 18.14</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 18 Taspoglutide versus placebo, Outcome 14 Lipid profiles.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">15 Beta‐cell function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01815"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=18.15&amp;caption=Comparison%2018%20Taspoglutide%20versus%20placebo%2C%20Outcome%2015%20Beta%E2%80%90cell%20function.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 18.15</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 18 Taspoglutide versus placebo, Outcome 15 Beta‐cell function.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">16 Subgroup <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01816"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=18.16&amp;caption=Comparison%2018%20Taspoglutide%20versus%20placebo%2C%20Outcome%2016%20Subgroup.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 18.16</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 18 Taspoglutide versus placebo, Outcome 16 Subgroup.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>16.1 Participants with HbA1c ≥8%</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD006423-tbl-0019"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 19.</span>&nbsp;<span class="table-title">LY2189265 versus placebo</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01901"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=19.1&amp;caption=Comparison%2019%20LY2189265%20versus%20placebo%2C%20Outcome%201%20HbA1c.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 19.1</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 19 LY2189265 versus placebo, Outcome 1 HbA1c.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 HbA1c &lt; 7% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01902"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=19.2&amp;caption=Comparison%2019%20LY2189265%20versus%20placebo%2C%20Outcome%202%20HbA1c%20%3C%207%25.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 19.2</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 19 LY2189265 versus placebo, Outcome 2 HbA1c &lt; 7%.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01903"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=19.3&amp;caption=Comparison%2019%20LY2189265%20versus%20placebo%2C%20Outcome%203%20Hypoglycaemia.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 19.3</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 19 LY2189265 versus placebo, Outcome 3 Hypoglycaemia.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.1 LY 0.5/1.0 QW</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Weight change (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01904"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-019-04.png?filename=nCD006423-CMP-019-04.ppt&amp;title=19.4&amp;caption=Comparison%2019%20LY2189265%20versus%20placebo%2C%20Outcome%204%20Weight%20change%20%28kg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 19.4</div> </div> <hr class="top"><img data-id="CD006423-fig-01904" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-019-04.png" alt="Comparison 19 LY2189265 versus placebo, Outcome 4 Weight change (kg)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 19 LY2189265 versus placebo, Outcome 4 Weight change (kg).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.1 LY 0.5/1.0 QW</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>130</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.32 [‐2.40, ‐0.24]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.2 LY 1.0/1.0 QW</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>128</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.22 [‐2.30, ‐0.14]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.3 LY 1.0/2.0 QW</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>128</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐2.43 [‐3.52, ‐1.34]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01905"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=19.5&amp;caption=Comparison%2019%20LY2189265%20versus%20placebo%2C%20Outcome%205%20Adverse%20events.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 19.5</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 19 LY2189265 versus placebo, Outcome 5 Adverse events.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Systolic blood pressure (mm Hg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01906"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-019-06.png?filename=nCD006423-CMP-019-06.ppt&amp;title=19.6&amp;caption=Comparison%2019%20LY2189265%20versus%20placebo%2C%20Outcome%206%20Systolic%20blood%20pressure%20%28mm%20Hg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 19.6</div> </div> <hr class="top"><img data-id="CD006423-fig-01906" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-019-06.png" alt="Comparison 19 LY2189265 versus placebo, Outcome 6 Systolic blood pressure (mm Hg)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 19 LY2189265 versus placebo, Outcome 6 Systolic blood pressure (mm Hg).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6.1 LY 0.5/1.0 QW</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6.2 LY 1.0/1.0 QW</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6.3 LY 1.0/2.0 QW</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Diastolic blood pressure (mm Hg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01907"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-019-07.png?filename=nCD006423-CMP-019-07.ppt&amp;title=19.7&amp;caption=Comparison%2019%20LY2189265%20versus%20placebo%2C%20Outcome%207%20Diastolic%20blood%20pressure%20%28mm%20Hg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 19.7</div> </div> <hr class="top"><img data-id="CD006423-fig-01907" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-019-07.png" alt="Comparison 19 LY2189265 versus placebo, Outcome 7 Diastolic blood pressure (mm Hg)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 19 LY2189265 versus placebo, Outcome 7 Diastolic blood pressure (mm Hg).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.1 LY 0.5/1.0 QW</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.2 LY 1.0/1.0 QW</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.3 LY 1.0/2.0 QW</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Fasting plasma glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01908"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=19.8&amp;caption=Comparison%2019%20LY2189265%20versus%20placebo%2C%20Outcome%208%20Fasting%20plasma%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 19.8</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 19 LY2189265 versus placebo, Outcome 8 Fasting plasma glucose (mmol/L).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">9 Beta‐cell function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-01909"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=19.9&amp;caption=Comparison%2019%20LY2189265%20versus%20placebo%2C%20Outcome%209%20Beta%E2%80%90cell%20function.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 19.9</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 19 LY2189265 versus placebo, Outcome 9 Beta‐cell function.</p> </div> </div> </div> </td> </tr> </tbody> </table> </div> <div class="table" id="CD006423-tbl-0020"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 20.</span>&nbsp;<span class="table-title">GLP‐1 agonist versus GLP‐1 agonist</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-02001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-020-01.png?filename=nCD006423-CMP-020-01.ppt&amp;title=20.1&amp;caption=Comparison%2020%20GLP%E2%80%901%20agonist%20versus%20GLP%E2%80%901%20agonist%2C%20Outcome%201%20HbA1c.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 20.1</div> </div> <hr class="top"><img data-id="CD006423-fig-02001" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-020-01.png" alt="Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 1 HbA1c."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 1 HbA1c.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.1 versus Liraglutide</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>464</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.33 [0.11, 0.55]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.2 versus Exenatide 2 mg once weekly</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>547</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.55 [0.26, 0.84]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 HbA1c &lt; 7% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-02002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-020-02.png?filename=nCD006423-CMP-020-02.ppt&amp;title=20.2&amp;caption=Comparison%2020%20GLP%E2%80%901%20agonist%20versus%20GLP%E2%80%901%20agonist%2C%20Outcome%202%20HbA1c%20%3C%207%25.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 20.2</div> </div> <hr class="top"><img data-id="CD006423-fig-02002" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-020-02.png" alt="Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 2 HbA1c < 7%."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 2 HbA1c &lt; 7%.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.1 versus Liraglutide</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>464</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.79 [0.66, 0.96]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.2 versus Exenatide 2 mg once weekly</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>511</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.65 [0.42, 1.01]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-02003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-020-03.png?filename=nCD006423-CMP-020-03.ppt&amp;title=20.3&amp;caption=Comparison%2020%20GLP%E2%80%901%20agonist%20versus%20GLP%E2%80%901%20agonist%2C%20Outcome%203%20Hypoglycaemia.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 20.3</div> </div> <hr class="top"><img data-id="CD006423-fig-02003" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-020-03.png" alt="Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 3 Hypoglycaemia."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 3 Hypoglycaemia.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.1 versus Liraglutide</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>467</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.32 [0.99, 1.75]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.2 versus Exenatide 2 mg once weekly</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>295</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.13 [0.45, 2.86]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-02004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=20.4&amp;caption=Comparison%2020%20GLP%E2%80%901%20agonist%20versus%20GLP%E2%80%901%20agonist%2C%20Outcome%204%20Hypoglycaemia.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 20.4</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 4 Hypoglycaemia.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Weight change <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-02005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-020-05.png?filename=nCD006423-CMP-020-05.ppt&amp;title=20.5&amp;caption=Comparison%2020%20GLP%E2%80%901%20agonist%20versus%20GLP%E2%80%901%20agonist%2C%20Outcome%205%20Weight%20change.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 20.5</div> </div> <hr class="top"><img data-id="CD006423-fig-02005" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-020-05.png" alt="Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 5 Weight change."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 5 Weight change.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.1 versus Liraglutide</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>464</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.37 [‐0.55, 1.29]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.2 versus Exenatide 2 mg once weekly</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>295</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.10 [‐1.29, 1.49]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Weight change <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-02006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=20.6&amp;caption=Comparison%2020%20GLP%E2%80%901%20agonist%20versus%20GLP%E2%80%901%20agonist%2C%20Outcome%206%20Weight%20change.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 20.6</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 6 Weight change.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Treatment satisfaction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-02007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=20.7&amp;caption=Comparison%2020%20GLP%E2%80%901%20agonist%20versus%20GLP%E2%80%901%20agonist%2C%20Outcome%207%20Treatment%20satisfaction.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 20.7</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 7 Treatment satisfaction.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.1 versus Liraglutide</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.2 versus Exenatide 2 mg once weekly</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-02008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=20.8&amp;caption=Comparison%2020%20GLP%E2%80%901%20agonist%20versus%20GLP%E2%80%901%20agonist%2C%20Outcome%208%20Adverse%20events.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 20.8</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 8 Adverse events.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8.1 versus Liraglutide</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8.2 versus Exenatide 2 mg once weekly</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">9 Systolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-02009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-020-09.png?filename=nCD006423-CMP-020-09.ppt&amp;title=20.9&amp;caption=Comparison%2020%20GLP%E2%80%901%20agonist%20versus%20GLP%E2%80%901%20agonist%2C%20Outcome%209%20Systolic%20blood%20pressure.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 20.9</div> </div> <hr class="top"><img data-id="CD006423-fig-02009" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-020-09.png" alt="Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 9 Systolic blood pressure."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 9 Systolic blood pressure.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9.1 versus Liraglutide</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>464</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.51 [‐2.72, 3.74]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9.2 versus Exenatide 2 mg once weekly</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>547</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.49 [‐0.71, 3.69]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">10 Fasting plasma glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-02010"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-020-10.png?filename=nCD006423-CMP-020-10.ppt&amp;title=20.10&amp;caption=Comparison%2020%20GLP%E2%80%901%20agonist%20versus%20GLP%E2%80%901%20agonist%2C%20Outcome%2010%20Fasting%20plasma%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 20.10</div> </div> <hr class="top"><img data-id="CD006423-fig-02010" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-020-10.png" alt="Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 10 Fasting plasma glucose (mmol/L)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 10 Fasting plasma glucose (mmol/L). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>10.1 versus Liraglutide</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>464</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.01 [0.46, 1.56]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>10.2 versus Exenatide 2 mg once weekly</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>547</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.18 [1.02, 1.33]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">11 Post‐prandial glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-02011"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=20.11&amp;caption=Comparison%2020%20GLP%E2%80%901%20agonist%20versus%20GLP%E2%80%901%20agonist%2C%20Outcome%2011%20Post%E2%80%90prandial%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 20.11</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 11 Post‐prandial glucose (mmol/L). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>11.1 versus Liraglutide</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>11.2 versus Exenatide 2 mg once weekly</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">12 Triglycerides (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-02012"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-020-12.png?filename=nCD006423-CMP-020-12.ppt&amp;title=20.12&amp;caption=Comparison%2020%20GLP%E2%80%901%20agonist%20versus%20GLP%E2%80%901%20agonist%2C%20Outcome%2012%20Triglycerides%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 20.12</div> </div> <hr class="top"><img data-id="CD006423-fig-02012" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-020-12.png" alt="Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 12 Triglycerides (mmol/L)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 12 Triglycerides (mmol/L).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>12.1 versus Liraglutide</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>464</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.18 [‐0.10, 0.46]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>12.2 versus Exenatide 2 mg once weekly</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>547</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.01 [‐0.04, 0.06]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">13 Total cholesterol (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-02013"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-020-13.png?filename=nCD006423-CMP-020-13.ppt&amp;title=20.13&amp;caption=Comparison%2020%20GLP%E2%80%901%20agonist%20versus%20GLP%E2%80%901%20agonist%2C%20Outcome%2013%20Total%20cholesterol%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 20.13</div> </div> <hr class="top"><img data-id="CD006423-fig-02013" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-020-13.png" alt="Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 13 Total cholesterol (mmol/L)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 13 Total cholesterol (mmol/L).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>13.1 versus Liraglutide</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>464</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.11 [‐0.09, 0.31]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>13.2 versus Exenatide 2 mg once weekly</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>547</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.31 [0.10, 0.51]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">14 HDL‐cholesterol (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-02014"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-020-14.png?filename=nCD006423-CMP-020-14.ppt&amp;title=20.14&amp;caption=Comparison%2020%20GLP%E2%80%901%20agonist%20versus%20GLP%E2%80%901%20agonist%2C%20Outcome%2014%20HDL%E2%80%90cholesterol%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 20.14</div> </div> <hr class="top"><img data-id="CD006423-fig-02014" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-020-14.png" alt="Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 14 HDL‐cholesterol (mmol/L)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 14 HDL‐cholesterol (mmol/L).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>14.1 versus Liraglutide</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>464</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.01 [‐0.07, 0.05]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>14.2 versus Exenatide 2 mg once weekly</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>547</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.00 [‐0.03, 0.04]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">15 LDL‐cholesterol (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-02015"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-020-15.png?filename=nCD006423-CMP-020-15.ppt&amp;title=20.15&amp;caption=Comparison%2020%20GLP%E2%80%901%20agonist%20versus%20GLP%E2%80%901%20agonist%2C%20Outcome%2015%20LDL%E2%80%90cholesterol%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 20.15</div> </div> <hr class="top"><img data-id="CD006423-fig-02015" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-020-15.png" alt="Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 15 LDL‐cholesterol (mmol/L)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 15 LDL‐cholesterol (mmol/L).</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>15.1 versus Liraglutide</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>464</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.04 [‐0.13, 0.21]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>15.2 versus Exenatide 2 mg once weekly</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>547</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.20 [0.09, 0.30]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">16 Beta‐cell function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006423-fig-02016"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=20.16&amp;caption=Comparison%2020%20GLP%E2%80%901%20agonist%20versus%20GLP%E2%80%901%20agonist%2C%20Outcome%2016%20Beta%E2%80%90cell%20function.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 20.16</div> </div> <hr class="top"> <hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 16 Beta‐cell function.</p> </div> </div> </div> </td> </tr> </tbody> </table> </div> </section> </section> <div class="figures-list"> <div class="figure" id="CD006423-fig-0001"> <img data-id="CD006423-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-AFig-FIG01.png" alt="Study flow diagram."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/full#CD006423-fig-0001" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-AFig-FIG01.png?filename=nCD006423-AFig-FIG01.ppt&amp;title=1&amp;caption=Study%20flow%20diagram.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-AFig-FIG01.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-0002"><img data-id="CD006423-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-AFig-FIG02.png" alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/full#CD006423-fig-0002" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-AFig-FIG02.png?filename=nCD006423-AFig-FIG02.ppt&amp;title=2&amp;caption=Risk%20of%20bias%20graph%3A%20review%20authors%27%20judgements%20about%20each%20risk%20of%20bias%20item%20presented%20as%20percentages%20across%20all%20included%20studies.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-AFig-FIG02.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-0003"><img data-id="CD006423-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-AFig-FIG03.png" alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/full#CD006423-fig-0003" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-AFig-FIG03.png?filename=nCD006423-AFig-FIG03.ppt&amp;title=3&amp;caption=Risk%20of%20bias%20summary%3A%20review%20authors%27%20judgements%20about%20each%20risk%20of%20bias%20item%20for%20each%20included%20study.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-AFig-FIG03.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00101"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="4" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>ALBI 30 mg weekly</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>ALBI 30 mg every 2 weeks</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Placebo</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A ‐ Rosenstock 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.87% (SD 0.65)</p> <p>7.1%</p> <p>P &lt; 0.05 versus placebo</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.79% (SD 0.98)</p> <p>7.2%</p> <p>P &lt; 0.05 versus placebo</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.17% (SD 1.01)</p> <p>7.7%</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Albiglutide versus placebo, Outcome 1 HbA1c (%).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00101" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=1.1&amp;caption=Comparison%201%20Albiglutide%20versus%20placebo%2C%20Outcome%201%20HbA1c%20%28%25%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00102"><img data-id="CD006423-fig-00102" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-001-02.png" alt="Comparison 1 Albiglutide versus placebo, Outcome 2 HbA1c ‐ with plot."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Albiglutide versus placebo, Outcome 2 HbA1c ‐ with plot.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00102" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-001-02.png?filename=nCD006423-CMP-001-02.ppt&amp;title=1.2&amp;caption=Comparison%201%20Albiglutide%20versus%20placebo%2C%20Outcome%202%20HbA1c%20%E2%80%90%20with%20plot.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-001-02.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00103"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="4" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>ALBI 30 mg weekly</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>ALBI 30 mg every 2 weeks</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Placebo</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A ‐ Rosenstock 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>52%</p> <p>(P value not given)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>50%</p> <p>(P value not given)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>20%</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Albiglutide versus placebo, Outcome 3 HbA1c &lt; 7%.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00103" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=1.3&amp;caption=Comparison%201%20Albiglutide%20versus%20placebo%2C%20Outcome%203%20HbA1c%20%3C%207%25.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00104"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="5" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Definition</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>ALBI 30 mg weekly</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>ALBI 30 mg every 2 weeks</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Placebo</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A ‐ Rosenstock 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>not given</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 0, P = NS</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n=1 (3.1%), P = NS</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 2 (3.9%)</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Albiglutide versus placebo, Outcome 4 Hypoglycaemia.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00104" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=1.4&amp;caption=Comparison%201%20Albiglutide%20versus%20placebo%2C%20Outcome%204%20Hypoglycaemia.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00105"><img data-id="CD006423-fig-00105" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-001-05.png" alt="Comparison 1 Albiglutide versus placebo, Outcome 5 Weight change ‐ with plot."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Albiglutide versus placebo, Outcome 5 Weight change ‐ with plot.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00105" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-001-05.png?filename=nCD006423-CMP-001-05.ppt&amp;title=1.5&amp;caption=Comparison%201%20Albiglutide%20versus%20placebo%2C%20Outcome%205%20Weight%20change%20%E2%80%90%20with%20plot.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-001-05.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00106"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="4" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>ALBI 30 mg weekly</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>ALBI 30 mg every 2 weeks</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Placebo</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A ‐ Rosenstock 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.4 kg (SD 2.4), P = NS</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.6 kg (SD 2.5), P = NS</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.7 kg (SD 2.9)</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Albiglutide versus placebo, Outcome 6 Weight change (kg).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00106" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=1.6&amp;caption=Comparison%201%20Albiglutide%20versus%20placebo%2C%20Outcome%206%20Weight%20change%20%28kg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00107"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="5" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>ALBI 30 mg weekly</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>ALBI 30 mg every 2 weeks</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Placebo</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A ‐ Rosenstock 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>any adverse event</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>83.9%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>84.4%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>66.7%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A ‐ Rosenstock 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>withdrawals</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>32.2%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>42.8%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>23.5%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A ‐ Rosenstock 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>adverse events similar across groups for:</p> <p>abdominal pain, headache, dizziness, hyperglycaemia, nasopharyngitis,</p> <p>influenza, upper respiratory tract infection, back pain</p> <p>no systemic allergic reactions to albiglutide</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A ‐ Rosenstock 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>nausea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 8 (25.8%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 8 (25%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 6 (11.8%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A ‐ Rosenstock 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>vomiting</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 4 (12.9%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 3 (9.4%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 1 (2%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A ‐ Rosenstock 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>diarrhoea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 5 (16.1%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 7 (21.9%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 2 (3.9%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A ‐ Rosenstock 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>cardiac disorders</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>none</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>none</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 1</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A ‐ Rosenstock 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>pancreatitis</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>none</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>none</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>none</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A ‐ Rosenstock 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>skin reactions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>15 events in 7 patients</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>11 events in 6 patients</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3 events in 3 patients</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A ‐ Rosenstock 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>positive immunogenicity test</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2 of 31 (6.4%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1 of 32 (3.1%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1 of 51 (2%)</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Albiglutide versus placebo, Outcome 7 Adverse events.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00107" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=1.7&amp;caption=Comparison%201%20Albiglutide%20versus%20placebo%2C%20Outcome%207%20Adverse%20events.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00108"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="5" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>ALBI 30 mg weekly</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>ALBI 30 mg every 2 weeks</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Placebo</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A ‐ Rosenstock 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>systolic BP (mm Hg)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐5.8 (SD 11.2), P = NS</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐7.4 (SD 14.2), P = NS</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.7 (SD 13.9)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A ‐ Rosenstock 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>diastolic BP (mm Hg)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.9 (SD 8.1), P = NS</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐4.4 (SD 8.9), P = NS</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.0 (SD 8.2)</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Albiglutide versus placebo, Outcome 8 Blood pressure (mm Hg).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00108" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=1.8&amp;caption=Comparison%201%20Albiglutide%20versus%20placebo%2C%20Outcome%208%20Blood%20pressure%20%28mm%20Hg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00109"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="5" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>ALBI 30 mg weekly</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>ALBI 30 mg every 2 weeks</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Placebo</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>FPG fluctuations</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A ‐ Rosenstock 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.44% (SD 2.03), P &lt; 0.05 versus placebo</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.58% (SD 2.06), P &lt; 0.05 versus placebo</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.10% (SD 2.90)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>according to figure 1C in the paper, the once weekly dosing schedules seemed to cause less fluctuation in FPG than the less frequent dosing schedules; however, data are only shown for 50 mg every 2 weeks and not for 30 mg every 2 weeks </p> <p>COMMENT: paper says "%" but should probably be "mmol/L"??</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Albiglutide versus placebo, Outcome 9 Fasting plasma glucose (mmol/L).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00109" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=1.9&amp;caption=Comparison%201%20Albiglutide%20versus%20placebo%2C%20Outcome%209%20Fasting%20plasma%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00110"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="5" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>ALBI 30 mg weekly</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>ALBI 30 mg every 2 weeks</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Placebo</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A ‐ Rosenstock 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>triglycerides (mmol/L)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>+0.1 (SD 0.9), P = NS</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.3 (SD 1.0), P = NS</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.4 (SD 1.7)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A ‐ Rosenstock 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>total cholesterol (mmol/L)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>+0.01 (SD 0.6), P = NS</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.18 (SD 0.45), P = NS</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>+0.1 (SD 0.77)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A ‐ Rosenstock 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>HDL (mmol/L)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.05 (SD 0.17), P = NS</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.03 (SD 0.14), P = NS</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.002 (SD 0.13)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A ‐ Rosenstock 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>LDL (mmol/L)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>+0.003 (SD 0.6), P = NS</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.06 (SD 0.39), P = NS</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>+0.19 (SD 0.6)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A ‐ Rosenstock 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>free fatty acids (mmol/L)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>+0.05 (SD 0.17), P = NS</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.01 (SD 0.25), P = NS</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>+0.08 (SD 0.2)</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Albiglutide versus placebo, Outcome 10 Lipid profiles.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00110" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=1.10&amp;caption=Comparison%201%20Albiglutide%20versus%20placebo%2C%20Outcome%2010%20Lipid%20profiles.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00111"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="5" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>ALBI 30 mg weekly</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>ALBI 30 mg every 2 weeks</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Placebo</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A ‐ Rosenstock 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>HOMA‐B endpoint</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>95.4</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>74.7</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>50.4</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A ‐ Rosenstock 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>HOMA‐B ratio at endpoint</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.4, P &lt; 0.05 versus placebo</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.2, P = NS</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.0</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Albiglutide versus placebo, Outcome 11 Beta‐cell function.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00111" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=1.11&amp;caption=Comparison%201%20Albiglutide%20versus%20placebo%2C%20Outcome%2011%20Beta%E2%80%90cell%20function.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00112"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Outcome</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Results / comments</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A ‐ Rosenstock 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>HbA1c</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Numerically greater reductions were seen in participants with baseline HbA1c ≥ 8.5% (no details given) </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Albiglutide versus placebo, Outcome 12 Subgroups.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00112" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=1.12&amp;caption=Comparison%201%20Albiglutide%20versus%20placebo%2C%20Outcome%2012%20Subgroups.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00201"><img data-id="CD006423-fig-00201" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-002-01.png" alt="Comparison 2 Exenatide 2 mg once weekly versus thiazolidinedione, Outcome 1 HbA1c (%)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Exenatide 2 mg once weekly versus thiazolidinedione, Outcome 1 HbA1c (%). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00201" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-002-01.png?filename=nCD006423-CMP-002-01.ppt&amp;title=2.1&amp;caption=Comparison%202%20Exenatide%202%20mg%20once%20weekly%20versus%20thiazolidinedione%2C%20Outcome%201%20HbA1c%20%28%25%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-002-01.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00202"><img data-id="CD006423-fig-00202" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-002-02.png" alt="Comparison 2 Exenatide 2 mg once weekly versus thiazolidinedione, Outcome 2 HbA1c < 7%."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Exenatide 2 mg once weekly versus thiazolidinedione, Outcome 2 HbA1c &lt; 7%. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00202" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-002-02.png?filename=nCD006423-CMP-002-02.ppt&amp;title=2.2&amp;caption=Comparison%202%20Exenatide%202%20mg%20once%20weekly%20versus%20thiazolidinedione%2C%20Outcome%202%20HbA1c%20%3C%207%25.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-002-02.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00203"><img data-id="CD006423-fig-00203" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-002-03.png" alt="Comparison 2 Exenatide 2 mg once weekly versus thiazolidinedione, Outcome 3 Hypoglycaemia (minor)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Exenatide 2 mg once weekly versus thiazolidinedione, Outcome 3 Hypoglycaemia (minor). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00203" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-002-03.png?filename=nCD006423-CMP-002-03.ppt&amp;title=2.3&amp;caption=Comparison%202%20Exenatide%202%20mg%20once%20weekly%20versus%20thiazolidinedione%2C%20Outcome%203%20Hypoglycaemia%20%28minor%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-002-03.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00204"><img data-id="CD006423-fig-00204" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-002-04.png" alt="Comparison 2 Exenatide 2 mg once weekly versus thiazolidinedione, Outcome 4 Weight change (kg)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Exenatide 2 mg once weekly versus thiazolidinedione, Outcome 4 Weight change (kg). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00204" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-002-04.png?filename=nCD006423-CMP-002-04.ppt&amp;title=2.4&amp;caption=Comparison%202%20Exenatide%202%20mg%20once%20weekly%20versus%20thiazolidinedione%2C%20Outcome%204%20Weight%20change%20%28kg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-002-04.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00205"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="5" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Exenatide 2 mg QW</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Pioglitazone 45 mg QD</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Difference between groups</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Bergenstal 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>IWQOL total score</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.15, 95% CI 3.11 to 7.19</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.20, 95% CI ‐0.87 to 3.28</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>EX vs PIO: 3.94, 95% CI 1.28 to 6.61, P = 0.0038</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Bergenstal 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Overall treatment satisfaction</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.96, 95% CI 2.78 to 5.15</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Exenatide 2 mg once weekly versus thiazolidinedione, Outcome 5 Quality of life. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00205" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=2.5&amp;caption=Comparison%202%20Exenatide%202%20mg%20once%20weekly%20versus%20thiazolidinedione%2C%20Outcome%205%20Quality%20of%20life.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00206"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="4" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Exenatide 2 mg QW</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Pioglitazone 45 mg QD</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Bergenstal 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Withdrawals due to adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6.9%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.6%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Bergenstal 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Nausea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>24%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Bergenstal 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Diarrhoea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>18%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Bergenstal 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Vomiting</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>11%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Bergenstal 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Urinary tract infection</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Bergenstal 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Headache</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Bergenstal 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Injection‐site pruritus</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Bergenstal 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Serious adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Bergenstal 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Anti‐Exenatide antibodies</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>either low (&lt; 1/625; n = 74, 48%) or not detectable (n = 61, 40%) titres</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Bergenstal 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Severe hypoglycaemia</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Exenatide 2 mg once weekly versus thiazolidinedione, Outcome 6 Adverse events. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00206" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=2.6&amp;caption=Comparison%202%20Exenatide%202%20mg%20once%20weekly%20versus%20thiazolidinedione%2C%20Outcome%206%20Adverse%20events.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00207"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="5" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Exenatide 2 mg QW</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Pioglitazone 45 mg QD</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Difference between groups</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Bergenstal 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Systolic blood pressure</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>EX vs. PIO: P = NS</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Bergenstal 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Diastolic blood pressure</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>EX vs. PIO: P = NS</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Exenatide 2 mg once weekly versus thiazolidinedione, Outcome 7 Blood pressure (mm Hg). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00207" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=2.7&amp;caption=Comparison%202%20Exenatide%202%20mg%20once%20weekly%20versus%20thiazolidinedione%2C%20Outcome%207%20Blood%20pressure%20%28mm%20Hg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00208"><img data-id="CD006423-fig-00208" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-002-08.png" alt="Comparison 2 Exenatide 2 mg once weekly versus thiazolidinedione, Outcome 8 Fasting plasma glucose (mmol/L)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Exenatide 2 mg once weekly versus thiazolidinedione, Outcome 8 Fasting plasma glucose (mmol/L). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00208" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-002-08.png?filename=nCD006423-CMP-002-08.ppt&amp;title=2.8&amp;caption=Comparison%202%20Exenatide%202%20mg%20once%20weekly%20versus%20thiazolidinedione%2C%20Outcome%208%20Fasting%20plasma%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-002-08.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00209"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="5" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Exenatide 2 mg QW</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Pioglitazone 45 mg QD</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Bergenstal 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Self‐monitored blood glucose</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>EX vs PIO: P = NS</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Exenatide 2 mg once weekly versus thiazolidinedione, Outcome 9 Post‐prandial glucose / glucose profiles. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00209" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=2.9&amp;caption=Comparison%202%20Exenatide%202%20mg%20once%20weekly%20versus%20thiazolidinedione%2C%20Outcome%209%20Post%E2%80%90prandial%20glucose%20%2F%20glucose%20profiles.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00210"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="5" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Exenatide 2 mg QW</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Sitagliptin 100 mg QD</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Difference between groups</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Bergenstal 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Fasting triglycerides (mmol/l)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>EX vs. SITA: P = NS; PIO vs. SITA: P = 0.0062</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Bergenstal 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Total cholesterol (mmol/l)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>EX vs. SITA: P = NS; PIO vs. SITA: P = NS</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Bergenstal 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>HDL (mmol/l)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>EX vs. SITA: P = NS; PIO vs. SITA: P &lt; 0.0001</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Bergenstal 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>LDL (mmol/l)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>EX vs. SITA: P = NS; PIO vs. SITA: P = NS</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Exenatide 2 mg once weekly versus thiazolidinedione, Outcome 10 Lipid profiles. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00210" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=2.10&amp;caption=Comparison%202%20Exenatide%202%20mg%20once%20weekly%20versus%20thiazolidinedione%2C%20Outcome%2010%20Lipid%20profiles.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00301"><img data-id="CD006423-fig-00301" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-003-01.png" alt="Comparison 3 Exenatide 2 mg once weekly versus DPP‐4 inhibitors, Outcome 1 HbA1c (%)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Exenatide 2 mg once weekly versus DPP‐4 inhibitors, Outcome 1 HbA1c (%).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00301" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-003-01.png?filename=nCD006423-CMP-003-01.ppt&amp;title=3.1&amp;caption=Comparison%203%20Exenatide%202%20mg%20once%20weekly%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%201%20HbA1c%20%28%25%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-003-01.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00302"><img data-id="CD006423-fig-00302" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-003-02.png" alt="Comparison 3 Exenatide 2 mg once weekly versus DPP‐4 inhibitors, Outcome 2 HbA1c < 7%."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Exenatide 2 mg once weekly versus DPP‐4 inhibitors, Outcome 2 HbA1c &lt; 7%. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00302" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-003-02.png?filename=nCD006423-CMP-003-02.ppt&amp;title=3.2&amp;caption=Comparison%203%20Exenatide%202%20mg%20once%20weekly%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%202%20HbA1c%20%3C%207%25.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-003-02.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00303"><img data-id="CD006423-fig-00303" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-003-03.png" alt="Comparison 3 Exenatide 2 mg once weekly versus DPP‐4 inhibitors, Outcome 3 Hypoglycaemia (minor)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Exenatide 2 mg once weekly versus DPP‐4 inhibitors, Outcome 3 Hypoglycaemia (minor). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00303" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-003-03.png?filename=nCD006423-CMP-003-03.ppt&amp;title=3.3&amp;caption=Comparison%203%20Exenatide%202%20mg%20once%20weekly%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%203%20Hypoglycaemia%20%28minor%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-003-03.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00304"><img data-id="CD006423-fig-00304" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-003-04.png" alt="Comparison 3 Exenatide 2 mg once weekly versus DPP‐4 inhibitors, Outcome 4 Weight change (kg)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Exenatide 2 mg once weekly versus DPP‐4 inhibitors, Outcome 4 Weight change (kg). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00304" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-003-04.png?filename=nCD006423-CMP-003-04.ppt&amp;title=3.4&amp;caption=Comparison%203%20Exenatide%202%20mg%20once%20weekly%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%204%20Weight%20change%20%28kg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-003-04.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00305"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="5" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Exenatide 2 mg QW</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Sitagliptin 100 mg QD</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Difference between groups</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Bergenstal 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>IWQOL total score</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.15, 95% CI 3.11 to 7.19</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.56, 95% CI 2.56 to 6.57</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>EX vs PIO: 3.94, 95% CI 1.28 to 6.61, P = 0.0038</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Bergenstal 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Overall treatment satisfaction</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.96, 95% CI 2.78 to 5.15</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.35, 95% CI 1.19 to 3.51</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>EX vs. SITA: 1.61, 95% CI 0.07 to 3.16, P = 0.0406</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Exenatide 2 mg once weekly versus DPP‐4 inhibitors, Outcome 5 Quality of life. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00305" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=3.5&amp;caption=Comparison%203%20Exenatide%202%20mg%20once%20weekly%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%205%20Quality%20of%20life.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00306"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="4" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Exenatide 2 mg QW</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Sitagliptin 100 mg QD</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Bergenstal 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Withdrawals due to adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6.9%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Bergenstal 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Nausea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>24%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>10%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Bergenstal 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Diarrhoea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>18%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>10%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Bergenstal 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Vomiting</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>11%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Bergenstal 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Urinary tract infection</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Bergenstal 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Headache</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Bergenstal 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Injection‐site pruritus</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Bergenstal 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Serious adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Bergenstal 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Anti‐Exenatide antibodies</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>either low (&lt; 1/625; n = 74, 48%) or not detectable (n = 61, 40%) titres</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Bergenstal 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Severe hypoglycaemia</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Exenatide 2 mg once weekly versus DPP‐4 inhibitors, Outcome 6 Adverse events. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00306" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=3.6&amp;caption=Comparison%203%20Exenatide%202%20mg%20once%20weekly%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%206%20Adverse%20events.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00307"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="5" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Exenatide 2 mg QW</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Sitagliptin 100 mg QD</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Difference between groups</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Bergenstal 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Systolic blood pressure</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>EX vs. SITA: ‐4 mm Hg (95% CI ‐6 to ‐1); P = 0.0055</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Bergenstal 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Diastolic blood pressure</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>EX vs. SITA: P = NS</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Exenatide 2 mg once weekly versus DPP‐4 inhibitors, Outcome 7 Blood pressure (mm Hg). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00307" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=3.7&amp;caption=Comparison%203%20Exenatide%202%20mg%20once%20weekly%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%207%20Blood%20pressure%20%28mm%20Hg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00308"><img data-id="CD006423-fig-00308" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-003-08.png" alt="Comparison 3 Exenatide 2 mg once weekly versus DPP‐4 inhibitors, Outcome 8 Fasting plasma glucose (mmol/L)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Exenatide 2 mg once weekly versus DPP‐4 inhibitors, Outcome 8 Fasting plasma glucose (mmol/L). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00308" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-003-08.png?filename=nCD006423-CMP-003-08.ppt&amp;title=3.8&amp;caption=Comparison%203%20Exenatide%202%20mg%20once%20weekly%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%208%20Fasting%20plasma%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-003-08.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00309"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="5" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Exenatide 2 mg QW</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Sitagliptin 100 mg QD</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Bergenstal 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Self‐monitored blood glucose</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>EX vs SITA: P &lt; 0.05</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 Exenatide 2 mg once weekly versus DPP‐4 inhibitors, Outcome 9 Post‐prandial glucose / glucose profiles. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00309" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=3.9&amp;caption=Comparison%203%20Exenatide%202%20mg%20once%20weekly%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%209%20Post%E2%80%90prandial%20glucose%20%2F%20glucose%20profiles.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00310"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="5" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Exenatide 2 mg QW</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Sitagliptin 100 mg QD</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Difference between groups</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Bergenstal 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Fasting triglycerides (mmol/l)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>EX vs. SITA: P = 0.9718; PIO vs. SITA: p=0.0062</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Bergenstal 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Total cholesterol (mmol/l)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>EX vs. SITA: P = 0.3424; PIO vs. SITA: P = 0.3424</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Bergenstal 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>HDL (mmol/l)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>EX vs. SITA: P = 0.9546; PIO vs. SITA: P &lt; 0.0001</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Bergenstal 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>LDL (mmol/l)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>EX vs. SITA: P = 0.6113; PIO vs. SITA: P = 0.9965</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 Exenatide 2 mg once weekly versus DPP‐4 inhibitors, Outcome 10 Lipid profiles. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00310" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=3.10&amp;caption=Comparison%203%20Exenatide%202%20mg%20once%20weekly%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%2010%20Lipid%20profiles.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00401"><img data-id="CD006423-fig-00401" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-004-01.png" alt="Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 1 HbA1c (%)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 1 HbA1c (%).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00401" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-004-01.png?filename=nCD006423-CMP-004-01.ppt&amp;title=4.1&amp;caption=Comparison%204%20Exenatide%202%20mg%20once%20weekly%20versus%20insulin%20glargine%2C%20Outcome%201%20HbA1c%20%28%25%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-004-01.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00402"><img data-id="CD006423-fig-00402" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-004-02.png" alt="Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 2 HbA1c < 7%."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 2 HbA1c &lt; 7%. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00402" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-004-02.png?filename=nCD006423-CMP-004-02.ppt&amp;title=4.2&amp;caption=Comparison%204%20Exenatide%202%20mg%20once%20weekly%20versus%20insulin%20glargine%2C%20Outcome%202%20HbA1c%20%3C%207%25.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-004-02.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00403"><img data-id="CD006423-fig-00403" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-004-03.png" alt="Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 3 Hypoglycaemia (symptoms only)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 3 Hypoglycaemia (symptoms only). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00403" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-004-03.png?filename=nCD006423-CMP-004-03.ppt&amp;title=4.3&amp;caption=Comparison%204%20Exenatide%202%20mg%20once%20weekly%20versus%20insulin%20glargine%2C%20Outcome%203%20Hypoglycaemia%20%28symptoms%20only%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-004-03.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00404"><img data-id="CD006423-fig-00404" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-004-04.png" alt="Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 4 Hypoglycaemia (minor)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 4 Hypoglycaemia (minor). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00404" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-004-04.png?filename=nCD006423-CMP-004-04.ppt&amp;title=4.4&amp;caption=Comparison%204%20Exenatide%202%20mg%20once%20weekly%20versus%20insulin%20glargine%2C%20Outcome%204%20Hypoglycaemia%20%28minor%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-004-04.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00405"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="4" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Exenatide 2 mg QW</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Insulin glargine</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Diamant 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Taking metformin only</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1 (0.4%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1 (0.4%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Diamant 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Taking both metformin and sulphonylureas</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>None</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1 (0.4%)</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 5 Severe hypoglycaemia. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00405" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=4.5&amp;caption=Comparison%204%20Exenatide%202%20mg%20once%20weekly%20versus%20insulin%20glargine%2C%20Outcome%205%20Severe%20hypoglycaemia.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00406"><img data-id="CD006423-fig-00406" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-004-06.png" alt="Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 6 Weight change (kg)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 6 Weight change (kg). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00406" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-004-06.png?filename=nCD006423-CMP-004-06.ppt&amp;title=4.6&amp;caption=Comparison%204%20Exenatide%202%20mg%20once%20weekly%20versus%20insulin%20glargine%2C%20Outcome%206%20Weight%20change%20%28kg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-004-06.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00407"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="4" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Exenatide 2 mg QW</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Insulin glargine</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Diamant 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>withdrawal due to adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>11 (4.7%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2 (0.9%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Diamant 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>nausea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>30 (13%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3 (1%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Diamant 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>vomiting</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>10 (4%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3 (1%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Diamant 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>diarrhoea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>20 (9%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8 (4%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Diamant 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Nasopharyngitis</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>30 (13%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>39 (17%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Diamant 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Headache</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>23 (10%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>16 (7%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Diamant 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Injection‐site reaction</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>30 (13%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4 (2%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Diamant 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Patients with one or more serious adverse events</p> <p>Pancreatitis</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>11 (5%)</p> <p>1 (0.4%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>10 (4%)</p> <p>None</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Diamant 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Deaths</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>None</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>None</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Diamant 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Anti‐exenatide antibodies</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>127/233 (54.5%) tested positive for anti‐exenatide antibodies. No effect on HbA1c</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 7 Adverse events. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00407" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=4.7&amp;caption=Comparison%204%20Exenatide%202%20mg%20once%20weekly%20versus%20insulin%20glargine%2C%20Outcome%207%20Adverse%20events.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00408"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="4" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Exenatide 2 mg QW</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Insulin glargine</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Diamant 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>IWQOL‐Lite (self‐esteem)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Significant improvement compared with insulin glargine; no data given</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 8 Quality of life. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00408" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=4.8&amp;caption=Comparison%204%20Exenatide%202%20mg%20once%20weekly%20versus%20insulin%20glargine%2C%20Outcome%208%20Quality%20of%20life.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00409"><img data-id="CD006423-fig-00409" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-004-09.png" alt="Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 9 Fasting plasma glucose (mmol/L)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 9 Fasting plasma glucose (mmol/L). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00409" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-004-09.png?filename=nCD006423-CMP-004-09.ppt&amp;title=4.9&amp;caption=Comparison%204%20Exenatide%202%20mg%20once%20weekly%20versus%20insulin%20glargine%2C%20Outcome%209%20Fasting%20plasma%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-004-09.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00410"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="5" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Exenatide 2 mg QW</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Insulin glargine</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Diamant 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8‐point SMBG</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Both treatments reduced PPG at all eight timepoints (all P &lt; 0.0001)</p> <p>0300 hour and before breafast: participants receiving insulin glargine had lower glucose concentrations than exenatide at 0300 hour (P = 0.022) and before breakfast (P &lt; 0.0001) </p> <p>Dinner, morning and evening meals: participants receiving exenatide had lower glucose concentrations after dinner than insulin glargine (P = 0.004). </p> <p>Morning and evening meals: participants receiving exenatide had lower postprandial glucose excursions than insulin glargine after morning (P = 0.001) and evening meals (P = 0.033). </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.10</div> <div class="figure-caption"> <p>Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 10 Postprandial glucose / glucose profiles. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00410" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=4.10&amp;caption=Comparison%204%20Exenatide%202%20mg%20once%20weekly%20versus%20insulin%20glargine%2C%20Outcome%2010%20Postprandial%20glucose%20%2F%20glucose%20profiles.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00501"><img data-id="CD006423-fig-00501" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-005-01.png" alt="Comparison 5 Liraglutide 0.6 mg daily versus placebo, Outcome 1 HbA1c (%)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Liraglutide 0.6 mg daily versus placebo, Outcome 1 HbA1c (%).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00501" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-005-01.png?filename=nCD006423-CMP-005-01.ppt&amp;title=5.1&amp;caption=Comparison%205%20Liraglutide%200.6%20mg%20daily%20versus%20placebo%2C%20Outcome%201%20HbA1c%20%28%25%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-005-01.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00502"><img data-id="CD006423-fig-00502" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-005-02.png" alt="Comparison 5 Liraglutide 0.6 mg daily versus placebo, Outcome 2 HbA1c < 7%."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Liraglutide 0.6 mg daily versus placebo, Outcome 2 HbA1c &lt; 7%.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00502" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-005-02.png?filename=nCD006423-CMP-005-02.ppt&amp;title=5.2&amp;caption=Comparison%205%20Liraglutide%200.6%20mg%20daily%20versus%20placebo%2C%20Outcome%202%20HbA1c%20%3C%207%25.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-005-02.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00503"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 0.6 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Placebo</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Kaku 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.17</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.01</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Liraglutide 0.6 mg daily versus placebo, Outcome 3 Hypoglycaemia rate (events/patient‐year). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00503" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=5.3&amp;caption=Comparison%205%20Liraglutide%200.6%20mg%20daily%20versus%20placebo%2C%20Outcome%203%20Hypoglycaemia%20rate%20%28events%2Fpatient%E2%80%90year%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00504"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 0.6 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Placebo</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Kaku 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>None</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>None</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Liraglutide 0.6 mg daily versus placebo, Outcome 4 Severe hypoglycaemia.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00504" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=5.4&amp;caption=Comparison%205%20Liraglutide%200.6%20mg%20daily%20versus%20placebo%2C%20Outcome%204%20Severe%20hypoglycaemia.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00505"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 0.6 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Placebo</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Kaku 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>+0.06. P &lt; 0.0001 versus placebo</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.12</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 Liraglutide 0.6 mg daily versus placebo, Outcome 5 Weight change (kg).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00505" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=5.5&amp;caption=Comparison%205%20Liraglutide%200.6%20mg%20daily%20versus%20placebo%2C%20Outcome%205%20Weight%20change%20%28kg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00506"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="4" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 0.6 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Placebo</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Kaku 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Withdrawals due to adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3 (3%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2 (2%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Kaku 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Overall adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>67 (76.1%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>66 (75%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Kaku 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Gastrointestinal adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>More subjects in the two liraglutide groups reported gastrointestinal adverse events during the first 4 weeks of the trial than subjects on placebo. No major differences in gastrointestinal adverse events across groups. </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Kaku 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Serious adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3 (3%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2 (2%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Kaku 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Pancreatitis</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>None</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>None</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Kaku 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Deaths</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>None</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>None</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5 Liraglutide 0.6 mg daily versus placebo, Outcome 6 Adverse events.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00506" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=5.6&amp;caption=Comparison%205%20Liraglutide%200.6%20mg%20daily%20versus%20placebo%2C%20Outcome%206%20Adverse%20events.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00507"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Kaku 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>SBP did not change in both groups; P = NS between groups</p> <p>DBP did not change in both groups; P = NS between groups</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5 Liraglutide 0.6 mg daily versus placebo, Outcome 7 Blood pressure (mm Hg). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00507" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=5.7&amp;caption=Comparison%205%20Liraglutide%200.6%20mg%20daily%20versus%20placebo%2C%20Outcome%207%20Blood%20pressure%20%28mm%20Hg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00508"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 0.6 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Placebo</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Kaku 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐2.3, P &lt; 0.0001 versus placebo</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.64</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5 Liraglutide 0.6 mg daily versus placebo, Outcome 8 Fasting plasma glucose (mmol/L). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00508" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=5.8&amp;caption=Comparison%205%20Liraglutide%200.6%20mg%20daily%20versus%20placebo%2C%20Outcome%208%20Fasting%20plasma%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00509"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="4" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 0.6 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Placebo</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Kaku 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7‐point SMBG profile</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐2.66, P &lt; 0.0001 versus placebo</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.35</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.9</div> <div class="figure-caption"> <p>Comparison 5 Liraglutide 0.6 mg daily versus placebo, Outcome 9 Post‐prandial glucose / glucose profiles. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00509" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=5.9&amp;caption=Comparison%205%20Liraglutide%200.6%20mg%20daily%20versus%20placebo%2C%20Outcome%209%20Post%E2%80%90prandial%20glucose%20%2F%20glucose%20profiles.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00601"><img data-id="CD006423-fig-00601" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-006-01.png" alt="Comparison 6 Liraglutide 0.9 mg daily versus placebo, Outcome 1 HbA1c (%)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Liraglutide 0.9 mg daily versus placebo, Outcome 1 HbA1c (%).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00601" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-006-01.png?filename=nCD006423-CMP-006-01.ppt&amp;title=6.1&amp;caption=Comparison%206%20Liraglutide%200.9%20mg%20daily%20versus%20placebo%2C%20Outcome%201%20HbA1c%20%28%25%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-006-01.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00602"><img data-id="CD006423-fig-00602" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-006-02.png" alt="Comparison 6 Liraglutide 0.9 mg daily versus placebo, Outcome 2 HbA1c < 7%."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Liraglutide 0.9 mg daily versus placebo, Outcome 2 HbA1c &lt; 7%.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00602" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-006-02.png?filename=nCD006423-CMP-006-02.ppt&amp;title=6.2&amp;caption=Comparison%206%20Liraglutide%200.9%20mg%20daily%20versus%20placebo%2C%20Outcome%202%20HbA1c%20%3C%207%25.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-006-02.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00603"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 0.9 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Placebo</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Kaku 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.96</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.01</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Liraglutide 0.9 mg daily versus placebo, Outcome 3 Hypoglycaemia rate (events/patient‐year). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00603" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=6.3&amp;caption=Comparison%206%20Liraglutide%200.9%20mg%20daily%20versus%20placebo%2C%20Outcome%203%20Hypoglycaemia%20rate%20%28events%2Fpatient%E2%80%90year%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00604"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 0.9 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Placebo</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Kaku 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>None</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>None</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Liraglutide 0.9 mg daily versus placebo, Outcome 4 Severe hypoglycaemia.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00604" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=6.4&amp;caption=Comparison%206%20Liraglutide%200.9%20mg%20daily%20versus%20placebo%2C%20Outcome%204%20Severe%20hypoglycaemia.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00605"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 0.9 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Placebo</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Kaku 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.37, P = 0.0071 versus placebo</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.12</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6 Liraglutide 0.9 mg daily versus placebo, Outcome 5 Weight change (kg).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00605" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=6.5&amp;caption=Comparison%206%20Liraglutide%200.9%20mg%20daily%20versus%20placebo%2C%20Outcome%205%20Weight%20change%20%28kg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00606"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="4" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 0.9 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Placebo</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Kaku 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Withdrawals due to adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2 (2%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2 (2%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Kaku 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Overall adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>69 (78.4%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>66 (75%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Kaku 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Gastrointestinal adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>More subjects in the two liraglutide groups reported gastrointestinal adverse events during the first 4 weeks of the trial than subjects on placebo. No major differences in gastrointestinal adverse events across groups. </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Kaku 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Serious adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2 (2%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2 (2%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Kaku 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Pancreatitis</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>None</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>None</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Kaku 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Deaths</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>None</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>None</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6 Liraglutide 0.9 mg daily versus placebo, Outcome 6 Adverse events.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00606" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=6.6&amp;caption=Comparison%206%20Liraglutide%200.9%20mg%20daily%20versus%20placebo%2C%20Outcome%206%20Adverse%20events.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00607"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Kaku 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>SBP did not change in both groups; P = NS between groups</p> <p>DBP did not change in both groups; P = NS between groups</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6 Liraglutide 0.9 mg daily versus placebo, Outcome 7 Blood pressure (mm Hg). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00607" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=6.7&amp;caption=Comparison%206%20Liraglutide%200.9%20mg%20daily%20versus%20placebo%2C%20Outcome%207%20Blood%20pressure%20%28mm%20Hg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00608"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 0.9 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Placebo</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Kaku 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐2.28, P &lt; 0.0001 versus placebo</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.64</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.8</div> <div class="figure-caption"> <p>Comparison 6 Liraglutide 0.9 mg daily versus placebo, Outcome 8 Fasting plasma glucose (mmol/L). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00608" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=6.8&amp;caption=Comparison%206%20Liraglutide%200.9%20mg%20daily%20versus%20placebo%2C%20Outcome%208%20Fasting%20plasma%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00609"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="4" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 0.9 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Placebo</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Kaku 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7‐point SMBG profile</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐2.89, P &lt; 0.0001 versus placebo</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.35</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.9</div> <div class="figure-caption"> <p>Comparison 6 Liraglutide 0.9 mg daily versus placebo, Outcome 9 Postprandial glucose / glucose profiles. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00609" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=6.9&amp;caption=Comparison%206%20Liraglutide%200.9%20mg%20daily%20versus%20placebo%2C%20Outcome%209%20Postprandial%20glucose%20%2F%20glucose%20profiles.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00701"><img data-id="CD006423-fig-00701" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-007-01.png" alt="Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 1 HbA1c."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 1 HbA1c.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00701" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-007-01.png?filename=nCD006423-CMP-007-01.ppt&amp;title=7.1&amp;caption=Comparison%207%20Liraglutide%201.2%20mg%20versus%20placebo%2C%20Outcome%201%20HbA1c.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-007-01.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00702"><img data-id="CD006423-fig-00702" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-007-02.png" alt="Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 2 HbA1c < 7%."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 2 HbA1c &lt; 7%.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00702" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-007-02.png?filename=nCD006423-CMP-007-02.ppt&amp;title=7.2&amp;caption=Comparison%207%20Liraglutide%201.2%20mg%20versus%20placebo%2C%20Outcome%202%20HbA1c%20%3C%207%25.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-007-02.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00703"><img data-id="CD006423-fig-00703" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-007-03.png" alt="Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 3 Hypoglycaemia."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 3 Hypoglycaemia.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00703" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-007-03.png?filename=nCD006423-CMP-007-03.ppt&amp;title=7.3&amp;caption=Comparison%207%20Liraglutide%201.2%20mg%20versus%20placebo%2C%20Outcome%203%20Hypoglycaemia.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-007-03.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00704"><img data-id="CD006423-fig-00704" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-007-04.png" alt="Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 4 Weight change."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 4 Weight change.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00704" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-007-04.png?filename=nCD006423-CMP-007-04.ppt&amp;title=7.4&amp;caption=Comparison%207%20Liraglutide%201.2%20mg%20versus%20placebo%2C%20Outcome%204%20Weight%20change.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-007-04.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00705"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="4" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 1.2 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Placebo</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>withdrawal due to adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>no significant differences across groups for: blood pressure; no significant changes is: ophthalmoscopy, biochemistry, urinalysis, haematology, ECG </p> <p>no deaths</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>nausea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>10.5% (highest)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.8% (lowest)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>vomiting</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.4%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>diarrhoea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.9%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>serious adverse events (mostly judged to be unlikely to be related to study medication)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>liraglutide auto‐antibodies</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9 to13%, no effect on HbA1c</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>withdrawal due to adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>10%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>withdrawal due to nausea/vomiting/diarrhoea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>no significant differences across groups for: physical examination findings, laboratory analyses, ECG, ophthalmoscopy </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>any GI event</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>40%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>17%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>nausea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>16%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3 to 4%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>vomiting</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5 to 7%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>diarrhoea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>serious adverse events: 2 deaths unrelated to liraglutide treatment; 1 participant in 1.2 mg liraglutide group withdrawn due to acute pancreatitis </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>injection site reactions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>auto‐immune response</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 4 Zinman 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>withdrawal due to adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 4 Zinman 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>withdrawal due to nausea/vomiting/diarrhoea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 4 Zinman 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>no significant differences across groups for: physical examination findings, laboratory analyses, ECG, ophthalmoscopy, cardiovascular adverse events </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 4 Zinman 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>any GI event</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>45%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>19%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 4 Zinman 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>nausea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>29%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 4 Zinman 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>vomiting</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 4 Zinman 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>diarrhoea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 4 Zinman 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>serious adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8 events in 8 participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>13 events in 12 participants</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 4 Zinman 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>injection site reactions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 4 Zinman 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>auto‐immune response</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.1% (no effect on HbA1c)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 5 Adverse events.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00705" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=7.5&amp;caption=Comparison%207%20Liraglutide%201.2%20mg%20versus%20placebo%2C%20Outcome%205%20Adverse%20events.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00706"><img data-id="CD006423-fig-00706" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-007-06.png" alt="Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 6 Systolic blood pressure."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.6</div> <div class="figure-caption"> <p>Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 6 Systolic blood pressure.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00706" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-007-06.png?filename=nCD006423-CMP-007-06.ppt&amp;title=7.6&amp;caption=Comparison%207%20Liraglutide%201.2%20mg%20versus%20placebo%2C%20Outcome%206%20Systolic%20blood%20pressure.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-007-06.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00707"><img data-id="CD006423-fig-00707" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-007-07.png" alt="Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 7 Fasting plasma glucose (mmol/L)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.7</div> <div class="figure-caption"> <p>Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 7 Fasting plasma glucose (mmol/L).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00707" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-007-07.png?filename=nCD006423-CMP-007-07.ppt&amp;title=7.7&amp;caption=Comparison%207%20Liraglutide%201.2%20mg%20versus%20placebo%2C%20Outcome%207%20Fasting%20plasma%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-007-07.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00708"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="5" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 1.2 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Placebo</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comments</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>average of values obtained 90 min after breakfast, lunch and evening meal</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐2.5 mmol/L</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.4 mmol/L</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Liraglutide 1.2 mg versus placebo: P &lt; 0.0001</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>from self‐monitored 7‐point plasma glucose measurements</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐2.3 mmol/L</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.6 mmol/L</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Liraglutide 1.2 mg versus placebo: P &lt; 0.001</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 4 Zinman 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>from self‐monitored 7‐point plasma glucose measurements</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐2.6 mmol/L</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.8 mmol/L</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Liraglutide 1.2 mg versus placebo: P &lt; 0.001; the postprandial increment (postmeal value minus premeal) was significantly reduced over breakfast with liraglutide treatment (‐0.9, ‐0.8, ‐0.3 mmol/L respectively; P &lt; 0.05 for both liraglutide groups versus placebo) but not for lunch and dinner. </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.8</div> <div class="figure-caption"> <p>Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 8 Post‐prandial glucose (mmol/L).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00708" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=7.8&amp;caption=Comparison%207%20Liraglutide%201.2%20mg%20versus%20placebo%2C%20Outcome%208%20Post%E2%80%90prandial%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00709"><img data-id="CD006423-fig-00709" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-007-09.png" alt="Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 9 Triglycerides (mmol/L)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.9</div> <div class="figure-caption"> <p>Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 9 Triglycerides (mmol/L).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00709" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-007-09.png?filename=nCD006423-CMP-007-09.ppt&amp;title=7.9&amp;caption=Comparison%207%20Liraglutide%201.2%20mg%20versus%20placebo%2C%20Outcome%209%20Triglycerides%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-007-09.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00710"><img data-id="CD006423-fig-00710" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-007-10.png" alt="Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 10 Total cholesterol (mmol/L)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.10</div> <div class="figure-caption"> <p>Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 10 Total cholesterol (mmol/L).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00710" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-007-10.png?filename=nCD006423-CMP-007-10.ppt&amp;title=7.10&amp;caption=Comparison%207%20Liraglutide%201.2%20mg%20versus%20placebo%2C%20Outcome%2010%20Total%20cholesterol%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-007-10.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00711"><img data-id="CD006423-fig-00711" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-007-11.png" alt="Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 11 HDL‐cholesterol (mmol/L)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.11</div> <div class="figure-caption"> <p>Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 11 HDL‐cholesterol (mmol/L).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00711" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-007-11.png?filename=nCD006423-CMP-007-11.ppt&amp;title=7.11&amp;caption=Comparison%207%20Liraglutide%201.2%20mg%20versus%20placebo%2C%20Outcome%2011%20HDL%E2%80%90cholesterol%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-007-11.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00712"><img data-id="CD006423-fig-00712" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-007-12.png" alt="Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 12 LDL‐cholesterol (mmol/L)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.12</div> <div class="figure-caption"> <p>Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 12 LDL‐cholesterol (mmol/L).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00712" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-007-12.png?filename=nCD006423-CMP-007-12.ppt&amp;title=7.12&amp;caption=Comparison%207%20Liraglutide%201.2%20mg%20versus%20placebo%2C%20Outcome%2012%20LDL%E2%80%90cholesterol%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-007-12.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00713"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="4" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 1.2 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Placebo</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>HOMA‐B (%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>99% SE 184.3 (+28%), P = 0.01 versus placebo</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>52% SE 107.3 (‐4%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>proinsulin‐to‐insulin ratio</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.33 SE 0.2 (‐0.12), p ≤ 0.02 versus placebo</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.46 SE 0.29 (+0.02)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>HOMA‐B (%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>+23%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐2%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>proinsulin‐to‐insulin ratio</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.1, P &lt; 0.0001 versus placebo</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>+0.1</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>proinsulin‐to‐C‐peptide ratio</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 4 Zinman 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>HOMA‐B (%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>+27% SD 59, P &lt; 0.05 vs placebo</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6% SD 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 4 Zinman 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>proinsulin‐to‐insulin ratio</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.029 SD 0.35, P &lt; 0.05 vs placebo</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.036 SD 39</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 4 Zinman 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>proinsulin‐to‐C‐peptide ratio</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.007 SD 0.01, P &lt; 0.05 vs placebo</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.002 SD 0.01</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.13</div> <div class="figure-caption"> <p>Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 13 Beta‐cell function.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00713" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=7.13&amp;caption=Comparison%207%20Liraglutide%201.2%20mg%20versus%20placebo%2C%20Outcome%2013%20Beta%E2%80%90cell%20function.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00801"><img data-id="CD006423-fig-00801" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-008-01.png" alt="Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 1 HbA1c."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 1 HbA1c.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00801" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-008-01.png?filename=nCD006423-CMP-008-01.ppt&amp;title=8.1&amp;caption=Comparison%208%20Liraglutide%201.8%20mg%20versus%20placebo%2C%20Outcome%201%20HbA1c.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-008-01.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00802"><img data-id="CD006423-fig-00802" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-008-02.png" alt="Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 2 HbA1c < 7%."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 2 HbA1c &lt; 7%.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00802" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-008-02.png?filename=nCD006423-CMP-008-02.ppt&amp;title=8.2&amp;caption=Comparison%208%20Liraglutide%201.8%20mg%20versus%20placebo%2C%20Outcome%202%20HbA1c%20%3C%207%25.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-008-02.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00803"><img data-id="CD006423-fig-00803" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-008-03.png" alt="Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 3 Hypoglycaemia."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 3 Hypoglycaemia.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00803" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-008-03.png?filename=nCD006423-CMP-008-03.ppt&amp;title=8.3&amp;caption=Comparison%208%20Liraglutide%201.8%20mg%20versus%20placebo%2C%20Outcome%203%20Hypoglycaemia.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-008-03.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00804"><img data-id="CD006423-fig-00804" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-008-04.png" alt="Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 4 Weight change."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 4 Weight change.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00804" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-008-04.png?filename=nCD006423-CMP-008-04.ppt&amp;title=8.4&amp;caption=Comparison%208%20Liraglutide%201.8%20mg%20versus%20placebo%2C%20Outcome%204%20Weight%20change.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-008-04.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00805"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="4" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 1.8 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Placebo</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>withdrawal due to adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>no significant differences across groups for: blood pressure; no significant changes is: ophthalmoscopy, biochemistry, urinalysis, haematology, ECG </p> <p>no deaths</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>nausea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.8% (lowest)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>vomiting</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>diarrhoea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>serious adverse events (mostly judged to be unlikely to be related to study medication)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>liraglutide auto‐antibodies</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9 to13%, no effect on HbA1c</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>withdrawal due to adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>12%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>withdrawal due to nausea/vomiting/diarrhoea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>no significant differences across groups for: physical examination findings, laboratory analyses, ECG, ophthalmoscopy </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>any GI event</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>44%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>17%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>nausea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>19%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>vomiting</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5 to 7%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>diarrhoea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>15%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>serious adverse events: 2 deaths unrelated to liraglutide treatment</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>injection site reactions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>anti‐liraglutide antibodies</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 4 Zinman 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>withdrawal due to adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>15%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 4 Zinman 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>withdrawal due to nausea/vomiting/diarrhoea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>11%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 4 Zinman 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>no significant differences across groups for: physical examination findings, laboratory analyses, ECG, ophthalmoscopy, cardiovascular adverse events </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 4 Zinman 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>any GI event</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>56%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>19%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 4 Zinman 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>nausea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>40%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 4 Zinman 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>vomiting</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>17%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 4 Zinman 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>diarrhoea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 4 Zinman 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>serious adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>10 events in 7 participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>13 events in 12 participants</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 4 Zinman 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>injection site reactions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 4 Zinman 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>anti‐liraglutide antibodies</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6.7% (no effect on HbA1c)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 5 Russell‐J 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>withdrawal due to adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.9%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 5 Russell‐J 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>no significant differences across groups for: nasopharyngitis, headache; no pancreatitis</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 5 Russell‐J 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>nausea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>13.9%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.5%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 5 Russell‐J 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>diarrhoea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>10.%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.3%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 5 Russell‐J 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>dyspepsia</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6.5%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.9%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 5 Russell‐J 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>vomiting</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6.5%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.5%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 5 Russell‐J 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>serious adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 5 Russell‐J 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>injection site reactions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 5 Russell‐J 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>anti‐liraglutide antibodies</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9.8% (no effect on HbA1c)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 5 Russell‐J 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 5 Adverse events.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00805" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=8.5&amp;caption=Comparison%208%20Liraglutide%201.8%20mg%20versus%20placebo%2C%20Outcome%205%20Adverse%20events.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00806"><img data-id="CD006423-fig-00806" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-008-06.png" alt="Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 6 Systolic blood pressure."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.6</div> <div class="figure-caption"> <p>Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 6 Systolic blood pressure.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00806" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-008-06.png?filename=nCD006423-CMP-008-06.ppt&amp;title=8.6&amp;caption=Comparison%208%20Liraglutide%201.8%20mg%20versus%20placebo%2C%20Outcome%206%20Systolic%20blood%20pressure.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-008-06.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00807"><img data-id="CD006423-fig-00807" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-008-07.png" alt="Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 7 Fasting plasma glucose (mmol/L)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.7</div> <div class="figure-caption"> <p>Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 7 Fasting plasma glucose (mmol/L).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00807" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-008-07.png?filename=nCD006423-CMP-008-07.ppt&amp;title=8.7&amp;caption=Comparison%208%20Liraglutide%201.8%20mg%20versus%20placebo%2C%20Outcome%207%20Fasting%20plasma%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-008-07.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00808"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="5" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 1.8 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Placebo</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comments</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>average of values obtained 90 min after breakfast, lunch and evening meal</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐2.7 mmol/L</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.4 mmol/L</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Liraglutide 1.8 mg versus placebo: P &lt; 0.0001</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>from self‐monitored 7‐point plasma glucose measurements</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐2.6 mmol/L</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.6 mmol/L</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Liraglutide 1.8 mg versus placebo: P &lt; 0.001</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 4 Zinman 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>from self‐monitored 7‐point plasma glucose measurements</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐2.7 mmol/L</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.8 mmol/L</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Liraglutide 1.8 mg versus placebo: P &lt; 0.001; the postprandial increment (postmeal value minus premeal) was significantly reduced over breakfast with liraglutide treatment (‐0.9, ‐0.8, ‐0.3 mmol/L respectively; P &lt; 0.05 for both liraglutide groups versus placebo) but not for lunch and dinner. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 5 Russell‐J 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>from self‐monitored 7‐point plasma glucose measurements</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.81 mmol/L</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.03 mmol/L</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Liraglutide 1.8 mg versus placebo: P &lt; 0.0001; there was a statistically significantly higher likelihood of achieving ADA targets for PPG (≤ 10 mmol/l) (P &lt; 0.0001) with liraglutide versus placebo. </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.8</div> <div class="figure-caption"> <p>Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 8 Post‐prandial glucose (mmol/L).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00808" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=8.8&amp;caption=Comparison%208%20Liraglutide%201.8%20mg%20versus%20placebo%2C%20Outcome%208%20Post%E2%80%90prandial%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00809"><img data-id="CD006423-fig-00809" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-008-09.png" alt="Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 9 Triglycerides (mmol/L)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.9</div> <div class="figure-caption"> <p>Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 9 Triglycerides (mmol/L).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00809" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-008-09.png?filename=nCD006423-CMP-008-09.ppt&amp;title=8.9&amp;caption=Comparison%208%20Liraglutide%201.8%20mg%20versus%20placebo%2C%20Outcome%209%20Triglycerides%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-008-09.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00810"><img data-id="CD006423-fig-00810" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-008-10.png" alt="Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 10 Total cholesterol (mmol/L)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.10</div> <div class="figure-caption"> <p>Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 10 Total cholesterol (mmol/L).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00810" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-008-10.png?filename=nCD006423-CMP-008-10.ppt&amp;title=8.10&amp;caption=Comparison%208%20Liraglutide%201.8%20mg%20versus%20placebo%2C%20Outcome%2010%20Total%20cholesterol%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-008-10.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00811"><img data-id="CD006423-fig-00811" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-008-11.png" alt="Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 11 HDL‐cholesterol (mmol/L)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.11</div> <div class="figure-caption"> <p>Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 11 HDL‐cholesterol (mmol/L).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00811" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-008-11.png?filename=nCD006423-CMP-008-11.ppt&amp;title=8.11&amp;caption=Comparison%208%20Liraglutide%201.8%20mg%20versus%20placebo%2C%20Outcome%2011%20HDL%E2%80%90cholesterol%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-008-11.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00812"><img data-id="CD006423-fig-00812" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-008-12.png" alt="Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 12 LDL‐cholesterol (mmol/L)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.12</div> <div class="figure-caption"> <p>Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 12 LDL‐cholesterol (mmol/L).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00812" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-008-12.png?filename=nCD006423-CMP-008-12.ppt&amp;title=8.12&amp;caption=Comparison%208%20Liraglutide%201.8%20mg%20versus%20placebo%2C%20Outcome%2012%20LDL%E2%80%90cholesterol%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-008-12.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00813"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="4" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 1.8 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Placebo</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>HOMA‐B (%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>91% SE 108.2 (+35%), P = 0.051 versus placebo</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>52% SE 107.3 (‐4%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>proinsulin‐to‐insulin ratio</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.36 SE 0.2 (‐0.12), p ≤ 0.02 versus placebo</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.46 SE 0.29 (+0.02)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>HOMA‐B (%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>+28%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐2%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>proinsulin‐to‐insulin ratio</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.1, P &lt; 0.0001 versus placebo</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>+0.1</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>proinsulin‐to‐C‐peptide ratio</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 4 Zinman 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>HOMA‐B (%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>+27% SD 56, P &lt; 0.05 vs placebo</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6% SD 60</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 4 Zinman 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>proinsulin‐to‐insulin ratio</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.085 SD 3.47, P &lt; 0.05 vs placebo</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.036 SD 39</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 4 Zinman 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>proinsulin‐to‐C‐peptide ratio</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.008 SD 0.01, P &lt; 0.05 vs placebo</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.002 SD 0.01</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 5 Russell‐J 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>proinsulin‐to‐C‐peptide ratio</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.00671 (95% CI: ‐0.00964, ‐0.00377, P &lt; 0.0001) versus placebo</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 5 Russell‐J 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 5 Russell‐J 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.13</div> <div class="figure-caption"> <p>Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 13 Beta‐cell function.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00813" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=8.13&amp;caption=Comparison%208%20Liraglutide%201.8%20mg%20versus%20placebo%2C%20Outcome%2013%20Beta%E2%80%90cell%20function.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00901"><img data-id="CD006423-fig-00901" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-009-01.png" alt="Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 1 HbA1c."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 1 HbA1c.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00901" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-009-01.png?filename=nCD006423-CMP-009-01.ppt&amp;title=9.1&amp;caption=Comparison%209%20Liraglutide%201.2%20mg%20versus%201.8%20mg%2C%20Outcome%201%20HbA1c.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-009-01.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00902"><img data-id="CD006423-fig-00902" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-009-02.png" alt="Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 2 Patients reaching HbA1c < 7%."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 2 Patients reaching HbA1c &lt; 7%. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00902" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-009-02.png?filename=nCD006423-CMP-009-02.ppt&amp;title=9.2&amp;caption=Comparison%209%20Liraglutide%201.2%20mg%20versus%201.8%20mg%2C%20Outcome%202%20Patients%20reaching%20HbA1c%20%3C%207%25.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-009-02.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00903"><img data-id="CD006423-fig-00903" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-009-03.png" alt="Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 3 Weight."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 3 Weight.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00903" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-009-03.png?filename=nCD006423-CMP-009-03.ppt&amp;title=9.3&amp;caption=Comparison%209%20Liraglutide%201.2%20mg%20versus%201.8%20mg%2C%20Outcome%203%20Weight.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-009-03.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-00904"><img data-id="CD006423-fig-00904" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-009-04.png" alt="Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 4 Systolic blood pressure."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.4</div> <div class="figure-caption"> <p>Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 4 Systolic blood pressure.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-00904" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-009-04.png?filename=nCD006423-CMP-009-04.ppt&amp;title=9.4&amp;caption=Comparison%209%20Liraglutide%201.2%20mg%20versus%201.8%20mg%2C%20Outcome%204%20Systolic%20blood%20pressure.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-009-04.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01001"><img data-id="CD006423-fig-01001" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-010-01.png" alt="Comparison 10 Liraglutide versus insulin glargine, Outcome 1 HbA1c."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10 Liraglutide versus insulin glargine, Outcome 1 HbA1c.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01001" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-010-01.png?filename=nCD006423-CMP-010-01.ppt&amp;title=10.1&amp;caption=Comparison%2010%20Liraglutide%20versus%20insulin%20glargine%2C%20Outcome%201%20HbA1c.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-010-01.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01002"><img data-id="CD006423-fig-01002" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-010-02.png" alt="Comparison 10 Liraglutide versus insulin glargine, Outcome 2 HbA1c < 7%."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10 Liraglutide versus insulin glargine, Outcome 2 HbA1c &lt; 7%.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01002" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-010-02.png?filename=nCD006423-CMP-010-02.ppt&amp;title=10.2&amp;caption=Comparison%2010%20Liraglutide%20versus%20insulin%20glargine%2C%20Outcome%202%20HbA1c%20%3C%207%25.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-010-02.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01003"><img data-id="CD006423-fig-01003" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-010-03.png" alt="Comparison 10 Liraglutide versus insulin glargine, Outcome 3 Hypoglycaemia."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10 Liraglutide versus insulin glargine, Outcome 3 Hypoglycaemia.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01003" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-010-03.png?filename=nCD006423-CMP-010-03.ppt&amp;title=10.3&amp;caption=Comparison%2010%20Liraglutide%20versus%20insulin%20glargine%2C%20Outcome%203%20Hypoglycaemia.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-010-03.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01004"><img data-id="CD006423-fig-01004" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-010-04.png" alt="Comparison 10 Liraglutide versus insulin glargine, Outcome 4 Weight change."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.4</div> <div class="figure-caption"> <p>Comparison 10 Liraglutide versus insulin glargine, Outcome 4 Weight change.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01004" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-010-04.png?filename=nCD006423-CMP-010-04.ppt&amp;title=10.4&amp;caption=Comparison%2010%20Liraglutide%20versus%20insulin%20glargine%2C%20Outcome%204%20Weight%20change.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-010-04.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01005"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="4" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 1.8 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Insulin glargine</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 5 Russell‐J 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>withdrawal due to adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 5 Russell‐J 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>no significant differences across groups for: nasopharyngitis, headache; no pancreatitis</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 5 Russell‐J 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>nausea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>13.9%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.3%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 5 Russell‐J 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>diarrhoea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>10.%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.3%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 5 Russell‐J 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>dyspepsia</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6.5%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.7%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 5 Russell‐J 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>vomiting</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6.5%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.4%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 5 Russell‐J 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>serious adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 5 Russell‐J 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>injection site reactions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 5 Russell‐J 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>anti‐liraglutide antibodies</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9.8% (no effect on HbA1c)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.5</div> <div class="figure-caption"> <p>Comparison 10 Liraglutide versus insulin glargine, Outcome 5 Adverse events.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01005" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=10.5&amp;caption=Comparison%2010%20Liraglutide%20versus%20insulin%20glargine%2C%20Outcome%205%20Adverse%20events.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01006"><img data-id="CD006423-fig-01006" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-010-06.png" alt="Comparison 10 Liraglutide versus insulin glargine, Outcome 6 Systolic blood pressure."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.6</div> <div class="figure-caption"> <p>Comparison 10 Liraglutide versus insulin glargine, Outcome 6 Systolic blood pressure.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01006" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-010-06.png?filename=nCD006423-CMP-010-06.ppt&amp;title=10.6&amp;caption=Comparison%2010%20Liraglutide%20versus%20insulin%20glargine%2C%20Outcome%206%20Systolic%20blood%20pressure.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-010-06.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01007"><img data-id="CD006423-fig-01007" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-010-07.png" alt="Comparison 10 Liraglutide versus insulin glargine, Outcome 7 Fasting plasma glucose (mmol/L)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.7</div> <div class="figure-caption"> <p>Comparison 10 Liraglutide versus insulin glargine, Outcome 7 Fasting plasma glucose (mmol/L). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01007" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-010-07.png?filename=nCD006423-CMP-010-07.ppt&amp;title=10.7&amp;caption=Comparison%2010%20Liraglutide%20versus%20insulin%20glargine%2C%20Outcome%207%20Fasting%20plasma%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-010-07.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01008"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="5" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 1.8 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Insulin glargine</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comments</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 5 Russell‐J 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>from self‐monitored 7‐point plasma glucose measurements</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.81 mmol/L</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.61 mmol/L</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>no significant difference</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.8</div> <div class="figure-caption"> <p>Comparison 10 Liraglutide versus insulin glargine, Outcome 8 Post‐prandial glucose (mmol/L). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01008" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=10.8&amp;caption=Comparison%2010%20Liraglutide%20versus%20insulin%20glargine%2C%20Outcome%208%20Post%E2%80%90prandial%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01009"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 1.8 mg</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 5 Russell‐J 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>proinsulin‐to‐C‐peptide ratio</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.00366 (95% CI ‐0.0057 to ‐0.00136, P = 0.0019) versus insulin glargine;</p> <p>‐0.00671 (95% CI ‐0.00964 to ‐0.00377, P &lt; 0.0001) versus placebo</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.9</div> <div class="figure-caption"> <p>Comparison 10 Liraglutide versus insulin glargine, Outcome 9 Beta‐cell function.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01009" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=10.9&amp;caption=Comparison%2010%20Liraglutide%20versus%20insulin%20glargine%2C%20Outcome%209%20Beta%E2%80%90cell%20function.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01101"><img data-id="CD006423-fig-01101" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-011-01.png" alt="Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 1 HbA1c (%)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 1 HbA1c (%).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01101" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-011-01.png?filename=nCD006423-CMP-011-01.ppt&amp;title=11.1&amp;caption=Comparison%2011%20Liraglutide%201.2%20mg%20daily%20versus%20thiazolidinedione%2C%20Outcome%201%20HbA1c%20%28%25%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-011-01.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01102"><img data-id="CD006423-fig-01102" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-011-02.png" alt="Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 2 HbA1c < 7%."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 2 HbA1c &lt; 7%. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01102" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-011-02.png?filename=nCD006423-CMP-011-02.ppt&amp;title=11.2&amp;caption=Comparison%2011%20Liraglutide%201.2%20mg%20daily%20versus%20thiazolidinedione%2C%20Outcome%202%20HbA1c%20%3C%207%25.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-011-02.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01103"><img data-id="CD006423-fig-01103" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-011-03.png" alt="Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 3 Hypoglycaemia (mild/moderate/overall)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.3</div> <div class="figure-caption"> <p>Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 3 Hypoglycaemia (mild/moderate/overall). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01103" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-011-03.png?filename=nCD006423-CMP-011-03.ppt&amp;title=11.3&amp;caption=Comparison%2011%20Liraglutide%201.2%20mg%20daily%20versus%20thiazolidinedione%2C%20Outcome%203%20Hypoglycaemia%20%28mild%2Fmoderate%2Foverall%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-011-03.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01104"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 1.2 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Rosiglitazone 4 mg QD</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.4</div> <div class="figure-caption"> <p>Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 4 Severe hypoglycaemia. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01104" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=11.4&amp;caption=Comparison%2011%20Liraglutide%201.2%20mg%20daily%20versus%20thiazolidinedione%2C%20Outcome%204%20Severe%20hypoglycaemia.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01105"><img data-id="CD006423-fig-01105" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-011-05.png" alt="Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 5 Weight change."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.5</div> <div class="figure-caption"> <p>Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 5 Weight change. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01105" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-011-05.png?filename=nCD006423-CMP-011-05.ppt&amp;title=11.5&amp;caption=Comparison%2011%20Liraglutide%201.2%20mg%20daily%20versus%20thiazolidinedione%2C%20Outcome%205%20Weight%20change.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-011-05.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01106"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="4" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 1.2 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Rosiglitazone 4 mg QD</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>withdrawal due to adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>11 (5%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7 (3%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>overall adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>nausea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>24 (10.5%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>vomiting</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>10 (4.4%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>diarrhoea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>18 (7.9%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>serious adverse events (mostly judged to be unlikely to be related to study medication)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9 (4%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7 (3%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>liraglutide auto‐antibodies</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9 to 13%, no effect on HbA1c</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>deaths</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>None</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>None</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>pancreatitis</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>None</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>None</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.6</div> <div class="figure-caption"> <p>Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 6 Adverse events. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01106" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=11.6&amp;caption=Comparison%2011%20Liraglutide%201.2%20mg%20daily%20versus%20thiazolidinedione%2C%20Outcome%206%20Adverse%20events.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01107"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="5" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 1.2 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Rosiglitazone 4 mg QD</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>p values</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Change from baseline</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐2.6 to ‐2.8</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.9 to 2.3</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>P = NS between groups</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.7</div> <div class="figure-caption"> <p>Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 7 Systolic blood pressure (mm Hg). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01107" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=11.7&amp;caption=Comparison%2011%20Liraglutide%201.2%20mg%20daily%20versus%20thiazolidinedione%2C%20Outcome%207%20Systolic%20blood%20pressure%20%28mm%20Hg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01108"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="5" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 1.2 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Rosiglitazone 4 mg QD</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>p values</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Change from baseline</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.7 to ‐1.4</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.7 to ‐1.4</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>P = NS between groups</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.8</div> <div class="figure-caption"> <p>Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 8 Diastolic blood pressure (mm Hg). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01108" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=11.8&amp;caption=Comparison%2011%20Liraglutide%201.2%20mg%20daily%20versus%20thiazolidinedione%2C%20Outcome%208%20Diastolic%20blood%20pressure%20%28mm%20Hg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01109"><img data-id="CD006423-fig-01109" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-011-09.png" alt="Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 9 Fasting plasma glucose (mmol/L)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.9</div> <div class="figure-caption"> <p>Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 9 Fasting plasma glucose (mmol/L). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01109" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-011-09.png?filename=nCD006423-CMP-011-09.ppt&amp;title=11.9&amp;caption=Comparison%2011%20Liraglutide%201.2%20mg%20daily%20versus%20thiazolidinedione%2C%20Outcome%209%20Fasting%20plasma%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-011-09.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01110"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="5" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 1.2 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Rosiglitazone 4 mg QD</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comments</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>average of values obtained 90 min after breakfast, lunch and evening meal</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐2.5 mmol/L</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.8 mmol/L</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>P = 0.043 1.2 mg versus rosiglitazone</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.10</div> <div class="figure-caption"> <p>Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 10 Post‐prandial glucose (mmol/L). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01110" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=11.10&amp;caption=Comparison%2011%20Liraglutide%201.2%20mg%20daily%20versus%20thiazolidinedione%2C%20Outcome%2010%20Post%E2%80%90prandial%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01111"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="4" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 1.2 mg</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>TZD</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>HOMA‐B (%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>99% SE 184.3 (+28%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>59% SE 63.3 (+13%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>proinsulin‐to‐insulin ratio</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.33 SE 0.2 (‐0.12)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.40 SE 0.2 (‐0.05)</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.11</div> <div class="figure-caption"> <p>Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 11 Beta‐cell function. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01111" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=11.11&amp;caption=Comparison%2011%20Liraglutide%201.2%20mg%20daily%20versus%20thiazolidinedione%2C%20Outcome%2011%20Beta%E2%80%90cell%20function.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01201"><img data-id="CD006423-fig-01201" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-012-01.png" alt="Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 1 HbA1c (%)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 1 HbA1c (%).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01201" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-012-01.png?filename=nCD006423-CMP-012-01.ppt&amp;title=12.1&amp;caption=Comparison%2012%20Liraglutide%201.8%20mg%20daily%20versus%20thiazolidinedione%2C%20Outcome%201%20HbA1c%20%28%25%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-012-01.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01202"><img data-id="CD006423-fig-01202" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-012-02.png" alt="Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 2 HbA1c < 7%."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 2 HbA1c &lt; 7%. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01202" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-012-02.png?filename=nCD006423-CMP-012-02.ppt&amp;title=12.2&amp;caption=Comparison%2012%20Liraglutide%201.8%20mg%20daily%20versus%20thiazolidinedione%2C%20Outcome%202%20HbA1c%20%3C%207%25.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-012-02.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01203"><img data-id="CD006423-fig-01203" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-012-03.png" alt="Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 3 Hypoglycaemia."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.3</div> <div class="figure-caption"> <p>Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 3 Hypoglycaemia.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01203" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-012-03.png?filename=nCD006423-CMP-012-03.ppt&amp;title=12.3&amp;caption=Comparison%2012%20Liraglutide%201.8%20mg%20daily%20versus%20thiazolidinedione%2C%20Outcome%203%20Hypoglycaemia.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-012-03.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01204"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 1.8 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Rosiglitazone 4 mg QD</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.4</div> <div class="figure-caption"> <p>Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 4 Severe hypoglycaemia. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01204" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=12.4&amp;caption=Comparison%2012%20Liraglutide%201.8%20mg%20daily%20versus%20thiazolidinedione%2C%20Outcome%204%20Severe%20hypoglycaemia.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01205"><img data-id="CD006423-fig-01205" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-012-05.png" alt="Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 5 Weight change (kg)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.5</div> <div class="figure-caption"> <p>Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 5 Weight change (kg). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01205" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-012-05.png?filename=nCD006423-CMP-012-05.ppt&amp;title=12.5&amp;caption=Comparison%2012%20Liraglutide%201.8%20mg%20daily%20versus%20thiazolidinedione%2C%20Outcome%205%20Weight%20change%20%28kg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-012-05.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01206"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="4" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 1.8 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Rosiglitazone 4 mg QD</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>withdrawal due to adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9 (4%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7 (3%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>overall adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>nausea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>vomiting</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>serious adverse events (mostly judged to be unlikely to be related to study medication)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>12 (5%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7 (3%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>liraglutide auto‐antibodies</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9 to 13%, no effect on HbA1c</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>deaths</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>None</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>None</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>pancreatitis</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>None</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>None</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.6</div> <div class="figure-caption"> <p>Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 6 Adverse events. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01206" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=12.6&amp;caption=Comparison%2012%20Liraglutide%201.8%20mg%20daily%20versus%20thiazolidinedione%2C%20Outcome%206%20Adverse%20events.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01207"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="5" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 1.8 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Rosiglitazone 4 mg QD</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>p values</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Change from baseline</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐2.6 to ‐2.8</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.9 to 2.3</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>P = NS between groups</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.7</div> <div class="figure-caption"> <p>Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 7 Systolic blood pressure (mm Hg). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01207" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=12.7&amp;caption=Comparison%2012%20Liraglutide%201.8%20mg%20daily%20versus%20thiazolidinedione%2C%20Outcome%207%20Systolic%20blood%20pressure%20%28mm%20Hg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01208"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="5" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 1.8 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Rosiglitazone 4 mg QD</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>p values</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Change from baseline</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.7 to 1.4</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.7 to ‐1.4</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>P = NS between groups</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.8</div> <div class="figure-caption"> <p>Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 8 Diastolic blood pressure (mm Hg). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01208" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=12.8&amp;caption=Comparison%2012%20Liraglutide%201.8%20mg%20daily%20versus%20thiazolidinedione%2C%20Outcome%208%20Diastolic%20blood%20pressure%20%28mm%20Hg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01209"><img data-id="CD006423-fig-01209" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-012-09.png" alt="Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 9 Fasting plasma glucose (mmol/L)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.9</div> <div class="figure-caption"> <p>Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 9 Fasting plasma glucose (mmol/L). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01209" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-012-09.png?filename=nCD006423-CMP-012-09.ppt&amp;title=12.9&amp;caption=Comparison%2012%20Liraglutide%201.8%20mg%20daily%20versus%20thiazolidinedione%2C%20Outcome%209%20Fasting%20plasma%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-012-09.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01210"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="5" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 1.8 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Rosiglitazone 4 mg QD</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comments</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>average of values obtained 90 min after breakfast, lunch and evening meal</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐2.7 mmol/L</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.8 mmol/L</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>P = 0.0022 1.8 mg versus rosiglitazone</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.10</div> <div class="figure-caption"> <p>Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 10 Post‐prandial glucose (mmol/L). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01210" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=12.10&amp;caption=Comparison%2012%20Liraglutide%201.8%20mg%20daily%20versus%20thiazolidinedione%2C%20Outcome%2010%20Post%E2%80%90prandial%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01211"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="5" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 1.8 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Rosiglitazone 4 mg QD</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Difference between groups</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>HOMA‐B (%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>91% SE 108.2 (+35%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>59% SE 63.3 (+13%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>30, 95% CI 2.00 to 58.6, p ≤ 0.05</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 1 Marre 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>proinsulin‐to‐insulin ratio</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.36 SE 0.2 (‐0.12)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.40 SE 0.2 (‐0.05)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.05, 95% CI ‐0.10 to ‐0.01, p ≤ 0.05</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.11</div> <div class="figure-caption"> <p>Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 11 Beta‐cell function. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01211" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=12.11&amp;caption=Comparison%2012%20Liraglutide%201.8%20mg%20daily%20versus%20thiazolidinedione%2C%20Outcome%2011%20Beta%E2%80%90cell%20function.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01301"><img data-id="CD006423-fig-01301" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-013-01.png" alt="Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 1 HbA1c (%)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 1 HbA1c (%).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01301" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-013-01.png?filename=nCD006423-CMP-013-01.ppt&amp;title=13.1&amp;caption=Comparison%2013%20Liraglutide%201.2%20mg%20daily%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%201%20HbA1c%20%28%25%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-013-01.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01302"><img data-id="CD006423-fig-01302" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-013-02.png" alt="Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 2 HbA1c < 7%."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.2</div> <div class="figure-caption"> <p>Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 2 HbA1c &lt; 7%. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01302" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-013-02.png?filename=nCD006423-CMP-013-02.ppt&amp;title=13.2&amp;caption=Comparison%2013%20Liraglutide%201.2%20mg%20daily%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%202%20HbA1c%20%3C%207%25.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-013-02.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01303"><img data-id="CD006423-fig-01303" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-013-03.png" alt="Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 3 Hypoglycaemia (mild/moderate/overall)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.3</div> <div class="figure-caption"> <p>Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 3 Hypoglycaemia (mild/moderate/overall). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01303" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-013-03.png?filename=nCD006423-CMP-013-03.ppt&amp;title=13.3&amp;caption=Comparison%2013%20Liraglutide%201.2%20mg%20daily%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%203%20Hypoglycaemia%20%28mild%2Fmoderate%2Foverall%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-013-03.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01304"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 1.2 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Sitagliptin 100 mg daily</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Pratley 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1 (0.45%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>None</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.4</div> <div class="figure-caption"> <p>Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 4 Severe hypoglycaemia.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01304" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=13.4&amp;caption=Comparison%2013%20Liraglutide%201.2%20mg%20daily%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%204%20Severe%20hypoglycaemia.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01305"><img data-id="CD006423-fig-01305" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-013-05.png" alt="Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 5 Weight change (kg)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.5</div> <div class="figure-caption"> <p>Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 5 Weight change (kg). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01305" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-013-05.png?filename=nCD006423-CMP-013-05.ppt&amp;title=13.5&amp;caption=Comparison%2013%20Liraglutide%201.2%20mg%20daily%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%205%20Weight%20change%20%28kg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-013-05.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01306"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="4" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 1.2 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Sitagliptin 100 mg daily</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Pratley 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>withdrawal due to adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>14 (6.3%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4 (1.8%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Pratley 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>overall adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>146 (66%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>127 (58%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Pratley 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>nausea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>46 (21%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>10 (5%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Pratley 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>vomiting</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>17 (8%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9 (4%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Pratley 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>diarrhoea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>16 (7%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>10 (5%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Pratley 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>other gastrointestinal adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>17 (8%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6 (3%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Pratley 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>serious adverse events (mostly judged to be unlikely to be related to study medication)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6 (3%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4 (2%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Pratley 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>liraglutide auto‐antibodies</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Pratley 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>deaths</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1 (&lt; 1%) unrelated to drug</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Pratley 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>pancreatitis</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>None</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>None</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.6</div> <div class="figure-caption"> <p>Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 6 Adverse events. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01306" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=13.6&amp;caption=Comparison%2013%20Liraglutide%201.2%20mg%20daily%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%206%20Adverse%20events.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01307"><img data-id="CD006423-fig-01307" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-013-07.png" alt="Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 7 Systolic blood pressure (mm Hg)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.7</div> <div class="figure-caption"> <p>Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 7 Systolic blood pressure (mm Hg). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01307" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-013-07.png?filename=nCD006423-CMP-013-07.ppt&amp;title=13.7&amp;caption=Comparison%2013%20Liraglutide%201.2%20mg%20daily%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%207%20Systolic%20blood%20pressure%20%28mm%20Hg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-013-07.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01308"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="5" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 1.2 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Sitagliptin 100 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>p values</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Pratley 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Change from baseline</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.71</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.78</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>P = NS between groups</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.8</div> <div class="figure-caption"> <p>Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 8 Diastolic blood pressure (mm Hg). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01308" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=13.8&amp;caption=Comparison%2013%20Liraglutide%201.2%20mg%20daily%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%208%20Diastolic%20blood%20pressure%20%28mm%20Hg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01309"><img data-id="CD006423-fig-01309" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-013-09.png" alt="Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 9 Fasting plasma glucose (mmol/L)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.9</div> <div class="figure-caption"> <p>Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 9 Fasting plasma glucose (mmol/L). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01309" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-013-09.png?filename=nCD006423-CMP-013-09.ppt&amp;title=13.9&amp;caption=Comparison%2013%20Liraglutide%201.2%20mg%20daily%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%209%20Fasting%20plasma%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-013-09.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01310"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="5" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 1.2 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Sitagliptin 100 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comments</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Pratley 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>PPG</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Reported in the paper that ' PPG was highly variable suggesting that glucose values were not PPG in many cases </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.10</div> <div class="figure-caption"> <p>Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 10 Post‐prandial glucose (mmol/L). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01310" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=13.10&amp;caption=Comparison%2013%20Liraglutide%201.2%20mg%20daily%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%2010%20Post%E2%80%90prandial%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01311"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="5" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 1.2 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Sitagliptin 100 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Difference between groups</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Pratley 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>HOMA‐B (%), mean change from baseline</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>27.23 % (95% CI 19.73 to 34.73)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.18 % (95% CI ‐3.27 to 11.62)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>23.05% (95% CI 12.95 to 33.15), P &lt; 0.0001</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Pratley 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>HOMA‐IR (%), mean change from baseline</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.06 % (95% CI ‐1.70 to ‐0.42)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.94 % (95% CI, ‐1.58 to ‐0.30)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.12% (95% CI ‐0.99 to 0.75), P = 0.7834</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Pratley 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Fasting insulin (pmol/L)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.12 (95% CI ‐4.34 to 14.59)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐6.77 (95% CI ‐16.18 to 2.64)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>11.89 (95% CI ‐0.84 to 24.63), P = 0.0672</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Pratley 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Fasting C‐peptide (nmol/L)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.09 (95% CI 0.03 to 0.15)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.04 (95% CI ‐0.10 to 0.02)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.13 (95% CI 0.05 to 0.21), P = 0.0011</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Pratley 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Fasting proinsulin‐to‐insulin ratio</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.08 (95% CI ‐0.11 to ‐0.05)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.03 (95% CI ‐0.06 to ‐0.00)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.05 (95% CI ‐0.09 to ‐0.01), P = 0.0121</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.11</div> <div class="figure-caption"> <p>Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 11 Beta‐cell function. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01311" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=13.11&amp;caption=Comparison%2013%20Liraglutide%201.2%20mg%20daily%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%2011%20Beta%E2%80%90cell%20function.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01401"><img data-id="CD006423-fig-01401" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-014-01.png" alt="Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 1 HbA1c (%)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.1</div> <div class="figure-caption"> <p>Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 1 HbA1c (%).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01401" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-014-01.png?filename=nCD006423-CMP-014-01.ppt&amp;title=14.1&amp;caption=Comparison%2014%20Liraglutide%201.8%20mg%20daily%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%201%20HbA1c%20%28%25%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-014-01.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01402"><img data-id="CD006423-fig-01402" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-014-02.png" alt="Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 2 HbA1c < 7%."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.2</div> <div class="figure-caption"> <p>Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 2 HbA1c &lt; 7%. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01402" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-014-02.png?filename=nCD006423-CMP-014-02.ppt&amp;title=14.2&amp;caption=Comparison%2014%20Liraglutide%201.8%20mg%20daily%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%202%20HbA1c%20%3C%207%25.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-014-02.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01403"><img data-id="CD006423-fig-01403" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-014-03.png" alt="Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 3 Hypoglycaemia."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.3</div> <div class="figure-caption"> <p>Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 3 Hypoglycaemia.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01403" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-014-03.png?filename=nCD006423-CMP-014-03.ppt&amp;title=14.3&amp;caption=Comparison%2014%20Liraglutide%201.8%20mg%20daily%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%203%20Hypoglycaemia.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-014-03.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01404"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 1.8 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Sitagliptin 100 mg daily</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Pratley 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR, presumably none</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR, presumably none</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.4</div> <div class="figure-caption"> <p>Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 4 Severe hypoglycaemia.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01404" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=14.4&amp;caption=Comparison%2014%20Liraglutide%201.8%20mg%20daily%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%204%20Severe%20hypoglycaemia.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01405"><img data-id="CD006423-fig-01405" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-014-05.png" alt="Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 5 Weight change (kg)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.5</div> <div class="figure-caption"> <p>Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 5 Weight change (kg). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01405" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-014-05.png?filename=nCD006423-CMP-014-05.ppt&amp;title=14.5&amp;caption=Comparison%2014%20Liraglutide%201.8%20mg%20daily%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%205%20Weight%20change%20%28kg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-014-05.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01406"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="4" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 1.8 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Sitagliptin 100 mg daily</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Pratley 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>withdrawal due to adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>15 (6.9%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4 (1.8%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Pratley 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>overall adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>159 (73%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>127 (58%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Pratley 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>nausea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>59 (27%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>10 (5%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Pratley 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>vomiting</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>21 (10%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9 (4%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Pratley 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>diarrhoea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>25 (11%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>10 (5%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Pratley 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>other gastrointestinal adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>11 (5%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6 (3%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Pratley 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>serious adverse events (mostly judged to be unlikely to be related to study medication)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6 (3%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4 (2%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Pratley 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>liraglutide auto‐antibodies</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Pratley 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>deaths</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1 (&lt; 1%) unrelated to drug</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1 (&lt; 1%) unrelated to drug</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Pratley 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>pancreatitis</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>None</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>None</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.6</div> <div class="figure-caption"> <p>Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 6 Adverse events. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01406" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=14.6&amp;caption=Comparison%2014%20Liraglutide%201.8%20mg%20daily%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%206%20Adverse%20events.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01407"><img data-id="CD006423-fig-01407" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-014-07.png" alt="Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 7 Systolic blood pressure (mm Hg)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.7</div> <div class="figure-caption"> <p>Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 7 Systolic blood pressure (mm Hg). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01407" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-014-07.png?filename=nCD006423-CMP-014-07.ppt&amp;title=14.7&amp;caption=Comparison%2014%20Liraglutide%201.8%20mg%20daily%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%207%20Systolic%20blood%20pressure%20%28mm%20Hg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-014-07.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01408"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="5" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 1.8 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Sitagliptin 100 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>p values</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Pratley 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Change from baseline</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.07</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.78</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>P = 0.0210 versus SITA</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.8</div> <div class="figure-caption"> <p>Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 8 Diastolic blood pressure (mm Hg). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01408" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=14.8&amp;caption=Comparison%2014%20Liraglutide%201.8%20mg%20daily%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%208%20Diastolic%20blood%20pressure%20%28mm%20Hg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01409"><img data-id="CD006423-fig-01409" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-014-09.png" alt="Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 9 Fasting plasma glucose (mmol/L)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.9</div> <div class="figure-caption"> <p>Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 9 Fasting plasma glucose (mmol/L). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01409" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-014-09.png?filename=nCD006423-CMP-014-09.ppt&amp;title=14.9&amp;caption=Comparison%2014%20Liraglutide%201.8%20mg%20daily%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%209%20Fasting%20plasma%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-014-09.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01410"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="5" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 1.8 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Sitagliptin 100 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comments</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Pratley 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>PPG</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Reported in the paper that ' PPG was highly variable suggesting that glucose values were not PPG in many cases </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.10</div> <div class="figure-caption"> <p>Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 10 Post‐prandial glucose (mmol/L). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01410" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=14.10&amp;caption=Comparison%2014%20Liraglutide%201.8%20mg%20daily%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%2010%20Post%E2%80%90prandial%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01411"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="5" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 1.8 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Sitagliptin 100 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Difference between groups</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Pratley 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Fasting insulin (pmol/L)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.29 (95% CI ‐8.04 to 10.62)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐6.77 (95% CI ‐16.18 to 2.64)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8.06 (95% CI ‐4.51 to 20.63), P = 0.2083</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Pratley 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.09 (95% CI 0.03 to 0.15)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.04 (95% CI ‐0.10 to 0.02)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.14 (95% CI 0.06 to 0.21), P = 0.0008</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Pratley 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Fasting insulin (pmol/L)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.29 (95% CI ‐8.04 to 10.62)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐6.77 (95% CI ‐16.18 to 2.64)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8.06 (95% CI ‐4.51 to 20.63), P = 0.2083</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Pratley 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.09 (95% CI 0.03 to 0.15)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.04 (95% CI ‐0.10 to 0.02)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.14 (95% CI 0.06 to 0.21), P = 0.0008</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Pratley 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.10 (95% CI ‐0.12 to ‐0.07)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.03 (95% CI ‐0.06 to ‐0.00)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.07 (95% CI ‐0.10 to ‐0.03), P = 0.0004</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.11</div> <div class="figure-caption"> <p>Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 11 Beta‐cell function. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01411" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=14.11&amp;caption=Comparison%2014%20Liraglutide%201.8%20mg%20daily%20versus%20DPP%E2%80%904%20inhibitors%2C%20Outcome%2011%20Beta%E2%80%90cell%20function.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01501"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="11" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>LIXI 5 μg QD</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>LIXI 10 μg QD</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>LIXI 20 μg QD</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>LIXI 30 μg QD</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>LIXI 5 μg BID</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>LIXI 10 μg BID</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>LIXI 20 μg BID</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>LIXI 30 μg BID</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Placebo</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>p values</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Lixi ‐ Ratner 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.47</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.5</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.69</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.76</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.65</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.78</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.75</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.87</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.18</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>change from baseline to end:</p> <p>LIXI: P &lt; 0.05 for all doses</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.1</div> <div class="figure-caption"> <p>Comparison 15 Lixisenatide versus placebo, Outcome 1 HbA1c (%).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01501" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=15.1&amp;caption=Comparison%2015%20Lixisenatide%20versus%20placebo%2C%20Outcome%201%20HbA1c%20%28%25%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01502"><img data-id="CD006423-fig-01502" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-015-02.png" alt="Comparison 15 Lixisenatide versus placebo, Outcome 2 HbA1c < 7%."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.2</div> <div class="figure-caption"> <p>Comparison 15 Lixisenatide versus placebo, Outcome 2 HbA1c &lt; 7%.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01502" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-015-02.png?filename=nCD006423-CMP-015-02.ppt&amp;title=15.2&amp;caption=Comparison%2015%20Lixisenatide%20versus%20placebo%2C%20Outcome%202%20HbA1c%20%3C%207%25.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-015-02.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01503"><img data-id="CD006423-fig-01503" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-015-03.png" alt="Comparison 15 Lixisenatide versus placebo, Outcome 3 Symptomatic hypoglycaemia."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.3</div> <div class="figure-caption"> <p>Comparison 15 Lixisenatide versus placebo, Outcome 3 Symptomatic hypoglycaemia.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01503" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-015-03.png?filename=nCD006423-CMP-015-03.ppt&amp;title=15.3&amp;caption=Comparison%2015%20Lixisenatide%20versus%20placebo%2C%20Outcome%203%20Symptomatic%20hypoglycaemia.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-015-03.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01504"><img data-id="CD006423-fig-01504" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-015-04.png" alt="Comparison 15 Lixisenatide versus placebo, Outcome 4 Weight change (kg)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.4</div> <div class="figure-caption"> <p>Comparison 15 Lixisenatide versus placebo, Outcome 4 Weight change (kg).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01504" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-015-04.png?filename=nCD006423-CMP-015-04.ppt&amp;title=15.4&amp;caption=Comparison%2015%20Lixisenatide%20versus%20placebo%2C%20Outcome%204%20Weight%20change%20%28kg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-015-04.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01505"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="11" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>LIXI 5 μg QD</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>LIXI 10 μg QD</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>LIXI 20 μg QD</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>LIXI 30 μg QD</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>LIXI 5 μg BID</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>LIXI 10 μg BID</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>LIXI 20 μg BID</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>LIXI 30 μg BID</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Placebo</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Lixi ‐ Ratner 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Withdrawals due to adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1 (1.8%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2 (3.8%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3 (5.5%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6 (11.1%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2 (3.6%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8 (14.8%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5 (9.3%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2 (1.8%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Lixi ‐ Ratner 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Any treatment‐emergent adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>31 (56.4%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>26 (50.0%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>37 (67.3%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>42 (77.8%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>30 (56.6%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>32 (57.1%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>38 (70.4%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>40 (74.1%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>65 (59.6%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Lixi ‐ Ratner 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Nausea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4 (7.3%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6 (11.5%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>14 (25.5%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>19 (35.2%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4 (7.5%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8 (14.3%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>12 (22.2%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>18 (33.3%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5 (4.6%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Lixi ‐ Ratner 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Vomiting</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2 (3.6%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3 (5.8%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3 (5.5%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>10 (18.5%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3 (5.7%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4 (7.1%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5 (9.3%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2 (3.7%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1 (0.9%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Lixi ‐ Ratner 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Diarrhoea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3 (5.5%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4 (7.7%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5 (9.1%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4 (7.4%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3 (5.7%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4 (7.1%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6 (11.1%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>14 (25.9%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8 (7.3%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Lixi ‐ Ratner 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Headache</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7 (12.7%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3 (5.8%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7 (12.7%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7 (13.0%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7 (13.2%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5 (8.9%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6 (11.1%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4 (7.4%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>11 (10.1%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Lixi ‐ Ratner 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Dizziness</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1 (1.8%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4 (7.7%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4 (7.3%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6 (11.1%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3 (5.7%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5 (8.9%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2 (3.7%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5 (9.3%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7 (6.4%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Lixi ‐ Ratner 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Any serious treatment‐emergent adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1 (1.9%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1 (1.8%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3 (5.6%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1 (1.8%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2 (3.7%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3 (2.8%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Lixi ‐ Ratner 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Pancreatitis</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Lixi ‐ Ratner 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Severe hypoglycaemia</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.5</div> <div class="figure-caption"> <p>Comparison 15 Lixisenatide versus placebo, Outcome 5 Adverse events.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01505" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=15.5&amp;caption=Comparison%2015%20Lixisenatide%20versus%20placebo%2C%20Outcome%205%20Adverse%20events.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01506"><img data-id="CD006423-fig-01506" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-015-06.png" alt="Comparison 15 Lixisenatide versus placebo, Outcome 6 Fasting plasma glucose (mmol/L)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.6</div> <div class="figure-caption"> <p>Comparison 15 Lixisenatide versus placebo, Outcome 6 Fasting plasma glucose (mmol/L).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01506" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-015-06.png?filename=nCD006423-CMP-015-06.ppt&amp;title=15.6&amp;caption=Comparison%2015%20Lixisenatide%20versus%20placebo%2C%20Outcome%206%20Fasting%20plasma%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-015-06.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01507"><img data-id="CD006423-fig-01507" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-015-07.png" alt="Comparison 15 Lixisenatide versus placebo, Outcome 7 Post‐prandial glucose (mmol/L)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.7</div> <div class="figure-caption"> <p>Comparison 15 Lixisenatide versus placebo, Outcome 7 Post‐prandial glucose (mmol/L).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01507" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-015-07.png?filename=nCD006423-CMP-015-07.ppt&amp;title=15.7&amp;caption=Comparison%2015%20Lixisenatide%20versus%20placebo%2C%20Outcome%207%20Post%E2%80%90prandial%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-015-07.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01508"><img data-id="CD006423-fig-01508" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-015-08.png" alt="Comparison 15 Lixisenatide versus placebo, Outcome 8 Average self‐monitored 7‐point blood glucose (mmol/L)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.8</div> <div class="figure-caption"> <p>Comparison 15 Lixisenatide versus placebo, Outcome 8 Average self‐monitored 7‐point blood glucose (mmol/L). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01508" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-015-08.png?filename=nCD006423-CMP-015-08.ppt&amp;title=15.8&amp;caption=Comparison%2015%20Lixisenatide%20versus%20placebo%2C%20Outcome%208%20Average%20self%E2%80%90monitored%207%E2%80%90point%20blood%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-015-08.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01601"><img data-id="CD006423-fig-01601" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-016-01.png" alt="Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 1 HbA1c."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.1</div> <div class="figure-caption"> <p>Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 1 HbA1c.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01601" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-016-01.png?filename=nCD006423-CMP-016-01.ppt&amp;title=16.1&amp;caption=Comparison%2016%20Liraglutide%201.2%20mg%20versus%20SU%2C%20Outcome%201%20HbA1c.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-016-01.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01602"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="5" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 1.2 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Glimepiride 4 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Difference between groups</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Yang 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Change in HbA1c</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.36</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.39</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.03, 95% CI ‐0.14 to 0.20</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.2</div> <div class="figure-caption"> <p>Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 2 HbA1c (%).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01602" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=16.2&amp;caption=Comparison%2016%20Liraglutide%201.2%20mg%20versus%20SU%2C%20Outcome%202%20HbA1c%20%28%25%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01603"><img data-id="CD006423-fig-01603" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-016-03.png" alt="Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 3 HbA1c < 7%."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.3</div> <div class="figure-caption"> <p>Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 3 HbA1c &lt; 7%.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01603" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-016-03.png?filename=nCD006423-CMP-016-03.ppt&amp;title=16.3&amp;caption=Comparison%2016%20Liraglutide%201.2%20mg%20versus%20SU%2C%20Outcome%203%20HbA1c%20%3C%207%25.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-016-03.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01604"><img data-id="CD006423-fig-01604" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-016-04.png" alt="Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 4 Hypoglycaemia."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.4</div> <div class="figure-caption"> <p>Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 4 Hypoglycaemia.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01604" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-016-04.png?filename=nCD006423-CMP-016-04.ppt&amp;title=16.4&amp;caption=Comparison%2016%20Liraglutide%201.2%20mg%20versus%20SU%2C%20Outcome%204%20Hypoglycaemia.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-016-04.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01605"><img data-id="CD006423-fig-01605" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-016-05.png" alt="Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 5 Weight change."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.5</div> <div class="figure-caption"> <p>Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 5 Weight change.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01605" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-016-05.png?filename=nCD006423-CMP-016-05.ppt&amp;title=16.5&amp;caption=Comparison%2016%20Liraglutide%201.2%20mg%20versus%20SU%2C%20Outcome%205%20Weight%20change.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-016-05.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01606"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="5" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 1.2 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Glimepiride 4 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>p value</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Yang 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Change from baseline</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐2.35 SD 2.4</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.08</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>LIR 1.2 vs. GLIM: P &lt; 0.0001</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.6</div> <div class="figure-caption"> <p>Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 6 Weight change (kg).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01606" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=16.6&amp;caption=Comparison%2016%20Liraglutide%201.2%20mg%20versus%20SU%2C%20Outcome%206%20Weight%20change%20%28kg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01607"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="4" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 1.2 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Glimepiride 4 mg daily</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>withdrawal due to adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>10%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>withdrawal due to nausea/vomiting/diarrhoea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>no significant differences across groups for: physical examination findings, laboratory analyses, ECG, ophthalmoscopy </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>any GI event</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>40%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>17%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>nausea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>16%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3 to 4%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>vomiting</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5 to7%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>diarrhoea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>serious adverse events: 2 deaths unrelated to liraglutide treatment; 1 participant each in 1.2 mg liraglutide group and in glimepiride group withdrawn due to acute pancreatitis </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>injection site reactions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>anti‐liraglutide antibodies</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Yang 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>withdrawal due to adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9.4%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.3%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Yang 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>serious adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.7 to 3.4%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.7 to 3.4%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Yang 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>pancreatitis</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>none</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>none</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Yang 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>deaths</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>none</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>none</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Yang 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>anti‐liraglutide antibodies</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 8 from all liraglutide groups</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Yang 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Yang 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Yang 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Yang 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Yang 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.7</div> <div class="figure-caption"> <p>Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 7 Adverse events.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01607" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=16.7&amp;caption=Comparison%2016%20Liraglutide%201.2%20mg%20versus%20SU%2C%20Outcome%207%20Adverse%20events.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01608"><img data-id="CD006423-fig-01608" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-016-08.png" alt="Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 8 Systolic blood pressure."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.8</div> <div class="figure-caption"> <p>Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 8 Systolic blood pressure.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01608" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-016-08.png?filename=nCD006423-CMP-016-08.ppt&amp;title=16.8&amp;caption=Comparison%2016%20Liraglutide%201.2%20mg%20versus%20SU%2C%20Outcome%208%20Systolic%20blood%20pressure.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-016-08.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01609"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="5" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 1.2 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Glimepiride 4 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>p values</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Systolic blood pressure, change from baseline</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐2.81 SD 13.32</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.4 SD 13.22</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Diastolic blood pressure, change from baseline</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No change</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No change</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Yang 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Systolic blood pressure, change from baseline</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Reduction of more than 3 mm Hg</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Reduction of 0.91 mm Hg</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Reduction in the liraglutide 1.2 group was significantly higher than that in the glimepiride; p value = NR </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Yang 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Diastolic blood pressure, change from baseline</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A slight decrease in mean diastolic BP was observed</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A slight decrease in mean diastolic BP was observed</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.9</div> <div class="figure-caption"> <p>Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 9 Blood pressure (mm Hg).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01609" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=16.9&amp;caption=Comparison%2016%20Liraglutide%201.2%20mg%20versus%20SU%2C%20Outcome%209%20Blood%20pressure%20%28mm%20Hg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01610"><img data-id="CD006423-fig-01610" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-016-10.png" alt="Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 10 Fasting plasma glucose (mmol/L)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.10</div> <div class="figure-caption"> <p>Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 10 Fasting plasma glucose (mmol/L).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01610" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-016-10.png?filename=nCD006423-CMP-016-10.ppt&amp;title=16.10&amp;caption=Comparison%2016%20Liraglutide%201.2%20mg%20versus%20SU%2C%20Outcome%2010%20Fasting%20plasma%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-016-10.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01611"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="5" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 1.2 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Glimepiride 4 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>p values</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Yang 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Change from baseline</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐2.05</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐2.18</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.11</div> <div class="figure-caption"> <p>Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 11 Fasting plasma glucose (mmol/L).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01611" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=16.11&amp;caption=Comparison%2016%20Liraglutide%201.2%20mg%20versus%20SU%2C%20Outcome%2011%20Fasting%20plasma%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01612"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="5" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 1.2 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Glimepiride 4 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comments</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Self‐monitored 7‐point plasma glucose measurements</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐2.3 mmol/L</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐2.5 mmol/L</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>no significant difference between groups</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Yang 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Self‐monitored 7‐point plasma glucose measurements</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐3.03 mmol/L</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐2.6 mmol/L</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>LIR 1.2 vs. GLIM: P = NS</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.12</div> <div class="figure-caption"> <p>Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 12 Post‐prandial glucose (mmol/L).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01612" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=16.12&amp;caption=Comparison%2016%20Liraglutide%201.2%20mg%20versus%20SU%2C%20Outcome%2012%20Post%E2%80%90prandial%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01613"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="5" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 1.2 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Glimepiride 4 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Difference between groups</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>HOMA‐B (%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>+23%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>+25%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No significant difference between liraglutide and glimepiride groups</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>proinsulin‐to‐insulin ratio</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.1, P &lt; 0.0001 versus placebo</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>similar to liraglutide groups but no value stated</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No significant difference between liraglutide and glimepiride groups</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Yang 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>HOMA‐B</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Increases between 14 and 21% points observed in all treatment groups.</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>see previous column</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No significant difference between liraglutide and glimepiride groups</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Yang 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Proinsulin‐to‐insulin ratio</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A slight decrease between 0.06 and 0.11 observed in all treatment groups.</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>see previous column</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No significant difference between liraglutide and glimepiride groups</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.13</div> <div class="figure-caption"> <p>Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 13 Beta‐cell function.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01613" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=16.13&amp;caption=Comparison%2016%20Liraglutide%201.2%20mg%20versus%20SU%2C%20Outcome%2013%20Beta%E2%80%90cell%20function.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01701"><img data-id="CD006423-fig-01701" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-017-01.png" alt="Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 1 HbA1c (%)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.1</div> <div class="figure-caption"> <p>Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 1 HbA1c (%).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01701" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-017-01.png?filename=nCD006423-CMP-017-01.ppt&amp;title=17.1&amp;caption=Comparison%2017%20Liraglutide%201.8%20mg%20daily%20versus%20SU%2C%20Outcome%201%20HbA1c%20%28%25%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-017-01.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01702"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="5" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 1.8 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Glimepiride 4 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Difference between groups</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Yang 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Change in HbA1c</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.45</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.39</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.06, 95% CI ‐0.23 to 0.11</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.2</div> <div class="figure-caption"> <p>Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 2 HbA1c (%).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01702" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=17.2&amp;caption=Comparison%2017%20Liraglutide%201.8%20mg%20daily%20versus%20SU%2C%20Outcome%202%20HbA1c%20%28%25%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01703"><img data-id="CD006423-fig-01703" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-017-03.png" alt="Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 3 HbA1c < 7%."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.3</div> <div class="figure-caption"> <p>Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 3 HbA1c &lt; 7%.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01703" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-017-03.png?filename=nCD006423-CMP-017-03.ppt&amp;title=17.3&amp;caption=Comparison%2017%20Liraglutide%201.8%20mg%20daily%20versus%20SU%2C%20Outcome%203%20HbA1c%20%3C%207%25.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-017-03.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01704"><img data-id="CD006423-fig-01704" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-017-04.png" alt="Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 4 Hypoglycaemia."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.4</div> <div class="figure-caption"> <p>Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 4 Hypoglycaemia.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01704" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-017-04.png?filename=nCD006423-CMP-017-04.ppt&amp;title=17.4&amp;caption=Comparison%2017%20Liraglutide%201.8%20mg%20daily%20versus%20SU%2C%20Outcome%204%20Hypoglycaemia.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-017-04.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01705"><img data-id="CD006423-fig-01705" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-017-05.png" alt="Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 5 Weight change (kg)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.5</div> <div class="figure-caption"> <p>Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 5 Weight change (kg).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01705" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-017-05.png?filename=nCD006423-CMP-017-05.ppt&amp;title=17.5&amp;caption=Comparison%2017%20Liraglutide%201.8%20mg%20daily%20versus%20SU%2C%20Outcome%205%20Weight%20change%20%28kg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-017-05.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01706"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="5" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 1.8 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Glimepiride 4 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>p value</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Yang 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Change from baseline</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐2.44 SD 2.6</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.08</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>LIR 1.8 vs. GLIM: P &lt; 0.0001</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.6</div> <div class="figure-caption"> <p>Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 6 Weight change (kg).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01706" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=17.6&amp;caption=Comparison%2017%20Liraglutide%201.8%20mg%20daily%20versus%20SU%2C%20Outcome%206%20Weight%20change%20%28kg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01707"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="4" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 1.8 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Glimepiride 4 mg daily</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>withdrawal due to adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>12%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>withdrawal due to nausea/vomiting/diarrhoea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>no significant differences across groups for: physical examination findings, laboratory analyses, ECG, ophthalmoscopy </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>any GI event</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>44%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>17%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>nausea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>19%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3 to 4%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>vomiting</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5 to 7%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>diarrhoea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>15%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>serious adverse events: 2 deaths unrelated to liraglutide treatment; 1 participant each in 1.2 mg liraglutide group and in glimepiride group withdrawn due to acute pancreatitis </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>injection site reactions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>anti‐liraglutide antibodies</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Yang 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>withdrawal due to adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>12.9%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.3%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Yang 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>serious adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.7 to 3.4%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.7 to 3.4%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Yang 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>pancreatitis</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>none</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>none</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Yang 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>deaths</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>none</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>none</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Yang 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>anti‐liraglutide antibodies</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 8 from all liraglutide groups</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Yang 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Yang 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Yang 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Yang 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Yang 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.7</div> <div class="figure-caption"> <p>Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 7 Adverse events.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01707" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=17.7&amp;caption=Comparison%2017%20Liraglutide%201.8%20mg%20daily%20versus%20SU%2C%20Outcome%207%20Adverse%20events.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01708"><img data-id="CD006423-fig-01708" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-017-08.png" alt="Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 8 Systolic blood pressure (mm Hg)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.8</div> <div class="figure-caption"> <p>Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 8 Systolic blood pressure (mm Hg). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01708" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-017-08.png?filename=nCD006423-CMP-017-08.ppt&amp;title=17.8&amp;caption=Comparison%2017%20Liraglutide%201.8%20mg%20daily%20versus%20SU%2C%20Outcome%208%20Systolic%20blood%20pressure%20%28mm%20Hg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-017-08.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01709"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="5" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 1.8 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Glimepiride 4 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>p values</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Systolic blood pressure, change from baseline</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐2.29 SD 12.91</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.4 SD 13.22</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Diastolic blood pressure, change from baseline</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No change</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No change</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Yang 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Systolic blood pressure, change from baseline</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Reduction of more than 3 mm Hg</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Reduction of 0.91 mm Hg</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Reduction in the liraglutide 1.2 group was significantly higher than that in the glimepiride; p value = NR </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Yang 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Diastolic blood pressure, change from baseline</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A slight decrease in mean diastolic BP was observed</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A slight decrease in mean diastolic BP was observed</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.9</div> <div class="figure-caption"> <p>Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 9 Blood pressure (mm Hg).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01709" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=17.9&amp;caption=Comparison%2017%20Liraglutide%201.8%20mg%20daily%20versus%20SU%2C%20Outcome%209%20Blood%20pressure%20%28mm%20Hg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01710"><img data-id="CD006423-fig-01710" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-017-10.png" alt="Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 10 Fasting plasma glucose (mmol/L)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.10</div> <div class="figure-caption"> <p>Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 10 Fasting plasma glucose (mmol/L). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01710" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-017-10.png?filename=nCD006423-CMP-017-10.ppt&amp;title=17.10&amp;caption=Comparison%2017%20Liraglutide%201.8%20mg%20daily%20versus%20SU%2C%20Outcome%2010%20Fasting%20plasma%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-017-10.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01711"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="5" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 1.8 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Glimepiride 4 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>p values</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Yang 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Change from baseline</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐2.12</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐2.18</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.11</div> <div class="figure-caption"> <p>Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 11 Fasting plasma glucose (mmol/L). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01711" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=17.11&amp;caption=Comparison%2017%20Liraglutide%201.8%20mg%20daily%20versus%20SU%2C%20Outcome%2011%20Fasting%20plasma%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01712"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="5" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 1.8 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Glimepiride 4 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comments</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Self‐monitored 7‐point plasma glucose measurements</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐2.6 mmol/L</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐2.5 mmol/L</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>no significant difference between groups</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Yang 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Self‐monitored 7‐point plasma glucose measurements</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐3.51 mmol/L</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐2.6 mmol/L</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>LIR 1.8 vs. GLIM: P &lt; 0.0001</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.12</div> <div class="figure-caption"> <p>Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 12 Post‐prandial glucose (mmol/L). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01712" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=17.12&amp;caption=Comparison%2017%20Liraglutide%201.8%20mg%20daily%20versus%20SU%2C%20Outcome%2012%20Post%E2%80%90prandial%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01713"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="5" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 1.8 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Glimepiride 4 mg daily</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Difference between groups</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>HOMA‐B (%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>+28%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>+25%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No significant difference between liraglutide and glimepiride groups</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 2 Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Proinsulin‐to‐insulin ratio</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.1, P &lt; 0.0001 versus placebo</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>similar to liraglutide groups but no value stated</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No significant difference between liraglutide and glimepiride groups</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Yang 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>HOMA‐B</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Increases between 14% and 21% points observed in all treatment groups.</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>see previous column</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No significant difference between liraglutide and glimepiride groups</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ Yang 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Proinsulin‐to‐insulin ratio</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A slight decrease between 0.06 and 0.11 observed in all treatment groups.</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>see previous column</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No significant difference between liraglutide and glimepiride groups</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.13</div> <div class="figure-caption"> <p>Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 13 Beta‐cell function.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01713" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=17.13&amp;caption=Comparison%2017%20Liraglutide%201.8%20mg%20daily%20versus%20SU%2C%20Outcome%2013%20Beta%E2%80%90cell%20function.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01801"><img data-id="CD006423-fig-01801" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-018-01.png" alt="Comparison 18 Taspoglutide versus placebo, Outcome 1 HbA1c (%)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.1</div> <div class="figure-caption"> <p>Comparison 18 Taspoglutide versus placebo, Outcome 1 HbA1c (%).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01801" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-018-01.png?filename=nCD006423-CMP-018-01.ppt&amp;title=18.1&amp;caption=Comparison%2018%20Taspoglutide%20versus%20placebo%2C%20Outcome%201%20HbA1c%20%28%25%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-018-01.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01802"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="4" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>20/30 mg (n = 33)</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>20/40 mg (n = 32)</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Placebo (n = 32)</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>T‐ Ratner 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.90 SD 0.57, P &lt; 0.0001 versus placebo</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.20 SD 0.57, P &lt; 0.0001 versus placebo</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.50 SD 0.57</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.2</div> <div class="figure-caption"> <p>Comparison 18 Taspoglutide versus placebo, Outcome 2 HbA1c (%).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01802" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=18.2&amp;caption=Comparison%2018%20Taspoglutide%20versus%20placebo%2C%20Outcome%202%20HbA1c%20%28%25%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01803"><img data-id="CD006423-fig-01803" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-018-03.png" alt="Comparison 18 Taspoglutide versus placebo, Outcome 3 HbA1c < 7%."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.3</div> <div class="figure-caption"> <p>Comparison 18 Taspoglutide versus placebo, Outcome 3 HbA1c &lt; 7%.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01803" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-018-03.png?filename=nCD006423-CMP-018-03.ppt&amp;title=18.3&amp;caption=Comparison%2018%20Taspoglutide%20versus%20placebo%2C%20Outcome%203%20HbA1c%20%3C%207%25.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-018-03.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01804"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="4" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>20/30 mg once weekly</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>20/40 mg once weekly</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Placebo</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>T‐ Ratner 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>53%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>70%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>19%</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.4</div> <div class="figure-caption"> <p>Comparison 18 Taspoglutide versus placebo, Outcome 4 HbA1c &lt; 7%.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01804" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=18.4&amp;caption=Comparison%2018%20Taspoglutide%20versus%20placebo%2C%20Outcome%204%20HbA1c%20%3C%207%25.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01805"><img data-id="CD006423-fig-01805" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-018-05.png" alt="Comparison 18 Taspoglutide versus placebo, Outcome 5 Hypoglycaemia."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.5</div> <div class="figure-caption"> <p>Comparison 18 Taspoglutide versus placebo, Outcome 5 Hypoglycaemia.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01805" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-018-05.png?filename=nCD006423-CMP-018-05.ppt&amp;title=18.5&amp;caption=Comparison%2018%20Taspoglutide%20versus%20placebo%2C%20Outcome%205%20Hypoglycaemia.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-018-05.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01806"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>T ‐ Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>hypoglycaemia not defined; no data reported for the separate comparison groups; overall, there were 7 hypoglycaemic events in 6 patients, 2 of which were asymptomatic; </p> <p>there were no cases of severe hypoglycaemia in the taspoglutide group</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.6</div> <div class="figure-caption"> <p>Comparison 18 Taspoglutide versus placebo, Outcome 6 Hypoglycaemia.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01806" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=18.6&amp;caption=Comparison%2018%20Taspoglutide%20versus%20placebo%2C%20Outcome%206%20Hypoglycaemia.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01807"><img data-id="CD006423-fig-01807" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-018-07.png" alt="Comparison 18 Taspoglutide versus placebo, Outcome 7 Weight change (kg)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.7</div> <div class="figure-caption"> <p>Comparison 18 Taspoglutide versus placebo, Outcome 7 Weight change (kg).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01807" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-018-07.png?filename=nCD006423-CMP-018-07.ppt&amp;title=18.7&amp;caption=Comparison%2018%20Taspoglutide%20versus%20placebo%2C%20Outcome%207%20Weight%20change%20%28kg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-018-07.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01808"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="4" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>20/30 mg once weekly</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>20/40 mg once weekly</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Placebo</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>T‐ Ratner 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐3 SD 1.72, P = 0.03 versus placebo</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐2.7 SD 2.26, P = 0.17 versus placebo</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐2 SD 1.70</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.8</div> <div class="figure-caption"> <p>Comparison 18 Taspoglutide versus placebo, Outcome 8 Weight change.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01808" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=18.8&amp;caption=Comparison%2018%20Taspoglutide%20versus%20placebo%2C%20Outcome%208%20Weight%20change.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01809"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="6" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>20/20 mg once weekly</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>20/30 mg once weekly</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>20/40 mg once weekly</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Placebo</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>T‐ Ratner 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Withdrawal due to adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 3</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 6</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 6</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 1</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>T‐ Ratner 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Nausea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>38%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>52%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>34%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>13%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>T‐ Ratner 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Headache</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>16%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>13%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>T‐ Ratner 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Diarrhoea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>13%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>21%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>T‐ Ratner 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Vomiting</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>13%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>27%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>13%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>T‐ Ratner 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Dyspepsia</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>19%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>15%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>16%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>T‐ Ratner 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Abdominal distension</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>12%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>T‐ Ratner 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Injection site reactions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>69%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>52%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>59%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>13%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>T‐ Ratner 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>serious adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 1, unrelated to study drug</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 1, unrelated to study drug</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>T‐ Ratner 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>severe hypoglycaemia</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.9</div> <div class="figure-caption"> <p>Comparison 18 Taspoglutide versus placebo, Outcome 9 Adverse events.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01809" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=18.9&amp;caption=Comparison%2018%20Taspoglutide%20versus%20placebo%2C%20Outcome%209%20Adverse%20events.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01810"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="6" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>10 mg weekly</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>20 mg weekly</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>20 mg every 2 weeks</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Placebo</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>T ‐ Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>withdrawal due to adverse event</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 2</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 3</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 1</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 0</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>T ‐ Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>adverse events similar across groups for: headache</p> <p>no clinically relevant abnormalities in ECG, vital signs, laboratory parameters</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>T ‐ Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>nausea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 12 (24%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 26 (52%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 20 (41%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 3 (6%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>T ‐ Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>vomiting</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 2 (4%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 11 (22%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 12 (24%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 2 (4%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>T ‐ Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>diarrhoea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 5 (10%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 5 (10%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 9 (18%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 4 (8%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>T ‐ Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>serious adverse events: 6 patients, 2 of which in placebo group</p> <p>considered to be unrelated to study treatment</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>T ‐ Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>mild and moderate injection site reactions which did not result in treatment discontinuation</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.10</div> <div class="figure-caption"> <p>Comparison 18 Taspoglutide versus placebo, Outcome 10 Adverse events.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01810" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=18.10&amp;caption=Comparison%2018%20Taspoglutide%20versus%20placebo%2C%20Outcome%2010%20Adverse%20events.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01811"><img data-id="CD006423-fig-01811" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-018-11.png" alt="Comparison 18 Taspoglutide versus placebo, Outcome 11 Fasting plasma glucose (mmol/L)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.11</div> <div class="figure-caption"> <p>Comparison 18 Taspoglutide versus placebo, Outcome 11 Fasting plasma glucose (mmol/L).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01811" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-018-11.png?filename=nCD006423-CMP-018-11.ppt&amp;title=18.11&amp;caption=Comparison%2018%20Taspoglutide%20versus%20placebo%2C%20Outcome%2011%20Fasting%20plasma%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-018-11.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01812"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="6" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>10 mg once weekly</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>20 mg once weekly</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>20 mg every 2 weeks</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Placebo</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>FPG fluctuations</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>T ‐ Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐2.5 mmol/L, P &lt; 0.0001</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐2.5 mmol/L, P &lt; 0.0001</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.4 mmol/L, P = 0.02</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.78 mmol/L</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>the fluctuation in FPG was less for the weekly regimens than for the dosing once every 2 weeks: </p> <p>0.6 mmol/L amplitude between week 2 and week 8 for both 10 mg and 20 mg per week versus 1.3 mmol/L amplitude between week 2 and week 8 for 20 mg every 2 weeks </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.12</div> <div class="figure-caption"> <p>Comparison 18 Taspoglutide versus placebo, Outcome 12 Fasting plasma glucose.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01812" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=18.12&amp;caption=Comparison%2018%20Taspoglutide%20versus%20placebo%2C%20Outcome%2012%20Fasting%20plasma%20glucose.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01813"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="6" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>10 mg once weekly</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>20 mg once weekly</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>20 mg every 2 weeks</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Placebo</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>T ‐ Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>plasma glucose 120 min after a mixed meal (% change from baseline)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐22.0%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐18.0%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐5.5%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐10.5%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>T ‐ Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>glucose AUC (% change from baseline)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐27.5% (SE 3.2)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐22.2% (SE 3.3)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐9.2% (SE 5.0)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐7.2% (SE3 .5)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>T ‐ Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>mean % change in plasma insulin at 120 min</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>+28.5%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>+44.9%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐13%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐15.3%</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.13</div> <div class="figure-caption"> <p>Comparison 18 Taspoglutide versus placebo, Outcome 13 Postprandial glucose and insulin.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01813" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=18.13&amp;caption=Comparison%2018%20Taspoglutide%20versus%20placebo%2C%20Outcome%2013%20Postprandial%20glucose%20and%20insulin.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01814"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="6" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>10 mg once weekly</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>20 mg once weekly</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>20 mg every 2 weeks</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Placebo</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>T ‐ Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Triglycerides (mmol/L)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.29 mmol/L</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.54 mmol/L</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.30 mmol/L</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>+0.10 mmol/L</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>T ‐ Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Total cholesterol (mmol/L)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.31 mmol/L</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.23 mmol/L</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.31 mmol/L</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>+0.18 mmol/L</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>T ‐ Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>HDL (mmol/L)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.05 mmol/L</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.03 mmol/L</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>+0 mmol/L</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>+0 mmol/L</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>T ‐ Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>LDL (mmol/L)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.21 mmol/L</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>+0.03 mmol/L</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.16 mmol/L</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>+0.13 mmol/L</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.14</div> <div class="figure-caption"> <p>Comparison 18 Taspoglutide versus placebo, Outcome 14 Lipid profiles.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01814" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=18.14&amp;caption=Comparison%2018%20Taspoglutide%20versus%20placebo%2C%20Outcome%2014%20Lipid%20profiles.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01815"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="6" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>10 mg once weekly</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>20 mg once weekly</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>20 mg every 2 weeks</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Placebo</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>T ‐ Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>proinsulin‐to‐insulin ratio</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.12, P = 0.0076</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.166, P = 0.0003</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.055, P = NS</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.002</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.15</div> <div class="figure-caption"> <p>Comparison 18 Taspoglutide versus placebo, Outcome 15 Beta‐cell function.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01815" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=18.15&amp;caption=Comparison%2018%20Taspoglutide%20versus%20placebo%2C%20Outcome%2015%20Beta%E2%80%90cell%20function.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01816"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="5" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>10 mg once weekly</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>20 mg once weekly</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>20 mg every 2 weeks</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Placebo</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" valign="" colspan="5" rowspan="1" bgcolor="#ffffff"> <p><b>Participants with HbA1c ≥8%</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>T ‐ Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.5%, P &lt; 0.0001 versus placebo</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.4%, P &lt; 0.0001 versus placebo</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.3%, P &lt; 0.0001 versus placebo</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.3%</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.16</div> <div class="figure-caption"> <p>Comparison 18 Taspoglutide versus placebo, Outcome 16 Subgroup.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01816" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=18.16&amp;caption=Comparison%2018%20Taspoglutide%20versus%20placebo%2C%20Outcome%2016%20Subgroup.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01901"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>LY 0.5/1.0 QW</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>LY 1.0/1.0 QW</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>LY 1.0/2.0 QW</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Placebo</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>p values</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>LY2189265 ‐Umpierrez 2011</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Change in HbA1c</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.38 SE 0.12</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.32 SE 0.12</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.59 SE 0.12</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not reported</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>All LY groups vs. placebo: P &lt; 0.001;</p> <p>Between LY groups: P &gt; 0.05</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.1</div> <div class="figure-caption"> <p>Comparison 19 LY2189265 versus placebo, Outcome 1 HbA1c.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01901" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=19.1&amp;caption=Comparison%2019%20LY2189265%20versus%20placebo%2C%20Outcome%201%20HbA1c.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01902"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Result</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>LY2189265 ‐Umpierrez 2011</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>HbA1c &lt; 7%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>49 to 54% of participants achieved a target HbA1c level of &lt; 7% at 16 weeks</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.2</div> <div class="figure-caption"> <p>Comparison 19 LY2189265 versus placebo, Outcome 2 HbA1c &lt; 7%.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01902" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=19.2&amp;caption=Comparison%2019%20LY2189265%20versus%20placebo%2C%20Outcome%202%20HbA1c%20%3C%207%25.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01903"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="6" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>LY 0.5/1.0</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>LY 1.0/1.0</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>LY 1.0/2.0</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Placebo</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" valign="" colspan="6" rowspan="1" bgcolor="#ffffff"> <p><b>LY 0.5/1.0 QW</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>LY2189265 ‐Umpierrez 2011</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Oveall hypoglycaemic episodes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 183</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 237</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 164</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 84</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>LY2189265 ‐Umpierrez 2011</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>number of hypoglycaemic episodes at 4 weeks</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 68</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 85</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 56</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 16</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>LY2189265 ‐Umpierrez 2011</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>number of hypoglycaemic episodes at 8 weeks</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 59</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 55</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 47</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 18</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>LY2189265 ‐Umpierrez 2011</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>number of hypoglycaemic episodes at 16 weeks</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 19</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 35</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 23</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 16</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>LY2189265 ‐Umpierrez 2011</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>severe hypoglycaemia</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.3</div> <div class="figure-caption"> <p>Comparison 19 LY2189265 versus placebo, Outcome 3 Hypoglycaemia.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01903" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=19.3&amp;caption=Comparison%2019%20LY2189265%20versus%20placebo%2C%20Outcome%203%20Hypoglycaemia.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01904"><img data-id="CD006423-fig-01904" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-019-04.png" alt="Comparison 19 LY2189265 versus placebo, Outcome 4 Weight change (kg)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.4</div> <div class="figure-caption"> <p>Comparison 19 LY2189265 versus placebo, Outcome 4 Weight change (kg).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01904" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-019-04.png?filename=nCD006423-CMP-019-04.ppt&amp;title=19.4&amp;caption=Comparison%2019%20LY2189265%20versus%20placebo%2C%20Outcome%204%20Weight%20change%20%28kg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-019-04.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01905"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>LY 0.5/1.0 QW</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>LY 1.0/1.0 QW</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>LY 1.0/2.0 QW</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Placebo</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>comments</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>LY2189265 ‐Umpierrez 2011</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>withdrawal due to adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3 (4.5%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4 (6.2%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4 (6.2%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1 (1.5%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>LY2189265 ‐Umpierrez 2011</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>nausea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9 (13.6%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>11 (16.9%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9 (13.8%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5 (7.6%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Nausea occurred more commonly in participants receiving LY.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>LY2189265 ‐Umpierrez 2011</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>diarrhoea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5 (7.6)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4 (6.2%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9 (13.8%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5 (7.6%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Higher LY dosage was generally associated with a higher prevalence of adverse events.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>LY2189265 ‐Umpierrez 2011</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>abdominal distention</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3 (4.5%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5 (7.7%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9 (13.8%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4 (6.1%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Higher LY dosage was generally associated with a higher prevalence of adverse events.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>LY2189265 ‐Umpierrez 2011</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>vomiting</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3 (4.5%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1 (1.5%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7 (10.8%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2 (3.0%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Higher LY dosage was generally associated with a higher prevalence of adverse events.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>LY2189265 ‐Umpierrez 2011</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Pancreatitis</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Both cases related to study drug. One participant approximately 5 months after last dose of LY 0.5/1.0, later this was regarded as serious. Second participant after the 11th weekly dose of LY 0.5/1.0 had approximately 1.5‐ and 2.5‐fold increase in amylase and lipase levels respectively with no obvious symptom or abnormality in the pancreas during abodominal CT scan. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>LY2189265 ‐Umpierrez 2011</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>possibly LY related adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>22 (33.3%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>20 (30.8%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>27 (41.5%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>15 (22.7%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>LY2189265 ‐Umpierrez 2011</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>serious adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3 (4.5%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2 (3.1%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1 (1.5%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1 (1.5%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>three serious adverse events related to study drug and included hallucination, cryptogenic organizing pneumonia and pancreatitis </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>LY2189265 ‐Umpierrez 2011</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>deaths</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.5</div> <div class="figure-caption"> <p>Comparison 19 LY2189265 versus placebo, Outcome 5 Adverse events.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01905" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=19.5&amp;caption=Comparison%2019%20LY2189265%20versus%20placebo%2C%20Outcome%205%20Adverse%20events.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01906"><img data-id="CD006423-fig-01906" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-019-06.png" alt="Comparison 19 LY2189265 versus placebo, Outcome 6 Systolic blood pressure (mm Hg)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.6</div> <div class="figure-caption"> <p>Comparison 19 LY2189265 versus placebo, Outcome 6 Systolic blood pressure (mm Hg).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01906" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-019-06.png?filename=nCD006423-CMP-019-06.ppt&amp;title=19.6&amp;caption=Comparison%2019%20LY2189265%20versus%20placebo%2C%20Outcome%206%20Systolic%20blood%20pressure%20%28mm%20Hg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-019-06.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01907"><img data-id="CD006423-fig-01907" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-019-07.png" alt="Comparison 19 LY2189265 versus placebo, Outcome 7 Diastolic blood pressure (mm Hg)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.7</div> <div class="figure-caption"> <p>Comparison 19 LY2189265 versus placebo, Outcome 7 Diastolic blood pressure (mm Hg).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01907" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-019-07.png?filename=nCD006423-CMP-019-07.ppt&amp;title=19.7&amp;caption=Comparison%2019%20LY2189265%20versus%20placebo%2C%20Outcome%207%20Diastolic%20blood%20pressure%20%28mm%20Hg%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-019-07.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01908"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>LY 0.5/1.0 QW</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>LY 1.0/1.0 QW</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>LY 1.0/2.0 QW</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Placebo</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>p values</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>LY2189265 ‐Umpierrez 2011</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Change in FPG</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐2.10</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐2.05</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐2.65</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.49</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>All LY groups vs. placebo: P &lt; 0.001;</p> <p>Between LY groups: P &gt; 0.05</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.8</div> <div class="figure-caption"> <p>Comparison 19 LY2189265 versus placebo, Outcome 8 Fasting plasma glucose (mmol/L).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01908" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=19.8&amp;caption=Comparison%2019%20LY2189265%20versus%20placebo%2C%20Outcome%208%20Fasting%20plasma%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-01909"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>LY 0.5/1.0 QW</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>LY 1.0/1.0 QW</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>LY 1.0/2.0 QW</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Placebo</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>p values</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>LY2189265 ‐Umpierrez 2011</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>β‐cell function (HOMA2‐%B)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>39.2 SE 45.6%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>44.3 SE 93.9%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>45.6 SE 55.2%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.0 SE 41.1%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>All LY groups vs. placebo: P &lt; 0.01</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>LY2189265 ‐Umpierrez 2011</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insulin sensitivity (HOMA2‐%S)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not reported</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not reported</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not reported</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not reported</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No statistically significant change in all LY groups</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>LY2189265 ‐Umpierrez 2011</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insulin resistance (HOMA2‐%IR)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not reported</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not reported</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not reported</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not reported</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No statistically significant change in all LY groups</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.9</div> <div class="figure-caption"> <p>Comparison 19 LY2189265 versus placebo, Outcome 9 Beta‐cell function.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-01909" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=19.9&amp;caption=Comparison%2019%20LY2189265%20versus%20placebo%2C%20Outcome%209%20Beta%E2%80%90cell%20function.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-02001"><img data-id="CD006423-fig-02001" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-020-01.png" alt="Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 1 HbA1c."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.1</div> <div class="figure-caption"> <p>Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 1 HbA1c.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-02001" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-020-01.png?filename=nCD006423-CMP-020-01.ppt&amp;title=20.1&amp;caption=Comparison%2020%20GLP%E2%80%901%20agonist%20versus%20GLP%E2%80%901%20agonist%2C%20Outcome%201%20HbA1c.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-020-01.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-02002"><img data-id="CD006423-fig-02002" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-020-02.png" alt="Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 2 HbA1c < 7%."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.2</div> <div class="figure-caption"> <p>Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 2 HbA1c &lt; 7%.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-02002" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-020-02.png?filename=nCD006423-CMP-020-02.ppt&amp;title=20.2&amp;caption=Comparison%2020%20GLP%E2%80%901%20agonist%20versus%20GLP%E2%80%901%20agonist%2C%20Outcome%202%20HbA1c%20%3C%207%25.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-020-02.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-02003"><img data-id="CD006423-fig-02003" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-020-03.png" alt="Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 3 Hypoglycaemia."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.3</div> <div class="figure-caption"> <p>Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 3 Hypoglycaemia.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-02003" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-020-03.png?filename=nCD006423-CMP-020-03.ppt&amp;title=20.3&amp;caption=Comparison%2020%20GLP%E2%80%901%20agonist%20versus%20GLP%E2%80%901%20agonist%2C%20Outcome%203%20Hypoglycaemia.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-020-03.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-02004"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="4" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Exenatide 10 µg BID</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Exenatide 2 mg QW</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Blevins 2011</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Minor hypoglycaemia occured only among participants using a concomitant SU (n = 74)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 4</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>n = 5</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Blevins 2011</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Major hypoglycaemia</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>None</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>None</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.4</div> <div class="figure-caption"> <p>Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 4 Hypoglycaemia.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-02004" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=20.4&amp;caption=Comparison%2020%20GLP%E2%80%901%20agonist%20versus%20GLP%E2%80%901%20agonist%2C%20Outcome%204%20Hypoglycaemia.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-02005"><img data-id="CD006423-fig-02005" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-020-05.png" alt="Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 5 Weight change."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.5</div> <div class="figure-caption"> <p>Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 5 Weight change.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-02005" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-020-05.png?filename=nCD006423-CMP-020-05.ppt&amp;title=20.5&amp;caption=Comparison%2020%20GLP%E2%80%901%20agonist%20versus%20GLP%E2%80%901%20agonist%2C%20Outcome%205%20Weight%20change.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-020-05.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-02006"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="5" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Exenatide 10 µg BID</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Exenatide 2 mg QW</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Difference between groups</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Blevins 2011</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Change in weight (kg)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.4</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐2.3</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.95 (95% CI ‐1.9 to 0.01)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Blevins 2011</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Proportion of participants experiencing weight loss by end of study, n (%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>77 (63)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>99 (77)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NR</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.6</div> <div class="figure-caption"> <p>Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 6 Weight change.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-02006" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=20.6&amp;caption=Comparison%2020%20GLP%E2%80%901%20agonist%20versus%20GLP%E2%80%901%20agonist%2C%20Outcome%206%20Weight%20change.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-02007"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="4" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Exenatide 10 µg BID</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Other GLP1 agonist</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" valign="" colspan="4" rowspan="1" bgcolor="#ffffff"> <p><b>versus Liraglutide</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 6 Buse 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Diabetes Treatment Satisfaction Questionnaire (6 of 8 items)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>13.3 SD6.94</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>15.18 SD 7.36, P = 0.0004 versus exenatide 10 µg BID</p> </td> </tr> <tr> <td align="center" valign="" colspan="4" rowspan="1" bgcolor="#ffffff"> <p><b>versus Exenatide 2 mg once weekly</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Drucker 2008</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Diabetes Treatment Satisfaction Questionnaire (8 of 8 items)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>29.97</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>31.17, P = NS versus exenatide 10 µg BID</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.7</div> <div class="figure-caption"> <p>Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 7 Treatment satisfaction.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-02007" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=20.7&amp;caption=Comparison%2020%20GLP%E2%80%901%20agonist%20versus%20GLP%E2%80%901%20agonist%2C%20Outcome%207%20Treatment%20satisfaction.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-02008"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="4" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Exenatide 10 µg BID</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Other GLP1 agonist</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" valign="" colspan="4" rowspan="1" bgcolor="#ffffff"> <p><b>versus Liraglutide</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 6 Buse 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>withdrawal due to adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>13%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>10%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 6 Buse 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>overall rate of adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>78.9%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>74.9%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 6 Buse 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>no significant differences across groups for: infections, headache, back pain, metabolism an nutrition disorders, general disorders and administration‐site conditions; 1 episode of mild pancreatitis in liraglutide group (considered to be chronic and unrelated to treatment </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 6 Buse 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>nausea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>28.0%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>25.5%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 6 Buse 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>diarrhoea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>12.1%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>12.3%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 6 Buse 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>dyspepsia</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.7%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8.9%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 6 Buse 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>vomiting</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9.9%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6.0%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 6 Buse 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>constipation</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.6%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.1%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 6 Buse 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>serious adverse events (only on event considered to be related to study medication (exenatide, severe hypoglycaemia)) </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.6%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.1%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 6 Buse 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>severe adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.7%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.2%</p> </td> </tr> <tr> <td align="center" valign="" colspan="4" rowspan="1" bgcolor="#ffffff"> <p><b>versus Exenatide 2 mg once weekly</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Blevins 2011</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>withdrawal due to adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Blevins 2011</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>nausea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>35%; events: n = 51</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>14%; events: n = 21</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Blevins 2011</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>vomiting</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8.9%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.7%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Blevins 2011</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>diarrhoea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.1%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9.3%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Blevins 2011</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>headache</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8.1%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.7%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Blevins 2011</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>dizziness</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6.5%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.3%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Blevins 2011</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>upper respiratory tract infection</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.1%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.0%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Blevins 2011</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>injection site erythema</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.4%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.4%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Blevins 2011</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>serious adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4%; one fatal myocardial infarction</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2%, one participant with a history of dyslipidemia was hospitalised and withdrew due to a diagnosis of pancreatitis. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Blevins 2011</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>anti‐exenatide antibody levels</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>51% participants positive for treatment‐emergent antibodies to exenatide</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>73% participants positive for treatment‐emergent antibodies to exenatide</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Drucker 2008</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>withdrawal due to adverse events</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.4%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6.1%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Drucker 2008</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>no clinically significant abnormalities in vital signs, ECG reports, haematological, chemistry or urinalysis values; no major hypoglycaemia </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Drucker 2008</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>nausea</p> <p>(modestly greater weight loss in people with nausea, but participants without nausea also lost weight) </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>34.5%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>26.4%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Drucker 2008</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>diarrhoea</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>13.1%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>13.5%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Drucker 2008</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>vomiting</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>18.6%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>10.8%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Drucker 2008</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>constipation</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6.2%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>10.8%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Drucker 2008</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>injection site pruritus</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.4%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>17.6%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Drucker 2008</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>injection site bruising</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>10.3%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.7%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Drucker 2008</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>serious adverse events (none considered to be related to study treatment)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.4%</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.4%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Drucker 2008</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>anti‐exenatide antibody levels</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>significantly more anti‐exenatide antibodies with exenatide once weekly, but mostly not detectable or low titre </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.8</div> <div class="figure-caption"> <p>Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 8 Adverse events.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-02008" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=20.8&amp;caption=Comparison%2020%20GLP%E2%80%901%20agonist%20versus%20GLP%E2%80%901%20agonist%2C%20Outcome%208%20Adverse%20events.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-02009"><img data-id="CD006423-fig-02009" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-020-09.png" alt="Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 9 Systolic blood pressure."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.9</div> <div class="figure-caption"> <p>Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 9 Systolic blood pressure.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-02009" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-020-09.png?filename=nCD006423-CMP-020-09.ppt&amp;title=20.9&amp;caption=Comparison%2020%20GLP%E2%80%901%20agonist%20versus%20GLP%E2%80%901%20agonist%2C%20Outcome%209%20Systolic%20blood%20pressure.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-020-09.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-02010"><img data-id="CD006423-fig-02010" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-020-10.png" alt="Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 10 Fasting plasma glucose (mmol/L)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.10</div> <div class="figure-caption"> <p>Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 10 Fasting plasma glucose (mmol/L). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-02010" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-020-10.png?filename=nCD006423-CMP-020-10.ppt&amp;title=20.10&amp;caption=Comparison%2020%20GLP%E2%80%901%20agonist%20versus%20GLP%E2%80%901%20agonist%2C%20Outcome%2010%20Fasting%20plasma%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-020-10.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-02011"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="5" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Exenatide 10 µg BID</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Other GLP1 agonist</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comments</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" valign="" colspan="5" rowspan="1" bgcolor="#ffffff"> <p><b>versus Liraglutide</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 6 Buse 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>from self‐monitored 7‐point plasma glucose measurements</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>after breakfast: 8.9 SE 0.4 mmol/L</p> <p>after dinner: 7.8 SE 0.4 mmol/L</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>after breakfast: 9.7 SE 0.5 mmol/L</p> <p>after dinner: 8.2 SE 0.3 mmol/L</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Exenatide reduced post‐prandial plasma glucose increment more than did liraglutide after breakfast and dinner; treatment difference after lunch was not significant. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 6 Buse 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="center" valign="" colspan="5" rowspan="1" bgcolor="#ffffff"> <p><b>versus Exenatide 2 mg once weekly</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Drucker 2008</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>from self‐monitored 7‐point plasma glucose measurements</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>both treatments reduced post‐prandial values compared to baseline</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E ‐ Drucker 2008</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2 h post‐prandial glucose, meal tolerance test (n = 51)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐6.9 mmol/L SE 0.5</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐5.3 mmol/L SE 0.5</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>P = 0.0124</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.11</div> <div class="figure-caption"> <p>Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 11 Post‐prandial glucose (mmol/L). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-02011" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=20.11&amp;caption=Comparison%2020%20GLP%E2%80%901%20agonist%20versus%20GLP%E2%80%901%20agonist%2C%20Outcome%2011%20Post%E2%80%90prandial%20glucose%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-02012"><img data-id="CD006423-fig-02012" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-020-12.png" alt="Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 12 Triglycerides (mmol/L)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.12</div> <div class="figure-caption"> <p>Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 12 Triglycerides (mmol/L).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-02012" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-020-12.png?filename=nCD006423-CMP-020-12.ppt&amp;title=20.12&amp;caption=Comparison%2020%20GLP%E2%80%901%20agonist%20versus%20GLP%E2%80%901%20agonist%2C%20Outcome%2012%20Triglycerides%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-020-12.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-02013"><img data-id="CD006423-fig-02013" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-020-13.png" alt="Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 13 Total cholesterol (mmol/L)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.13</div> <div class="figure-caption"> <p>Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 13 Total cholesterol (mmol/L).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-02013" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-020-13.png?filename=nCD006423-CMP-020-13.ppt&amp;title=20.13&amp;caption=Comparison%2020%20GLP%E2%80%901%20agonist%20versus%20GLP%E2%80%901%20agonist%2C%20Outcome%2013%20Total%20cholesterol%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-020-13.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-02014"><img data-id="CD006423-fig-02014" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-020-14.png" alt="Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 14 HDL‐cholesterol (mmol/L)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.14</div> <div class="figure-caption"> <p>Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 14 HDL‐cholesterol (mmol/L).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-02014" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-020-14.png?filename=nCD006423-CMP-020-14.ppt&amp;title=20.14&amp;caption=Comparison%2020%20GLP%E2%80%901%20agonist%20versus%20GLP%E2%80%901%20agonist%2C%20Outcome%2014%20HDL%E2%80%90cholesterol%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-020-14.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-02015"><img data-id="CD006423-fig-02015" src="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-020-15.png" alt="Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 15 LDL‐cholesterol (mmol/L)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.15</div> <div class="figure-caption"> <p>Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 15 LDL‐cholesterol (mmol/L).</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-02015" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/image_n/nCD006423-CMP-020-15.png?filename=nCD006423-CMP-020-15.ppt&amp;title=20.15&amp;caption=Comparison%2020%20GLP%E2%80%901%20agonist%20versus%20GLP%E2%80%901%20agonist%2C%20Outcome%2015%20LDL%E2%80%90cholesterol%20%28mmol%2FL%29.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/image_n/nCD006423-CMP-020-15.png">Open in new tab</a></div> </div> <div class="figure" id="CD006423-fig-02016"> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="4" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Exenatide 10 µg BID</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide 1.8 mg daily</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 6 Buse 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>HOMA‐B (%)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>+2.74% SD 103</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>+32.12% SD 103, P &lt; 0.0001 versus exenatide 10 µg BID</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L ‐ LEAD 6 Buse 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>proinsulin‐to‐insulin ratio</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.02 SD 0.46</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.00 SD 0.46, P = NS</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.16</div> <div class="figure-caption"> <p>Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 16 Beta‐cell function.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-fig-02016" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/ppt/CDSR/CD006423/?filename=&amp;title=20.16&amp;caption=Comparison%2020%20GLP%E2%80%901%20agonist%20versus%20GLP%E2%80%901%20agonist%2C%20Outcome%2016%20Beta%E2%80%90cell%20function.&amp;citation=Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon%E2%80%90like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, 10. Art. No.: CD006423. DOI: http://dx.doi.org/10.1002/14651858.CD006423.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006423.pub2/media/CDSR/CD006423/">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD006423-tbl-0021"> <div class="table-heading"><span class="table-label">Table 1.</span>&nbsp;<span class="table-title">Overview of study populations</span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Characteristic ►</b> </p> <p><b>GLP analogue ▼</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>[n] screened</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>[n] randomised</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>[n] safety</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>[n] ITT</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>[n] finishing study</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>[%] of randomised participants<br> finishing study</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b> EXENATIDE</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Exenatide versus TZD and DPP‐4 inhibitors</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Bergenstal 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: ‐</p> <p>C1: ‐</p> <p>T: 958</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 170</p> <p>C1: 172</p> <p>C2: 172</p> <p>T: 514</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 160</p> <p>C1: 165</p> <p>C2: 166</p> <p>T: 491</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 160</p> <p>C1: 165</p> <p>C2: 166</p> <p>T: 491</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 127</p> <p>C1: 131</p> <p>C2: 144</p> <p>T: 402</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 74.70</p> <p>C1: 76.16</p> <p>C2: 83.72</p> <p>T: 78.21</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Exenatide versus insulin glargine</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Diamant 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: ‐</p> <p>C1: ‐</p> <p>T: 659</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 233</p> <p>C1: 223</p> <p>T: 456</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 233</p> <p>C1: 223</p> <p>T: 456</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 233</p> <p>C1: 223</p> <p>T: 456</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 209</p> <p>C1: 209</p> <p>T: 418</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 89.69</p> <p>C1: 93.72</p> <p>T: 91.66</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b> LIRAGLUTIDE</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide versus placebo and TZD</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>LEAD 1 (Marre 2009)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: ‐</p> <p>I2: ‐</p> <p>C1: ‐</p> <p>C2: ‐</p> <p>T: 1712</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 228</p> <p>I2: 234</p> <p>C1: 114</p> <p>C2: 232</p> <p>T*: 808</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 228</p> <p>I2: 234</p> <p>C1: 114</p> <p>C2: 231</p> <p>T*: 807</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 228</p> <p>I2: 234</p> <p>C1: 114</p> <p>C2: 231</p> <p>T*: 807</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 196</p> <p>I2: 213</p> <p>C1: 83</p> <p>C2: 194</p> <p>T*: 686</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 85.96</p> <p>I2: 91.02</p> <p>C1: 72.80</p> <p>C2: 83.62</p> <p>T*: 84.90</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide versus placebo and SU</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>LEAD 2 (Nauck 2009)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: ‐</p> <p>I2: ‐</p> <p>C1: ‐</p> <p>C2: ‐</p> <p>T: 1662</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 241</p> <p>I2: 242</p> <p>C1: 122</p> <p>C2: 244</p> <p>T*: 849</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 240</p> <p>I2: 242</p> <p>C1:121</p> <p>C2: 242</p> <p>T*: 845</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 240</p> <p>I2: 242</p> <p>C1: 121</p> <p>C2: 242</p> <p>T*: 845</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 197</p> <p>I2: 191</p> <p>C1: 74</p> <p>C2: 210</p> <p>T*: 672</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 81.74</p> <p>I2: 78.92</p> <p>C1: 60.65</p> <p>C2: 80.06</p> <p>T*: 79.15</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide versus placebo and insulin</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>LEAD 5 (Russell‐Jones 2008)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: ‐</p> <p>C1: ‐</p> <p>C2: ‐</p> <p>T: 973</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 232</p> <p>C1: 115</p> <p>C2: 234</p> <p>T: 581</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 230</p> <p>C1: 114</p> <p>C2: 232</p> <p>T: 576</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 230</p> <p>C1: 114</p> <p>C2: 232</p> <p>T: 576</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 207</p> <p>C1: 96</p> <p>C2: 219</p> <p>T: 522</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 89.22</p> <p>C1: 83.48</p> <p>C2: 93.59</p> <p>T: 89.84</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide versus placebo</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>LEAD 4 (Zinman 2009)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: ‐</p> <p>I2: ‐</p> <p>C1: ‐</p> <p>T: 821</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 178</p> <p>I2: 178</p> <p>C1: 177</p> <p>T: 533</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 178</p> <p>I2: 178</p> <p>C1: 177</p> <p>T: 533</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 178</p> <p>I2: 178</p> <p>C1: 177</p> <p>T: 533</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 153</p> <p>I2: 133</p> <p>C1: 121</p> <p>T: 407</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 85.95</p> <p>I2: 74.72</p> <p>C1: 68.36</p> <p>T: 76.36</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Kaku 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: ‐</p> <p>I2: ‐</p> <p>C1: ‐</p> <p>T: 308</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 88</p> <p>I2: 88</p> <p>C1: 88</p> <p>T: 264</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 88</p> <p>I2: 88</p> <p>C1: 88</p> <p>T: 264</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 88</p> <p>I2: 88</p> <p>C1: 88</p> <p>T: 264</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 83</p> <p>I2: 84</p> <p>C1: 74</p> <p>T: 241</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 94.32</p> <p>I2: 95.45</p> <p>C1: 84.09</p> <p>T: 91.29</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide versus SU</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Yang 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: ‐</p> <p>I2: ‐</p> <p>C1: ‐</p> <p>T: ‐</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 233</p> <p>I2: 234</p> <p>C1: 231</p> <p>T*: 698</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 233</p> <p>I2: 233</p> <p>C1: 231</p> <p>T*: 697</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: ‐</p> <p>I2: ‐</p> <p>C1: ‐</p> <p>T*: ‐</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 187</p> <p>I2: 175</p> <p>C1: 215</p> <p>T*: 577</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 80.25</p> <p>I2: 74.79</p> <p>C1: 93.07</p> <p>T*: 82.66</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide versus DPP‐4 inhibitors</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Pratley 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: ‐</p> <p>I2: ‐</p> <p>C1: ‐</p> <p>T: 1302</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 225</p> <p>I2: 221</p> <p>C1: 219</p> <p>T: 665</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 221</p> <p>I2: 218</p> <p>C1: 219</p> <p>T: 658</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 221</p> <p>I2: 218</p> <p>C1: 219</p> <p>T: 658</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 169</p> <p>I2: 191</p> <p>C1: 194</p> <p>T: 554</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 75.11</p> <p>I2: 86.42</p> <p>C1: 88.58</p> <p>T: 83.30</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b> LIXISENATIDE</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Lixisenatide versus placebo</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Ratner 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: ‐</p> <p>I2: ‐</p> <p>I3: ‐</p> <p>I4: ‐</p> <p>I5: ‐</p> <p>I6: ‐</p> <p>I7: ‐</p> <p>I8: ‐</p> <p>C1: ‐</p> <p>T: 1466</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 55</p> <p>I2: 52</p> <p>I3: 55</p> <p>I4: 54</p> <p>I5: 53</p> <p>I6: 56</p> <p>I7: 54</p> <p>I8: 54</p> <p>C1: 109</p> <p>T: 542</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 55</p> <p>I2: 52</p> <p>I3: 55</p> <p>I4: 54</p> <p>I5: 53</p> <p>I6: 56</p> <p>I7: 54</p> <p>I8: 54</p> <p>C1: 109</p> <p>T: 542</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 55</p> <p>I2: 50</p> <p>I3: 53</p> <p>I4: 51</p> <p>I5: 51</p> <p>I6: 54</p> <p>I7: 52</p> <p>I8: 53</p> <p>C1: 107</p> <p>T: 526</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 53</p> <p>I2: 47</p> <p>I3: 46</p> <p>I4: 45</p> <p>I5: 51</p> <p>I6: 51</p> <p>I7: 46</p> <p>I8: 47</p> <p>C1: 103</p> <p>T: 489</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 96.36</p> <p>I2: 90.38</p> <p>I3: 83.64</p> <p>I4: 83.33</p> <p>I5: 96.23</p> <p>I6: 91.10</p> <p>I7: 85.18</p> <p>I8: 87.04</p> <p>C1: 94.50</p> <p>T: 90.22</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b> LY2189265 </b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>LY2189265 versus placebo</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Umpierrez 2011</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: ‐</p> <p>I2: ‐</p> <p>I3: ‐</p> <p>C1: ‐</p> <p>T: ‐</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 66</p> <p>I2: 65</p> <p>I3: 65</p> <p>C1: 66</p> <p>T: 262</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 66</p> <p>I2: 65</p> <p>I3: 65</p> <p>C1: 66</p> <p>T: 262</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 66</p> <p>I2: 65</p> <p>I3: 65</p> <p>C1: 66</p> <p>T: 262</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 58</p> <p>I2: 58</p> <p>I3: 56</p> <p>C1: 60</p> <p>T: 232</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 87.88</p> <p>I2: 89.23</p> <p>I3: 86.15</p> <p>C1: 90.90</p> <p>T: 88.55</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b> TASPOGLUTIDE</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Taspoglutide versus placebo</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Nauck 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: ‐</p> <p>I2: ‐</p> <p>I3: ‐</p> <p>I4: ‐</p> <p>I5: ‐</p> <p>C1: ‐</p> <p>T: 572</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: ‐</p> <p>I2: ‐</p> <p>I3: ‐</p> <p>I4: ‐</p> <p>I5: ‐</p> <p>C1: ‐</p> <p>T: 306</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 50</p> <p>I2: 49</p> <p>I3: 50</p> <p>I4: 50</p> <p>I5: 49</p> <p>C1: 49</p> <p>T:297</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 50</p> <p>I2: 49</p> <p>I3: 50</p> <p>I4: 50</p> <p>I5: 49</p> <p>C1: 49</p> <p>T:297</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 49</p> <p>I2: 45</p> <p>I3: 44</p> <p>I4: 46</p> <p>I5: 46</p> <p>C1: 47</p> <p>T: 277</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: ‐</p> <p>I2: ‐</p> <p>I3: ‐</p> <p>I4: ‐</p> <p>I5: ‐</p> <p>C1: ‐</p> <p>T: 90.52</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Ratner 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: ‐</p> <p>I2: ‐</p> <p>I3: ‐</p> <p>C1: ‐</p> <p>T: ‐</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 33</p> <p>I2: 34</p> <p>I3: 33</p> <p>C1: 33</p> <p>T: 133</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 32</p> <p>I2: 33</p> <p>I3: 32</p> <p>C1: 32</p> <p>T: 129</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: ‐</p> <p>I2: ‐</p> <p>I3: ‐</p> <p>C1: ‐</p> <p>T: 125</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 32</p> <p>I2: 31</p> <p>I3: 27</p> <p>C1: 27</p> <p>T: 117</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 96.97</p> <p>I2: 91.18</p> <p>I3: 81.82</p> <p>C1: 81.82</p> <p>T: 87.97</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b> ALBIGLUTIDE</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Albiglutide versus placebo</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Rosenstock 2009</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: ‐</p> <p>I2: ‐</p> <p>C1: ‐</p> <p>T: 774</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 31</p> <p>I2: 33</p> <p>C1: 52</p> <p>T*: 116</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 31</p> <p>I2: 32</p> <p>C1: 51</p> <p>T*: 114</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 29</p> <p>I2: 32</p> <p>C1: 50</p> <p>T*: 111</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 22</p> <p>I2: 24</p> <p>C1: 40</p> <p>T*: 86</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I3: 70.97</p> <p>I5: 72.73</p> <p>C1: 76.92</p> <p>T*: 74.14</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b> GLP‐1 versus GLP‐1</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blevins 2011</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: ‐</p> <p>C1: ‐</p> <p>T: ‐</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: ‐</p> <p>C1: ‐</p> <p>T: 303</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 148</p> <p>C1: 147</p> <p>T: 295</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 148</p> <p>C1: 147</p> <p>T: 295</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 128</p> <p>C1: 130</p> <p>T: 258</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 86.49</p> <p>C1: 88.43</p> <p>T: 87.46</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Drucker 2008</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: ‐</p> <p>C1: ‐</p> <p>T: ‐</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: ‐</p> <p>C1: ‐</p> <p>T: 254</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 129</p> <p>C1: 123</p> <p>T: 252</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 129</p> <p>C1: 123</p> <p>T: 252</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 109</p> <p>C1: 95</p> <p>T: 204</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 84.5</p> <p>C1: 77.23</p> <p>T: 80.95</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>LEAD 6 (Buse 2009)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: ‐</p> <p>C1: ‐</p> <p>T:663</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 233</p> <p>C1: 231</p> <p>T: 464</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 235</p> <p>C1: 232</p> <p>T: 467</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 233</p> <p>C1: 231</p> <p>T: 464</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 202</p> <p>C1: 187</p> <p>T: 389</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: 86.69</p> <p>C1: 80.95</p> <p>T: 83.84</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b><i>Total</i> </b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><i><b>I#: 4051</b> </i> </p> <p><i><b>C#: 2679</b> </i> </p> <p><i><b>T##: 6899</b> </i> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><i><b>I: 3878</b> </i> </p> <p><i><b>C: 2653</b> </i> </p> <p><i><b>T: 6531</b> </i> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>"‐" denotes not reported</p> <p>C: control; GLP: glucagon‐like peptide; I: intervention; ITT: intention‐to‐treat; T: Total </p> <p>“*” indicate totals of the patients whose data were included in this review</p> <p>‘#’ indicate that the total is missing for some data for both I and C group as they were not reported </p> <p>‘##’ indicate that this is the actual total number of patients randomised. Please note ‘T’ for all trials were added to get this number </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span>&nbsp;<span class="table-title">Overview of study populations</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/full#CD006423-tbl-0021" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD006423-tbl-0022"> <div class="table-heading"><span class="table-label">Table 2.</span>&nbsp;<span class="table-title">Overview of comparisons</span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Characteristic ►</b> </p> <p><b>GLP analogue ▼</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b> Intervention</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b> Control</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b> Duration</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b> Quality (of 7)</b> </p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b> EXENATIDE</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Exenatide versus TZD</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Bergenstal 2010</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E QW+M+Placebo</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>TZD+M+Placebo</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>26 weeks</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Exenatide versus DPP‐4 inhibitors</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Bergenstal 2010</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E QW+M+Placebo</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>DPP‐4+M+Placebo</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>26 weeks</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Exenatide versus insulin glargine</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Diamant 2010</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E QW+M/(M+SU)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>GLAR+M/(M+SU)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>26 weeks</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b> LIRAGLUTIDE</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>&nbsp;</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>&nbsp;</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide versus placebo</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>&nbsp;</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>&nbsp;</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>&nbsp;</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>&nbsp;</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>LEAD 1 (Marre 2009)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L+SU</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>SU</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>26 weeks</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>LEAD 2 (Nauck 2009)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L+M</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>M</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>26 weeks</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>LEAD 5 (Russell‐Jones 2008)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L+M+SU</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>M+SU</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>26 weeks</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>LEAD 4 (Zinman 2009)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L+M+TZD</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>M+TZD</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>26 weeks</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide versus insulin</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>LEAD 5 (Russell‐Jones 2008)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L+M+SU</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>GLAR+M+SU</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>26 weeks</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide versus SU</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>LEAD 2 (Nauck 2009)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L+M</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>M+SU</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>26 weeks</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Yang 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L+M+Placebo</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>SU+M+Placebo</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>16 weeks</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide versus TZD</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>LEAD 1 (Marre 2009)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L+SU</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>TZD+SU</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>26 weeks</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Liraglutide versus DPP‐4 inhibitors</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Pratley 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L+M</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>DPP‐4+M</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>26 weeks</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b> LIXISENATIDE</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Lixisenatide versus placebo</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Ratner 2010</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>LIXI QD or BID</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Placebo</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>13 weeks</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b> LY2189265 </b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>LY2189265 versus placebo</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Umpierrez 2011</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>LY QW</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Placebo</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>16 weeks</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b> TASPOGLUTIDE</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>&nbsp;</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>&nbsp;</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Nauck 2009</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>T+M</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>M</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8 weeks</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Ratner 2010</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>T+M</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Placebo+M</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8 weeks</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b> ALBIGLUTIDE</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Rosenstock 2009</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A+M</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>M</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>16 weeks</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b> GLP1 versus GLP1</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blevins 2011</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E QW+/‐M+/‐SU+/‐TZD</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E BID+/‐M+/‐SU+/‐TZD</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>24 weeks</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Drucker 2008</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E BID+M</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E QW+M&nbsp;</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>30 weeks</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>LEAD 6 (Buse 2009)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>L+M/SU</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>E+M/SU</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>26 weeks</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>A: albiglutide; BID: twice daily; DPP‐4: dipeptidyl peptidase‐4 inhibitor; E: exenatide; GLAR: glargine; GLP: glucagon‐like peptide; L: liraglutide; LIXI: lixisenatide; LY: LY2189265; M: metformin; QD: once daily; QW: once weekly; SU: sulphonylurea; T: taspoglutide; TZD: thiazolidinedione.</sup> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span>&nbsp;<span class="table-title">Overview of comparisons</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/full#CD006423-tbl-0022" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD006423-tbl-0001" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 1.</span>&nbsp;<span class="table-title">Albiglutide versus placebo</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 HbA1c ‐ with plot <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.1 ALBI 30 mg weekly</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>79</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.7 [‐1.07, ‐0.33]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.2 ALBI 30 mg every 2 weeks</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>82</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.62 [‐1.06, ‐0.18]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 HbA1c &lt; 7% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Weight change ‐ with plot <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.1 ALBI 30 mg weekly</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>79</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.7 [‐1.89, 0.49]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.2 ALBI 30 mg every 2 weeks</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>82</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.9 [‐2.08, 0.28]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Weight change (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Blood pressure (mm Hg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">9 Fasting plasma glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">10 Lipid profiles <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">11 Beta‐cell function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">12 Subgroups <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span>&nbsp;<span class="table-title">Albiglutide versus placebo</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-tbl-0001" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD006423-tbl-0002" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 2.</span>&nbsp;<span class="table-title">Exenatide 2 mg once weekly versus thiazolidinedione</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 HbA1c &lt; 7% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Hypoglycaemia (minor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Weight change (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Blood pressure (mm Hg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Fasting plasma glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">9 Post‐prandial glucose / glucose profiles <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">10 Lipid profiles <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span>&nbsp;<span class="table-title">Exenatide 2 mg once weekly versus thiazolidinedione</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-tbl-0002" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD006423-tbl-0003" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 3.</span>&nbsp;<span class="table-title">Exenatide 2 mg once weekly versus DPP‐4 inhibitors</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 HbA1c &lt; 7% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Hypoglycaemia (minor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Weight change (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Blood pressure (mm Hg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Fasting plasma glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">9 Post‐prandial glucose / glucose profiles <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">10 Lipid profiles <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span>&nbsp;<span class="table-title">Exenatide 2 mg once weekly versus DPP‐4 inhibitors</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-tbl-0003" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD006423-tbl-0004" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 4.</span>&nbsp;<span class="table-title">Exenatide 2 mg once weekly versus insulin glargine</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 HbA1c &lt; 7% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Hypoglycaemia (symptoms only) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Hypoglycaemia (minor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Severe hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Weight change (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">9 Fasting plasma glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">10 Postprandial glucose / glucose profiles <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span>&nbsp;<span class="table-title">Exenatide 2 mg once weekly versus insulin glargine</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-tbl-0004" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD006423-tbl-0005" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 5.</span>&nbsp;<span class="table-title">Liraglutide 0.6 mg daily versus placebo</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 HbA1c &lt; 7% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Hypoglycaemia rate (events/patient‐year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Severe hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Weight change (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Blood pressure (mm Hg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Fasting plasma glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">9 Post‐prandial glucose / glucose profiles <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span>&nbsp;<span class="table-title">Liraglutide 0.6 mg daily versus placebo</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-tbl-0005" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD006423-tbl-0006" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 6.</span>&nbsp;<span class="table-title">Liraglutide 0.9 mg daily versus placebo</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 HbA1c &lt; 7% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Hypoglycaemia rate (events/patient‐year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Severe hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Weight change (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Blood pressure (mm Hg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Fasting plasma glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">9 Postprandial glucose / glucose profiles <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span>&nbsp;<span class="table-title">Liraglutide 0.9 mg daily versus placebo</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-tbl-0006" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD006423-tbl-0007" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 7.</span>&nbsp;<span class="table-title">Liraglutide 1.2 mg versus placebo</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1058</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.15 [‐1.33, ‐0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 HbA1c &lt; 7% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1058</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.91 [1.74, 4.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1058</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.54 [0.54, 4.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Weight change <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1058</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.75 [‐1.95, 0.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Systolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>716</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐3.26 [‐7.71, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Fasting plasma glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1058</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐2.13 [‐2.59, ‐1.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Post‐prandial glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">9 Triglycerides (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">10 Total cholesterol (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">11 HDL‐cholesterol (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">12 LDL‐cholesterol (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">13 Beta‐cell function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span>&nbsp;<span class="table-title">Liraglutide 1.2 mg versus placebo</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-tbl-0007" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD006423-tbl-0008" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 8.</span>&nbsp;<span class="table-title">Liraglutide 1.8 mg versus placebo</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1410</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.15 [‐1.31, ‐0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 HbA1c &lt; 7% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1410</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.25 [1.97, 5.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1410</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.66 [1.15, 2.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Weight change <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1410</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.33 [‐2.38, ‐0.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Systolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1062</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐2.42 [‐4.90, 0.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Fasting plasma glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1410</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐2.21 [‐2.49, ‐1.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Post‐prandial glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">9 Triglycerides (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">10 Total cholesterol (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">11 HDL‐cholesterol (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">12 LDL‐cholesterol (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">13 Beta‐cell function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span>&nbsp;<span class="table-title">Liraglutide 1.8 mg versus placebo</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-tbl-0008" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD006423-tbl-0009" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 9.</span>&nbsp;<span class="table-title">Liraglutide 1.2 mg versus 1.8 mg</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1739</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.10 [‐0.03, 0.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Patients reaching HbA1c &lt; 7% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2206</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.99 [0.84, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Weight <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1739</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.48 [0.16, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Systolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1739</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.22 [‐1.48, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span>&nbsp;<span class="table-title">Liraglutide 1.2 mg versus 1.8 mg</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-tbl-0009" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD006423-tbl-0010" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 10.</span>&nbsp;<span class="table-title">Liraglutide versus insulin glargine</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 HbA1c &lt; 7% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Weight change <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Systolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Fasting plasma glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Post‐prandial glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">9 Beta‐cell function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span>&nbsp;<span class="table-title">Liraglutide versus insulin glargine</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-tbl-0010" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD006423-tbl-0011" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 11.</span>&nbsp;<span class="table-title">Liraglutide 1.2 mg daily versus thiazolidinedione</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 HbA1c &lt; 7% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Hypoglycaemia (mild/moderate/overall) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Severe hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Weight change <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Systolic blood pressure (mm Hg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Diastolic blood pressure (mm Hg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">9 Fasting plasma glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">10 Post‐prandial glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">11 Beta‐cell function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span>&nbsp;<span class="table-title">Liraglutide 1.2 mg daily versus thiazolidinedione</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-tbl-0011" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD006423-tbl-0012" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 12.</span>&nbsp;<span class="table-title">Liraglutide 1.8 mg daily versus thiazolidinedione</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 HbA1c &lt; 7% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Severe hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Weight change (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Systolic blood pressure (mm Hg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Diastolic blood pressure (mm Hg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">9 Fasting plasma glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">10 Post‐prandial glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">11 Beta‐cell function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span>&nbsp;<span class="table-title">Liraglutide 1.8 mg daily versus thiazolidinedione</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-tbl-0012" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD006423-tbl-0013" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 13.</span>&nbsp;<span class="table-title">Liraglutide 1.2 mg daily versus DPP‐4 inhibitors</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 HbA1c &lt; 7% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Hypoglycaemia (mild/moderate/overall) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Severe hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Weight change (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Systolic blood pressure (mm Hg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Diastolic blood pressure (mm Hg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">9 Fasting plasma glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">10 Post‐prandial glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">11 Beta‐cell function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span>&nbsp;<span class="table-title">Liraglutide 1.2 mg daily versus DPP‐4 inhibitors</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-tbl-0013" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD006423-tbl-0014" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 14.</span>&nbsp;<span class="table-title">Liraglutide 1.8 mg daily versus DPP‐4 inhibitors</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 HbA1c &lt; 7% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Severe hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Weight change (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Systolic blood pressure (mm Hg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Diastolic blood pressure (mm Hg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">9 Fasting plasma glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">10 Post‐prandial glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">11 Beta‐cell function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 14.</span>&nbsp;<span class="table-title">Liraglutide 1.8 mg daily versus DPP‐4 inhibitors</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-tbl-0014" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD006423-tbl-0015" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 15.</span>&nbsp;<span class="table-title">Lixisenatide versus placebo</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 HbA1c &lt; 7% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.1 LIXI 5 µg QD</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.2 LIXI 10 µg QD</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.3 LIXI 20 µg QD</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.4 LIXI 30 µg QD</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.5 LIXI 5 µg BID</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.6 LIXI 10 µg BID</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.7 LIXI 20 µg BID</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.8 LIXI 30 µg BID</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Symptomatic hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.1 LIXI 5 µg QD</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.2 LIXI 10 µg QD</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.3 LIXI 20 µg QD</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.4 LIXI 30 µg QD</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.5 LIXI 5 µg BID</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.6 LIXI 10 µg BID</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.7 LIXI 20 µg BID</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.8 LIXI 30 µg BID</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Weight change (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.1 LIXI 5 μg QD</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.2 LIXi 10 μg QD</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.3 LIXI 20 μg QD</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.4 LIXI 30 μg QD</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.5 LIXI 5 μg BID</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.6 LIXI 10 μg BID</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.7 LIXI 20 μg BID</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.8 LIXI 30 μg BID</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Fasting plasma glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6.1 LIXI 5 μg QD</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6.2 LIXI 10 μg QD</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6.3 LIXI 20 μg QD</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6.4 LIXI 30 μg QD</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6.5 LIXI 5 μg BID</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6.6 LIXI 10 μg BID</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6.7 LIXI 20 μg BID</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6.8 LIXI 30 μg BID</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Post‐prandial glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.1 LIXI 5μg QD</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.2 LIXI 10μg QD</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.3 LIXI 20μg QD</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.4 LIXI 30μg QD</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.5 LIXI 5μg BID</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.6 LIXI 10μg BID</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.7 LIXI 20μg BID</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.8 LIXI 30μg BID</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Average self‐monitored 7‐point blood glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8.1 LIXI 5 μg QD</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8.2 LIXI 10 μg QD</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8.3 LIXI 20 μg QD</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8.4 LIXI 30 μg QD</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8.5 LIXI 5 μg BID</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8.6 LIXI 10 μg BID</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8.7 LIXI 20 μg BID</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8.8 LIXI 30 μg BID</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 15.</span>&nbsp;<span class="table-title">Lixisenatide versus placebo</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-tbl-0015" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD006423-tbl-0016" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 16.</span>&nbsp;<span class="table-title">Liraglutide 1.2 mg versus SU</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 HbA1c (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 HbA1c &lt; 7% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>946</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.98 [0.84, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>946</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.06 [0.00, 1.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Weight change <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Weight change (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Systolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">9 Blood pressure (mm Hg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">10 Fasting plasma glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">11 Fasting plasma glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">12 Post‐prandial glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">13 Beta‐cell function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 16.</span>&nbsp;<span class="table-title">Liraglutide 1.2 mg versus SU</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-tbl-0016" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD006423-tbl-0017" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 17.</span>&nbsp;<span class="table-title">Liraglutide 1.8 mg daily versus SU</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 HbA1c (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 HbA1c &lt; 7% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>949</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.09 [0.94, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>949</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.13 [0.07, 0.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Weight change (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Weight change (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Systolic blood pressure (mm Hg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">9 Blood pressure (mm Hg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">10 Fasting plasma glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">11 Fasting plasma glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">12 Post‐prandial glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">13 Beta‐cell function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 17.</span>&nbsp;<span class="table-title">Liraglutide 1.8 mg daily versus SU</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-tbl-0017" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD006423-tbl-0018" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 18.</span>&nbsp;<span class="table-title">Taspoglutide versus placebo</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.1 Taspoglutide 10 mg once weekly verus placebo</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>98</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.0 [‐1.19, ‐0.81]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.2 Taspoglutide 20 mg once weekly versus placebo</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>163</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.87 [‐1.16, ‐0.58]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.3 Taspoglutide 20 mg once every 2 weeks versus placebo</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>98</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.8 [‐0.99, ‐0.61]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 HbA1c (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 HbA1c &lt; 7% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.1 Taspoglutide 10 mg once weekly versus placebo</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>98</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.88 [2.55, 9.33]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.2 Taspoglutide 20 mg once weekly versus placebo</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>163</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.41 [2.70, 7.22]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.3 Taspoglutide 20 mg once every two weeks versus placebo</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>98</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.88 [1.99, 7.56]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 HbA1c &lt; 7% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.1 Taspoglutide 20/20 mg once weekly versus placebo</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>64</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.0 [0.07, 15.30]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.2 Taspoglutide 20/30 mg once weekly versus placebo</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>65</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.91 [0.32, 26.53]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.3 Taspoglutide 20/40 mg once weekly versus placebo</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>64</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.0 [0.19, 20.97]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Weight change (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.1 Taspoglutide 10 mg once weekly versus placebo</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>88</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.3 [‐2.13, ‐0.47]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.2 Taspoglutide 20 mg once weekly versus placebo</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>153</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.07 [‐2.93, 0.79]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.3 Taspoglutide 20 mg once every two weeks versus placebo</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>80</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.10 [‐1.93, ‐0.27]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Weight change <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">9 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">10 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">11 Fasting plasma glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>11.1 Taspoglutide 20/20 mg once weekly versus placebo</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>64</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.70 [‐2.53, ‐0.87]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>11.2 Taspoglutide 20/30 mg once weekly versus placebo</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>65</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.0 [‐1.83, ‐0.17]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>11.3 Taspoglutide 20/40 mg once weekly versus placebo</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>64</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.6 [‐2.43, ‐0.77]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">12 Fasting plasma glucose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">13 Postprandial glucose and insulin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">14 Lipid profiles <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">15 Beta‐cell function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">16 Subgroup <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>16.1 Participants with HbA1c ≥8%</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 18.</span>&nbsp;<span class="table-title">Taspoglutide versus placebo</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-tbl-0018" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD006423-tbl-0019" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 19.</span>&nbsp;<span class="table-title">LY2189265 versus placebo</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 HbA1c &lt; 7% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.1 LY 0.5/1.0 QW</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Weight change (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.1 LY 0.5/1.0 QW</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>130</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.32 [‐2.40, ‐0.24]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.2 LY 1.0/1.0 QW</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>128</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐1.22 [‐2.30, ‐0.14]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.3 LY 1.0/2.0 QW</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>128</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐2.43 [‐3.52, ‐1.34]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Systolic blood pressure (mm Hg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6.1 LY 0.5/1.0 QW</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6.2 LY 1.0/1.0 QW</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6.3 LY 1.0/2.0 QW</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Diastolic blood pressure (mm Hg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.1 LY 0.5/1.0 QW</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.2 LY 1.0/1.0 QW</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.3 LY 1.0/2.0 QW</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Fasting plasma glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">9 Beta‐cell function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 19.</span>&nbsp;<span class="table-title">LY2189265 versus placebo</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-tbl-0019" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD006423-tbl-0020" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 20.</span>&nbsp;<span class="table-title">GLP‐1 agonist versus GLP‐1 agonist</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 HbA1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.1 versus Liraglutide</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>464</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.33 [0.11, 0.55]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.2 versus Exenatide 2 mg once weekly</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>547</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.55 [0.26, 0.84]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 HbA1c &lt; 7% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.1 versus Liraglutide</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>464</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.79 [0.66, 0.96]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.2 versus Exenatide 2 mg once weekly</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>511</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.65 [0.42, 1.01]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.1 versus Liraglutide</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>467</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.32 [0.99, 1.75]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.2 versus Exenatide 2 mg once weekly</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>295</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.13 [0.45, 2.86]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Weight change <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.1 versus Liraglutide</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>464</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.37 [‐0.55, 1.29]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.2 versus Exenatide 2 mg once weekly</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>295</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.10 [‐1.29, 1.49]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Weight change <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Treatment satisfaction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.1 versus Liraglutide</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.2 versus Exenatide 2 mg once weekly</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8.1 versus Liraglutide</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8.2 versus Exenatide 2 mg once weekly</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">9 Systolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9.1 versus Liraglutide</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>464</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.51 [‐2.72, 3.74]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9.2 versus Exenatide 2 mg once weekly</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>547</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.49 [‐0.71, 3.69]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">10 Fasting plasma glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>10.1 versus Liraglutide</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>464</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.01 [0.46, 1.56]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>10.2 versus Exenatide 2 mg once weekly</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>547</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.18 [1.02, 1.33]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">11 Post‐prandial glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>11.1 versus Liraglutide</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>11.2 versus Exenatide 2 mg once weekly</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">12 Triglycerides (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>12.1 versus Liraglutide</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>464</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.18 [‐0.10, 0.46]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>12.2 versus Exenatide 2 mg once weekly</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>547</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.01 [‐0.04, 0.06]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">13 Total cholesterol (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>13.1 versus Liraglutide</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>464</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.11 [‐0.09, 0.31]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>13.2 versus Exenatide 2 mg once weekly</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>547</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.31 [0.10, 0.51]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">14 HDL‐cholesterol (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>14.1 versus Liraglutide</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>464</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.01 [‐0.07, 0.05]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>14.2 versus Exenatide 2 mg once weekly</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>547</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.00 [‐0.03, 0.04]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">15 LDL‐cholesterol (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>15.1 versus Liraglutide</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>464</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.04 [‐0.13, 0.21]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>15.2 versus Exenatide 2 mg once weekly</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>547</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.20 [0.09, 0.30]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">16 Beta‐cell function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other data</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 20.</span>&nbsp;<span class="table-title">GLP‐1 agonist versus GLP‐1 agonist</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006423.pub2/references#CD006423-tbl-0020" class="tableList">Navigate to table in Review</a></div> </div> </div> <section class="translation-notes-modal" style="display: none" data-modal-title="Translation notes" data-modal-class="translation-notes" data-ok-btn-selector=".ok-btn"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD006423-note-1210">Español</a> </li> <li class="section-language"> <a class="" href="fr#CD006423-note-1209">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD006423-note-1202">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD006423-note-1207">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD006423-note-1208">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="za#CD006423-note-1211">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" id="citeProcText" data-load-error="Unable to load citation data"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a href="#" class="addthis_button_citeulike at300b btn btn-link">CiteULike</a></li> <li><a href="#" class="addthis_button_mendeley at300b btn btn-link">Mendeley</a></li> <li><a href="#" class="citation-btn-refworks at300b btn btn-link" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <h4>Copy or download citation</h4> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button type="button" class="btn btn-link">Plain text</button></li> <li class="citation-option" data-option="endnote"><button type="button" class="btn btn-link">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button type="button" class="btn btn-link">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button type="button" class="btn btn-link">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button type="button" class="btn btn-link">BibteX</button></li> </nav> <div class="citation-content"> <pre id="citationContent" tabindex="0" data-load-error="Unable to load citation data"></pre> </div> <div class="clearfix"> <form class="download-citation-form" method="GET" target="citation-download-iframe" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=citation-citeproc&p_p_cacheability=cacheLevelPage&p_p_col_id=column-1&p_p_col_count=1"> <input type="hidden" id="siteId" name="siteId" value="" /> <input type="hidden" id="downloadType" name="downloadType" value="" /> <input type="hidden" id="style" name="style" value="" /> <input type="hidden" id="articleId" name="articleId" value="" /> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay" /><input name="p_p_lifecycle" type="hidden" value="2" /><input name="p_p_state" type="hidden" value="normal" /><input name="p_p_mode" type="hidden" value="view" /><input name="p_p_resource_id" type="hidden" value="citation-download" /><input name="p_p_cacheability" type="hidden" value="cacheLevelPage" /><input name="p_p_col_id" type="hidden" value="column-1" /><input name="p_p_col_count" type="hidden" value="1" /> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withAbstract"> <input class="checkbox" type="checkbox" name="withAbstract" /> <span class="checkbox-label">Include abstract</span> </label> </div> </form> <iframe title="Citation download frame" name="citation-download-iframe" src="" style="display: none; visibility: hidden" aria-hidden="true"></iframe> </div> </div> </div> </div> <div class="print-modal" style="display: none;" data-modal-title="Print this review"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input title="Select/deselect all" type="checkbox" class="print-options-select-all" checked="checked" /> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i class="fa fa-print" aria-hidden="true"></i> Print</button> </div> </div> <div class="download-stats-data-modal" style="display: none;" data-modal-title="Download statistical data"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <p> Downloaded data can only be viewed using <a class="external" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MNYX45LWN3VYI8JPMNYXG4DTMFYGKLUQPJUB/tools/review-production-tools/revman-5" target="_blank">Review Manager software.</a> </p> <p> Please note that: <ul> <li>data are only available for Cochrane Reviews that contain one or more forest plots; and</li> <li>data in the downloaded RevMan file are editable and therefore the review data can be amended without warning.</li> </ul> </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input type="hidden" name="content-disposition" value="attachment" /> <input type="hidden" name="mime-type" value="application/octet-stream" /> <p class="print-options-controls"> <input type="checkbox" class="download-stats-data-toc-check-box" aria-label="I agree to these terms and conditions" /> <span class="checkbox-label" aria-hidden="true">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i class="fa fa-download" aria-hidden="true"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" style="display:none;" data-modal-title="Share this review"> <div class="add-this"> <div class="addthis_toolbox addthis_default_style addthis_32x32_style"> <nav class="stacked-nav-list"> <li> <a href="#" class="addthis_button_twitter at300b" title="Tweet">Twitter</a> </li> <li> <a href="#" class="addthis_button_mendeley at300b" target="_blank" title="Mendeley">Mendeley</a> </li> <li> <a href="#" class="addthis_button_facebook at300b" title="Facebook">Facebook</a> </li> <li> <a href="#" class="addthis_button_linkedin at300b" target="_blank" title="LinkedIn">LinkedIn</a> </li> <li> <a href="#" class="addthis_button_email at300b" target="_blank" title="Email">Email</a> </li> <li> <a href="#" class="addthis_button_whatsapp at300b" target="_blank" title="WhatsApp">WhatsApp</a> </li> <li class="clearfix"> <a href="#" class="addthis_button_more btn primary pull-right" target="_blank" title="View more"> <i class="fa fa-plus" aria-hidden="true"></i> View more</a> </li> </ul> </div> </div> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button type="button" class="btn btn-link" id="figureOptionBtn">Figures</button></li> <li class="table-options-btn-container"><button type="button" class="btn btn-link" id="tableOptionBtn">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div id="figureThumbnails" class="figure-thumbnails is-visible"></div> <div id="tableThumbnails" class="table-thumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a href="#" class="figure-viewer-menu-toggle"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-table-show-text="Show table list" data-table-hide-text="Hide table list" data-figure-show-text="Show thumbnails" data-figure-hide-text="Hide thumbnails">Hide thumbnails</span> </a> <a href="#" class="figure-viewer-zoomin"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a href="#" class="figure-viewer-zoomout"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a href="#" class="figure-viewer-nav previous"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a href="#" class="figure-viewer-nav next"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_  portlet-static portlet-static-end kaleo-designer-portlet " id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a title="Cochrane logo" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/P75YPLUDN7SXR6UBN3TT655TMH/">
<img class="footer-logo logo-part-1" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/footer-logo-part-1.png" alt="Cochrane logo" /> <img class="footer-logo logo-part-2" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/footer-logo-part-2.png" alt="" /> </a> </div> <nav class="footer-links"> <ul class="root"> <li class="footer-item"> <a class="footer-item-link" href="/about-cochrane1">About Cochrane</a> <ul class="child"> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/evidence" target="_blank">Cochrane.org</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/about-us" target="_blank">Who we are</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/NJYXT5SPMNYXG4DTMFYGKLUQPJUB/" target="_blank">Get involved</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYX665WNWTYE63PMNYXG4DTMFYGKLUQPJUB/" target="_blank">Consumer Network</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/about-us/our-funders-and-partners" target="_blank">Partners</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYXZ5DQPF4XT7LNF3SX8Z5IPJRX63JPN73GH/" target="_blank">Colloquium</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/news" target="_blank">In the news</a> </li> </ul> </li> <li class="footer-item"> <a class="footer-item-link" href="/publications">Publications</a> <ul class="child"> <li class="footer-item"> <a class="footer-item-link" href="/library">Cochrane Library</a> <ul class="child"> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/" target="_blank">Library Homepage</a> </li> <li class="footer-item"> <a class="footer-item-link" href="cdsr/about-cdsr" target="_blank">Cochrane Reviews (CDSR)</a> </li> <li class="footer-item"> <a class="footer-item-link" href="/central" target="_blank">Trials (CENTRAL)</a> </li> <li class="footer-item"> <a class="footer-item-link" href="/cca/about" target="_blank">Cochrane Clinical Answers</a> </li> </ul> </li> <li class="footer-item"> <a class="footer-item-link" href="/about/cochrane-library-app" target="_blank">Cochrane Library App</a> </li> <li class="footer-item"> <a class="footer-item-link" href="/cdsr/journal-club" target="_blank">Journal Club</a> </li> <li class="footer-item"> <a class="footer-item-link" href="/about/podcasts" target="_blank">Podcasts</a> </li> </ul> </li> <li class="footer-item"> <a class="footer-item-link" href="/community">Community</a> <ul class="child"> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MNYX45LWN3VYI8JPMNYXG4DTMFYGKLUQPJUB/" target="_blank">Community</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MF3GG4DJMVYGG55DNB3GC5UFF3YYE3D/" target="_blank">Archie log-in</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/PS3GC4LPNFYGPLUDN7SXR6UBN3TT655TMH/" target="_blank">Training and support</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/NWTYI4DQMS3T6Z5QMNVHEZLPMVYG86UH/" target="_blank">Methods</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYX45LWN3VYI8JPMNYXG4DTMFYGKLUQPJUB/help" target="_blank">Software</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/news/jobs" target="_blank">Jobs and opportunities</a> </li> </ul> </li> <li class="footer-item"> <a class="footer-item-link" href="/contact-us">Contact Us</a> <ul class="child"> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/P75YPLUDN7SXR6UBN3TT655TMH/contact" target="_blank">General enquiries</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/help/contact-us" target="_blank">Cochrane Library support</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYX45LWN3VYI8JPMNYXG4DTMFYGKLUQPJUB/organizational-info/people/central-executive-team/chief-executive-officers-office/team" target="_blank">Chief Executive Officer</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MNYX45LWN3VYI8JPMNYXG4DTMFYGKLUQPJUB/organizational-info/people/central-executive-team/editorial-methods/team" target="_blank">Editor in Chief</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/about-us/our-global-community" target="_blank">Cochrane groups</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/P75YPLUDN7SXR6UBN3TT655TMH/media" target="_blank">Media</a> </li> <li class="footer-item"> <a class="footer-item-link" href="/accessibility" target="_blank">Accessibility</a> </li> </ul> </li> </ul> </nav> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/advertisers">Advertisers & Agents</a></li> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/NB4XELUYNFXGK8JPMNYXN/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/NB4XELUYNFXGK8JPMNYXN/community/support/cochrane-library">Help & Support</a></li> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/terms-and-conditions">Terms & Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright &copy; 2000 - 2020 by <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/P75YPLUYNFXGK8JPMNYXN/" class="">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br /> Review our <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUYNFXGK8JPMNYXN/en-gb/privacy"><strong>Privacy Policy</strong></a> </p> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MW4T675JNSTYTLUDN7XB/"><img class="logo" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/en-US_wiley-footer-logo.png" alt="Wiley logo" /></a> </div> </div> <span class="wiley-semi-circle"></span> </div> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" style="display: none" data-modal-title="Feature in English only" data-modal-class="english-only-modal"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script src="/cochrane-theme/vendor/ie9.js?t=1581422282000" type="text/javascript"></script> <!--<![endif]--> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/js/theme.js?t=1581422282000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYX67DFN34C66UFMFTGG7LCMVYGG55N/cochrane/checkout.js"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYX67DFN34C66UFMFTGG7LCMVYGG55N/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MN3G865UNWRYE43NMNTG6LUDPJYYG65TMWUC655TMH/widget/v2.0/widget.js" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MRZXE8DIHB4XC63SNWYHPN3PMNXG87LEM33G85UVF3YGK7A/assets/embed.js" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718173000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718249000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718249000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718173000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006423\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006423\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dreferences\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006423\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006423\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006423\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006423\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006423\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006423\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dreferences\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006423\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006423\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006423\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006423\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dreferences\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006423\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006423\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006423\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006423\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dreferences\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006423\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006423\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581422282000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a href="#" class="rh-nav-close-btn"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a href="#" class="rh-nav-open-btn"> <span>Review tools & navigation</span> </a> </div> <iframe title="Print frame" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" aria-hidden="true"></iframe> <div class="mobile-navigation"> <div class="close-container"> <a href="#" class="main-nav-back-btn" aria-label="Navigate back"><i class="fa fa-chevron-left"></i></a> <a href="#" class="main-nav-close-btn" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end " id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img id="ymag__null__null" src="/scolaris-search/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_auth=EfT7x5RD&p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=1&p_p_state=normal&p_p_mode=view&_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input type="hidden" name="searchType" value="basic" /> <input type="hidden" name="facetDisplayName" value="" /> <input type="hidden" name="facetQueryTerm" value="" /> <input type="hidden" name="facetQueryField" value="" /> <input type="hidden" name="facetCategory" value="" /> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select title="Search by options" aria-label="Search by options" name="searchBy" class="custom-select-enabled search-type"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" style="display: none;" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=topics-list&p_p_cacheability=cacheLevelPage"> <select class="search-select-topic-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input type="text" size="30" class="field browser-search search-text ui-autocomplete-input" value="" aria-label="Enter search term" id="searchText" name="searchText" placeholder="Search">
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button type="submit" class="searchByBtn" aria-label="Search">
<i class="fa fa-search" aria-hidden="true"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=references&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006423.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006423.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
<a href="/en/browse-by-topic" class="btn secondary">Browse </a>
<a href="/en/advanced-search" class="btn secondary advanced-search-button">Advanced search</a>
</div>
<div class="menu-items parent">
<ul>
<li class="nav-root-item parent">
<a href="#" title="Select language" class="language-selection-title-link">
<span class="mobile-nav-language-title">Select your preferred language</span><span class="icon fa fa-caret-down"></span>
<ul class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_  portlet-static portlet-static-end  " id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img id="fdkn__null__null" src="/scolaris-language-portlet/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hr, ja, ko, ms, pl, pt, ru, ta, th, zh, za]"> <a title="Select your preferred language" class="language-select-mobile" href="#"> <i class="fa fa-file-text"></i> English </a> <a title="Select your preferred language" class="language-select-mobile" href="#"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane Review language</h3> <p>Select your preferred language for Cochrane Reviews. You will see translated Review sections in your preferred language. Sections without translation will be in English.</p> <div id="active-content-language" class="dropdown-trigger"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de" class="content-language-selector " data-languagecode="de">Deutsch</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en" class="content-language-selector is-active" data-languagecode="en">English</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es" class="content-language-selector " data-languagecode="es">Español</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa" class="content-language-selector " data-languagecode="fa">فارسی</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr" class="content-language-selector " data-languagecode="fr">Français</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr" class="content-language-selector " data-languagecode="hr">Hrvatski</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja" class="content-language-selector " data-languagecode="ja">日本語</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko" class="content-language-selector " data-languagecode="ko">한국어</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms" class="content-language-selector " data-languagecode="ms">Bahasa Malaysia</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl" class="content-language-selector " data-languagecode="pl">Polski</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt" class="content-language-selector " data-languagecode="pt">Português</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru" class="content-language-selector " data-languagecode="ru">Русский</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta" class="content-language-selector " data-languagecode="ta">தமிழ்</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th" class="content-language-selector " data-languagecode="th">ภาษาไทย</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh" class="content-language-selector " data-languagecode="zh">简体中文</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=za" class="content-language-selector " data-languagecode="za">繁體中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div id="active-portal-language" class="dropdown-trigger"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a href="/en/cdsr/doi/10.1002/14651858.CD006423.pub2/references/en" class="portal-language-selector is-active" data-portallanguage="en">English</a> <a href="/es/cdsr/doi/10.1002/14651858.CD006423.pub2/references/es" class="portal-language-selector " data-portallanguage="es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</ul>
</a>
</li>
<li class="parent">
<a class="mobile-link signin" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/c/portal/login?p_l_id=20757&redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006423.pub2%2Freferences" data-redirect="false" rel="nofollow">
Sign In
</a>
</li>
</ul>
<div class="menu-items-footer">
<div class="utility-links">
<a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/P75YPLUDN7SXR6UBN3TT655TMH/" class="cochrane-link" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
<div class="basic-login-form-content" style="display: none;" data-modal-title="Sign in">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_  portlet-static portlet-static-end portlet-login " id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img id="dbam__null__null" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/spacer.png" alt="" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;" /> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <form action="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" class="form sign-in-form " id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm" autocomplete="on"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1583245519605" /> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false" /> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006423&#x2e;pub2&#x2f;references" /> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false" /> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value="" /> </div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value="" /> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true" /> <input checked class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onClick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true" /> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button type="submit" class="btn primary">Sign in</button> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/user-registration" target="_blank" class="btn secondary">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&p_p_lifecycle=0&p_p_state=normal&p_p_mode=view&_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </fieldset> </form> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" style="display: none;" data-modal-title="Institutional login">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_  portlet-static portlet-static-end scolaris-content-display-portlet " id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img id="obft__null__null" src="/scolaris-content-display/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form method="post" action="/shibboleth" id="institutionLoginForm"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" name="institutionName" id="institutionName" value="" type="text">
</div>
<button class="btn primary" type="submit" name="button">Go</button>
</div>
<div id="institutionLookupErrorDiv" class="message error" style="display:none">
'<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
</div>
</div>
<input type="hidden" id="entityId" name="entityId" value="">
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_  portlet-static portlet-static-end portlet-login " id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img id="joiu__null__null" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/spacer.png" alt="" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;" /> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" class="form sign-in-form " id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm" autocomplete="on"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1583245519611" /> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false" /> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006423&#x2e;pub2&#x2f;references" /> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false" /> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value="" /> </div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value="" /> </div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true" /> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button type="submit" class="btn primary">Sign in</button> </div> </div> </fieldset> </form> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" style="display: none;" data-modal-title="Unlock the potential of Cochrane evidence">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_  portlet-static portlet-static-end scolaris-content-display-portlet " id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img id="wpdq__null__null" src="/scolaris-content-display/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form method="post" action="/shibboleth" id="institutionLoginForm"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" name="institutionName" id="institutionName" value="" type="text"> </div> <button class="btn primary" type="submit" name="button">Go</button> </div> <div id="institutionLookupErrorDiv" class="message error" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input type="hidden" id="entityId" name="entityId" value=""> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'> <input type="hidden" name="openlabel" id="openlabel" value='Open access'> </div> </section> </div> </div>  <script>window.urlTitle="/cdsr/doi/10.1002/14651858.CD006423.pub2";addthis_config={pubid:"ra-593597d01cdf9a55",ui_508_compliant:true};addthis_share={url:window.location.href,title:document.title};</script> <script src="//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-593597d01cdf9a55"></script> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> </body> </html> 